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Abstract 
 
Over the last 15 years the malaria burden has globally declined, but not evenly across 
endemic areas. In areas with substantial decline, elimination became realistic. However, 
malaria elimination has to, in a cost-effective way, overcome problems such as increasing 
drug and insecticide resistance and the increasing heterogeneity in transmission as the 
transmission intensity declines. Vaccines are proven cost-effective tools in infectious disease 
control and substantial progress was made with the RTS, S vaccine. However, vaccine 
development is hampered by the lack of reliable immune correlates of protection.  
We have analysed antibody responses in relation to the incidence of febrile malaria in young 
children, with the specific objective of investigating their contribution to the apparent 
resistance of young infants to febrile malaria. We have also analysed the dynamics of 
antibodies in relation to previously established protective thresholds.  
We found that the antibody responses to 6 different falciparum antigens were not associated 
with protection against febrile malaria in young children and that their levels were 
consistently below the protective thresholds.  Furthermore, we found that antibody titres 
were often actually associated with increasing risk of febrile malaria.  A likely explanation 
is that the antibodies were markers of exposure and hence associated with higher risk.  
We therefore analysed geo-spatial data on malaria risk to identify hotspots of clinical malaria 
and their association with hotspots of serological responses to malaria antigens. 
We found that 1) antibody responses correlated well with asymptomatic parasitaemia 
detected by polymerase chain reaction, and 2) there was substantial overlapping between the 
hotspots detected using these markers. 
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Our data suggest that other mechanisms are responsible for the apparent resistance of infants 
to febrile malaria. Moreover, our data suggest that serology or polymerase chain reaction 
results may be used as markers for the detection of hotspots when the transmission declines 
to very low levels.  
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In 2015, around 3.2 billion (about half the world’s population)  people were at risk of malaria 
worldwide (WHO 2015). An estimate of 214 (149-303) million malaria cases have been 
reported globally the same year, resulting in 438000 (236000-635000) deaths, of which 90% 
were recorded in the WHO African region (WHO 2015) where some countries have 100% 
of their population at risk of malaria (Gething, Patil et al. 2011). However, these figures may 
have been underestimated since many cases are likely to be unreported (Hay, Okiro et al. 
2010, Murray, Rosenfeld et al. 2012). Malaria contributed to  7.4%, 7.3% and 10% of the 
global mortality of children under five years of age in 2010 (Liu, Johnson et al. 2012) 2013 
(Liu, Oza et al. 2015) and 2015 (WHO 2015) respectively. In 2015, 70% of the 438000 
malaria deaths occurred globally in children under-five (WHO 2015). The global pattern of 
the distribution of malaria burden remains unchanged with sub-Saharan Africa being 
disproportionately affected with 90% of malaria deaths (WHO 2015). 
Malaria affects the well-being of communities beyond the direct effect of clinical disease 
through the economic burden it engenders. A study conducted in a holo-endemic area of 
Nigeria found an estimate of household expenditure of  between 12.57 US$ and 23.20 US$ 
per case for outpatient visits and inpatient stays respectively (Onwujekwe, Uguru et al. 
2013). In Ghana, it has been estimated that a household spends on average 13.9 US$ for the 
management of each case of malaria (Dalaba, Akweongo et al. 2014). In high-burden malaria 
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countries, the malaria related expenses at household level can become quickly difficult to 
meet for the poorest households, pushing them further into poverty. There is growing 
evidence of an association between malaria and poverty. At country level, it has been shown 
that countries with the highest malaria burden have 1.3% lower annual economic growth 
than other countries (Gallup and Sachs 2001). These complex associations are often 
described as the “vicious circle of poverty and malaria” (Tusting, Willey et al.).  
The global malaria control effort has yielded encouraging results in the last fifteen years with 
the estimated malaria incidence and mortality rate falling respectively by 37% and 60% 
globally and the number of deaths averted estimated at 6.2 million lives (WHO 2015). 
Similar findings, 40% decline in malaria incidence, were reported by Bhatt and colleagues 
for Africa especially for the same period (Bhatt, Weiss et al. 2015).   
These recent gains in malaria control, driven to a large degree by early treatment with 
artemisinin-based combination therapies, universal coverage of insecticide-treated nets and 
indoor residual spraying, are however fragile considering emerging drug and insecticide 
resistance (Ashley, Dhorda et al. 2014, Sovi, Djegbe et al. 2014), the underlying poverty in 
the most affected areas in sub-Saharan Africa (Gallup and Sachs 2001) and the potential 
adverse effects of climate and environmental change on vector distribution and vectorial 
capacity in the long run especially in areas of declining or unstable malaria transmission. On 
the latter factor, substantial work is being done to try predict malaria vectors redistribution 
under different climatic change scenarios (Ermert, Fink et al. 2012, Tonnang, Tchouassi et 
al. 2014). The consolidation of the current gains in malaria control is expected to benefit 
from a vaccine and a better understanding of the immune targets and mechanisms would 
guide and accelerate the development of a malaria vaccine with high and long lasting 
protective efficacy. The vaccine received a positive scientific opinion by the European 
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Medicines Agency (EMA) for use outside the European Union, although its protective 
efficacy is limited (Morrison 2015). Improved vaccination strategies may be guided by 
immuno-epidemiological data on appropriate antigens to target.   
Malaria is caused by a parasitic single-cell apicomplexan micro-organism of the genus 
Plasmodium that was first identified in 1880 within red blood cells using light microscopy 
by Alphonse Laveran in Algeria (Bruce-Chuvatt 1981). To date, human malaria has been 
linked to five species of the genus Plasmodium: P. falciparum, P. malariae, P. ovale (curtisi 
and wallikeri), P. vivax and P. knowlesi. The malaria global public health problem is 
essentially driven by the virulence and/or the spread of P. falciparum and P. vivax (Gething, 
Patil et al. 2011, Gething, Elyazar et al. 2012). 
1.2.1 Plasmodium falciparum 
The population at risk of P. falciparum transmission in 2010 was estimated at 2.57 billion 
people living in highly variable transmission intensity areas; of the 1.44 billion people living 
in stable P. falciparum transmission areas, Africa and Asia are home to respectively 52 % 
and 46 % of them (Gething, Patil et al. 2011).  P. falciparum is the most virulent species in 
humans. It has biological features that predispose it to cause severe forms of malaria under 
certain immunological conditions, especially in children aged less than five years (Marsh, 
Forster et al. 1995) and pregnant women (Desai, ter Kuile et al.). The origin of P. falciparum 
is not clearly established, but there is some evidence of a close relationship with the 
chimpanzee malaria parasite P. reichenowi (Escalante, Freeland et al. 1998, Conway, 
Fanello et al. 2000). 
1.2 The human malaria parasites 
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1.2.2 Plasmodium vivax 
In 2010, it has been estimated that 2.48 billion people were at risk of P. vivax transmission 
worldwide. Central Asia was home to the majority of these people (82 %). Africa accounted 
for only 3 % of this at risk population (Gething, Elyazar et al. 2012). The very limited 
transmission of P. vivax in African populations (especially West and Central Africa) has 
been linked to the lack of a red blood cell membrane protein, the Duffy antigen, expressed 
on the surface of erythrocytes and reticulocytes and acting as a receptor for their invasion by 
the parasite (Miller, Mason et al. 1976).  However, infections have been reported in Duffy-
negative individuals, suggesting the existence of alternative RBC invasion pathways 
(Ménard, Barnadas et al. 2010). P. vivax was usually considered as a causal agent of mild 
malaria, but recent reports suggest it may also cause severe clinical disease (Andrade, Reis-
Filho et al. 2010). P. vivax is known for its ability to establish dormant forms in the liver that 
are a source of subsequent relapses few weeks to one year later (White 2011). The stimuli 
that trigger the relapses are unclear, but other infectious diseases including P. falciparum 
malaria have been suggested as risk factors (Shanks and White 2013). Southeast Asian non-
human primates (macaques) were previously thought to be the origin of P. vivax (Escalante, 
Cornejo et al. 2005) but there is now evidence of an African origin (African apes) where the 
high prevalence of Duffy negative phenotype is hypothesized to have resulted from the 
selective pressure of P. vivax (Liu, Li et al. 2014).  
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1.2.3 Plasmodium ovale 
A number of P. ovale malaria cases have been reported in Southeast Asia, Western Pacific 
islands and the Middle East but it is mainly established in sub-Saharan Africa (Lysenko and 
Beljaev 1969, Collins and Jeffery 2005, Mueller, Zimmerman et al. 2007).  P. ovale has been 
historically described as a cause of mild clinical malaria with usually low parasitaemia and 
low incidence (Faye, Spiegel et al. 2002, Roucher, Rogier et al. 2014). P. ovale shares with 
P. vivax the ability to establish  dormant forms in the liver, from where it can cause relapses  
(Collins and Jeffery 2005). Arisue and colleagues have recently related P. ovale to rodent 
malaria parasites (P. yoelii, P. berghei, P. chabaudi) in a phylogenetic study (Arisue, 
Hashimoto et al. 2012). Based on genetic characterization, it has been recently proposed that 
P. ovale be now viewed as two different species, P. ovale curtisi and P. ovale wallikeri 
(Sutherland, Tanomsing et al. 2010). 
1.2.4 Plasmodium malariae  
P. malariae appears as the least studied human malaria parasite. Although less prevalent, its 
distribution is broad, following that of P. falciparum, with the highest prevalence reported 
in sub-Saharan Africa (Collins and Jeffery 2007). P. malariae is characterized by a longer 
pre-patent period (16-59 days), a longer development cycle in RBC (an extra 24 hours 
compared with the other human malaria parasites), lower parasitaemia levels and its ability 
to cause long-lasting (decades) asymptomatic infections despite absence of latent forms 
(Collins and Jeffery 2007). The illness caused by P. malariae is usually mild but it has been 
recognized in earlier studies as a possible cause of chronic glomerulopathy through the 
formation of immune complexes (Gilles and Hendrickse 1963, Ward and Kibukamusoke 
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1969). The  phylogenetic origin of P. malariae is still unclear (Arisue, Hashimoto et al. 
2012). 
1.2.5 Plasmodium knowlesi 
P. knowlesi is primarily a Southeast Asian simian malaria parasite; it has been recently 
recognized as the fifth human malaria parasite (Singh, Sung et al. 2004). It should actually 
currently be considered as a zoonosis since direct human to human transmission has yet to 
be evidenced. P. knowlesi infection has been clearly associated with severe and fatal illness 
(Cox-Singh, Hiu et al. 2010, Seilmaier, Hartmann et al. 2014). There is growing evidence 
on the extent of the morbidity attributable to P. knowlesi in Southeast Asia (William, 
Rahman et al. 2013, Yusof, Lau et al. 2014) but not enough to map its geographical 
distribution with reasonable certainty. However, Moyes and colleagues have established a 
map of the geographical distribution of its potential reservoir which is limited to Southeast 
Asia and Western Pacific Islands (Moyes, Henry et al. 2014). An important current hurdle 
to the study of the epidemiology of P. knowlesi is its frequent misdiagnosis with P. malariae 
using light microscopy, the current standard for malaria species identification (Barber, 
William et al. 2013, Jeremiah, Janagond et al. 2014). 
1.2.6 A potential emerging malaria parasite: Plasmodium cynomolgi 
Other simian malaria parasites are currently recognized as zoonotic parasites (transmissible 
to humans) (Ramasamy 2014) but their natural transmission to humans has yet to be 
established. Ta and colleagues have recently reported the first identified case of natural 
infection with P. cynomolgi in Malaysia (Ta, Hisam et al. 2014). Land use changes 
(deforestation, farming, mining) as a result of the growing need of human populations for 
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natural resources create ideal conditions for increased human-wildlife interaction, hence a 
substantial potential for the emergence of these zoonotic malaria parasites. 
1.2.7 Mixed malarial infections 
In malaria endemic areas, several species of Plasmodia are often circulating concomitantly. 
In tropical Africa, the species involved in the most common co-infection are P. falciparum 
and P. malariae while in sub-tropical areas P. falciparum and P. vivax make up the most 
common mixed infection (Gilles 2002). Bousema and colleagues have found evidence for 
an association of mixed malariae-falciparum infections with higher P. falciparum 
gametocyte production (Bousema, Drakeley et al. 2008) which is in contradiction with the 
findings of Gneme and colleagues (Gnémé, Guelbéogo et al. 2013).  In a study in West 
Africa, Doderer-Lang and colleagues recently found exceptionally high sero-prevalence of 
mixed infections; 45.3% of the participants were seropositive to the antigens of P. 
falciparum, P. malariae and P. ovale at the same time (Doderer-Lang, Atchade et al. 2014). 
In a study in Myanmar in Southeast Asia, Jiang and colleagues found that, for an overall P. 
knowlesi prevalence of 21.9 %, mono-infections accounted for only 2.7 %. P. knowlesi was 
preferentially involved in co-infection with P. falciparum or P. vivax (Jiang, Chang et al. 
2010). Mixed infections with falciparum and malariae are less frequently reported. In a 
study in Ivory Coast in West Africa, a prevalence between 6-11 % (depending on the season) 
for mixed falciparum-malariae infection was reported(Black, Hommel et al. 1994) (Dossou-
Yovo, Ouattara et al. 1994)  while a study in India reported a prevalence of 1 % (Sri, Praveen 
et al. 2015). 
1.3 The human malaria vectors 
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The relationship between malaria and mosquitoes was formally established in 1895 in India 
by Sir Ronald Ross who identified the causative parasite in the midgut of mosquitoes in his 
study of avian malaria. It was later, in 1898, that Giovani Battista Grassi provided evidence 
that malaria is transmitted by mosquitoes (Cox 2010). Only female mosquitoes of the genus 
Anopheles are able to transmit malaria. The genus Anopheles is part of the Anophelini tribe, 
Culicinae sub-family, Culicidae family, Nematocera sub-order, Diptera order (Gilles 2002). 
Around 40 Anopheles species have been identified as capable of transmitting human malaria 
parasites with differing vectorial capacity (http://www.map.ox.ac.uk/explore/mosquito-
malaria-vectors/).  
1.3.1 Larval habitats, reproduction and fitness to survival 
Anopheles mosquitoes breed on various types of habitats which may be natural, man-made 
or animal-made, standing or running, fresh or brackish water, permanent, semi-permanent 
or transient water bodies, with or without floating or emerging vegetation. The preference 
for the type of breeding site varies between species. The choice of a breeding site depends 
on factors such as ambient temperature, sunlight exposure, humidity, water salinity and 
organic content (Gilles 2002). 
Anopheles gambiae ss, predominant in sub-Saharan Africa and reported as the most efficient 
malaria vector, typically breeds in temporary, still, shallow, clean and sunlit fresh water. 
However, there is evidence of its ability to adapt to polluted water in urban areas when clean 
water is not readily available (Awolola, Oduola et al. 2007). The reproduction of Anopheles 
mosquitoes follows a cycle termed gonotrophic (period between two subsequent 
ovipositions). It is believed that a single mating is enough to lead to all the subsequent 
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gonotrophic cycles. The short duration of the gonotrophic cycle (48 hours) allows the female 
Anopheles to lay multiple batches of eggs, provided the blood meal sources necessary for 
egg maturation are readily available (Gillies 1953). The eggs develop successively into 
larvae, pupae and adult form; the duration of this cycle is highly variable, depending on the 
ambient temperature and the species, between 7 (at 31°C) and 20 (at 20°C) days (Gilles 
2002). 
Anopheles mosquitoes are susceptible to ecological and climatic challenges represented by 
a wide range of predators and the long, harsh dry season that occurs in some sub-Saharan 
geographical areas. Indeed, natural predators (Araneae, Diptera, Coleoptera, Amphibia) are 
responsible of a high larval mortality rate of Anopheles gambiae such that less than 10 % 
reach adult stage (Service 1973). Given the limited resistance of Anopheles larvae to 
desiccation and the relatively short life span of adult mosquitoes, it seems surprising that 
even after long and severe droughts, the mosquito population almost immediately 
reconstitutes after the return of rains. There are two main hypotheses to explain this mosquito 
fitness to survival: long distance migration and aestivation. Lehmann et al. have provided 
definitive evidence for Anopheles gambiae aestivation in a mark-release-recapture 
experiment in the Sahel. Indeed, they have recaptured a female Anopheles gambiae marked 
7 months earlier at the end of the previous rainy season (Lehmann, Dao et al. 2010), 
confirming the aestivation hypothesis suggested by earlier laboratory experiments (Holstein 
1954, Omer and Cloudsley-Thompson 1968). The hypothesis of long distance migration 
remains to be demonstrated. 
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1.3.2 Anopheles dispersal, feeding and resting habits 
Anopheles mosquito dispersal can be described as active, when the mosquito moves by 
means of its own wings, and passive when mosquitoes are displaced by mechanical means 
such as wind or any kind of vehicle (truck, boat, airplane or train) (Gilles 2002). Active 
dispersal of mosquitoes is mainly studied by mark-release-recapture experiments where 
mosquitoes can be marked either by fluorescent substance or radioactivity. Anopheles 
mosquitoes seldom actively spread more than two kilometres from their breeding sites 
(Costantini, Li et al. 1996, Midega, Mbogo et al. 2007, Liu, Liu et al. 2012, Thomas, Cross 
et al. 2013). Passive dispersal of infected mosquitoes by aeroplane, is responsible of “airport 
malaria” (malaria cases occurring in the vicinity of international airports) and may serve as 
a route for reintroduction of malaria in areas where it has been previously eliminated (Tatem, 
Rogers et al. 2006). Climatic factors such as wind direction, that is a major force for passive 
mosquito dispersal, may be of public health importance as it can help identify major larval 
sites in relation to the location of malaria hotspots (Midega, Smith et al. 2012).  
Male Anopheles mosquitoes feed exclusively on natural sugar sources (flower nectar, fruit 
juice) whereas females feed mainly on warm-blooded animals. Based on host preferences, 
female Anopheles mosquitoes are classified as anthropophylic (preference for feeding on 
humans) or zoophylic (preference for feeding on animals). Based on their preferred place of 
feeding, they are classified as endophagic (indoor-biting preference) or exophagic (outdoor-
biting preference) mosquitoes. Based on their preferred place for resting, they are classified 
as endophylic (preference for indoor-resting) or exophylic (preference for outdoor-resting) 
mosquitoes. These behavioural features have critical importance for vector control 
strategies.  
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Anopheles gambiae, described as the most efficient malaria vector, is typically 
anthropophylic, endophagic, endophilic and nocturnal but actually adapts its behaviour to 
the location and accessibilibity of the blood meal source (Faye, Konate et al. 1997, 
Mwangangi, Mbogo et al. 2003, Lefèvre, Gouagna et al. 2009). There is empirical evidence 
of a high variability in human attractiveness to Anopheles mosquitoes. Earlier studies 
suggested that the distribution of bites is uneven with regards to age with older children and 
adults bearing the bulk of bites compared with children below two years of age (Muirhead-
Thomson 1951, Carnevale, Frezil et al. 1978). A recent study suggested that body odour, 
heat and moisture are the major explanatory factors (Mukabana, Takken et al. 2002). A wide 
range of other biological and physical factors have been studied, but no conclusive 
explanation of the variability of human attractiveness to mosquitoes has been established 
yet. 
There is evidence that once the blood source is chosen, the choice of biting site on the human 
body is not random. A recent study reported that the Anopheles gambiae complex 
preferentially bites closer to ground level, whatever the position of the body is. When sitting, 
feet, ankles and legs are the most affected by bites. When lying down, the lower edge of the 
body is the most affected (Braack, Hunt et al. 2015). 
The recent scale up of vector control measures in the last decade has elicited Anopheles 
gambiae survival responses. Universal coverage of ITNs and IRS campaigns have modified 
the feeding and resting behaviour of the malaria vectors and triggered the emergence of 
resistant strains. Behavioural shifts from nocturnal to diurnal biting, endophagic to 
exophagic and anthropophylic to zoophylic  phenotype have been reported (Ndiath, Mazenot 
et al. 2014). 
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The vertebrate host is considered as intermediary since it does not support the sexual 
reproduction. The host preference for the female Anopheles seeking blood meal is species-
specific. Anopheles mosquitoes are either anthropophilic or zoophilic but there is no clear-
cut limit between both phenotypes. Depending on the conditions, host availability and 
accessibility, the anthropophilic Anopheles mosquitoes may occasionally feed on animals 
and the zoophilic on humans. The major human malaria vectors, Anopheles gambiae ss and 
Anopheles funestus ss, have been reported to feed on a wide range of domestic animals kept 
in the vicinity of households (cattle, sheep, goats, pigs, donkeys, horses, dogs, cats, poultry) 
(Sousa, Pinto et al. 2001, Lefèvre, Gouagna et al. 2009). This observed preference 
(Anopheles arabiensis) or alternative (Anopheles gambiae, Anopheles funestus) feeding on 
domestic animals has led to a concept termed zooprohylaxis. Indeed, pyrethroids and 
Ivermectin have been extensively studied in vector control livestock-based interventions 
with variable results; besides evidence for reduction of mosquito lifespan, egg-laying 
capacity, malaria incidence and prevalence, a lot of potential drawbacks were reported 
(Rowland, Durrani et al. 2001, Fritz, Siegert et al. 2009). This approach has been recently 
applied to the human vertebrate host in the treatment of uncomplicated malaria using a 
combination of Ivermectin and ACTs. Direct membrane feeding assays (DMFA) following 
administration of this combination showed evidence of association with mosquito lifespan 
reduction (Ouédraogo, Bastiaens et al. 2015). 
The different species of the genus Plasmodium have in common a complex life cycle made 
of an asexual multiplication (schizogony) in a vertebrate (intermediary) host and a sexual 
1.4 The vertebrate host 
1.5 The malaria parasite life cycle  
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reproduction (sporogony) in an invertebrate (definitive) host. The life cycle of Plasmodium 
spp is illustrated in figure 1.1. 
1.5.1 The sporogonic phase 
The sporogonic cycle starts when the female Anopheles mosquito takes a blood meal from 
an infected human host. The circulating sexual stages of the parasite (male and female 
gametocytes) are then ingested by the mosquito and the digestion process starts in the midgut 
lumen. It is believed that the sudden drop in temperature, rise in pH and  concentration of 
xanthurenic acid , a byproduct of tryptophan catabolism in the mosquito, trigger the 
activation of gametocytes, which then egress from the parasitophorous vacuole membrane 
and the RBC plasma membrane (Billker, Shaw et al. 1997, Garcia, Wirtz et al. 1998) thanks 
to pore-forming proteins (Wirth, Glushakova et al. 2014). The male gametocyte undergoes 
nuclear division that yields four to eight motile microgametes in a process termed 
exflagellation. The fertilization of the macrogamete (female gamete) requires only one 
microgamete. Following adherence of the microgamete to the macrogamete, their plasma 
membranes and their nuclei merge resulting in a rounded diploid body called the zygote. The 
zygote then undergoes meiosis to achieve tetraploidy and differentiates into a motile invasive 
elongated form called the ookinete equipped with an apical complex. The ookinete then 
moves to and traverses the peritrophic matrix and the midgut epithelium before it establishes 
on the outer surface of the midgut wall, between this epithelium and its basal lamina. It then 
develops into an oocyst that undergoes several nuclear divisions to form the haploid 
sporozoites. When the oocysts are mature, they burst and release the sporozoites in the 
haemolymph stream that bathes the outer surface of the basal lamina. The sporozoites then 
migrate up to the salivary glands where they traverse the basement membrane and epithelium 
to accumulate inside and remain there until the next blood meal. It has been hypothesized 
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that sporozoites localize in salivary glands through chemotactism to high molecular mass 
proteins or carbohydrate-binding proteins (Akaki and Dvorak 2005) and shown that 
sporozoite entry in the glands is a receptor mediated process (Mueller, Kohlhepp et al. 2010). 
Parasite population dynamics studies suggest that the sporogonic phase is an inefficient 
process. Indeed, it has been shown that a 40-fold and 69-fold decrease occur respectively in 
the transition from macrogametocytes to ookinetes and from ookinetes to oocyst (Vaughan, 
Noden et al. 1992) but this contrasts with in vivo experiments which found that very low 
gametocytemia (less than 1 gametocyte/µL blood) is sufficient to establish infection in 
Anopheles mosquitoes (Churcher, Bousema et al. 2013). From the 2000-5000 sporozoites 
released in the haemocel by each mature oocyst (Rosenberg and Rungsiwongse 1991), 80-
90% never get to the salivary glands (Hillyer, Barreau et al. 2007). There is compelling 
evidence that the sporogonic phase kinetics is highly influenced by ambient temperature with 
suitable development temperatures ranging from 16 to30°C. Higher temperatures were 
shown to be detrimental to early stages of sporogony while the transitions ookinete-oocyst-
sporozoite appear less affected by temperatures above 30°C (Vanderberg and Yoeli 1966, 
Okech, Gouagna et al. 2004). The events occurring from the end of the blood meal uptake 
to the crossing of the midgut by the ookinete constitute the “early sporogony” and last 
approximately 48 hours. That early sporogony is followed by the “mid-sporogony” covers 
the development of the oocyst and lasts approximately one week. The release of the 
sporozoites by the mature oocyst and their migration to the mosquito salivary glands 
constitute the last phase called “late sporogony”. Overall, the sporogony lasts ten to sixteen 
days (Zollner, Ponsa et al. 2006). 
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1.5.2 The schizogonic cycle 
The schizogonic cycle occurs in the human host and may be divided into two phases: the 
pre-erythrocytic and erythrocytic phases. 
1.5.2.1 The pre-erythrocytic phase 
The pre-erythrocytic phase starts when a blood meal is taken by an infected female 
Anopheles mosquito from a human host. The saliva, injected to prevent pain and blood 
coagulation during the blood meal (Ribeiro 1995, Ha, Oh et al. 2014), conveys and deposits 
the sporozoites in the skin. Incidentally, few sporozoites may be injected directly in the 
probed blood vessel. It has been estimated that a median number of 15 sporozoites (range 0-
978) were injected during an infected mosquito blood meal (Rosenberg 2008). Once 
deposited in the dermis, three scenarios may happen. Some sporozoites migrate through skin 
cells until they reach a blood vessel and traverse its endothelium to enter the blood stream 
(Kebaier, Voza et al. 2009). Alternatively, it has been estimated that around 20% of 
sporozoites end up in skin lymphatic vessels and are drained to skin-draining lymph nodes 
where they are stopped, phagocytized and processed by antigen presenting cells 
(Chakravarty, Cockburn et al. 2007, Yamauchi, Coppi et al. 2007, Radtke, Kastenmüller et 
al. 2015). Finally, other sporozoites may not be able to leave the skin where it has been 
shown in mice models that they can complete the pre-erythrocytic life cycle to develop into 
infective merozoites (Gueirard, Tavares et al. 2010). Once in the blood stream, the 
sporozoites quickly home to the liver. They migrate through the fenestrated sinusoidal 
endothelium, Kupffer cells, space of Disse and several hepatocytes before they finally settle 
within one of them (Mota, Pradel et al. 2001, Tavares, Formaglio et al. 2013). Kupffer cells 
are liver resident macrophages but do not seem to prevent sporozoite invasion of 
 Page 16 of 349 
 
hepatocytes. There is evidence that sporozoites are capable of Kupffer cells 
immunosuppression through prevention of reactive oxygen species (ROS) release, 
downregulation of pro-inflammatory cytokines and upregulation of anti-inflammatory 
cytokines (Usynin, Klotz et al. 2007, Klotz and Frevert 2008). In the home hepatocyte, the 
sporozoite forms a parasitophorus vacuole, expels its invasion machinery and develops into 
a liver trophozoite, the feeding form of the parasite. The trophozoite grows and undergoes 
several rounds of nucleus and organelles replication and becomes a schizont. In mature liver 
schizonts, each nucleus is packaged with the necessary organelles by repeated parasite 
plasma membrane invaginations to form daughter merozoites (Lindner, Miller et al. 2012). 
The sporozoites undergo a single schizogonic cycle in the hepatocytes. 
Following enzymatic degradation of the parasitophorous vacuole membrane, the merozoites 
are packaged with the hepatocyte membrane into vesicles called merozomes (few to 
thousands merozoites) that are expelled into the liver sinusoides to initiate the erythrocytic 
phase (Graewe, Rankin et al. 2011).  
1.5.2.2 The erythrocytic phase 
The merosomes circulate in the blood stream, evading the immune system wrapped by the 
hepatocyte plasma membrane, up to the lung microvasculature where they rupture and 
release the non-motile merozoites into the blood stream (Lindner, Miller et al. 2012). The 
half-life of free merozoites was estimated to approximately 5 minutes at 37°C and they can 
remain invasive up to 10 minutes following contact with the erythrocytes (Boyle, Wilson et 
al. 2010). The process of the merozoites attachment to erythrocytes through their surface 
proteins is rapid, subsequent to which they reorient so that their apex come into contact with 
the erythrocyte membrane realizing a tight junction. The merozoites then enter the 
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erythrocytes through a membrane invagination process, leaving their protein coat outside 
(Figure 1.2). This process is completed quickly within 30 to 60 s (Gilson and Crabb 2009). 
At the end of the process, the parasite loses its internal organelles and settles within a 
parasitophorous vacuole. It is now called a young trophozoite. The young trophozoite feeds, 
enlarges and becomes ameboid (mature trophozoite) before it starts several rounds of nuclear 
division. At this stage it is called an early schizont. When the cytoplasm divides and packs 
around the daughter nuclei, it is called a mature schizont. During the intra-erythrocytic 
development of the parasite, alteration of the infected erythrocyte cytoskeleton leads to a 
reduced deformability and the formation of small protrusions termed knobs spread across 
the infected erythrocyte surface (Mills, Diez-Silva et al. 2007, Shi, Liu et al. 2013). The 
duration of each cycle is 48 hours for P. falciparum at the end of which the mature schizonts 
burst and release the merozoites in the blood stream and the cycle is repeated (Millholland, 
Chandramohanadas et al. 2011).  
A number of hypotheses on the stimuli for trophozoites differentiation into sexual stages 
during the erythrocytic phase have been advanced, but none of them has been conclusive to 
date (Baker 2010). Gametocytes have been reported to appear in the peripheral blood 
between one and three weeks after the start of the erythrocytic phase and circulate in the 
blood stream for up to 60 days (Shute and Maryon 1951, Bousema and Drakeley 2011). 
Gametocytogenesis has been characterized into five distinct morphological phases (I-V) 
during which the early rounded gametocyte progressively turns into crescent-shaped body 
(Hawking, Wilson et al. 1971). Early gametocytes (I) are difficult to differentiate from the 
young trophozoites from which they derive and only mature stages (V) are detectable in 
peripheral circulation. Indeed, there is evidence that immature gametocytes sequester in the 
bone marrow to achieve maturation (Farfour, Charlotte et al. 2012). There is evidence that 
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the sexual determination of schizonts occurs prior to nuclear division and that each sexually-
committed schizont yields either male or female gametocytes. The sex ratio of gametocytes 
is variable with a tendency to be biased towards females (Smith, Lourenco et al. 2000). A 
better understanding of the mechanisms of gametocytogenesis is critical as it may lead to the 
development of new and additional tools for malaria transmission control. 
                  
Figure 1.1. The life cycle of malaria parasite. Evidence of dormant forms exists only for P. vivax and 
P. ovale. Adapted from (Winzeler 2008). 
          
Figure 1.2. Erythrocyte invasion process by Plasmodium falciparum merozoite. Adapted from (Kats, 
Cooke et al. 2008) 
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Epidemiology is the study of the distribution and determinants of diseases in human 
populations (Woodward 2014). In order to conduct an epidemiological study one must select 
a specific marker/definition to identify cases. In any epidemiological study, the population 
described as being at a certain prevalence will contain sub-populations with heterogeneities 
in prevalence. It would therefore be instructive to analyse the spatial and temporal 
distribution of the health event of interest. In the case of malaria, parasitological, serological 
and/or molecular markers have been used. 
1.6.1 Global and regional determinants of the global distribution of malaria 
Malaria is a disease of tropical and sub-tropical areas, predominant in sub-Saharan Africa, 
South-East Asia and South America and climatic factors determine the distribution of 
malaria at a global level. Indeed, the above-mentioned most affected regions are 
characterized by warm temperatures, substantial rainfall and humidity, though seasonal 
variations exist in some areas. Paaijmans and colleagues have shown that the gonotrophic 
and sporogonic cycles are very sensitive to daily temperature variability (Paaijmans, 
Blanford et al. 2010). The optimal temperature for sporogony ranges between 25-30°C with 
extremes at 16-35°C beyond which a considerable slowing down is observed (Gilles 2002). 
The association between rainfall and malaria transmission is more apparent in areas of 
seasonal rains and in dry areas when they experience unusually high rainfall (Grover-Kopec, 
Kawano et al. 2005). In the first situation, although the proposed methods for defining 
seasonality of malaria transmission may not include rainfall (Roca-Feltrer, Schellenberg et 
al. 2009, Cairns, Walker et al. 2015), there is evidence of a strong correlation between 
rainfall and febrile malaria incidence with a few weeks’ time lag accounting for the vector 
1.6 Spatial epidemiology of malaria 
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and parasite development (Krefis, Schwarz et al. 2011). Altitude and land cover have also 
been associated with malaria distribution. Githeco and colleagues have shown that altitude 
was inversely correlated with anopheline mosquito densities and malaria prevalence on the 
one hand, and positively correlated with parasite density in young children on the other hand 
(Githeko, Ayisi et al. 2006). This could be explained by the strong inverse correlation 
between altitude and temperature with an average 0.5°C drop for every 100 m increase 
(Gilles 2002). Although the association is weak at the extremes (desert areas and forests), a 
strong correlation exists between land cover and rainfall (Ding, Zhang et al. 2007).  
Despite the substantial evidence for association between climatic factors (temperature, 
rainfall) and the malaria vector biology, the effect of climate change on malaria transmission 
is still unclear. The general concern is that climate change, especially global warming, may 
worsen the global malaria burden, although there is limited evidence in support to this 
hypothesis. Indeed, there is a striking contrast between the global warming over the last 
century (Hansen, Sato et al. 2006) and the global decline in the global malaria geographical 
distribution and endemicity (Lafferty 2009, Gething, Smith et al. 2010). The relationship 
between global warming and malaria epidemiology is complex and conflicting results seen 
in different studies. While Hay and colleagues conclude that factors other than climate 
change have driven malaria resurgence in the East African highlands, Siraj and colleagues 
predict that malaria would spread vertically to the usually cooler highlands as a consequence 
of warmer temperatures, more suitable for malaria parasite development within the mosquito 
vector (Hay, Cox et al. 2002, Siraj, Santos-Vega et al. 2014).. Droughts often have a 
detrimental effect on mosquito vector populations and therefore malaria transmission 
(Mouchet, Faye et al. 1996)  but they have also been associated with epidemics, increased 
morbidity and mortality in the subsequent year. For instance, one of the worst malaria 
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epidemics in history took place in Russia after drought-breaking rains following a two-year 
drought (Bruce-Chwatt 1959). While some studies suggest that global warming would 
exacerbate drougths (Dai 2013), other studies suggest that it is not associated with global 
drought (Sheffield, Wood et al. 2012) or it is associated with increased rainfall in arid 
regions, especially the Sahel (Dong and Sutton 2015). Increased rainfall in association with 
increased temperature is predicted to have variable effects on mosquito densities and 
vectorial capacity (Yamana and Eltahir 2013). Areas with current intense and stable 
transmission are less likely to experience a significant increase in malaria incidence 
compared with highlands and areas at the fringes of endemic zones where malaria 
transmission has been unstable (Martens, Niessen et al. 1995). 
Malaria is also considered a disease of poverty on a global scale. Although the distribution 
of malaria is primarily determined by ecological factors suitable for the development of the 
vector, its distribution overlaps the world poorest countries.  
 
Figure 1.3. P. falciparum endemicity map. Adapted from (Hay, Guerra et al. 2009). 
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1.6.2 Microepidemiologcal determinants of malaria 
The heterogeneity of the distribution of malaria is relatively easy to observe at global and 
regional scales, as shown in figure 1.3, but also exists at finer scales. As malaria elimination 
becomes a realistic objective in an increasing number of areas, the need of a better 
characterization of fine-scale space-time patterns of malaria distribution and determinants 
grows. There is evidence that clustering of malaria infections can be detected down to the 
level of the smallest spatial unit (homestead for instance) (Bejon, Williams et al. 2014).  
A wide range of factors have been associated with increased risk of malaria at the community 
and household level including temperature, altitude, wind direction, agricultural practices, 
dams construction and irrigation projects, heritable genetic traits, housing, household 
income, natural disasters and mass population displacement (Protopopoff, Van Bortel et al. 
2009). 
Income, literacy, housing and nutrition are somewhat related and low education level, poor 
housing and poor nutrition are all proxies for low-income. Tusting and colleagues have 
shown that within the same area, the poorest children have twice the odds of malaria 
infection than the least poor ones (Tusting, Willey et al. 2013). Although it is not a causal 
relationship, it suggests that wealth has a protective effect against malaria. There is a growing 
body of evidence that poor housing is associated with an increased risk of malaria (Sonko, 
Jaiteh et al. 2014, Snyman, Mwangwa et al. 2015, Tusting, Ippolito et al. 2015). Poor housing 
is mostly defined as mud-walled and thatched-roofed houses (Snyman, Mwangwa et al. 
2015); they are predominant in rural areas and characterized by open eaves that allow traffic 
of malaria mosquito vectors between the indoor and outdoor space (Njie, Dilger et al. 2009). 
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In slum habitats, non-brick walled houses have been associated with increased risk of 
malaria (Sur, von Seidlein et al. 2006).  
Forcibly displaced populations, whether it is an internal movement or a refugee movement 
and whatever the reason is (natural disaster, inter-community violence, and war), are often 
established in overcrowded temporary settlements with poor housing, poor sanitation, and 
limited access to standard healthcare, health education and control measures. These local 
conditions put them at higher risk of malaria, although heterogeneity of exposure to malaria 
is possible within this vulnerable group.  Within a refugee camp, Bayoh and colleagues have 
observed a spatial clustering of malaria infections near clusters of larval sites (Nabie Bayoh, 
Akhwale et al. 2011). Outbreaks of malaria are more likely to occur if the displacement is 
from low to higher endemicity area.  
Natural disasters, especially flooding, can also increase the burden of malaria in resident 
populations by creating local environmental conditions that enhance the development of the 
local malaria mosquito vectors (Saenz, Bissell et al. 1995). 
Bejon and colleagues have shown that malaria infections can cluster at the homestead level 
(Bejon, Williams et al. 2014) and Fernandez-Grandon and colleagues found a significantly 
higher correlation of attractiveness of body odour to mosquitoes in identical twins compared 
with non-identical twins (Fernández-Grandon, Gezan et al. 2015). Genetic factors might then 
be contributing to fine-scale clustering of malaria infection through increased malaria 
exposure of the entire household. 
Water bodies, that serve as mosquito breeding sites, are critical elements of malaria 
epidemiology and their proximity to homesteads has been associated with increased risk of 
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malaria (Zhou, Zhang et al. 2012). Similarly, wind direction has been shown to determine 
the location of hotspots of homesteads with increased risk of malaria (Midega, Smith et al. 
2012). Although there is evidence that some malaria mosquito vectors can adapt to unusual 
breeding sites (Awolola, Oduola et al. 2007), not all water bodies are suitable breeding sites 
for malaria mosquito vectors. 
1.6.3 Malaria transmission markers, metrics, classification and seasonality  
In the study of the epidemiology of malaria, the choice of the exposure/transmission marker 
matters a lot as they have different sensitivity and specificity at differing transmission levels. 
Several human-based or vector-based, direct or indirect markers have been used, including 
clinical, parasitological, serological, biomolecular, haematological and entomological 
markers, each with its advantages and drawbacks (Tusting, Bousema et al. 2014). 
Malariometric indices are then derived from these markers and serve mainly to classify 
malaria endemicity level and measure spontaneous or intervention-driven changes in malaria 
transmission intensity over time and space. These markers have also been used to study the 
space-time distribution of malaria in areas of differing endemicities (Ernst, Adoka et al. 
2006, Bejon, Williams et al. 2010, Bousema, Drakeley et al. 2010). 
The traditional gold standard vector-based metric for malaria transmission is the 
entomological inoculation rate (EIR) i.e. the number of infectious bites per individual per 
year. The EIR is itself derived from two other metrics: the human biting rate (number of 
bites/person/year) and the sporozoite rate (proportion of sporozoite-infected mosquitoes). 
Although considered as the gold standard, the EIR suffers from the lack of standardization 
of its methods, logistical and ethical constraints (Tusting, Bousema et al. 2014). In practice, 
malaria transmission intensity (endemicity) was initially graded using the prevalence of a 
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clinical manifestation, the spleen enlargement improperly termed “spleen rate”, in children 
aged 2-9 years as follows: hypoendemic, mesoendemic, hyperendemic and holoendemic for 
a prevalence of <10%, 11-50%, 51-75% and >75% respectively. It has the advantage of 
being non-invasive but, lacks specificity (Hay, Smith et al. 2008). The prevalence of asexual 
parasitaemia detected by light microscopy in children aged 2-9 years (improperly termed 
“parasite rate”) later supplanted the “spleen rate” as the metric for malaria endemicity 
classification with the only difference being  that only children aged less than one year were 
considered in the holoendemic level definition (WHO 1950). Parasite rate has since then 
been widely used (Smith, Guerra et al. 2007, Hay, Guerra et al. 2009). The correspondence 
between the different classifications is shown in table 1.1. 
 
Table 1.1. Classification of malaria endemicity. The spleen rate and parasite rate are measured in 
children aged 2-9 years (Adapted from (Reyburn and Drakeley 2005)). 
Spleen Rate *               Parasite Rate*  EIR                     Endemicity  
< 10 < 10 < 1 Hypoendemic  
10-50 10-50 1-10 Mesoendemic  
51-75 51-75 11-100 Hyperendemic  
> 75 > 75 > 100 Holoendemic  
 
A different more recent classification is challenging the one based on parasite rate and 
defines two main levels of transmission intensity: stable and unstable malaria. “Stable 
malaria transmission” denotes areas where the pattern of transmission is maintained over the 
years. The transmission may be seasonal or not, malaria inoculation rate is variable but 
regular, clinical immunity is acquired earlier and malaria epidemics are unlikely. “Unstable 
malaria transmission” denotes areas where the pattern of malaria transmission in space and 
time is highly variable. The malaria challenge is irregular and low to moderate, clinical 
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immunity is acquired later and quickly lost, epidemics and severe malaria are more likely to 
occur (Carter and Mendis 2002).  
Serology plays a growing use in malaria epidemiology, although its use is not new (Otieno, 
Lelijveld et al. 1971), especially in low transmission conditions (Bruce-Chwatt, Draper et 
al. 1973, Bruce-Chwatt, Draper et al. 1975). When malaria transmission declines to low 
levels as it is currently the case in a number of settings worldwide (WHO 2015), 
entomological metrics become much less reliable because of the scarcity and heterogeneity 
in vector distribution, and parasitological metrics such as the prevalence of asymptomatic 
parasitaemia by microscopy are either of low sensitivity or may not be cost-effective for 
large scale and long term surveillance (molecular methods). Serology reflects past 
cumulative exposure and may be insensitive to short-term variations in transmission. 
Antibody responses therefore appear more appropriate to study historical changes in 
transmission, especially where baseline data is missing. Malaria seroconversion rate (annual 
rate at which  individuals change from seropositive to seronegative), derived from age-
specific seroprevalence, has been proposed to estimate variations in malaria transmission 
(Drakeley, Corran et al. 2005) although it has limitations in estimating recent changes, 
especially intervention-induced ones. This limitation could be offset by the concomitant 
direct measure of actual transmission marker (parasitaemia) using molecular methods (PCR) 
that have higher sensitivity compared with microscopy (Bejon, Andrews et al. 2006). 
The basic reproductive number (R0), defined as the number of secondary cases that can stem 
from an index infected individual introduced in a completely susceptible population (Dietz 
1993), would also make an ideal transmission metric. However, R0 is not directly measurable 
and requires statistical modelling based on the human and entomological parameters 
described above (Smith, McKenzie et al. 2007).  
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Other less widely used host-based metrics include febrile malaria incidence, slide positivity 
rate or malaria positive fraction, proportion of fevers with P. falciparum malaria, 
seroconversion rate, force of infection, multiplicity of infection (Bejon, Williams et al. 2014, 
Tusting, Bousema et al. 2014).  
Malaria transmission is often described as seasonal, but how seasonality is defined is 
generally unclear. It is believed that there is some degree of seasonality in most endemic 
settings as peaks of a given metric is often reported (Roca-Feltrer, Schellenberg et al. 2009). 
In a study conducted in a high transmission setting in Tanzania, Smith and colleagues did 
not find any seasonal pattern in fevers, parasite prevalence or density in children and adults; 
however, they reported a marked seasonal variation in the EIR (Smith, Charlwood et al. 
1993). Roca-Feltrer and colleagues have proposed a method that discriminates well two 
categories: “marked seasonality” when 75% or more febrile episodes occur in six months or 
less of the year and “no marked seasonality” if the 75% episodes occur in more than six 
months (Roca-Feltrer, Schellenberg et al. 2009). 
In a global context of declining malaria transmission, the study of the fine scale distribution 
of malaria is of increasing importance as targeting control interventions to restricted areas 
with the highest risk is expected to be more effective than unfocused control, benefiting 
individuals in the foci and the surrounding community. The choice of the marker to identify 
and map these transmission foci / hotspots should be studied since hotspots need to be 
identified accurately for targeted control to be effective.   
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1.6.4 The use of serology for malaria risk mapping 
The use of serological markers to map malaria transmission is relatively recent. Traditional 
markers of transmission, including parasite prevalence and entomological inoculation rate 
have been used to map the risk of malaria often at a global scale (Kleinschmidt, Omumbo et 
al. 2001, Gething, Patil et al. 2011, Gething, Elyazar et al. 2012). Other methods using 
remote sensing (satellite-based measure of vegetation index, land surface and air 
temperature, altitude…) have also been used for large scale mapping of malaria transmission 
(Omumbo, Hay et al. 2002, Dambach, Sié et al. 2009). The interest in serological markers 
has grown in a context where a number of countries have progressed to pre-elimination stage 
unveiling the issue of controlling malaria in residual transmission foci whose identification 
is challenging. Drakeley and colleagues have compared seroprevalence with others malaria 
transmission markers and found that seroprevalence reflected better spatial heterogeneity of 
transmission than the alternative markers (parasite rate, haemoglobin concentration) 
(Drakeley, Corran et al. 2005). Teun and colleagues found that age-specific sero-conversion 
rates (annual rate at which  individuals change from seropositive to sero-negative) well 
correlated with malaria incidence and were better predictors of clinical hotspots than 
entomological markers or seroprevalence (Bousema, Drakeley et al. 2010). In their study, 
Bejon and colleagues found that antibody titres predicted clinical and parasitological 
hotspots better than seroprevalence or sero-conversion rates (Bejon, Williams et al. 2010). 
Serological markers have then been used in a number of studies to map the risk of malaria 
(Noor, Mohamed et al. 2011, Kobayashi, Chishimba et al. 2012, Ashton, Kefyalew et al. 
2015, Rosas-Aguirre, Speybroeck et al. 2015, Lynch, Cook et al. 2016) using different 
methods. 
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Bruce Chwatt, as cited in (Doolan, Dobaño et al. 2009),  defined immunity to malaria as “the 
state of resistance to the infection brought about by all those processes which are involved 
in destroying the plasmodia or by limiting their multiplication. Natural (innate) immunity to 
malaria is an inherent property of the host, a refractory state or an immediate inhibitory 
response to the introduction of the parasite, not dependent on any previous infection with it. 
Acquired immunity may be either active or passive. Active (acquired) immunity is an 
enhancement of the defence mechanism of the host as a result of a previous encounter with 
the pathogen (or parts thereof). Passive (acquired) immunity is conferred by the prenatal or 
postnatal transfer of protective substances from mother to child or by the injection of such 
substances.  
1.7.1 Innate immunity to malaria 
1.7.1.1 The organization and function of the innate immune system 
The innate immune system can be divided into cells (phagocytes and lymphocytes) and 
humoral factors (complement and cytokines). The cells involved in the innate immune 
system are ubiquitous and are found either patrolling in peripheral blood, or stationed in 
lymphoid organs as well as peripheral non-lymphoid tissues (Ferlazzo and Münz 2004). 
Monocytes which can differentiate into macrophages and dendritic cells are phagocytes 
which express pattern recognition receptors (TLR2, TLR4, TLR9 for malaria parasite) to 
recognize pathogen-associated molecules (e.g. haemozoin or GPI for malaria). In addition 
to recognition, uptake and destruction (lysis) of parasites, a major role of these phagocytes 
is to present the pathogen antigens to the other effectors of the innate and adaptive immune 
systems. Professional antigen-presenting cells include dendritic cells, macrophages and 
1.7 Immunity to malaria 
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neutrophils. Pathogen antigens bound to TLR9 are further bound to MHC class II molecule 
before they are presented on the surface of the APC to the T and B cells, activating the 
adaptive response. The third important function of these APC is to enhance the recruitment 
of cells involved in the innate response. The tissue-resident macrophages in the skin, the 
lymph nodes, the liver and the spleen are called Langerhans cells, histiocytes, Kupffer cells 
and red pulp macrophages respectively. 
There is evidence for an association between interferon gamma (IFN-γ) production and 
resistance to malaria and stimulation of nitric oxide production (directly involved in parasite 
killing) has been advanced as the effector mechanism. Though IFN-γ production is not 
specific to innate immunity cells (King and Lamb 2015), its production in the early stages 
of the infection has been attributed to natural killer cells (lymphocytes of the innate immune 
system) (Artavanis-Tsakonas and Riley 2002). NK cells are also able to sense directly, stick 
to and destroy infected erythrocytes by direct cytotoxicity through the release of perforin, 
granzymes A, B and M.  
The complement system is a family of over 30 soluble or membrane-bound proteins 
synthetized primarily in the liver (hepatocytes) and secondarily by various extra-hepatic 
tissues / cells (macrophages, monocytes, neutrophils, lymphocytes, platelets, epithelial & 
endothelial cells, adipocytes, fibroblastes, glial cells, glomerular mesangial, epithelial and 
endothelial cells) (Marsh, Zhou et al. 2001). They circulate in the blood stream in precursor 
forms that are activated through three possible pathways (classical, alternative, lectin) by 
molecules present at the surface of pathogen surfaces or antigen-antibody complexes (Sarma 
and Ward 2011). The complement system is involved in opsonic phagocytosis and direct 
killing of pathogens (through membrane attack complexes) (Merle, Noe et al. 2015). 
However, a number of studies suggest that excessive activation of the complement system 
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may be associated with severe malaria (Silver, Higgins et al. 2010, Biryukov and Stoute 
2014, Berg, Otterdal et al. 2015). 
1.7.1.2 The major inherited traits that protect against malaria  
Most of the inherited protective biological traits are actually genetic characteristics that 
occur at high frequencies in high-burden malaria endemic areas. This forms the basis of the 
“malaria hypothesis” which stipulates that these genetic anomalies result from the strong 
natural evolutionary selection pressure for genes (even deleterious in some circumstances) 
that confer fitness to malaria mortality (Tzoneva, Bulanov et al. 1980, Hill, Flint et al. 1987, 
Piel, Patil et al. 2010). 
Sickle cell haemoglobin 
Sickle haemoglobin is widespread across continents, but the burden is highest in equatorial 
Africa that is home to around 85% of cases  of sickle cell disease(Modell and Darlison 2008). 
Piel and colleagues have shown that areas with high frequencies of sickle cell trait 
approximately overlap areas with high burden of P. falciparum malaria, especially in sub-
Saharan Africa, in keeping with the “Malaria hypothesis” (Piel, Patil et al. 2010). Sickle 
haemoglobin is the result of a single point mutation of the gene coding for the beta-chain of 
haemoglobin where the glutamate at position 6 is replaced by a valine (Ingram 1958). It has 
been shown that the mutation occurred independently in four areas in Africa (Senegal, Benin, 
Central African Republic, Cameroun) and one area in Asia (Saudi Arabia/India) (Pagnier, 
Mears et al. 1984, Kulozik, Wainscoat et al. 1986, Lapoumeroulie, Dunda et al. 1992) but 
another point of view assumes one African origin and one Asian origin (Piel, Patil et al. 
2010). Heterozygous individuals are said to be sickle cell trait carriers and homozygous 
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individuals are said to have sickle cell disease. Sickle cell trait is associated with reduced 
risk of severe and mild P. falciparum malaria (Allison 1954, Williams, Mwangi et al. 2005, 
Taylor, Parobek et al. 2012)  but this protection comes at the cost of an early high mortality 
rate for homozygous individuals (Makani, Cox et al. 2011). The existence of a protective 
effect against asymptomatic infection is still controversial (Williams, Mwangi et al. 2005, 
Billo, Johnson et al. 2012). The mechanism of the protective effect of sickle cell trait is not 
clearly understood and a number of biochemical and immunological hypotheses based on 
theory, in vitro or mouse models have been proposed (Gong, Parikh et al. 2013). Increased 
sickling (Luzzatto, Nwachuku-Jarrett et al. 1970), higher levels of antibodies to PfEMP1 
(Marsh, Otoo et al. 1989, Cabrera, Cot et al. 2005, Verra, Simpore et al. 2007) and enhanced 
phagocytosis of infected red blood cells by monocytes (Ayi, Turrini et al. 2004) have been 
reported. Tolerance to infection mediated by an increased expression of heme oxygenase-1 
(Ferreira, Marguti et al. 2011), impaired rosette formation (possibly related to increased 
sickling and/or reduced expression of surface adhesion proteins) (Carlson, Nash et al. 1994) 
and impaired cytoadherence of infected erythroytes (possibly related to altered expression 
of PfEMP1) (Cholera, Brittain et al. 2008) have been hypothesized as mechanisms of 
protection against severe malaria.  
Haemoglobin C 
Haemoglobin C is a red blood cell polymorphism that is geographically predominant in West 
Africa, where it coexists at high frequencies with sickle haemoglobin (Piel, Howes et al. 
2013). In haemoglobin C, the glutamate at position 6 of the beta-chain is replaced by a 
lysine1 (Itano and Neel 1950). The mutation is believed to have initially occurred in West 
Africa (Boehm, Dowling et al. 1985) although an isolated different haplotype has been 
reported in Thailand (Sanchaisuriya, Fucharoen et al. 2001). Compared to sickle cell disease, 
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the homozygous form (CC) is less pathogenic and chronic haemolytic anaemia occurs to a 
lesser extent than in sickle cell disease when it is combined with haemoglobin S (SC) (Ballas, 
Lewis et al. 1982). Heterozygous (AC) and homozygous (CC) forms of haemoglobin C have 
been associated with reduced risk of severe P. falciparum malaria (Agarwal, Guindo et al. 
2000, Modiano, Luoni et al. 2001, Mockenhaupt, Ehrhardt et al. 2004) but a protective effect 
against asymptomatic and uncomplicated malaria has not been found (Taylor, Parobek et al. 
2012). An hypothesized mechanism is an impairment of cytoadherence and sequestration 
through reduced PfEMP1 expression and abnormal knobs display (Fairhurst, Bess et al. 
2012). 
Haemoglobin E 
Haemoglobin E is predominant in South-East Asia with reported prevalence exceeding 50 
% at the borders of Thailand, Laos and Cambodia, in what has been termed the “haemoglobin 
E triangle” (Fucharoen and Winichagoon 2011). It results from a single point mutation of 
the gene coding for the beta-chain of haemoglobin where the glutamate at position 26 is 
replaced by a lysine. There is evidence supporting independent origins of this mutation in 
Asia and Europe (Antonarakis, Orkin et al. 1982, Kazazian, Waber et al. 1984) . The 
phenotypes AE, EE, SE are associated with mild disease. Severe manifestations are observed 
in Individuals carrying the association Hb E-beta-thalassemia (Vichinsky 2007). Compared 
to haemoglobin S and C, fewer clinical studies have been conducted on haemoglobin E and 
no convincing evidence of a protective effect of haemoglobin E has been established yet. A 
retrospective study in Thailand found that haemoglobin E trait may protect against severe 
malaria, but recent studies yielded opposite conclusions (Naka, Ohashi et al. 2008, Taylor, 
Parobek et al. 2012). 
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Thalassemias 
Thalassemias are inherited haemoglobin chain production disorders  which result in reduced 
production of the alpha globin chain (alpha-thalassemia) or the beta globin chain (beta-
thalassemia) of haemoglobin (Harteveld and Higgs 2010). Thalassemias are spread 
worldwide. They have been described in Africa, the Mediterranean region, Asia, north and 
west America and are now considered a major public health problem (Vichinsky 2005, 
Galanello and Origa 2010). 
Alpha-thalassemia results from the deletion of a variable number of the genes (HBA1, 
HBA2) coding for the alpha globin chain. The severity of manifestations of alpha-
thalassemia is variable, increasing with the number of deleted alpha globin genes (Galanello 
and Cao 2011). α+ thalassemia is the condition in which one linked pair of the alpha globin 
genes is deleted and α0 thalassemia the condition in which both the linked pairs are deleted. 
The latter condition is lethal. Evidence of the association of α+ thalassemia with reduced 
risk of severe malaria has been firmly established (Williams, Wambua et al. 2005). 
Contrary to alpha-thalassemia, deletions of the beta globin gene are relatively rare. However, 
more than 200 mutations of the beta globin gene have been described (Galanello and Origa 
2010). It has been suggested that beta-thalassemia trait is associated with resistance to 
malaria infection (Willcox, Bjorkman et al. 1983) but this association has been much less 
studied compared to the protective effect of alpha-thalassemia and remains to be confirmed. 
Thalassemias are often inherited in combination with other haemoglobin variants that confer 
protection to clinical malaria, but the resulting associations are not necessary have additive 
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or multiplicative protective effects. Indeed, evidence of possible negative epistasis has been 
reported between alpha-thalassemia and haemoglobin S (Williams, Mwangi et al. 2005). 
The red blood cell enzyme disorders 
Glucose-6-phosphate-deshydrogenase (G6PD) is a cytosolic enzyme of the pentose 
phosphate pathway which produces nicotinamide adenine dinucleotide phosphate 
(NADPH), an important molecule in the mechanism of protection of RBCs against oxidative 
damage. Mutations of the X-linked gene coding for G6PD, most of which are single point 
substitutions, translate into deficits in production of the enzyme, resulting in the condition 
termed G6PD deficiency. The G6PD gene is highly polymorphic with several variants, of 
which only few encountered variants have been associated with severe clinical symptoms 
(Minucci, Moradkhani et al. 2012, Monteiro, Franca et al. 2014). In general, individuals 
harbouring the trait remain asymptomatic until exposed to dietary, pharmacologic, infectious 
or metabolic factors triggering haemolysis with possible life-threatening complications 
(Eziefula, Pett et al. 2014, Monteiro, Franca et al. 2014). G6PD is the most common 
enzymopathy in humans, widespread worldwide with a global prevalence estimate of 8% 
and the highest prevalences reported in sub-Saharan Africa (Nkhoma, Poole et al. 2009, 
Howes, Piel et al. 2012). G6PD A- common in Africa and America, and G6PD 
Mediterranean common in the Mediterranean area, Middle East and Asia, are the most 
prevalent allelic variants, but both alleles coexist in several populations (Howes, Piel et al. 
2012, Howes, Dewi et al. 2013, Monteiro, Val et al. 2014). There is compelling evidence of 
the protective effects of G6PD deficiency against severe malaria (Malaria Genomic 
Epidemiology Network 2014), but reports have been conflicting as regards to the 
heterozygous females carrying the trait. Guindo et al. provided some evidence that it protects 
hemizygous males from P. falciparum severe malaria, but not heterozygous females 
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(Guindo, Fairhurst et al. 2007) while Manjourano et al. later provided evidence of protection 
against severe malaria in heterozygous females harbouring the trait in a larger study 
(Manjurano, Sepulveda et al. 2015). Leslie et reported protection against P. vivax infection 
in hemizygous males and heterozygous or homozygous females (Leslie, Briceño et al. 2010). 
An increased susceptibility to phagocytosis at an early stage of parasite development in 
infected-RBCs may be the mechanism of protection (Cappadoro, Giribaldi et al. 1998). 
Pyruvate kinase deficiency 
Pyruvate kinase is a critical enzyme of glycolysis. Its deficiency is due to mutations of the 
pyruvate kinase gene. Several studies reporting its prevalence in African, European, Asian, 
American populations support its worldwide distribution (Baronciani, Magalhaes et al. 1995, 
Beutler and Gelbart 2000, Machado, Manco et al. 2012, Warang, Kedar et al. 2013). PK 
deficiency is emerging as a protective factor that fits to the “malaria hypothesis”. Indeed, a 
study based on mouse models has reported a protective effect against murine malaria 
conferred by PK deficiency (Min-Oo, Fortin et al. 2003). A human in vitro study later 
provided support for this hypothesis by providing evidence of resistance of PK deficient-
erythrocytes to P. falciparum infection. The actual protective mechanism is currently 
unknown (Durand and Coetzer 2008). 
Southeast Asian ovalocytosis  
Southeast Asian ovalocytosis (SAO) is a RBC membrane disorder resulting from a deletion 
on the gene coding for the band 3 protein involved in trans-membrane anion exchange 
(Jarolim, Palek et al. 1991).  It is believed to have originated from Southeast Asia around 
10000 years ago (Paquette, Harahap et al.). SAO seems to be confined to Southeast Asia and 
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the Southwest Pacific where it remains at relatively low frequencies. Its presence in the 
Malgashi population has been interpreted as a vestige of the original occupation of the island 
by people of Indonesian origin (Rabe, Jambou et al. 2002). Heterozygous SAO has been 
reported to cause only mild disease, but homozygous forms are presumed to be lethal and 
recently, a case of homozygous SAO was reported with severe clinical manifestations (Liu, 
Jarolim et al. 1994, Picard, Proust et al. 2014).  SAO has been compellingly associated with 
protection against severe P. falciparum malaria (Foo, Rekhraj et al. 1992, Allen, O'Donnell 
et al. 1999, Rosanas-Urgell, Lin et al. 2012). In vitro studies have shown that RBC invasion 
by merozoites is impaired (Kidson, Lamont et al. 1981) but whether this is the protective 
mechanism is still unclear. 
1.7.1.3 Other putative protective biological parameters  
Human leucocyte antigens (HLA class I, II and III) are antigens expressed on the surface of 
all the body cells. They are involved in the initiation of immune responses by activating 
cytotoxic T lymphocytes (HLA class I) or Helper T lymphocytes (HLA class II) through 
antigen presentation. Alleles in HLA class I and class II that are prevalent in West African 
populations have been associated with protection against severe malaria (Hill, Allsopp et al. 
1991, Hill, Allsopp et al. 1992) and the global distribution patterns of HLA alleles, in relation 
to the distribution of populations at risk of malaria, is highly suggestive of a positive selective 
pressure of malaria (Garamszegi 2014).  
The predominance of blood group O observed in areas of high malaria burden has made it a 
candidate protective factor positively selected by P. falciparum malaria pressure. Though 
different studies have yielded conflicting results about the association of blood group O and 
the risk of uncomplicated malaria (Uneke 2007), there is now conclusive evidence that blood 
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group O confers resistance to severe malaria through reduced rosetting (Rowe, Handel et al. 
2007). In pregnancy, blood group O has been associated with reduced risk of placental 
malaria in primiparae, but not in multiparae (Bedu-Addo, Gai et al. 2014) while other 
previous studies found no association (Boel, Rijken et al. 2012). Foetal haemoglobin (HbF) 
in young infants has been suggested as a putative protective mechanism, though convincing 
evidence from field observational studies is scarce (Mmbando, Mgaya et al. 2015). It has 
been compellingly shown that P. falciparum invade and grow normally in HbF-containing 
cells and suggested that foetal haemoglobin mediates protection by impairing cytoadherence 
of infected cord blood erythrocytes through reduction of expression and alteration of display 
of PfEMP1 at the surface these cells (Amaratunga, Lopera-Mesa et al. 2011, Sauerzopf, 
Honkpehedji et al. 2014). 
1.7.2 Naturally acquired immunity to malaria 
As compared with other infectious diseases, immunity to malaria is a very complex 
phenomenon and there is no unique definition as levels of  resistance may vary in respect of  
the symptomatology of the disease (asymptomatic infection, mild and severe malaria) 
(Langhorne, Ndungu et al. 2008). Natural immunity to malaria has been classified into two 
main types: innate resistance to malaria and acquired immunity to malaria (Gilles 2002). 
1.7.2.1 Population-level dynamics of naturally acquired immunity to malaria 
Naturally acquired immunity (NAI) to malaria can be defined as the resistance to malaria 
that develops in response to repeated parasite challenge. The main interest in studying 
immunity is to gather the knowledge that would guide the design of a vaccine that would 
protect better than natural immunity. 
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Naturally acquired immunity to malaria is age-dependent and builds gradually as it is 
parasite species and strain-specific and theoretically requires repeated exposure to the 
different circulating strains of a parasite in a given setting. There is epidemiological evidence 
that immunity to severe malaria develops first quickly after relatively few infective bites 
(Gupta, Snow et al. 1999) although a recent study suggested that it could be being acquired 
more gradually than previously thought (Griffin, Hollingsworth et al. 2015). The acquisition 
of this immunity to severe malaria is followed by immunity to mild malaria and then anti-
parasite immunity (Langhorne, Ndungu et al. 2008) as illustrated in figure 1.4. The final 
“equilibrium state” where clinical manifestations are absent in presence of a chronic low 
parasitaemia is called “premunition” (Perignon and Druilhe 1994). To date, sterile immunity 
(resistance to infection) has been achieved in humans only under experimental conditions 
using irradiated whole sporozoites (Hoffman, Goh et al. 2002) and no observed case of 
sterile NAI has been reported.  
                     
Figure 1.4. Population indices of immunity to malaria. Adapted from (Marsh and Kinyanjui 2006). 
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The age pattern of the acquisition of natural immunity is also strongly influenced by the 
transmission intensity. In high transmission settings, the risk of life-threatening malaria 
(mainly malaria with impaired consciousness, severe respiratory distress and/or severe 
anaemia (Marsh, Forster et al. 1995)) increases from around four months of age up to four 
years before it declines sharply after five years of age (Gilles 2002). In areas of low 
transmission intensity, the risk of life-threatening malaria also declines with age. However, 
immunity to severe malaria establishes much later as even adults become at risk and though 
the predominant clinical form differs (impaired consciousness in adults vs severe anaemia 
in children) (Luxemburger, Ricci et al. 1997). This underlines a potential consequence of 
effective malaria control interventions that would bring transmission to such low levels that 
immunity would take longer to establish, increasing the upper limit of the age range of mild 
and life-threatening malaria up to adults (Ghani, Sutherland et al. 2009). 
An important characteristic of NAI is memory. Anti-malaria antibodies have a short half-
lives (a few days to a few months) that has been attributed to short-lived (a few days) plasma 
cell production (Kinyanjui, Conway et al. 2007). However, antibody levels can be 
maintained by long-lived (few months) plasma cell production (Slifka, Antia et al. 1998) or 
re-stimulation of memory B cells by chronic infections (Gatto, Martin et al. 2007). There is 
now evidence that even without re-exposure to infective bites, malaria memory B cells can 
be maintained up to sixteen years (Ndungu, Lundblom et al. 2013) arguing against the idea 
of a loss of memory after long periods of non-exposure. Akpogheneta and colleagues found 
that, in the absence of persistent infection, a rapid decline of antibodies occurs in the 
youngest children aged less than years (attributed to the predominance of short-lived plasma 
cells) compared with older children aged more than 5 years (attributed to the predominance 
of long-lived plasma cells) (Akpogheneta, Duah et al. 2008). However, it has also been 
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assumed that both short-lived and long-lived components coexist and a bi-phasic decline is 
fitted to the serology data revealing an initial rapid decay followed by slower and longer 
decay (White, Griffin et al. 2014, White, Verity et al. 2015). Average catabolic half-life of 
human antibody subclasses (1, 2 and 4) has been estimated at 21 days (Morell, Terry et al. 
1970). The half-life of anti-malaria antibodies have been estimated using different models 
and children populations of differing age groups with variable results, but most estimates lie 
between to 4-31 days, although older children tend to have longer antibody half-lives 
(Kinyanjui, Conway et al. 2007, White, Griffin et al. 2014). In a vaccine trial where a 
biphasic decay has been assumed, the half-lives of antibodies have been estimated to 45 days 
and 591 days for the short-lived and long-lived components respectively (White, Verity et 
al. 2015). 
1.7.2.2 Mechanisms and measures of naturally acquired immunity to malaria 
T cells and plasma cells (antibody producing cells differentiated from B cells) constitute the 
effector cells of the adaptive components of the natural immunity to malaria (CA, P et al. 
2001).  
Circulating antibodies bind to proteins expressed on the surface of the exposed circulating 
invasive parasites (sporozoites and merozoites) or to proteins expressed on the surface of 
infected cells (hepatocytes and erythrocytes) and mediate protection through many ways. 
They can then inhibit the host cell entry by the parasite by binding to the parasite surface 
proteins involved in the invasion process and therefore prevent them from binding to their 
ligands displayed on the surface of the host cells: this mechanism is called neutralization. It 
has been recently shown that antibodies interact with an innate humoral factor, complement, 
 Page 42 of 349 
 
to prevent invasion. Indeed, Boyle and colleagues have demonstrated that most antibodies 
were non-inhibitory without complement fixation on merozoites and that complement 
fixation was strongly positively associated with age and clinical protection; this mechanism 
is called antibody-mediated complement dependent invasion-inhibitory activity (Boyle, 
Reiling et al. 2015).  
By sticking to the surface antigens of infected erythrocytes or merozoites, they mark them 
for phagocytosis by antigens presenting cells (macrophages and monocytes): this mechanism 
is called opsonic phagocytosis (Chua, Brown et al. 2013, Osier, Feng et al. 2014). Other 
studies suggested that opsonization of infected erythrocytes and merozoites promote 
phagocytosis by neutrophils (Celada, Cruchaud et al. 1983, Pleass, Ogun et al. 2003). 
Since both cyto-adherence (binding of infected erythrocytes to endothelial cells) and 
rosetting (binding of infected erythrocytes to other infected or uninfected erythrocytes) are 
mediated by a protein expressed on the surface of P. falciparum infected erythrocytes 
(PfEMP1), antibodies can also prevent or limit the occurrence of these phenomena.  
The interaction of opsonized merozoites and monocytes receptors to antibodies (Fc 
receptors) trigger the release of soluble factors that can inhibit parasite growth in infected 
erythrocytes: this mechanism is called antibody-dependent cellular inhibition (ADCI) 
(Khusmith and Druilhe 1983). It has been also shown that opsonized merozoites can promote 
the release of oxygen radicals by peripheral blood monocytes and neutrophils (Kharazmi, 
Jepsen et al. 1987), and that oxygen radical generation was inversely correlated with parasite 
clearance time (Greve, Lehman et al. 1999).  
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The findings of Pombo and colleagues in a challenge study, where malaria-naïve individuals 
were challenged with subclinical infections and treated, are suggestive of the existence of an 
antibody-independent protective role of T cells in (Pombo, Lawrence et al. 2002). However, 
the effector mechanisms in T cell responses to malaria are less clear than those of antibodies.  
Some experimental studies in mouse models suggested that antibodies, T-cells (CD8+ and 
CD4+) have independent anti-parasitic effects against pre-erythrocytic stages and thus may 
all contribute to pre-erythrocytic immunity (Rodrigues, Nussenzweig et al. 1993) while other 
studies (mice, Rhesus monkeys) suggested that pre-erythrocytic immunity is mediated 
primarily by CD8+ T-cell activity (Schofield, Villaquiran et al. 1987, Weiss, Sedegah et al. 
1988, Weiss and Jiang 2012). Evidence for associations between antibodies to pre-
erythrocytic stages and protection against malaria have been found in human observational 
studies (John, Moormann et al. 2005, John, Tande et al. 2008). Interventional (CSP-based 
vaccine) and experimental studies (radiation-attenuated sporozoites vaccine) in humans have 
shown that CD8+ responses (Ewer, O’Hara et al. 2013)  and CD4+ T-cell responses (Reece, 
Pinder et al. 2004) play a major role in pre-erythrocytic immunity. T cell-mediated immunity 
to malaria has been attributed to interferon gamma production by CD4+, CD8+ T cells (Sun, 
Schwenk et al. 2003) as well as the promotion of inducible nitric oxide synthase production 
by peripheral blood mononuclear cell (Pombo, Lawrence et al. 2002). Sterile protective 
immunity induced by immunization with radiation-attenuated sporozoites has yet to be 
achieved outside experimental conditions (Hoffman, Goh et al. 2002). 
Protective immunity has been practically difficult to measure and define, and a number of 
metrics have been proposed. These metrics are based on antibody responses only 
(seropositivity, protective thresholds) or antibody-dependent cellular responses (growth 
inhibition assay, antibody-dependent cellular inhibition, antibody-dependent respiratory 
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burst, opsonic phagocytosis) but there is increasing advocacy to use functional assays (Osier, 
Fegan et al. 2008, Joos, Marrama et al. 2010, Duncan, Hill et al. 2012, Murungi, Kamuyu et 
al. 2013, Osier, Mackinnon et al. 2014, Tiendrebeogo, Adu et al. 2015). To date, 
standardized and validated correlates of protection against malaria that meet agreement for 
generalized use have yet to be established. 
1.7.2.3 Immune responses to malaria: marker of immunity or marker of exposure? 
Acquired (adaptive) immune responses develop in response to exposure of antigen-
presenting cells to the parasite antigens. In endemic settings, all residents are theoretically 
exposed to malaria, but this exposure is not constant over space and time. Malaria 
transmission is often seasonal and the heterogeneity of exposure to malaria has been 
observed at global, continental, regional up to the finest geographical scale (homestead). 
Since immune responses and exposure to infection are both associated with the risk of 
malaria, in any study of the association between immune responses and risk of malaria, 
confounding by heterogeneity of exposure need to be accounted for to avoid biased results 
(Bousema, Kreuels et al. 2011). 
Various approaches have been suggested. Randomization is the usual approach to control 
confounding factors in clinical trials, but even trial estimates of vaccine efficacy may be 
biased by heterogeneity of exposure (White, Griffin et al. 2010). A simpler approach is to 
define zones of differing exposure intensity for a given area and adjust accordingly. These 
zones may be defined based on altitude (Drakeley, Carneiro et al. 2005), distance to 
mosquito breeding sites (Clarke, Bogh et al. 2002), wind direction (Midega, Smith et al. 
2012), distance to forest fringe (Kreuels, Kobbe et al. 2008). Administrative divisions are 
used with the limit that they are arbitrary, especially when the zones are contigous. A 
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different approach consists of the use of baseline serological markers with the limit that 
antibody titres may not reflect recent / current exposure to malaria (Osier, Fegan et al. 2008). 
Bejon and colleagues have proposed an approach in which uninfected (assumed unexposed) 
individuals are removed from the analysis, leaving only asymptomatically infected 
individuals and individuals with febrile malaria in the analysis  (Bejon, Warimwe et al. 
2009). The findings of Greenhouse and colleagues suggest that restricting the analysis to the 
periods when individuals are parasitaemic reveals the protective effect of antibodies 
(Greenhouse, Ho et al. 2011). More recently, Olotu and colleagues have developed a 
quantitative spatial approach with the advantage of an estimation of exposure at the 
individual level (Olotu, Fegan et al. 2012). There is currently no consensus or validated 
method for adjusting for heterogeneity of exposure to malaria. 
1.7.2.4 Plasmodium falciparum merozoite antigens associated with immunity 
The genome of Plasmodium falciparum (clone 3D7) made of 14 chromosomes harbouring 
about 5300 genes encoding an equivalent number of proteins. At least 1.3% of the genes are 
known to be involved in interaction with host cells and 3.9% in immune evasion. Other 
proteins are involved in “housekeeping activities” (transport activities, DNA replication and 
repair…etc.) but the exact function of most proteins remains unknown (Gardner, Hall et al. 
2002). Any protein displayed on the surface of the parasite, especially free invasive forms 
(sporozoites and merozoites), is a potential target for the immune system. We describe below 
some of the most studied Plasmodium falciparum antigens that have been or are being tested 
as candidate vaccines. 
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The apical membrane antigen (AMA1) 
Plasmodium falciparum AMA1 is an 83 kDA micronemal type I transmembrane protein 
(Peterson, Marshall et al. 1989) encoded by a single-locus gene (PF3D7_1133400) located 
on chromosome 11 (http://www.genedb.org). This protein is present in the invasive forms 
of malaria parasites (sporozoite and merozoite), synthetized in late schizont stage during 
asexual multiplication and has homologues in all Plasmodium species (Triglia, Healer et al. 
2000). The 83 kDA precursor protein is then processed into a 66 kDA protein in the 
micronemes before it translocates to the parasite surface just prior to the host cell invasion 
process where there it undergoes further processing (Howell, Withers-Martinez et al. 2001). 
AMA1 has been reported as involved in the parasite reorientation following initial 
attachment, the formation of the parasite-host cell tight-junction and invasion in cooperation 
with another parasite protein called rhoptry neck protein 2 (RON2) (Mitchell, Thomas et al. 
2004, Srinivasan, Beatty et al. 2011, Yap, Azevedo et al. 2014). In contrast, other studies 
suggest that AMA1 may not be essential for host cell invasion (Bargieri, Andenmatten et al. 
2013). Invasion assays have shown that antibodies to AMA1 can inhibit erythrocyte invasion 
and impaired proteolytic processing or binding to AMA1 to prevent interaction with its 
partner proteins have been suggested as possible effector mechanisms (Dutta, Haynes et al. 
2005, Collins, Withers-Martinez et al. 2009). In humans, antibodies to AMA1 have been 
associated with protection from clinical malaria in some sero-epidemiological studies 
(Polley, Mwangi et al. 2004, Osier, Fegan et al. 2008, Greenhouse, Ho et al. 2011). While 
immunization in non-human primates (Stowers, Kennedy et al. 2002, Dutta, Sullivan et al. 
2009) and phase 1 clinical trials (Dicko, Diemert et al. 2007, Dicko, Sagara et al. 2008) 
showed encouraging results, the results of phase 2 clinical trials of monovalent vaccine 
candidates were rather disappointing (Sagara, Dicko et al. 2009, Thera, Doumbo et al. 2011). 
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The merozoite surface protein (MSP3) 
Plasmodium falciparum MSP3 is an abundant 40 kDA soluble protein (no transmembrane 
domain or GPI anchor) in the form of oligomeric (dimers and tetramers) aggregates (Imam, 
Singh et al. 2014) encoded by a single-locus gene (PF3D7_1035400) on Plasmodium 
falciparum chromosome 10 (http://www.genedb.org). It appears as a 5 to 15 μm long 
filamentous structure attached to the merozoite surface (Imam, Singh et al. 2014) possibly 
through protein-protein interaction (Trucco, Fernandez-Reyes et al. 2001). Though its exact 
functional role is poorly understood, MSP3 is believed to play a role in host cell invasion 
and parasite protection. Indeed, MSP3 is shed with other surface proteins at the tight junction 
during the host cell invasion and this suggests that MSP3 plays a role in the initial contact 
and invasion events (Boyle, Langer et al. 2014). MSP3 has also heme-binding properties and 
this is suggestive of a possible a role in the protection of the parasite from potential heme-
related damages (Imam, Singh et al. 2014). MSP3 was identified as an antigen capable of 
eliciting protective immune response using the antibody-dependent cellular inhibition 
(ADCI) assay in which the parasite growth inhibition is mediated by monocytes in 
cooperation with antibodies (Oeuvray, Bouharoun-Tayoun et al. 1994). This protective 
response elicited by MSP3 has been evidenced in a number of field studies (Soe, Theisen et 
al. 2004, Nebie, Tiono et al. 2008, Osier, Fegan et al. 2008, Greenhouse, Ho et al. 2011) and 
Fowkes and colleagues have reported the lowest pooled relative risk (RR=0.46) for 
antibodies to MSP3 among other anti-merozoite antibodies (Fowkes, Richards et al. 2010). 
Immunization in non-human primates yielded evidence of protective effect (Hisaeda, Saul 
et al. 2002) and after satisfactory phase 1 clinical trials (Lusingu, Gesase et al. 2009, Sirima, 
Tiono et al. 2009) the testing of MSP3 progressed to a phase 2 trial in Mali 
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(ClinicalTrials.gov Identifier: NCT00652275). Unfortunately to date the results are not 
published. 
The merozoite surface protein 2 (MSP2) 
Plasmodium falciparum MSP2 is an approximately 30 kDA GPI-anchored merozoite surface 
protein (Gerold, Schofield et al. 1996) encoded by a single-locus gene (PF3D7_0206800) on 
the Plasmodium falciparum chromosome 2 (http://www.genedb.org). MSP2 has no ordered 
three-dimensional structure (intrinsically unstructured protein); it forms amyloid-like fibrils 
in physiological conditions and is thus believed to be a component of the fibrillar coat on the 
surface of the merozoite (Adda, Murphy et al. 2009). The exact role of MSP2 is unclear. 
Failure of genetic deletion of MSP2 suggest that the protein plays a critical role in parasite 
biology (Sanders, Kats et al. 2006). MSP2 is not shed during host cell invasion by the 
merozoite; it is internalized and immediately degraded (within 10 minutes) upon completion 
of the invasion, suggesting a function during the invasion process (Boyle, Langer et al. 
2014). As for other Plasmodium falciparum antigens, antigens to MSP2 have been 
associated with protection against malaria in some (Metzger, Okenu et al. 2003, Polley, 
Conway et al. 2006, Osier, Fegan et al. 2008, Reddy, Anders et al. 2012) , but not all studies. 
MSP2 was initially tested in humans as a multicomponent vaccine (Combination B: MSP1, 
MSP2-3D7 and RESA) (Genton, Al-Yaman et al. 2000, Genton, Betuela et al. 2002, Genton, 
Al-Yaman et al. 2003). The allele-specific component of the humoral response to MSP2 
induced by this vaccine (Flück, Smith et al. 2004) was not clearly seen in sero-
epidemiological studies (Osier, Murungi et al. 2010). However, a subsequent clinical trial of 
a vaccine made of recombinant forms of the two allele families (3D7 and FC27) yielded 
good immunogenicity but poor tolerance, raising safety questions and the trial was 
terminated early (McCarthy, Marjason et al. 2011). 
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The merozoite surface protein 1 (MSP1) 
Plasmodium falciparum MSP1 is a GPI-anchored merozoite surface protein encoded by a 
single-locus gene (PF3D7_0930300) on Plasmodium falciparum chromosome 9 
(http://www.genedb.org). It is the most abundant and the first merozoite surface protein to 
be identified. After its synthesis during schizogony (liver and blood phases), the 195 kDA 
precursor MSP1 traffics to the parasite plasma membrane and its processing starts in late 
schizogony just before merozoites are released in the blood stream (Das, Hertrich et al. 
2015). This initial processing yields four fragments of varying molecular weight (MSP1-83, 
MSP1-30, MSP1-38 and MSP1-42 named after their respective molecular weights 83, 30, 
38 and 42 kDA) that form a non-covalent complex at the parasite surface (McBride and 
Heidrich 1987). MSP1-42 is further cleaved into a 19 and 33 kDA fragments just prior to 
the host cell invasion and MSP1-33 is shed from the surface in the form of a protein complex 
with other proteins and the fragments from the primary cleavage; MSP1-19, the only 
fragment that remains on the surface of the merozoite during the invasion process is carried 
into the parasitized erythrocyte (Blackman, Heidrich et al. 1990, Blackman and Holder 
1992). The lethality of the genetic disruption of MSP1 suggests that it plays a critical 
function in parasite biology (O'Donnell, Saul et al. 2000). MSP1-19 is believed to play a 
critical role in initial parasite attachment to erythrocyte and in the invasion process through 
interaction with the RBC most abundant surface receptor: band 3 (Goel, Li et al. 2003). 
Though some field studies reported no association with protection (Dodoo, Theander et al. 
1999), many others found that antibody responses to MSP1 were protective against malaria 
supporting its testing as a candidate malaria vaccine (Riley, Allen et al. 1992, Al-Yaman, 
Genton et al. 1996, Cavanagh, Dodoo et al. 2004, Dodoo, Aikins et al. 2008, Osier, Fegan 
et al. 2008). MSP1 (block 3 and 4) was first tested as a mixture of 3 antigens (Combination 
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B) (Genton, Betuela et al. 2002). MSP1-42 has reached phase 2 clinical trial, but the results 
did not warrant further testing (Ogutu, Apollo et al. 2009). MSP1-19 has been tested in 
association with other antigens, AMA1 in PfCP-2.9 (Hu, Chen et al. 2008), EBA175 in 
JAIVAC-1 (Chitnis, Mukherjee et al. 2015). 
The glutamate-rich protein (GLURP) 
Plasmodium falciparum GLURP is a 220 kDA GPI-anchored protein encoded by a single 
copy gene (PF3D7_1035300) located on Plasmodium falciparum chromosome 10 
(http://www.genedb.org). GLURP is expressed in all the stages of the parasite in the human 
host as evidenced by the reactivity of anti-GLURP antibodies with asexual liver and blood 
stages  of the parasite (Borre, Dziegiel et al. 1991). GLURP is shed from the merozoite 
surface during the invasion and anti-GLURP antibodies do not directly inhibit host cell 
invasion (Theisen, Soe et al. 1998). Though its role is unknown, the presence of GLURP in 
the different stages of the parasite in the human host is suggestive of a critical function in 
the parasite biology (Borre, Dziegiel et al. 1991). It has been shown that antibodies targeted 
at GLURP inhibit parasite growth through a cooperation with monocytes (antibody-
dependent monocyte-mediated growth inhibition) (Theisen, Soe et al. 1998).  In field studies, 
antibodies to GLURP have been associated with protection against clinical malaria in some 
studies (Oeuvray, Theisen et al. 2000, Soe, Theisen et al. 2004, Lusingu, Vestergaard et al. 
2005, Dodoo, Aikins et al. 2008, Nebie, Tiono et al. 2008) but not all. After a phase 1 clinical 
trial, the testing of GLURP continued as a hybrid protein GMZ2 in which it is fused to MSP3. 
After satisfactory phase 1 studies (Esen, Kremsner et al. 2009, Mordmüller, Szywon et al. 
2010, Bélard, Issifou et al. 2011) GMZ2 testing has progressed to phase 2 clinical trial and 
elicited low vaccine efficacy (Sirima, Mordmüller et al. 2016).  
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Genetic polymorphism and implication for field and clinical studies 
Genetic polymorphism has been defined as a variation in the DNA sequence that occur with 
a frequency ≥ 1% in a population (Brookes 1999, Karki, Pandya et al. 2015). There is 
extensive evidence for allelic polymorphism (antigenic diversity) in Plasmodium falciparum 
genes in many different populations (Hoffmann, Da Silveira et al. 2001, Zhong, Afrane et 
al. 2007, Osier, Weedall et al. 2010, Mwingira, Nkwengulila et al. 2011). This is believed to 
be a parasite strategy for immune evasion (Healer, Murphy et al. 2004) and represents a 
major hurdle in vaccine development, interpretation of the results of sero-epidemiological 
studies and vaccine efficacy trials, as adaptive immunity may be strain-specific and acquired 
progressively with repeated encounters with various strains of the parasite (Doolan, Dobaño 
et al. 2009, Griffin, Hollingsworth et al. 2015). Indeed, allele-specific immunity was 
evidenced in some sero-epidemiological studies (Osier, Polley et al. 2007, Polley, Tetteh et 
al. 2007) and vaccine trials (Genton, Betuela et al. 2002, Ouattara, Takala-Harrison et al. 
2013).  
Heterologous expression of Plasmodium falciparum proteins 
Copies of Plasmodium falciparum native proteins (recombinant proteins) can be produced 
in desired quantity for structural and functional studies using heterologous expression 
systems (bacterial or yeast systems). For instance, diverse bacteria (Escherichia coli 
(Theisen, Vuust et al. 1995), Lactococcus lactis (Theisen, Soe et al. 2004), Mycobacterium 
bovis (Nurul and Norazmi 2011)) and yeast (Saccharomyces cerevisiae (Kaslow, Hui et al. 
1994), Pichia pastoris (Kocken, Withers-Martinez et al. 2002)) have been used. Alternative 
expression systems, less frequently used than bacteria and yeast, include baculovirus-
infected insect cells, other parasites (amoeba Dictyostelium discoideum, Toxoplasma 
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gondii), mammalian cells, frog cells, tobacco plant cells and cell-free expression systems 
(reviewed in (Birkholtz, Blatch et al. 2008)). Basically, in these expression systems, a clone 
(copy) of the gene (piece of DNA) of interest is transfected into the DNA of the host cell 
using a vector (plasmid, virus); the desired protein is then expressed by the resulting 
recombinant DNA along with the host cell protein (Nurul and Norazmi 2011). A major 
shortcoming in protein expression is the risk of incorrect protein folding (3-dimensional 
structure) that is critical to its function and that may bias the results of immunoassays. 
Recombinant proteins are often expressed fused to a carrier protein (tag) to enhance 
solubility and achieve native protein folding among other objectives. Maltose binding 
protein (MBP) and glutathione-S-transferase (GST) are among the most commonly used tag 
for Plasmodium falciparum recombinant proteins (Esposito and Chatterjee 2006, Bell, 
Engleka et al. 2013). 
1.7.2.5 The choice of the study design 
As described above, some protective factors are inherited and last lifelong but other factors 
are fluctuating. Many previous field studies have measured naturally acquired immunity and 
susceptibility to malaria infection and / or febrile malaria using cross-sectional studies, but 
it has been pointed out that the risk of misclassification is high with this design (Marsh and 
Kinyanjui 2006) given that anti-malaria antibodies are short-lived and that the body 
temperature and parasitaemia show very short-term temporal variations (Delley, Bouvier et 
al. 2000). Longitudinal studies with repeated measurements have then been recommended 
(White, Griffin et al. 2013) as they are more likely to capture the true picture of the immune 
responsiveness and susceptibility to malaria. However, for logistical reasons, when the aim 
is large-scale and / or long-term surveillance, cross-sectional measures of the same 
parameters may be more suitable (Drakeley, Corran et al. 2005). For the study of protective 
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immunity to malaria, we have chosen an area of stable malaria transmission in western 
Burkina Faso as suggested by White and colleagues (White, Griffin et al. 2013) and for the 
study of malaria transmission hotspots, we have chosen a low transmission area in coastal 
Kenya as targeted interventions are expected to have more impact in pre-elimination 
conditions (Bousema, Griffin et al. 2012). We have also chosen a low transmission area in 
Senegal (Keur Soce) to study the comparative effect of low transmission condition on the 
dynamics of anti-malaria antibodies in young children. 
In most studies of immunity to malaria, children represent a logical focus because of the 
high burden of the disease in this age group, but infants paradoxically exhibit a pattern of 
resistance to malaria similar to that of adults (Kitua, Smith et al. 1996, Snow, Nahlen et al. 
1998), though their immune system is generally described as immature or actively 
suppressed (Gervassi and Horton 2014). The reasons for this observation are still unclear 
and a better understanding of this phenomenon may help in the development and / or 
improvement of malaria control tools and strategies, especially malaria vaccines. Targeting 
control interventions to spatial units of higher transmission intensity is also expected to be 
efficient in controlling malaria, but there is no consensus on how to reliably identify these 
spatial units called hotspots.  
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General objective:  
The present work aimed at investigating the association between anti-malarial antibodies 
and the risk of febrile malaria in children. 
Specific objectives: 
 To investigate the role of antibodies in the resistance of young infants against febrile 
malaria 
 To examine the dynamics and kinetics of antibodies to merozoite surface proteins in 
the first two years of life and compare the antibody levels measured in young children 
to previously established protective thresholds 
 To examine the place of serological markers among other biomarkers in the detection 
of hotspots of malaria transmission in a context of declining malaria transmission. 
  
1.8 Study objectives 
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Naturally acquired immunity to malaria is a complex phenomenon and despite advances 
achieved in a wealth of studies investigating the mechanisms of protection, defining 
immunity to malaria is still a challenge and there is no current universal consensus on the 
definition of immunity to malaria (Moormann and Stewart 2014). Evidence for an 
association between protection and immune responses in observational studies and malaria 
vaccine trials still mainly rely on epidemiological evidence with various approaches to 
address the issue of confounding by heterogeneity of exposure  (Bejon, Warimwe et al. 2009, 
Ali, Bakli et al. 2012, Olotu, Fegan et al. 2012, Diop, Richard et al. 2014, Helb, Tetteh et al. 
2015).  
Children under five bear the bulk of malaria burden (WHO 2015) and there is strong 
evidence of a substantial asymptomatic malaria prevalence in young infants (<6 months) 
(Serign, Lamine et al. 2015). However, severe malaria is exceptional, clinical malaria is rare 
and predominantly low density parasitaemias have been reported in the early months of life 
(McGuinness, Koram et al. 1998, Afolabi, Salako et al. 2001). Most studies suggest that the 
resistance to malaria lasts until around four months of age (Achidi, Salimonu et al. 1996, 
McGuinness, Koram et al. 1998, Wagner, Koram et al. 1998, Kitua, Urassa et al. 1999, Klein 
Klouwenberg, Oyakhirome et al. 2005).  
2. CHAPTER 2: Are antibodies to some P. falciparum merozoite antigens protective 
against febrile malaria in children in their first two years of life 
 
2.1 Introduction  
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A positive association between mosquito bites and age (Muirhead-Thomson 1951, 
Carnevale, Frezil et al. 1978),  surface area or weight (Carnevale, Frezil et al. 1978, Port, 
Boreham et al. 1980), an exclusive breast feeding realising low para-amino-benzoic acid diet 
(Kassim, Ako-Anai et al. 2000, Kicska, Ting et al. 2003), foetal haemoglobin (Pasvol, 
Weatherall et al. , Amaratunga, Lopera-Mesa et al. 2011) and  transplacentally transferred 
gamma-globulins have been advanced as possible protecting factors against malaria in early 
life.  However, the most robust evidence of protection against P. falciparum febrile malaria 
has been reported for circulating gamma-globulins. Indeed, the capacity of antibodies to 
control malaria (fever and parasitaemia) has been demonstrated in human gamma-globulin 
passive transfer therapeutic experiments (Cohen, McGregor et al. 1961, Edozien, Gilles et 
al. 1962, McGregor, Carrington et al. 1963, Sabchareon, Burnouf et al. 1991). Subsequent 
observational studies in adults, older children and young infants, that mainly investigated 
the role of specific immune responses to blood-stage antigens were less consistent in their 
findings but have served nonetheless as a basis of malaria vaccine candidate selection 
(Fowkes, Richards et al. 2010). 
Immune correlates of protection against malaria have been extensively studied in adults and 
older children (Hogh, Petersen et al. 1992, Dziegiel, Rowe et al. 1993, Dodoo, Theisen et al. 
2000, Oeuvray, Theisen et al. 2000, Meraldi, Nebie et al. 2004, Soe, Theisen et al. 2004, 
Lusingu, Vestergaard et al. 2005, Roussilhon, Oeuvray et al. 2007, Dodoo, Aikins et al. 
2008, Nebie, Tiono et al. 2008, Osier, Fegan et al. 2008, Courtin, Oesterholt et al. 2009, 
Dodoo, Atuguba et al. 2011, Mamo, Esen et al. 2013). However, relatively fewer studies 
have specifically investigated the risk of malaria in infancy in relation to antibodies.  
Antibodies circulating in early infancy mainly come from transplacental transfer and are 
mostly IgG (Pitcher-Wilmott, Hindocha et al. 1980). Thereafter they are endogenously 
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produced by the infant (IgM and IgG). In addition, there is evidence that very early in life, 
some foetuses are able to mount an immune response to prenatal exposure through 
transplacental transfer of soluble malaria antigens (Metenou, Suguitan et al. 2007, May, 
Grube et al. 2009) although this may be associated with immuno-suppression (Brustoski, 
Möller et al. 2006). Whether antibodies play a role in early life resistance to febrile malaria 
is still unclear.  
Most sero-epidemiological studies investigating the implication of antibodies in the 
protection of infants against malaria did not find evidence for the hypothesised protective 
effect of specific antibodies to the individual antigens tested (CSP, LSA-1, crude schizont 
extract, MSP1, MSP2, Pf155/RESA and the vaccine candidate SPf66) (Achidi, Salimonu et 
al. 1996, Wagner, Koram et al. 1998, Kitua, Urassa et al. 1999, Riley, Wagner et al. 2000, 
Zhou, Xiao et al. 2002). However, two studies conducted independently in Liberia and 
Kenya (Høgh, Marbiah et al. 1995, Branch, Udhayakumar et al. 1998) yielded evidence for 
a protective effect of antibodies to MSP1-19. In the present study, we have followed 
recommendations for the design of studies of associations between markers of immunity and 
resistance to malaria (high transmission location, longitudinal prospective monitoring, active 
detection, repeated measures and analysis of immune responses as continuous variables) 
(White, Griffin et al. 2013) and we have investigated responses to two antigens that were not 
previously tested in young children. 
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We conducted the present longitudinal prospective infant cohort study in the south-western 
region of Burkina Faso in West Africa with the following objectives: 
Primary objective:  
To investigate the association between antibodies to some P. falciparum merozoite antigens 
and the risk of febrile malaria in the first two years of life. We initially planned to test a wide 
range of P.falciparum antigens including pre-erythrocytic (CSP or LSA-1) and merozoite 
antigens (EBA-175, MSP1-19, MSP2, MSP3, AMA1, GLURP) but in the end, we had access 
to MSP3 and two fragments of GLURP (R0 and R2), kindly provided by Statens Serum 
Institute, Copenhagen, Denmark.  
Secondary objectives: 
 To investigate the role of selected potential risk factors for febrile malaria in young 
children 
 To investigate possible risk factors affecting antibody responses 
 To determine the dynamics of antibody titres in the first two years of life 
 To examine the spatial distribution of febrile malaria episodes in the study area 
 
2.3.1 Ethical consideration  
This study was approved by the Institutional Review Board of Centre National de Recherche 
et de Formation sur le Paludisme (CNRFP) in Burkina Faso. The study was conducted 
2.2 Study objectives 
2.3 Methods  
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according to the principles of the Declaration of Helsinki. Individual written informed 
consent was obtained from the parents of each child before any study procedure was 
performed. For parents who could not read and write, the information was read to them and 
discussed in their own language in the presence of an independent witness who completed 
the consent form at the end of the discussion on their behalf before they sign it with their 
thumb print. The IRB approved this consent procedure. 
2.3.2 Study site  
The study was conducted in the Banfora department (Figure 2.1) where malaria transmission 
is stable in south-western Burkina Faso at around 500 km from the capital city Ouagadougou. 
The climate is of tropical Savanah type with a single pronounced dry season (October-May) 
and a single wet season (June-September). Banfora is located at an average altitude of 300 
m from sea level with a total annual rainfall at 900-1200 mm.  
Most of inhabitants rely on subsistence farming (maize, millet, yam, rice) but the substantial 
rainfall and permanent rivers of the Comoe hydrographic basin, in which Banfora lies, allow 
additional commercial crop farming (cotton, sugar cane, cashew nuts).  
The study area encompasses four health catchment areas covered by four dispensaries 
reporting to Banfora district hospital. Two of these dispensaries (Flantama and Korona) are 
located within Banfora town with water and power supply and mainly cement brick houses 
with iron sheet roofing. The other two dispensaries are located in Banfora sub-urban villages 
(Nafona and Bounouna) with predominant adobe-walled houses with thatched roofing.  
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Figure 2.1. Health catchment areas of Banfora Department. The yellow circle indicates the study area. 
 
Malaria transmission is seasonal with an incidence in children under five estimated at 1.18 
episodes/child/year using active case detection (Tiono, Kangoye et al. 2014) with P. 
falciparum being responsible for more than 90% malaria cases. 
2.3.3 Study population  
A cohort of 140 infants aged between four and six weeks was recruited into the study. The 
primary endpoint for the sample size calculation was the incidence of febrile malaria. Based 
on an assumption of an incidence of one or more episodes of febrile malaria of 20% during 
 Page 61 of 349 
 
one year of follow up, it was calculated that a sample size of 140 infants (including 10% lost 
to of follow up) would allow this incidence to be determined within a 95% confidence 
interval of 13-27%. The parents were informed of the study aims and procedures during the 
early post-natal visits at the study dispensaries, prior to the children reaching one month of 
age. The primary endpoint of the larger multi-country study was not the study of the maternal 
antibodies, but the incidence of febrile malaria and the children were not recruited at birth 
but a few weeks later. Recruitment was carried out simultaneously at the four health 
catchment areas of the study site from November 2010 to February 2011.  
The inclusion criteria were 1) age between four and six weeks, 2) signed informed consent 
given by the caregivers and 3) availability and willingness to remain within the study area 
for the follow up period. Children were excluded from the study if they had a documented 
malaria infection or a febrile malaria episode, haemoglobin level < 8 g/dL, a confirmed or 
suspected immuno-deficiency syndrome, prematurity (< 37 weeks gestation) (Lawn, Gravett 
et al. 2010), a congenital anomaly or any other clinical condition for which the risks related 
to participation in the study outweigh the benefits. 
Infants who had either a documented previous episode of malaria or a positive blood smear 
at the baseline visit were then excluded from the study; nevertheless, some infants might 
have had malaria infections that were unobserved. After the recruitment of the study 
participants, the geodetic coordinates (longitude, latitude) of their homesteads were recorded 
using handheld Global Positioning System (GPS) devices (eTrex Summit® HC). The 
approximate centre of each family compound was the reference point to record these 
coordinates. The altitude of the homesteads involved in the study ranged from 259 to 344 m 
with a mean of 306.7 m above sea. The distance to the nearest study dispensary ranged from 
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0.15 to 4.34 km with a geometric mean at 0.8 km (95 % CI, 0.71-0.91). The biggest diameter 
of the study area is approximately 8 km. 
2.3.4 Surveillance of malaria morbidity and healthcare 
To detect malaria infections, the children were followed up actively by weekly home visits 
and passively by dispensary monitoring for two years.  
The weekly home visits were performed by fieldworkers whose main tasks were to check 
the children’s health status, perform rapid malaria tests, perform thick and thin blood smears 
on the same slide in case of fever (i.e. a reported history of fever in the past 24 hours and/or 
axillary temperature ≥ 37.5°C). Febrile children with positive rapid malaria test were 
administered a first dose of paediatric fixed-dose combination of artesunate-amodiaquine by 
the study nurse and the subsequent doses were administered by the caregivers. Febrile 
children with positive RDT and a concomitant health condition unrelated to malaria or 
febrile children with negative rapid malaria test or children with afebrile health conditions 
were referred to the study dispensaries further clinical investigation. Those children who 
could not be properly managed at the study dispensary were referred to the clinical trial 
facility located within the Banfora regional referral hospital and then to the paediatric unit 
of that hospital if necessary for specialized healthcare. The time window for the weekly 
home visits was ± 2 days. In addition, to monitor the first occurrence of asymptomatic 
parasitaemia, blood smears were systematically collected on a monthly basis until the 
detection of the first malaria infection regardless of the axillary temperature. 
In the passive follow-up, the caregivers were encouraged to bring their children to the nearby 
study dispensary or the clinical research unit at any time should the child appear unwell.  
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Thick and thin blood smears were performed on the same slide in case of fever (i.e. a reported 
history of fever in the past 24 hours and/or axillary temperature ≥ 37.5°C). The children who 
became ill over the course of the study received health care free of charge either at the 
dispensaries, the clinical research unit or the paediatric unit of the regional referral hospital 
when necessary. 
Capillary blood samples (500 µL each) were collected in EDTA-coated Eppendorf tubes by 
finger or heel prick at 1-6, 9, 12, 15, 18, 21 and 24 months of follow up for malaria serology. 
Previous studies reported that maternal antibodies wane within the first six months (Achidi, 
Perlmann et al. 1995, Riley, Wagner et al. 2000) and sampling at one month interval during 
this period was a trade-off between risks and discomfort related to bleeding in the children 
and collecting enough data for a parameter that rapidly wanes. Continuing bleeding at this 
frequency for the remaining 18 months would have increased the risk of dropout and a 
quarterly bleeding was chosen instead. The plasma was separated by refrigerated 
centrifugation of the whole blood samples at 3000 rpm for 5 minutes, aliquoted into labelled 
cryotubes and kept at -20 °C on the site until transfer to the central storage facility where 
they were kept at -80 °C until testing.  
2.3.5 Parasitological examination  
The collected blood smears were air dried and GIEMSA-stained as described elsewhere 
(Tiono, Ouedraogo et al. 2014). The parasite density was estimated by two independent 
microscopists using 100x oil immersion objective. Asexual parasites were counted against 
white blood cells (at least 200 WBC and up to 1000 WBC if less than ten parasites were 
counted against the first 200 WBC). Before a slide is reported negative for malaria parasites, 
at least 200 thick film fields are screened and ascertained parasite-free. The density of sexual 
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forms was estimated by counting gametocytes against 1000 WBC. The estimated 
parasitaemia was extrapolated from the slide parasite density assuming a constant WBC 
count of 8000/µL of whole blood. The parasitaemia estimated by the two microscopists were 
then compared for consistency. When their results were concordant (parasitaemia ratio <1.5 
or >0.67), the arithmetic mean was recorded as the final result. Otherwise a third 
microscopist was involved and the final result was the arithmetic mean of the two most 
concordant parasite densities. 
2.3.6 Haemoglobin typing  
High Pressure Liquid Chromatography (HPLC) was used to quantify the fractions of foetal 
haemoglobin and haemoglobin variants in the children. The assays were performed by an 
independent laboratory at the Faculty of Medicine of Ouagadougou University in Burkina 
Faso. 
2.3.7 Antibody quantification  
Enzyme-linked immunosorbent assay (ELISA) was used to quantify total IgG to P. 
falciparum MPS3 and GLURP as described elsewhere (Nebie, Tiono et al. 2008). Microtiter 
microplates were coated with P. falciparum antigens MSP3-LSP (Druilhe, Spertini et al. 
2005) at 1 μg/ml, GLURP R0 or R2 (Theisen, Vuust et al. 1995) at 0.1 μg/ml and incubated 
overnight at room temperature. The plates were then washed four times with PBS-0.05% 
Tween 20 (PBST) and the binding sites of the wells blocked with 1% bovine serum albumin 
in PBST. After one hour of blocking, the plates were washed four times with PBST and 
reacted with plasma diluted at 1:200 in 0.5% BSA-PBST solution for one hour at room 
temperature. After washing the plates four times with PBST, a goat anti-human antibody 
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preparation diluted at 1:3000 in 0.5% BSA-PBST, was added to the wells and left for 
incubation for one hour at room temperature. The plates were then washed four times with 
PBST before a substrate (p-nitro-phenyl-phosphate (Sigma)) diluted at 1 mg/ml in 0.5% 
BSA-PBST was added to the wells. After 30 minutes, the reaction was stopped by the 
addition of sulphuric acid H2SO4 and the absorbance was read at 450 nm by a microplate 
reader. The assays were performed in duplicates. Assays were repeated for duplicates for 
which the coefficient of variation ([standard deviation/mean]*100) was > 20. In order to 
adjust for day-to-day variation, for each antigen tested, a positive control serum was added 
in duplicate on each plate. The absorbances of study serum samples were then adjusted for 
day-to-day variation by multiplying absorbance by an adjustment factor that is the ratio of 
the average absorbance of positive controls on each plate by that of a reference plate. The 
positive control was a pool of adult Burkinabe sera and the negative controls were Danish 
serum samples obtained through Statens Serum Institute (Copenhagen, Denmark). 
2.3.8 Statistical analysis  
Definition of febrile malaria 
Fever was defined as an axillary temperature ≥ 37.5°C and / or a reported history of fever in 
the past 24 hours. Malaria infection was defined as any positive parasitaemia regardless of 
the axillary temperature. Two definitions were set for febrile malaria; definition 1 included 
all febrile episodes with any level of asexual P. falciparum parasitaemia, and definition 2 
included only febrile episodes associated with asexual P. falciparum parasite density 
≥10000/µL.  This latter definition was derived after examining the distributions of the log-
transformed parasite densities in children with and without fever in cross-sectional surveys 
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(Figure 2.2). Febrile malaria episodes occurring within a 21 days or less interval in the same 
individual were considered a single episode.  
 
Figure 2.2. Parasite density threshold for febrile malaria. The box-and-whisker plot represents the 
median and the inter-quartile range of the parasite density in a log10 scale in the febrile and afebrile 
children groups. Given the limited data available, I opted to pragmatically define a pyrogenic threshold 
as 10
4 
parasites, corresponding to the 75
th
 centile of the afebrile cases and 25
th
 centile of the febrile cases.    
More formal methods are available for determining sensitivity and specificity based on malaria 
attributable fractions from logistic regression modelling (Smith, Schellenberg et al. 1994) but I judged 
these to be unwarranted based on the limited data available. 
 
Calculation of individual malaria exposure index 
We have adapted a previously published method for calculating individual exposure indexes 
(EI) to our cohort with time-to-event data (Olotu, Fegan et al. 2012).  The assumptions 
behind this method are that 1) the risk of malaria is not evenly distributed in the study area, 
2) for a given index individual, the faster the time to the first malaria infection in his 
neighbourhood, the higher his risk of malaria infection is and 3) the estimated exposure index 
is constant over time. The individual malaria exposure index (EI) was computed as the 
median time to the first malaria infection in the surrounding neighbours of each index child 
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within a circle of a given radius around him at the middle of the circle.  We have computed 
median time to the first malaria infection using the neighbourhood included in circles of 
predefined radii (0.5 to 2 km in steps of 0.25 km). EIs were transformed to negative values 
so that the most exposed has the highest exposure index. We then tested each of the exposure 
variables generated in a univariate Cox regression model and found that exposure indexes 
calculated using a 1.5 km radius circle best predicted the risk of malaria (lowest log 
likelihood ratio) in our dataset (see Figure 2.3). The study area lies in a 4 Km radius circle 
and, on average, 21 homesteads were included in the neighbourhood (1.5 Km radius circle) 
of each index child. 
 
Figure 2.3. Selection of the radius that yielded exposure indexes that best predicted the risk of malaria. 
The lowest log likelihood in the univariate Cox regression analysis was the selection criteria for the 
most appropriate radius. 
 
Detection of hotspots of high exposure intensity and febrile malaria cases 
We have examined the fine scale spatial clustering of febrile malaria cases and high 
individual malaria exposure indexes using the scan statistic method by Kuldorff (Kulldorff 
1997) implemented in the SatScan software. Discrete Poisson and Normal probability 
models were used to detect hotspots of febrile malaria cases and hotspots of high malaria 
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exposure indexes respectively. The detection of malaria hotspots is an exploratory objective 
in this chapter and we set the scanning window shape to “circular” and the maximum cluster 
size to 50% of the population at risk (the default cluster size in SatScan). The p values are 
adjusted for multiple comparisons using the Bonferroni correction in SatScan. 
 
Analysis of risk of febrile malaria 
The antibody titres expressed in arbitrary units were log10-transformed to approximate a 
normal distribution. We fitted a multiple fractional polynomial regression of antibody titres 
on age to estimate the nonlinear relationship between anti-malaria antibody titre and age. 
Indeed, naturally acquired immunity is often assumed to be nonlinear in its dynamics and 
multiple fractional polynomials represents a robust, flexible alternative to other approaches 
(logistic regression, splines) to model non-linear relationships, although the complexity of 
the regression equation makes the interpretation of coefficients almost impossible. We fitted 
a linear regression model to estimate the relationship between a set of potential predictors 
and anti-malaria antibody titres. In this linear model, antibody titre was included as a time-
changing outcome, i.e. the antibody titre measured at the beginning of each time interval 
within which malaria infections were recorded, and age as fractional polynomials. Within-
person lack of independence between repeated measurements was accounted for by the 
Huber-White Sandwich estimator. 
We fitted a Cox regression model to estimate the relationship between the time to first febrile 
malaria episode and a set of covariates of interest. Cox regression was chosen among other 
possible models for time to event analysis of follow-up data (Bradburn, Clark et al. 2003) 
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because of its simplicity, flexibility and our literature review indicated that it is the most 
commonly used regression analysis in studies similar to ours (Wagner, Koram et al. 1998, 
Kitua, Urassa et al. 1999, Riley, Wagner et al. 2000).. Resistance to malaria can also be 
estimated based on the frequency of episodes over a time period and the count data analysis 
makes it possible to use all the events that were recorded over the entire observation period 
for each child, and not only the first occurrence. We also fitted a negative binomial 
regression model to estimate the association between multiple malaria episodes and a set of 
potential explanatory covariates. Indeed, it is often assumed that the distribution of malaria 
episodes follows a Poisson distribution, but negative binomial regression fits the data better 
when there is evidence for overdispersion (variance > mean) (Mwangi, Fegan et al. 2008, 
RTSS_Clinical_Trial_Partnership 2014, RTS 2015). Antibodies were fitted in two ways; a) 
applying the baseline antibody titre throughout the period of monitoring and b) applying 
time-varying antibody titre, i.e. the antibody titre measured at the most recent time point, 
which therefore changed throughout the period of monitoring.  The log likelihood ratio test 
was used to test the significance of categorical variables with multiple levels. The 
assumption of proportional hazards for Cox regression was tested based on the Kaplan Meier 
method and the Schoenfeld residuals.  We used the Huber-White Sandwich estimator to 
adjust for clustering by individual in negative binomial regression models. The significance 
level for hypothesis testing was set to 0.05.  
We used the bootstrap method to calculate the 95% CI for medians and Spearman correlation 
test to examine the correlations between distance and incidence of febrile malaria episodes, 
parasitaemia and age, antigen-specific antibodies and antibody titres at consecutive time 
points for each antigen. 
The data were analysed using Stata 13 (StataCorp, College Station, Texas). 
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2.4.1 Study population characteristics 
In total, 216 mothers of newborns were invited to attend study screening visits during early 
post-natal visits at the four dispensaries of the study area. Of these, 148 (68.5%) attended 
the study screening visit with their infants. A total of 140 infants were recruited during a 
three- month period from mid-November 2010 to mid-February 2011. The baseline 
characteristics of the infants and their mothers are summarised in Table 2.1. 
2.4.2 Follow-up of participants and malaria morbidity 
Twenty-three children (16.4%) were lost to follow-up before completing 24 months with a 
median [Inter Quartile Range-IQR] follow up time of 9.8 [2, 14.75] months. Among them, 
six migrated out of the study area, 10 withdrew their consent, four died and three dropped 
out of the study and were no longer reachable.  
One or more episodes of febrile malaria (fever + asexual parasitaemia>0) were experienced 
by 79.6% of all children during follow-up with a median time to first febrile malaria episode 
of 9.8 months (95% CI: 8.3, 11.3).  Sixty-three children (45.98%) had at least one malaria 
infection in their first year of life and 46 (76.66%) of the remaining 60 children in their 
second year. The monthly distribution of the febrile malaria cases is shown in figure 2.4. 
As shown in Figure 2.4, the transmission of malaria has a pronounced seasonality with 93% 
of febrile malaria cases recorded between June and November. It starts approximately one 
month after the beginning of the rains and peaks at the end of the rains from where it starts 
declining up to the lowest levels from January to May. 
2.4 Results  
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Table 2.1. Study population baseline characteristics. MUAC: mid upper arm circumference. Hb: 
haemoglobin. EPI: expanded programme on immunization. ITN: insecticide-treated bednets. IPTp: 
intermittent preventive treatment in pregnancy. 1, 2, 3: number of observations with missing data. 
Characteristic  Statistic  
Male, n (%)  67   (47.9%)  
Age infants(days), median [min, max]  33   [27, 42]  
Weight (kg), median [min, max] 1  4.1   [2.8, 5.9]  
Length (cm), median [min, max]  1 54    [48, 61] 
MUAC (cm), median [min, max]  12   [8.5, 16]  
Hb conc. (g/dL), median [min, max] 12.6  [8.7, 17.6]  
Foetal Hb (%), median [min, max]  3 59.6  [20.1, 89.6]  
Hb phenotype, n (%) 3   
                AA 
                AA  
113  (80.71)  
                AC  18  (13.14)  
                AS  1  (0.73)  
                CC  5  (3.65)  
Delivery way, n (%) 3  
                Natural 133 (95) 
                Ceasarian section 5 (3.6) 
Neonatal rescucitation, n (%) 12  (8.6) 
Neonatal infection, n (%)   2  (1.43)  
EPI (up to date at 1 month), n (%)   124  (88.6)  
Age groups mothers (years), n (%)   
                 ≤19  10  (7.1)  
                 20-29 89  (63.6)  
                 ≥30  37  (26.4)  
ITN use during pregnancy, n (%) 1   123  (87.9)  
IPTp courses, n (%)   
                 No treatment 10  (7.14)  
                 1 dose 28  (20)  
                 2 doses 100  (71.43)  
                 3 doses 2  (1.43)  
Gravidity status, n (%) 2  
                 Primigravidae  32  (22.86)  
                 Multigravidae  106  (75.71)  
Education level of mothers, n (%) 1  
                 No formal education  78  (55.71)  
                 Primary school  39  (27.86)  
                 Secondary school or above  22  (15.71)  
Distribution of study population, n (%)  
                 Bounouna 34 (22.97) 
                 Nafona 41 (27.7) 
                 Korona 16 (10.81) 
                 Flantama 49 (33.11) 
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Figure 2.4. Temporal distribution of febrile malaria (any parasitaemia with fever) cases over the 
monitoring period.  
 
The distribution of the number of febrile malaria cases per child is summarized in Figure 
2.5. This distribution takes into account the entire monitoring period. 
 
 
Figure 2.5. Distribution of the number of febrile malaria episodes in the study population. 
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The geometric mean shortest straight-line distance to the healthcare facilities involved in the 
passive case detection is 0.8 km (95 % CI, 0.71-0.91) which seem reasonable compared to 
the national standards (5 km). Looking at the correlation between shortest straight-distance 
to study dispensary (including the clinical trial facility) and the number of febrile malaria 
episodes recorded, we found a weak correlation (rho=0.22, p=0.01). Restricting the analysis 
to febrile episodes recorded in passive case detection reduced the strength and statistical 
significance of the correlation (rho=0.14, p=0.112). 
In all, 296 febrile malaria episodes were recorded over 249 child-years, with the number of 
cases peaking in October each year, giving an incidence rate of 1.2 episodes / child / year 
(95%CI, 1.06-1.33). In the first six months of life, five infections (two asymptomatic and 
three febrile) were detected, of which three occurred in the rains, in children aged above five 
months. P. falciparum was present in all the positive slides. Only two mixed infections 
involving P. falciparum and P. malariae were detected in two children. The two year 
cumulative gametocyte prevalence was 13.6%. Asexual P. falciparum parasitaemia was 
weakly correlated to age (rho=0.216, p<0.001). The geometric mean (95% CI) P. falciparum 
asexual parasitaemia was 14646.53/µL (12320.07, 17412.31). 
2.4.3 Fine scale spatial heterogeneity of malaria transmission 
We found that febrile malaria cases and children with the highest exposure clustered in the 
northern peripheral area (Nafona) of the Banfora Town (Figure 2.6). We then examined the 
correlation between the frequency of febrile malaria episodes and individual malaria 
exposure indexes, we found a statistically significant and moderate correlation between both 
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the indicators (rho=0.43, p<0.001). However, around the two dispensaries located to the west 
of the study area, we noticed a cluster with high exposure to malaria with paradoxically low 
malaria incidence. Using the Kulldorff’s spatial scan statistic, we formally tested the 
hypothesis of a spatial clustering of individuals with high exposure indexes, high incidence 
of febrile malaria and aimed at visualizing the extent of overlapping between the hotspots of 
febrile malaria cases and the hotspots of high exposure indexes. We found considerable 
overlapping between a single hotspot of high malaria exposure with three overlapping 
hotspots of febrile malaria (Figure 2.7). 
 
 
Figure 2.6. Spatial distribution of febrile malaria episodes in the study area. Each dot represents a child. 
The colour shading increases with the frequency of febrile malaria episodes or intensity of exposure to 
malaria experienced by the child. Blue triangles represent study dispensaries. The red triangle 
represents the regional referral hospital 
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Figure 2.7. Spatial clustering of febrile malaria episodes and high exposure indexes in the study area. 
Each green dot represents a homestead. The red circles represent hotspots of febrile malaria cases. 
The orange circle represents the single hotspot of high exposure indexes.  
 
In the present infant cohort study, we have detected hotspots of febrile malaria cases and this 
could serve as a basis for targeted malaria control interventions. However febrile malaria 
might not be an ideal marker in older children or adults, especially in a high and stable 
transmission context since high exposure would lead to a rapid development of clinical 
immunity and instability of the hotspots what would complicate the planning of control 
interventions (Bejon, Williams et al. 2010, Bousema, Griffin et al. 2012). Other transmission 
markers have been used in different studies, but data on the relationship between these 
markers, that might guide the choice of the marker, is scarce.
   
 
2.4.4 Anti-malaria antibody kinetics  
Anti-GLURP R0 and anti-GLURP R2 antibodies were more closely correlated to each other 
(r=0.52, p<0.001) than either anti-GLURP sub-unit antibody was correlated with anti-MSP3 
antibody titres (r=0.35, p<0.001 and r=0.4, p<0.001 respectively).  
Antibody titres at one time point were weakly to moderately correlated with antibody titres 
at the next time point (rho ranging from -0.28 to 0.55; 0.31 to 0.58 and 0.15 to 0.60, 
respectively for anti-MSP3, anti-GLURP R0 and anti-GLURP R2 antibody titres) with the 
strongest correlations observed from baseline to month 3, and months 9 to 12 (Table 2.2).    
Table 2.2. Variability in antibody titres. The correlations are examined between every two consecutive 
time points for antibody measurement. Antibody titres are in log2 scale. 
Time points (months) Anti-MSP3* Anti-GLURP R0* Anti-GLURP R2* 
 r P r p r P 
M0M3 0.5460 <0.0001 0.5514 <0.0001 0.6022 <0.0001 
M3M6 0.1805 0.0852 0.3410 0.0009 0.3480 0.0007 
M6M9 0.4015 0.0001 0.4074 0.0001 0.2448 0.0187 
M9M12 0.4265 <0.0001 0.5885 <0.0001 0.4444 <0.0001 
M12M18 0.3054 0.0031 0.3657 0.0003 0.2819 0.0065 
M18M24 -0.2800 0.0069 0.3148 0.0022 0.1489 0.1565 
             
The time-course of individual antibody kinetics is shown in figure 2.8. In follow-up studies, 
both analytical and biological variation contribute to the overall variation of repeated 
measurements (Monach 2012). The present study samples antibody titres were measured in 
the same laboratory following a standard operating procedure. Samples were not processed 
the same day, but the results were adjusted for plate to plate (duplicate testing) and day to 
day variation to limit analytical bias. Samples were also collected, processed and stored 
following a standard procedure. Though we cannot precisely quantify the contribution of 
analytical and pre-analytical bias resulting from laboratory variation in antibody titres, we 
hypothesize that biological variation explains most of the observed dynamics, since the 
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decline observed in the first six months of follow-up is in keeping with what is expected for 
the maternal antibodies from a biological perspective. 
 
Figure 2.8. Individual trajectories of antibody responses to MSP3, GLURP R0 and GLURP R2. 
 
 
Figure 2.9. Lines of best fit for antibody dynamics in the first two years of life. 
 
In Figure 2.9, we show the individual antibody titres and the best-fit line using multiple 
fractional polynomials of age.  There is an overall decline of total IgG titres to the three 
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antigens from one to four months of age, presumably indicating the waning of maternally-
derived anti-malaria antibodies. Thereafter, both the anti-GLURP R2 and anti-GLURP R0 
total IgG titres rise slightly with increasing age, while anti-MSP3 total IgG titres remain 
constant.  
2.4.5 Predictive factors for the changing antibody titres. 
In this analysis, there was one observation per individual per observation period and 
observations were clustered by individual in the analysis to adjust for repeated measures. 
Univariate analysis 
In the univariate analysis, the only common predictor that was statistically significantly and 
consistently associated with antibody titres was age. There was a tendency for residence in 
the urban zone and higher education level to be associated with lower antibody levels. 
Exposure index, number of previous episodes, haemoglobin type, number of IPTp courses 
had variable effects on the levels of antibodies to the different merozoite antigens. The 
univariate analysis is summarized in table 2.3. 
 
 
 
   
Table 2.3. Predictive model for changing anti-malaria antibody titres using linear regression. Univariate 
analysis. *Powers of multiple fractional polynomials of age. **Only one participant had haemoglobin 
phenotype AS. 
 IgG anti-MSP3 IgG anti-GLURP R0 IgG anti-GLURP R2 
Predictor Coef.  95% CI p Coef. 95%CI P Coef. 95%CI p 
Age power (-2/-5/-5)* 0.02 [0.02, 0.03] <0.001 0.24 [0.10, 0.39] 0.001 0.51 [0.36, 0.66] <0.001 
Age power (NA/0/-5)* - - - -0.10 [-0.21, 0.02] 0.093 -0.19 [-0.24, -0.14] <0.001 
Sex          
        Male 0 - - 0 - - 0 - - 
        Female -0.18 [-0.42, 0.07] 0.154 0.14 [-0.11, 0.40] 0.273 -0.22 [-0.54, 0.10] 0.179 
Weight (baseline) -0.04 [-0.25, 0.17] 0.723 -0.06 [-0.26, 0.15] 0.589 -0.20 [-0.46, 0.07] 0.139 
Length (baseline) 0.02 [-0.02, 0.06] 0.310 -0.002 [-0.05, 0.05] 0.944 -0.04 [-0.11, 0.02] 0.182 
MUAC (baseline) 0.05 [-0.07, 0.18] 0.425 0.002 [-0.11, 0.11] 0.976 -0.04 [-0.17, 0.09] 0.563 
Foetal Hb rate (baseline) 0.006 [-0.006, 0.02] 0.317 0.001 [-0.01, 0.01] 0.893 0.01 [-0.003, 0.02] 0.144 
Haemoglobin type          
        AA 0 - - 0 - - 0 - - 
        AS** NA - - NA - - NA - - 
        AC -0.22 [-0.44, -0.17] 0.276 0.05 [-0.38, 0.48] 0.832 0.04 [-0.49, 0.56] 0.885 
        CC 0.04 [-0.65, 0.73] 0.911 0.01 [-0.55, 0.58] 0.963 0.36 [0.003, 0.71] 0.048 
Month of birth          
        October 0 - - 0 - - 0 - - 
        November 0.30 [-0.07, 0.66] 0.108 0.17 [-0.25, 0.59] 0.421 0.07 [-0.40, 0.55] 0.757 
        December 0.07 [-0.30, 0.44] 0.724 0.10 [-0.32, 0.52] 0.636 -0.30 [-0.80, 0.20] 0.235 
        January -0.02 [-0.41, 0.38] 0.927 0.30 [-0.19, 0.80] 0.222 0.14 [-0.40, 0.68] 0.603 
EPI status (Baseline)          
        Up to date 0 - - 0 - - 0 - - 
        Not up to date 0.22 [-0.20, 0.63] 0.307 0.29 [-0.08, 0.66] 0.121 -0.01 [-0.45, 0.43] 0.961 
Age mother (baseline) 0.02 [-0.001, 0.04] 0.057 0.01 [-0.005, 0.03] 0.138 0.02 [-0.01, 0.04] 0.166 
Gravidity status          
        Primigravidae 0 - - 0 - - 0 - - 
        Multigravidae 0.18 [-0.11, 0.47] 0.213 0.05 [-0.20, 0.29] 0.704 0.01 [-0.34, 0.37] 0.945 
ITN use (pregnancy)          
        Yes 0 - - 0 - - 0 - - 
        No -0.10 [-0.47, 0.27] 0.599 0.15 [-0.26, 0.55] 0.471 0.21 [-0.26, 0.68] 0.372 
IPTp courses          
        0 0 - - 0 - - 0 - - 
        1 0.56 [0.17, 0.94] 0.005 -0.22 [-0.93, 0.50] 0.549 -0.73 [-1.49, 0.03] 0.060 
        2 0.35 [0.07, 0.64] 0.017 -0.24 [-0.89, 0.40] 0.462 -0.75 [-1.47, -0.03] 0.040 
        3 0.20 [-0.06, 0.45] 0.127 -0.12 [-0.81, 0.57] 0.737 -1.88 [-3.06, -0.70] 0.002 
Education level (mother)          
        None 0 - - 0 - - 0 - - 
        Primary 0.18 [-0.07, 0.43] 0.150 -0.07 [-0.38, 0.25] 0.648 -0.21 [-0.57, 0.16] 0.260 
        Secondary or above -0.36 [-0.76, 0.08] 0.116 -0.31 [-0.63, 0.01] 0.057 -0.50 [-0.87, -0.12] 0.010 
Zone of residence          
        Rural 0 - - 0 - - 0 - - 
        Urban -0.25 [-0.53, 0.02] 0.074 -0.44 [-0.72, -0.15] 0.003 -0.70 [-1.05, -0.36] <0.001 
        Mixed 0.21 [-0.10, 0.53] 0.175 -0.43 [-0.77, -0.10] 0.010 -0.35 [-0.74, 0.03] 0.072 
Season          
        Dry season 0 - - 0 - - 0 - - 
        Rains -0.10 [-0.32, 0.12] 0.355 0.11 [-0.04, 0.26] 0.133 -0.08 [-0.31, 0.14] 0.461 
Malaria exposure index 0.03 [0.01, 0.05] 0.011 -0.0003 [-0.02, 0.02] 0.976 0.02 [-0.002, 0.05] 0.069 
Number previous infections 0.05 [-0.06, 0.17] 0.373 0.28 [0.17, 0.38] <0.001 0.28 [0.14, 0.41] <0.001 
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Multivariable analysis 
The Wald test was used to select variables. Some variables, nonsignificant in our univariate 
analysis, were retained in the final model based on compelling evidence for their association 
with immune responses in the published literature. Age and variables directly related to 
exposure such as ITN use were then kept in the final model. In the final multivariable model, 
age, season and the number of malaria episodes recorded immediately before the blood 
sample collection were the statistically significant predictors of the titres of antibodies to 
MSP3, GLURP R0 and GLURP R2. The results of multivariable analysis are shown in table 
2.4.  
 Table 2.4. Multivariable predictive model for changing anti-malaria antibody titres. 
a
 Age is 
transformed in multiple fractional polynomials with the corresponding powers for antibodies to MSP3, 
GLURP R0 and GLURP R2 indicated in brackets.
 b
 Number of malaria infections recorded before the 
following time point for antibody measurement. 
 
 
 
 
 
 IgG anti-MSP3 IgG anti-GLURP R0 IgG anti-GLURP R2 
Predictor Coef. 95% CI p Coef. 95%CI p Coef. 95%CI p 
Age power (-2/-5/-5) a 0.02 [0.02, 0.03] <0.001 2 [1.49, 2.50] <0.001 -2.04 [-2.98, -1.10] <0.001 
Age power (NA/0/-5) a - - - 1.19 [0.79, 1.58] <0.001 -0.92 [-1.21, -0.62] <0.001 
ITN use (pregnancy)          
        Yes 0 - - 0 - - 0 - - 
        No -0.11 [-0.49, 0.26] 0.548 0.16 [-0.22, 0.53] 0.413 0.02 [-0.44, 0.48] 0.918 
Season          
        Dry season 0 - - 0 - - 0 - - 
        Rains 0.35 [0.13, 0.57] 0.002 0.33 [0.19, 0.47] <0.001 0.28 [0.07, 0.50] 0.011 
Malaria exposure index 0.02 [-0.003, 0.04] 0.098 -0.01 [-0.03, 
0.006] 
0.202 0.01 [-0.01, 0.04] 0.393 
Number previous infectionsb 0.12 [-0.002, 0.24] 0.053 0.28 [0.17, 0.39] <0.001 0.31 [0.17, 0.45] <0.001 
 Page 81 of 349 
 
2.4.6 Antibody titres and risk of febrile malaria 
Kaplan Meier estimates of survival to febrile malaria 
By the end of the monitoring period, 74.4% of the children had experienced at least one 
episode of febrile malaria (fever + asexual parasitaemia>10000/µL). In Figure 2.10 we can 
also discern the seasonality and stability of the malaria transmission in the study area. 
 
Figure 2.10. Kaplan Meier survival estimates of the children over the first two years of life. 
 
The results of the test for the proportionality of hazards are summarized in Figure 2.11 and 
Figure 2.12. Overall, there was no significant variation in the proportionality of hazards over 
time, but there was borderline variation in varying hazards for the exposure index (p=0.082, 
in the direction of decreasing hazard over time) and for foetal haemoglobin (p=0.098, in the 
direction of increasing hazard over time). 
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Figure 2.11. Kaplan Meier estimates of survival to febrile malaria with respect to febrile malaria risk 
factors categorized into tertiles. The log-rank test compares the survival distribution between the three 
groups for each factor. 
 
                      
Figure 2.12. Test of proportional hazards assumption: Schoenfeld residuals plots. 
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Univariate analysis 
Only month of birth and residence in the urban zone of the study site were associated with 
reduced risk of febrile malaria. Indeed, children born in January were at lower risk of malaria 
compared to those born in the last quarter of the year. Anti-MSP3 antibody titres were 
significantly associated with an increased risk of febrile malaria and no evidence of 
association between anti-GLURP antibody titres and risk of febrile malaria was found.  The 
extrinsic predictors that were associated with higher risk of febrile malaria were the wet 
season and the individual malaria exposure. The results of the univariate analysis are shown 
in table 2.5. 
Table 2.5. Univariate models of risk of malaria. 
 Cox regression Negative binomial regression 
Predictor HR 95% CI P IRR 95% CI P 
Age     1.12 [1.10, 1.13] <0.001 
Sex       
        Male 1 - - 1 - - 
        Female 0.86 [0.57, 1.30] 0475 0.87 [0.63, 1.21] 0.418 
Weight (baseline) 1.06 [0.75, 1.50] 0.754 1.10 [0.83, 1.44] 0.509 
Length (baseline) 1.03 [0.95, 1.13] 0.442 1.03 [0.98, 1.10] 0.259 
MUAC (baseline) 1.13 [0.95, 1.34] 0.182 1.22 [1.04, 1.42] 0.012 
Foetal Hb rate (baseline) 0.98 [0.97, 
1.001] 
0.075 0.99 [0.98, 1.003] 0.133 
Haemoglobin type       
        AA 1 - - 1 - - 
        AS* NA - - NA - - 
        AC 1.30 [0.71, 2.39] 0.401 1.15 [0.76, 1.74] 0.510 
        CC 0.50 [0.12, 2.03] 0.330 0.65 [1.16, 2.69] 0.557 
Anti-MSP3 (changing) 1.41 [1.16, 1.70] <0.001 1.12 [1.01, 1.24] 0.037 
Anti-GLURP R0 (changing) 1.11 [0.90, 1.37] 0.326 1.12 [1.02, 1.24] 0.021 
Anti-GLURP R2 (changing) 1.03 [0.89, 1.20] 0.664 1.01 [0.92, 1.10] 0.915 
Anti-MSP3 (baseline) 0.96 [0.85, 1.07] 0.460 0.99 [0.91, 1.10] 0.986 
Anti-GLURP R0 (baseline) 1.01 [0.87, 1.16] 0.945 1.05 [0.95, 1.17] 0.331 
Anti-GLURP R2 (baseline) 1.04 [0.92, 1.18] 0.534 1.08 [0.99, 1.18] 0.090 
Month of birth       
        October 1 - - 1 - - 
        November 1.41 [0.64, 3.08] 0.392 0.44 [0.22, 0.88] 0.020 
        December 1.33 [0.61, 2.88] 0.476 0.61 [0.40, 0.92] 0.018 
        January 2.49 [1.10, 5.64] 0.029 0.66 [0.44, 0.98] 0.040 
EPI status (baseline)       
        Up to date 1 - - 1 - - 
        Not up to date 1.24 [0.69, 2.23] 0.476 1.38 [0.95, 1.99] 0.089 
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 Cox regression Negative binomial regression 
Predictor HR 95% CI P IRR 95% CI P 
Age mother (baseline) 1.02 [0.98, 1.05] 0.348 1.02 [1, 1.05] 0.055 
Gravidity status       
        Primigravidae 1 - - 1 - - 
        Multigravidae 0.99 [0.59, 1.64] 0.957 1.16 [0.78, 174] 0.470 
ITN use (pregnancy)       
        Yes 1 - - 1 - - 
        No 0.87 [0.44, 1.74] 0.703 1.11 [0.65, 1.91] 0.705 
IPTp courses       
        0 1 - - 1 - - 
        1 1.71 [0.62, 4.53] 0.284 2.04 [0.89, 4.67] 0.090 
        2 1.26 [0.51, 3.14] 0.618 1.5 [0.68, 3.31] 0.314 
        3 0.65 [0.08, 5.54] 0.691 0.71 [0.13, 3.79] 0.684 
Education level (mother)       
        None 1 - - 1 - - 
        Primary 1.39 [0.88, 2.17] 0.156 1.21 [0.87, 1.68] 0.254 
        Secondary or above 0.64 [0.33, 1.27] 0.203 0.33 [0.20, 0.55] <0.001 
Zone of residence       
        Rural 1 - - 1 - - 
        Urban 0.43 [0.25, 0.73] 0.002 0.38 [0.24, 0.59] <0.001 
        Mixed 1.32 [0.82, 2.14] 0.252 1.15 [0.84, 1.58] 0.383 
Season       
        Dry season 1   1 - - 
        Rains 10.10 [2.83, 36] <0.001 2.02 [1.48, 2.76] <0.001 
Malaria exposure index 1.08 [1.04, 1.11] <0.001 1.06 [1.03, 1.10] <0.001 
 
 Multivariate analysis 
The results of negative binomial regression were consistent with the Cox regression analysis 
(Table 2.6). Changing anti-MSP3 antibody titres were significantly associated with 
increased risk of febrile malaria episodes in both models.  Season and individual malaria 
exposure index were significantly associated with increased risk of febrile malaria episodes.  
The baseline foetal haemoglobin fraction showed a protective effect in the multivariable 
model (HR=0.97, p=0.003); this was dependent on adjusting for exposure index in the 
multivariable model and we noted a non-significant correlation between foetal haemoglobin 
and exposure index (r=0.17, p=0.064). Belonging to the haemoglobin CC type group was 
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also significantly associated with decreased malaria risk (IRR=0.44, p=0.046) after adjusting 
for the other covariates. 
Table 2.6. Multivariable models of risk of malaria using changing anti-malaria antibody titres. 
a
 MUAC: 
mid upper arm circumference. 
b
 Hb: haemoglobin. 
c
 NA not applicable; only one child had 
haemoglobin AS type. 
d
 HR: hazard ratio. 
e
 IRR: incidence rate ratio. 
 Cox regression Negative binomial regression 
Predictor HR d 95%CI p IRR e 95%CI p 
Age NA - - 1.11 [1.09, 1.13] <0.001 
MUAC (baseline) a - - - 1.26 [1.09, 1.45] 0.002 
Foetal Hb rate (baseline) b 0.97 [0.96, 0.99] 0.003 0.98 [0.97, 0.99] 0.013 
Haemoglobin type       
        AA 1 - - 1 - - 
        AS c NA c - - NA c - - 
        AC 1.29 [0.68, 2.47] 0.430 1.14 [0.75, 1.72] 0.540 
        CC 0.52 [0.12, 2.19] 0.370 0.44 [0.19, 0.99] 0.046 
Anti-MSP3 (changing) 1.34 [1.08, 1.66] 0.007 1.17 [1.04, 1.30] 0.007 
Anti-GLURP R0 (changing) 1.15 [0.91, 1.44] 0.233 1.003 [0.88, 1.14] 0.968 
Anti-GLURP R2 (changing) 0.98 [0.83, 1.16] 0.859 0.92 [0.82, 1.03] 0.149 
ITN use (pregnancy)       
        Yes 1 - - 1 - - 
        No 0.86 [0.41, 1.79] 0.687 1.23 [0.80, 1.88] 0.348 
Season       
        Dry season 1 - - 1 - - 
        Rains 10.85 [2.80, 42.15] 0.001 1.4 [1.02, 1.92] 0.037 
Malaria exposure index 1.08 [1.04, 1.13] <0.001 1.06 [1.03, 109] <0.001 
 
 
In this study, we observed a very low incidence of febrile malaria in the first six months of 
life with a median time to first infection of 9.8 months in a context of stable but markedly 
seasonal malaria transmission. The two-year cumulative febrile malaria incidence was 
79.6% with an incidence rate of 1.2 episodes / child / year (95%CI, 1.06-1.33). Anti-malaria 
antibodies and foetal haemoglobin were investigated in relation to resistance to malaria in a 
cohort of 140 infants. Antibody titres to GLURP and MSP3 were found to decline in the first 
2.5 Discussion  
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four months of life, presumably due to the loss of maternal antibodies. Endogenous 
production was responsible for the subsequent increase in the case of GLURP and 
stabilization of the loss of antibodies for MSP3.  Contrary to our expectations, there was no 
association between antibody titres to GLURP (R0 and R2) and the risk of febrile malaria in 
the first two years of life; antibody titres to MSP3 even appeared as a marker of exposure 
since it was statistically significantly positively associated with the risk of febrile malaria 
and inversely associated with time to first febrile malaria episode. Confounding between 
malaria risk and antibody titres by variation in exposure has previously been reported (Bejon, 
Cook et al. 2011, Greenhouse, Ho et al. 2011). Besides that, we observed a spatial clustering 
of highly exposed children and febrile malaria cases in the Northern part of the study area.  
We found that the incidence of febrile malaria in young infants was low in our study. 
However, the timing of the study was not ideal to assess the role of maternally-derived 
antibodies per se in this apparent resistance. The median time to first malaria infection in 
our study (9.8 months) was much higher than previously reported in a mesoendemic area in 
Benin (4.88 and 6.11 months in children born from infected and uninfected placentas 
respectively) (Le Port, Watier et al. 2011). This is likely due to the timing of the recruitment 
that took place during the dry season and there were 4 to 5 months of dry season remaining 
before the malaria season began. The observation of a low febrile malaria incidence in a 
cluster of high exposure may be explained by a more rapid acquisition of immunity to febrile 
malaria in children residing in this cluster due to a more intense exposure (Filipe, Riley et 
al. 2007). The spatial clustering of febrile malaria cases in the northern part of the study area 
is likely due to the presence of more suitable environmental factors for malaria vectors. 
Indeed, this zone is marshy and mainly rural in contrast to the southern part that overlaps 
with Banfora town. Long distances to dispensaries constitute a factor for poor accessibility 
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to healthcare in impoverished areas (Müller, Smith et al. 1998) and we wanted to investigate 
if residing far from dispensaries affected the healthcare seeking behaviour. The weak 
positive correlation found between distance to health facility and incidence of febrile 
malaria, further reduced by restricting the analysis to passive case detection, do not suggest 
a bias in sensitivity for cases based on distance to dispensary. 
The lack of association between antibodies to GLURP (R0 and R2) and protection against 
clinical malaria in our study is partially concordant with the findings of a previous study in 
older children in Burkina Faso. Nebie and colleagues investigated total IgG to GLURP (R0 
and R2) among others antigens in children aged 6 months to 10 years and found a protective 
effect for antibodies to GLURP R0 but not to GLURP R2 when the antibody titres were 
analysed individually. When antibody titres to the four antigens we have tested (NANP, 
GLURP R0 and R2, MSP3) were included in the multivariable model, antibodies to GLURP 
(R0 and R2) were no longer associated with protection against malaria (Nebie, Tiono et al. 
2008). In Ghana, Dodoo and colleagues reported a protective effect of total IgG and IgG 
subclasses to GLURP (R0 and R2) in the univariate analysis. However, neither total IgG nor 
IgG subclasses to GLURP (R0 and R2) were significantly protective when all the serological 
covariates were included in the final multivariable model (Dodoo, Aikins et al. 2008, Dodoo, 
Atuguba et al. 2011). In a study conducted in Tanzania by Lusingu and colleagues, total IgG 
to GLURP R0 was not associated with protection against febrile malaria; among IgG 
subclasses only IgG1 was associated with protection (Lusingu, Vestergaard et al. 2005).  
In contrast, other studies have demonstrated a protective association for antibodies to 
GLURP (R0 and R2) in older children and adults (Dodoo, Theisen et al. 2000, Oeuvray, 
Theisen et al. 2000, Meraldi, Nebie et al. 2004, Courtin, Oesterholt et al. 2009). In a study 
in Myanmar that investigated antibodies to MSP1, MSP3, GLURP (R0, R1, R2), only 
 Page 88 of 349 
 
antibodies to GLURP R0 showed a protective effect when all the antibodies were included 
in the multivariable analysis (Soe, Theisen et al. 2004). 
Antibodies to MSP3 have been associated with protection in previous sero-epidemiological 
studies (Meraldi, Nebie et al. 2004, Soe, Theisen et al. 2004, Roussilhon, Oeuvray et al. 
2007, Osier, Fegan et al. 2008) and a vaccine trial (Sirima, Cousens et al. 2011) although the 
assessment of efficacy was not the primary objective in the latter. However, other studies 
did not find a protective effect of antibodies to MSP3 (Dodoo, Aikins et al. 2008, Courtin, 
Oesterholt et al. 2009, Dodoo, Atuguba et al. 2011) but none of these studies concluded on 
antibodies to MSP3 appearing as a marker of exposure.   
Although antibodies to MSP3 and GLURP have not been previously studied in newborn 
cohorts, antibodies to other P. falciparum antigens have been investigated. In sero-
epidemiological newborn cohort studies, antibodies to crude P. falciparum schizont extract 
and MSP2 were found to be associated with higher risk of malaria infection in infants 
(Wagner, Koram et al. 1998, Riley, Wagner et al. 2000). Evidence for an association with 
protection against clinical malaria has been reported only for antibodies to MSP1-19 (Høgh, 
Marbiah et al. 1995, Branch, Udhayakumar et al. 1998). Antibodies to MSP3 and GLURP 
(R0 and R2) were not associated with protection in our study, and we suggest that 
confounding due to exposure led to an apparent association with increased risk for antibodies 
to MSP3.   
Interestingly, foetal haemoglobin was significantly inversely associated with febrile malaria 
risk, although the effect size was relatively small.  The effect was only statistically 
significant on multivariable analysis, and appeared to depend on adjusting for exposure 
index.  Furthermore the effect seems to be evident after 6 months of age, when we would 
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expect foetal haemoglobin to have been lost from the circulation.  We speculate that an 
interaction between malaria exposure and foetal haemoglobin may be responsible for a 
delayed protective effect, perhaps due to an early but controlled infection in the presence of 
high levels of foetal haemoglobin leading to more rapid acquisition of immunity (Pombo, 
Lawrence et al. 2002).  Children who carried the haemoglobin CC type appeared to have a 
significantly lower risk of malaria as compared to haemoglobin AA type children, as it has 
been previously reported (Modiano, Luoni et al. 2001, Bougouma, Tiono et al. 2012). 
The limitations of our study include the fact that the high malaria transmission season began 
5-7 months after recruitment.  Therefore the majority of the maternal antibodies were likely 
gone by the time that febrile malaria episodes began, and children were exposed during a 
period of lower antibody titres.  We did not use an external control to quantify malaria 
antibodies as performed elsewhere (Murungi, Kamuyu et al. 2013). However, we speculate 
that antibody titres at 5 months and beyond were lower than those previously reported to be 
protective (Høgh, Marbiah et al. 1995, Branch, Udhayakumar et al. 1998). 
In conclusion, the present study did not find any evidence for an association between 
antibody titres to MSP3 and GLURP (R0 and R2) and protection against P. falciparum 
febrile malaria in children in their first two years of life. However the humoral immune 
response to malaria is expansive, directed to a broad repertoire of antigens and we cannot 
rule out a possible protective effect of antibodies. Sero-epidemiological studies are more 
informative when they include a wide range of immune targets and when they are 
standardized to allow comparisons across sites.  
2.6 Conclusion  
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In the previous chapter, we have examined the relationship between antibodies to synthetic 
GLURP and MSP3 and the risk of febrile malaria in young children.  We found associations 
between increasing antibody levels and increasing risk of malaria, and no evidence for 
protective antibody responses.  Limitations of this previous study were the limited number 
of antigens that were tested, and the lack of standardized controls that would have allowed 
the estimation of relative antibody concentrations and a comparison with protective 
thresholds. 
Indeed, in the search of immune correlates of protection to help disentangle conflicting 
results previously reported from sero-epidemiological studies, it has been recently shown 
that antibodies need to reach a threshold concentration to achieve protection against febrile 
malaria in children (Murungi, Kamuyu et al. 2013, Rono, Osier et al. 2013). Briefly, for each 
specific antibody response, they used a modified Poisson regression to model the association 
between the risk of clinical malaria and antibody concentration categorised into high vs low 
responders using a series of arbitrary cut-offs within the range of the levels measured in their 
study cohort . The protective threshold concentration was then selected based on the log 
pseudolikelihood of the regression model. These thresholds have then been validated in a 
3. CHAPTER 3: Does transmission intensity affect young children’s antibody titres in 
relation to established protective threshold antibody concentrations in their first two years 
of life  
 
3.1 Introduction 
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second independent cohort of lower transmission intensity in Kenya (Murungi, Kamuyu et 
al. 2013). The same methods were used to derive protective thresholds in a child cohort study 
in coastal Tanzania (Rono, Osier et al. 2013).  
In this chapter, I describe our use of the sample and data set described in chapter 2, but with 
the following additions: a) access to an additional set of antigens, b) a quantification of 
antibodies using standards and c) a comparison of antibody levels with an additional sample 
set from Senegal.  
As described in chapter 2, initial antigen selection was driven largely by availability. Here I 
selected 4 further antigens which are used in KEMRI-Wellcome, Kilifi, as reviewed above 
in 1.7.2.4. 
Furthermore, I was able to compare antibody levels in two different sites with differing 
malaria transmission (i.e. Burkina Faso vs Senegal) with the hypothesis that transmission 
intensity might determine differences in the starting levels of maternally-derived antibodies, 
the antibody decay rate and the subsequent endogenous production. The study in Senegal 
was conducted by the Department of parasitology of Cheikh Anta Diop University in Keur 
Soce Health and demographic surveillance system to assess malaria morbidity in infancy 
and investigate the association between antibodies and the risk of malaria. This study in Keur 
Soce was conducted in collaboration with CNRFP and KEMRI-WTRP within the Malaria 
Vectored Vaccines Consortium (MVVC). Aliquots of the plasma samples in Banfora 
(Burkina Faso) and Keur Soce (Senegal) were then prepared and transferred, frozen in dry 
ice, to KEMRI-CGMRC laboratories (Kenya) where it was possible to use an external 
control allowing a comparison of the measured antibody levels with these previously 
established protective thresholds.  
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We conducted the present study with the following objectives. 
Primary objective:  
To investigate the impact of transmission intensity on the dynamics of antibody levels and 
kinetics in the first 18 months of life.  
Secondary objectives:  
 To expand the panel of P. falciparum antigens in the ELISA to test the hypothesis of 
an association between total IgG merozoite antigens and protection against clinical 
malaria 
 To include an external control so that antibody levels could be estimated in 
comparison with established protective threshold concentrations.  
 
3.3.1 Ethical statement 
The ethical approval for the work in Burkina Faso was obtained from the Institutional 
Review Board of Centre National de Recherche et de Formation sur le Paludisme (CNRFP) 
in Burkina Faso. In Senegal, the study was approved by the National Ethics Committee. The 
parents of each child were informed and an individual written consent obtained prior to 
performing any study-specific procedure on the child. The studies in both settings were 
conducted according to the principles of the Declaration of Helsinki.  
3.2 Study objectives 
3.3 Methods  
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3.3.2 Study site and population 
The study was conducted in Banfora (Burkina Faso) and Keur Soce (Senegal) in parallel. 
The Banfora site and study population have been described in detail in chapter two. In Keur 
Soce, the annual rainfall is less than Banfora, at 300 mm with rains from July to 
October.  Transmission of malaria has previously been stable and seasonal, but has recently 
reduced (Trape, Tall et al.).  The parasite rate in children aged less than ten years and  living 
in Keur Soce was 0.3% in 2010 (Sylla, Tine et al. 2015). In all, 150 infants were recruited 
into the Keur Soce cohort. 
3.3.3 Surveillance of malaria morbidity, parasitological examination and haemoglobin 
typing 
The Keur Soce infant cohort was recruited at the same time and using the same criteria as 
described in chapter two for the Banfora cohort, and the children were monitored as their 
counterparts in Banfora. No haemoglobin typing was performed for the Keur Soce cohort.  
3.3.4  Selection of samples for serological tests 
For a subset of 40 children at each site (sampled randomly without replacement among all 
children with complete serum sample sets using Stata 13.1), samples at baseline, 2, 3, 4, 5, 
6, 9, 12, 15 and 18 months were analysed to compare antibody dynamics. The samples of 
the remaining children in the Banfora cohort were analysed only at baseline, 3, 6, 9, 12 and 
18 months and included in the analysis of the association between antibody levels and risk 
of clinical malaria in that cohort. The decision to select exactly 40 children at each site was 
arbitrary. 
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3.3.5 P. falciparum merozoite antigens tested in the assays 
The following four recombinant merozoite antigens were tested in this study: the His-tagged 
AMA1 of the 3D7 allelic form (Osier, Weedall et al. 2010), the GST-tagged MSP1-19 of the 
Wellcome parasite line (Burghaus and Holder 1994), the GST-tagged MSP2 of the Dd2 
parasite line (Taylor, Smith et al. 1995) and the MBP-tagged MSP3 of the 3D7 allelic form 
(Osier, Fegan et al. 2008). We have used all the antigens that were available to us at the time 
of the assays. 
3.3.6 Antibody titres measurement by indirect ELISA 
Plasma total IgG to AMA1-3D7, MSP1-19, MSP2-Dd2 and MSP3-3D7 were measured as 
described elsewhere (Osier, Polley et al. 2007, Murungi, Kamuyu et al. 2013) with samples 
diluted at 1:500. The indirect ELISA assays testing AMA1-3D7, MSP2-Dd2 and MSP3-3D7 
were done in duplicates for the first 372 samples (representing 26% of the total number of 
samples to analyse) to estimate the variability (coefficient of variation, CV) between the 
duplicates. The coefficient of variation was calculated as follows: CV= (standard 
deviation/mean)*100. We met a pre-set criterion that <5% of sample pairs had a CV>20 (i.e. 
0%, 0.81% and 1.88% respectively for responses to AMA1-3D7, MSP2-Dd2 and MSP3-
3D7) and so proceeded with assays in singles rather than duplicates.  
Ninety six wells microplates were coated with 200 µL/well of the P. falciparum merozoite 
antigens diluted at 50 ng/100 µL of coating buffer (15 mm Na2CO3, 35 mm NaHCO3, 
pH 9·3) and incubated overnight at 4°C. The wells were then washed four times in washing 
buffer (Phosphate Buffered Saline + 0.05% Tween 20 (PBST)) to remove unbound proteins, 
and blocked for five hours at room temperature with 200 µL/well of blocking buffer (1% 
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skimmed milk in PBST) to reduce subsequent non-specific antibody binding. At the end of 
the blocking time, the plates were washed four times in PBST and the wells reacted overnight 
at 4°C with 100 µL/well of plasma samples diluted at 1:500 in blocking buffer. After 
washing the plates four times in PBST to remove unbound human antibodies, 100 µL of a 
secondary antibody (HRP-conjugated rabbit anti-human IgG / Dako Ltd, Buckinghamshire, 
UK) at 1:5000 dilution in blocking buffer was added to each wells and left for incubation at 
room temperature for three hours. The plates were then washed four times with PBST before 
a substrate solution (distilled water + 0.1M Citric acid + 0.2M Na2HPO4 + H2O2 + O-
phenylenediamine (Sigma, St. Louis, MO, USA)) is reacted with the wells for fifteen 
minutes. The reaction was then stopped by addition of 25ul of 2M sulphuric acid and the 
absorbance read at 492 nm. Each plate included positive controls in two wells (Malaria 
Immune Globulin (MIG) reagent with total IgG concentration of 50mg/ml from the Central 
Laboratory Blood Transfusion Service SRC, Switzerland) and negative control sera from 
malaria-naïve UK donors. 
All the samples were not assayed the same day. Day to day variation factors were calculated 
as the ratio of the average optical density (OD) of the positive control on a reference plate 
by the average OD of the positive control on each other plate. The day to day variation factor 
of the reference plate is 1. The ODs were then adjusted for day to day variation by 
multiplying the ODs of the samples on each plate by the corresponding variation factor. 
After adjusting ODs for day to day variation, for antigens that are GST or MBP-tagged, the 
actual OD of each sample was obtained by subtracting the OD of the tag. A four-parameter 
logistic regression was used to model the relationship between serial dilutions of a purified 
IgG standard (MIG) and the corresponding ODs, and therefore to allow conversion of the 
study samples ODs into antibody concentrations. Antibody concentrations were then 
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transformed into arbitrary units (AU) as previously described (Murungi, Kamuyu et al. 
2013). Briefly, antibody concentrations were first transformed from log to normal scale, 
multiplied by the sample dilution factor (500) to get the concentration in µg/mL and finally 
divided by 1000 to get the concentration in mg/mL assuming that the MIG (50mg/mL) 
contained 50 AU of antigen-specific antibodies. In the study samples for which the OD could 
not be converted because they did not fall within the span of the standard curve, the missing 
concentrations were replaced by the lowest or the highest interpolated concentration for very 
low ODs and very high ODs, respectively.  
3.3.7 Statistical methods 
Analysis of the dynamics of antibody titres 
We used Pearson correlation tests on log-transformed values to measure how strong the 
relationship is between antibody levels to a given antigen from one time point to the 
following one and between antigen-specific antibody titres. To estimate the overall decline 
of antibodies, we used a Random-Effects regression model of antibody titres on age to 
account for between and within-infant variability of antibody titres. We calculated the cut-
off value for seropositivity as the mean OD of negative controls plus 3 standard deviations. 
A Fisher Exact test was used to compare seroprevalence of antibodies to the P.f. merozoite 
antigens between both the sites at baseline.  Fractional polynomial regression models were 
constructed to fit the nonlinear relationship between anti-malaria antibody titre and age. The 
protective thresholds (for antibodies to AMA1-3D7, MSP1-19, MSP2-Dd2 and MSP3-3D7) 
displayed in the graphs have been taken from the results of studies conducted in the Kenyan 
Coast (Murungi, Kamuyu et al. 2013, Rono, Osier et al. 2013). 
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Analysis of correlates of protection 
The outcome measure, febrile malaria, was defined in chapter two as the association of fever 
(axillary temperature ≥ 37.5°C and/or reported fever in the past 24 hours) plus asexual 
parasitaemia ≥ 10000/µL. An individual malaria exposure index was calculated as described 
in chapter one. We have investigated the relationship between the putative correlates of 
protection (seropositivity and antibody titres) and febrile malaria using two approaches. 
First, we used Cox proportional hazards regression to model the relationship between 
antibodies and time to first febrile malaria episode, and tested the proportional hazards 
assumption using Kaplan Meier Method and Schoenfeld residuals. The second approach 
consisted of modelling the relationship between antibodies and the number of febrile malaria 
episodes experienced using a negative binomial regression with the Huber-White Sandwich 
estimator to account for clustering by individual. In the latter approach, the analysis period 
was restricted to the three months following each time point for malaria serology to account 
for the short half-life of anti-malaria antibodies (Kinyanjui, Bejon et al. 2009). The antibody 
titres of the study samples were included in the models as time-changing covariates with the 
measured value at the beginning of each interval related to the febrile episodes recorded 
within this interval. The overall significance of categorical variables was estimated using a 
Wald test. All the antibody titres used in the data analysis are arbitrary units in log10 scale. 
The data were analysed using GraphPad Prism version 6.00 for Windows, GraphPad 
Software and Stata 13.1 for Windows, StataCorp LP. 
3.4 Results 
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3.4.1 Malaria morbidity 
The characteristics of the Banfora infant cohort, follow up and malaria morbidity are 
described in detail in chapter two. Briefly, 296 febrile malaria episodes were recorded over 
249 child-years, with the number of cases peaking in October each year, giving an incidence 
rate of 1.2 episodes / child / year (95%CI, 1.06-1.33). In the first six months of life, five 
infections (two asymptomatic and three febrile) were detected, of which three occurred in 
the rains, in children aged above five months. In Keur Soce only 4 episodes of asymptomatic 
malaria were identified in the cohort of 150 infants, and no symptomatic episodes were 
identified.  This is consistent with long-term trends of malaria described elsewhere in 
Northern Senegal (Trape, Tall et al. 2014). 
3.4.2 Variability of antibody titres with time and transmission intensity 
Overall, antibody levels were moderately correlated to each other as shown in Table 3.1. 
Table 3.1. Correlations between the different antigen-specific antibodies (Banfora cohort). 
 AMA1-3D7 MSP1-19 MSP2-Dd2 MSP3-3D7 
AMA1-3D7 1    
MSP1-19 0.364 (p<0.001) 1   
MSP2-Dd2 0.466 (p<0.001) 0.472 (p<0.001) 1  
MSP3-3D7 0.392 (p<0.001) 0.214 (p<0.001)  0.413 (p<0.001) 1 
 
Antibody titres to AMA1-3D7, MSP1-19, MSP2-Dd2, MSP3-3D7 were strongly correlated  
from time point to time point during the first six months of life in both settings regardless of 
the transmission intensity (r, 0.86-0.98 in Keur Soce, 0.86-0.91 in Banfora for AMA-1) 
(Figure 3.1).  After the first 6 months of life, antibody titres were weakly to moderately 
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correlated to each other in Keur Soce (r, 0.21-0.47) but not correlated in Banfora (-0.21 to 
0.03).  
At baseline, the seroprevalence of antibodies to merozoite antigens was significantly higher 
in the Banfora cohort compared with Keur Soce cohort except for antibodies to MSP1-19 
(Table 3.2).  After a steady decline in the first six months of life regardless of the 
transmission intensity, the seroprevalence for responses to all the antigens tested was below 
20% for the remaining monitoring period in Keur Soce, the low transmission area. In 
Banfora where the transmission is higher, the seroprevalence peaked after six months for 
MSP1-19 and MSP3-3D7 corresponding approximately to the beginning of the first rainy 
season experienced by the children (Figure 3.2). 
Table 3.2. Differences in seroprevalence of antibodies to merozoite antigens at baseline between 
Banfora (high transmission intensity) and Keur Soce (low transmission intensity). *One-sided Fisher’s 
Exact test. 
 AMA1-3D7 MSP1-19 MSP2-Dd2 MSP3-3D7 
Banfora 0.97 (0.92, 1.02) 0.33 (0.19, 0.48) 0.95 (0.88, 1.02) 0.61 (0.46, 0.77) 
Keur Soce 0.80 (0.68, 0.92) 0.25 (0.12, 0.38) 0.57 (0.42, 0.73) 0.23 (0.10, 0.35) 
 p=0.016* p=0.285* p<0.001* p<0.001* 
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Figure 3.1. Correlation matrix of antibodies to AMA1-3D7 between time points for antibody titres 
measurement from baseline to month 18. The X and Y axis indicate antibody titres at the respective 
timepoints. 
              
Figure 3.2. Comparative dynamics of anti-merozoite antibody seroprevalences between Banfora (high 
transmission intensity) and Keur Soce (low transmission intensity). The next rainy season following the 
recruitment started approximately 5 months following the end of the recruitment. We then hypothesize 
that the sudden increase in the seroprevalence in Banfora is mostly explained by seasonality of malaria 
transmission. 
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No confidence interval was reported for the protective thresholds established by Murungi 
and colleagues (Murungi, Kamuyu et al. 2013); however, the antibody levels in our cohorts 
were mostly well below the protective thresholds throughout the follow up. Only anti-MSP2 
antibodies increased appreciably from month 9 in the high transmission setting (Figure 3.3, 
Figure 3.4).   
 
Figure 3.3. Comparative dynamics of individual antibody titres between Keur Soce and Banfora 
children. The dashed lines represent the protective thresholds established in children living in the 
Kenyan Coast. Each line represents an individual trajectory of antibody concentration. 
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Figure 3.4. Lines of best fit for the concentrations of antibodies to P. falciparum merozoite antigens.  
 
The average antibody decay rates were similar at both sites only for antibodies to MSP1-19, 
higher in Banfora for MSP2-Dd2 and MSP3-3D7 and moderately higher in Keur Soce for 
AMA1-3D7 (Table 3.3). 
 
Table 3.3. Average antibody decay rates in Banfora (High transmission intensity) and Keur Soce (Low 
transmission intensity). Excepting MSP1-19, average antibody decay rates were different in both the 
sites. 
 Banfora cohort (site 1) Keur Soce cohort (site 2) 
Interaction 
Age vs site Antigens  
Decay rate 
(log10 AU/month), 95 % 
CI 
p value Decay rate 
(log10 AU/month), 95 % CI 
p value 
AMA1-3D7 -0.49 (-0.52, -0.45) p<0.001 -0.56 (-0.59, -0.53) p<0.001 p=0.003 
MSP1-19 -0.32 (-0.37, -0.27) p<0.001 -0.27 (-0.32, -0.22) p<0.001 p=0.221 
MSP2-Dd2 -0.47 (-0.50, -0.44) p<0.001 -0.23 (-0.27, -0.19) p<0.001 p<0.001 
MSP3-3D7 -0.23 (-0.26, -0.20) p<0.001 -0.12 (-0.15, -0.10) p<0.001 p<0.001 
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3.4.3 Relationship between antibodies and incidence of febrile malaria 
Univariate analysis 
This analysis applies to Banfora only.  In the time to event univariate analysis none of the 
antigen-specific antibodies, in terms of levels or seropositivity, was associated with 
protection. Antibodies to AMA1-3D7 (HR: 1.34, 95%CI: 1.11-1.62, p=0.002) and MSP1-
19 (HR: 1.44, 95%CI: 1.19-1.74, p<0.001) were significantly associated with a higher risk 
of febrile malaria, but season was the strongest significant risk factor for febrile malaria (HR: 
8.28, 95%CI: 2.18-31.44, p=0.002). The results of the event count analysis were similar 
except for anti-AMA1-3D7 antibodies that appeared as significantly associated with 
protection against febrile malaria episodes (HR: 0.89, 95%CI: 0.80-0.98, p=0.015). Children 
with haemoglobin CC type had a lower risk of febrile malaria compared with haemoglobin 
AA children. Age was significantly associated with risk of febrile malaria (Table 3.4). In 
both the models, the highest level of education was significantly associated with protection 
and children born in the last quarter of the year had significantly lower risk of febrile malaria 
compared to those born in January. The results of the univariate models of risk of malaria 
are shown in table 3.4. 
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1
Table 3.4. Univariate models of risk of P. falciparum febrile malaria. 
 Cox Proportional Hazards 
models 
Negative binomial models 
Predictor HR 95% CI p IRR 95% CI p 
Age - - - 1.14 [1.12, 1.17] <0.001 
Sex       
        Male 1 - - 1 - - 
        Female 0.84 [0.52, 1.35] 0.472 0.76 [0.50, 1.16] 0.205 
Weight (baseline) 0.95 [0.64, 1.42] 0.817 1.07 [0.75, 1.51] 0.722 
Length (baseline) 1.02 [0.92, 1.12] 0.715 1.04 [0.97, 1.12] 0.300 
Fetal Hb rate (baseline) 0.98 [0.96, 1.001] 0.072 0.99 [0.97, 1.002] 0.084 
Haemoglobin type       
        AA 1 - - 1 - - 
        AS* NA - 
0.198 
NA - 
<0.001 
        AC 1.81 [0.97, 3.38] 1.32 [0.81, 2.16] 
        CC 0.36 [0.05, 2.59] 0.54 [0.09, 3.11] 
Anti-AMA1 titres 1.34 [1.11, 1.62] 0.002 0.89 [0.80, 0.98] 0.015 
Anti-MSP1 titres 1.44 [1.19, 1.74] <0.001 1.28 [1.16, 1.42] <0.001 
Anti-MSP2 titres 1.27 [0.95, 1.70] 0.103 1.01 [0.85, 1.21] 0.911 
Anti-MSP3 titres 1.28 [0.70, 2.34] 0.428 0.73 [0.42, 1.26] 0.260 
Seropositivity to AMA1       
        Seronegative 
 
1 - - 1 - - 
        Seropositive 1.62 [0.92, 2.87] 0.096 0.70 [0.47, 1.05] 0.087 
Seropositivity to MSP1       
        Seronegative 
 
1 - - 1 - - 
        Seropositive 2.99 [1.55, 5.76] 0.001 2.10 [1.46, 3.03] <0.001 
Seropositivity to MSP2       
        Seronegative 
 
1 - - 1 - - 
        Seropositive 2.003 [1.09, 3.68] 0.025 1.04 [0.72, 1.50] 0.842 
Seropositivity to MSP3       
        Seronegative 
 
1 - - 1 - - 
        Seropositive 1.39 [0.76, 2.56] 0.290 0.65 [0.41, 1.03] 0.064 
Month of birth       
        January 1 - - 1 - - 
        October 0.19 [0.06, 0.64] 
0.012 
0.21 [0.07, 0.64] 0.002 
 
        November 0.44 [0.23, 0.83] 0.45 [0.27, 0.73] 
        December 0.53 [0.29, 0.96] 0.66 [0.41, 1.06] 
EPI status (baseline)       
        Up to date 1 - - 1 - - 
        Not up to date 0.94 [0.45, 1.96] 0.862 1.06 [0.60, 1.86] 0.845 
Age mother (baseline) 1.04 [1.001, 1.08] 0.042 1.02 [0.99, 1.06] 0.135 
Gravidity status       
        Primigravidae 1 - - 1 - - 
        Multigravidae 1.12 [0.61, 2.06] 0.709 1.08 [0.61, 1.89] 0.797 
ITN use (pregnancy)       
        Yes 1 - - 1 - - 
        No 1.24 [0.61, 2.50] 0.550 1.35 [0.75, 2.45] 0.320 
                                               
1 Note that the analysis approach is similar to that taken in the previous chapter for table 2.5, except for slight 
variations in the individuals missing serological results and therefore there are slight variations in the coefficients 
presented between the tables 
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 Cox Proportional Hazards 
models 
Negative binomial models 
Predictor HR 95% CI p IRR 95% CI p 
IPTp courses       
        0 1 - - 1 - - 
        1 1.47 [0.49, 4.41] 0.639 1.70 [0.71, 4.09] 0.149 
        2 or 3 1.15 [0.41, 3.19] 1.07 [0.47, 2.42] 
Education level 
(mother) 
      
        None 1 - - 1 - - 
        Primary 1.52 [0.92, 2.51] 0.031 1.38 [0.91, 2.09] <0.001 
        Secondary or 
above 
0.45 [0.18, 1.15] 0.31 [0.15, 0.64] 
Zone of residence       
        Rural 1 - - 1 - - 
        Urban 0.31 [0.16, 0.61] <0.001 0.30 [0.16, 0.56] <0.001 
        Mixed 1.32 [0.78, 2.23] 1.22 [0.80, 1.84] 
Season       
        Dry season 1   1 - - 
        Rains 8.28 [2.18, 31.44] 0.002 4.32 [2.88, 6.49] <0.001 
Malaria Exposure 
index 
1.10 [1.05, 1.14] <0.001 1.08 [1.03, 1.13] 0.001 
 
Multivariable analysis 
There was only limited collinearity between the different antibody titres (VIFs<2; mean 
VIF=1.44) and no significant deviation from the proportional hazards assumption (Figure 
3.5, Figure 3.6).In the multivariable time to event analysis, foetal haemoglobin rate was 
weakly but significantly associated with protection (HR: 0.97, 95%CI: 0.94-0.99, p=0.004). 
Season remained the strongest risk factor (HR: 9.39, 95%CI: 2.32-37.99, p=0.002), and 
exposure index was also associated with a risk of malaria (HR: 1.10, 95%CI: 1.05-1.15, 
p<0.001). There was a tendency of anti-MSP1-19 antibodies to be associated with higher 
risk of febrile malaria (HR: 1.40, 95%CI: 1.09-1.80, p=0.008), but overall the correlation 
between antibodies and increased risk of malaria was reduced by adjusting for exposure 
index and season.  In the event count analysis, none of the antigen-specific antibodies was 
significantly associated with febrile malaria. Season was confirmed as the strongest risk 
factor. An interaction of weak effect size between season and individual exposure index was 
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observed (IRR=1.06, p=0.042) in the event count analysis. The results of the multivariable 
analysis of risk of malaria are shown in table 3.5. 
 
Figure 3.5. Estimation of child survival in relation to anti-malaria antibody tertiles. (A) antibodies to 
AMA1-3D7, (B) antibodies to MSP1-19, (C) antibodies to MSP2-Dd2, (D) antibodies to MSP3-3D7. 
 
Figure 3.6. Proportional Hazards assumption test. The lowess line shows the variation in hazard over 
time. 
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Table 3.5. Multivariable models of risk of P. falciparum febrile malaria. 
 Cox Proportional Hazards model Negative Binomial model 
Predictor HR 95%CI p IRR 95%CI P 
Age - - - 1.14 [1.09, 1.19] <0.001 
Anti-AMA1 titres 1.14 [0.92, 1.42] 0.216 1.05 [0.92, 1.20] 0.504 
Anti-MSP1 titres 1.40 [1.09, 1.80] 0.008 1.14 [0.99, 1.31] 0.052 
Anti-MSP2 titres 0.89 [0.63, 1.27] 0.528 0.87 [0.72, 1.02] 0.079 
Anti-MSP3 titres 1.20 [0.63, 2.27] 0.578 0.93 [0.66, 1.33] 0.704 
Fetal Hb rate (baseline) 0.97 [0.94, 0.99] 0.004 0.98 [0.97, 0.99] 0.041 
Haemoglobin type       
        AA 1 - - 1 - - 
        AS* NA - 
0.121 
NA - 
<0.001 
        AC 1.75 [0.88, 3.51] 1.44 [0.95, 2.19] 
        CC 0.28 [0.04, 2.19] 0.47 [0.15, 1.46] 
ITN use (pregnancy)       
        Yes 1 - - 1 - - 
        No 1.05 [0.47, 2.36] 0.912 
 
1.32 [0.78, 2.25] 0.305 
Month of birth       
        January - - - - - - 
        October 0.27 [0.07, 1.01] 
0.269 
0.49 [0.21, 1.16] 
0.062 
        November 0.71 [0.34, 1.50] 0.91 [0.56, 1.50] 
        December 0.70 [0.36, 1.39] 1.14 [0.74, 1.73] 
Season       
        Dry season 1   1 - - 
        Rains 9.39 [2.32, 37.99] 0.002 3.17 [2.17, 4.62] <0.001 
Malaria exposure index 1.10 [1.05, 1.15] <0.001 1.08 [1.03, 1.12] 0.001 
 
The titres of antibodies to all the four antigens tested were below the protective thresholds 
except for a few outlying results.  After a consistent decline up to six months of age, only 
antibodies to MSP2 showed a steady increase up to month 18 in the high transmission setting 
(Banfora). Overall, we did not find any protective effect in the investigation of the 
association between antibodies to P. falciparum merozoite antigens and febrile malaria. 
Antibody titres to some merozoite antigens (AMA1-3D7 and MSP1-19) were rather a maker 
of exposure to malaria, evidenced by the association with risk and the fact that this 
association was diminished after adjusting for the exposure index.  
3.5 Discussion 
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Average antibody decay rates were similar in both the settings only for antibodies to MSP1-
19. Reduced exposure to infectious bites during the first six months in the high and seasonal 
transmission setting (Banfora) is a likely explanation of this similarity since only five malaria 
infections were detected during this period in Banfora, of which three occurred in the first 
rainy season in children aged above five months. However, infections were detected by 
microscopy in our study and we cannot rule out the possibility of submicroscopic infections 
in the high transmission setting (Banfora). The limited acquisition of antibodies and the 
strong correlation of antibody levels between time points in Keur Soce indicates reduced 
exposure throughout the monitoring period.  In contrast, in Banfora antibody levels were 
more variable from time point to time point, indicating that exposure to malaria was 
stimulating antibody production in some children, and furthermore that increases in antibody 
titres were often transient. Indeed, it has been previously shown that antibody titres are short-
lived in children (Kinyanjui, Conway et al. 2007). 
In the first six months of life, antibody concentrations were mostly below protective levels 
in both sites regardless of the transmission intensity. We would have expected this in Keur 
Soce but not in Banfora where the transmission is high. The existence of a saturation point 
for transplacental antibody transfer from mothers with high antibody concentrations has been 
suggested by previous studies (Palmeira, Quinello et al. 2012). If such a saturation point was 
below the protective levels, that could explain these paradoxically low antibody levels in the 
infants born from the mothers living in the high transmission setting. Two other studies have 
reported similar findings in the sense that young children were seen to be slow in their 
endogenous antibody production following the decline of maternally-derived antibodies 
(Duah, Miles et al. 2010, Murungi, Sondén et al. 2016). 
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Differing intensity of exposure to malaria may or may not have an impact on the 
development of endogenous antibodies in infants. Singer and colleagues have even reported 
paradoxically higher antibody response in infants with lower malaria exposure for MSP1-19 
(Singer, Mirel et al. 2003). In our study, we did not observe this and mean antibody levels 
were significantly higher or similar between high and low transmission settings throughout 
the time course of the study.  
We found that anti-AMA1-3D7 antibodies appeared as a marker of exposure (positively 
associated with the risk of febrile malaria) in our univariate analysis, which is consistent 
with the conclusions of Riley et al. (Riley, Wagner et al. 2000). Furthermore, adjusting for 
exposure using the exposure index attenuated the positive association between anti-AMA1 
antibodies and increasing risk, consistent with anti-AMA1 antibodies acting as a marker of 
exposure in our study. Our results are in keeping with the findings of previous studies in 
older children (Dodoo, Aikins et al. 2008, Nebie, Tiono et al. 2008). Similarly, in our study, 
antibody titres to MSP1-19, MSP2-Dd2 and MSP3-3D7 were not associated with protection 
as in other infant cohort studies (Kitua, Urassa et al. 1999, Riley, Wagner et al. 2000, Zhou, 
Xiao et al. 2002).  
The apparent variation in results between infants and older children may be explained by the 
presence of a protective threshold. Murungi et al. and Rono et al. have analysed two 
independent cohorts of children and established protective threshold concentrations for some 
merozoite antigens (Murungi, Kamuyu et al. 2013, Rono, Osier et al. 2013).  Even in a high 
transmission setting such as Burkina Faso, we found that antibody titres in the first six 
months of life for the four tested antigens were well below these protective threshold 
concentrations. Furthermore, there was no association with protection.  We conclude that 
these maternally acquired antibodies are not the protective mechanism.  If the antibody levels 
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are not protective in these infants, then what is the basis of their apparent early and short-
lived protection period against clinical manifestations of malaria? 
In the present study, we have investigated the role of antibodies (total IgG) in the resistance 
to the clinical manifestations of blood-stage malaria infection. However, there is evidence 
for an association between the cytophilic subclasses (IgG3 and IgG1) and clinical protection 
(Bouharoun-Tayoun and Druilhe 1992, Soe, Theisen et al. 2004, Lusingu, Vestergaard et al. 
2005, Roussilhon, Oeuvray et al. 2007). We have not measured the titres of the cytophilic 
subclasses and therefore cannot rule out the existence of a protective effect of these 
cytophilic subclasses. Other possibilities are that other effector mechanisms or other factors 
are working in the background. Indeed, although we have tested few additional P. falciparum 
antigens in this study, hundreds of potential immune targets remain unexplored. Osier and 
colleagues have shown that some poorly investigated or untested P. falciparum proteins have 
similar and even superior potential protective efficacy against clinical malaria than the 
extensively studied current malaria vaccine candidates. Moreover, they have shown that the 
cumulative responses of some top-ranked antigens best correlate with protection (Osier, 
Mackinnon et al. 2014). Besides that, there is evidence that other antibody-mediated 
protective mechanisms not necessarily correlated with ELISA measurements may be 
operating. Indeed, Osier and colleagues have consistently shown that opsonic phagocytosis 
was strongly associated with protection when no significant protective effect was observed 
with total IgG or IgG sub-classes (Osier, Feng et al. 2014).  Joos and colleagues, 
investigating another mechanism, found that antibody-dependent respiratory burst (ADRB) 
well correlated with protection against clinical malaria when anti-merozoite IgG levels did 
not (Joos, Marrama et al. 2010) although they recently reported high correlation of IgG 
responses with ADRB (Joos, Varela et al. 2015). Although evidence from observational or 
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experimental studies in humans is lacking,  low para-aminobenzoic acid diet that would be 
achieved in exclusive breastfeeding has been associated with resistance to malaria in mice 
experiments (Kicska, Ting et al. 2003). The role of foetal haemoglobin in the reduced 
susceptibility of young infants to febrile malaria remains unclear. Initially believed to impair 
parasite growth in infected erythrocytes (Pasvol, Weatherall et al.), it was later suggested 
that it rather acts cooperatively with antibodies to impair cyto-adherence of infected 
erythrocytes (Amaratunga, Lopera-Mesa et al. 2011). Earlier entomological studies found 
an increasing biting rate with increasing age (therefore body size or surface), suggesting that 
the apparent early infancy resistance to clinical malaria is actually a reduced exposure to 
infectious mosquito bites (Muirhead-Thomson 1951, Carnevale, Frezil et al. 1978). Recent 
studies suggest an association between skin microbiome and attractiveness to malaria vectors 
(Verhulst and Takken 2014) and it might be worthy to investigate whether particular features 
of young infants’ microbiome makes them less attractive to mosquitoes in search of blood 
meals.  Previous data on passive transfer of antibodies from cord blood suggest that 
antibodies are involved (Edozien, Gilles et al. 1962).  
Even at high intensity of malaria transmission, antibody levels to the tested P. falciparum 
merozoite antigens (AMA1-3D7, MSP1-19, MSP2-Dd2 and MSP3-3D7) remained low 
compared to the previously established protective threshold concentrations. In addition, the 
antibodies were not significantly associated with a reduced risk of malaria raising more 
questions on the basis of the early apparent protection against febrile malaria.   
However, these results should be interpreted with caution because of the limitations of this 
study.  The protective thresholds used in the present study have been established in cohorts 
3.6 Conclusion 
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including children more than 2 years old in addition to infants. In our cohort, the lack of any 
protective effect did not allow us to determine specific thresholds for this age group.  
Furthermore, the overlapping of the first few months of life with the low malaria 
transmission season made it practically impossible to assess the role of maternal antibodies 
at the higher titres seen in that period.  However, if antibody thresholds are related to real 
biological phenomena than we would expect, the thresholds should be similar across study 
sites and age group.  Hence the main contribution of our work is the demonstration that 
antibody levels in infants to the selected merozoite antigens are well below previously 
defined protective thresholds, and therefore that these are unlikely to be responsible for 
mediating protection in vivo. Further work to identify protective antibody responses might 
include assessment of antibodies to other targets, including red cell surface antigens, and 
functional assays in which the interaction of antibodies with immune cells is taken into 
account (Osier, Feng et al. 2014). 
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The previous chapters have examined antibody responses as potential markers of protection.  
In both instances, we found that antibodies were in fact markers of exposure rather than 
protection.  This raises the question of confounding in observational immuno-
epidemiological studies due to heterogeneity of exposure.  This present chapter examines in 
more detail the spatial heterogeneity of exposure to malaria and different metrics which can 
be used to characterize it. 
Heterogeneity of the distribution of infectious disease seems to be a universal phenomenon. 
It has been well characterized for sexually transmitted and some vector-borne diseases with 
80% of the disease burden tending to cluster in only 20% of the population at risk 
(Woolhouse, Dye et al. 1997). This phenomenon has been observed and reported for malaria 
(Gamage-Mendis, Carter et al. 1991, Mwangi, Fegan et al. 2008). Moreover, seasonality is 
observed in most malaria transmission settings and most malaria cases occur in rainy seasons 
during which conditions are suitable for the spread of malaria mosquito vectors (Roca-
Feltrer, Schellenberg et al. 2009). This heterogeneity in distribution can be translated into 
spatial or space-time clusters of disease cases that have the practical advantage of being more 
accessible for disease surveillance and control interventions.  
The concept of hotspot, sometimes termed cluster, has been applied to various disciplines 
such as criminology, forestry, wildlife research (Fei 2010, Maingi, Mukeka et al. 2012, 
4. CHAPTER 4: Role of serology among different biomarkers used for malaria 
transmission hotspots detection  
 
4.1 Introduction 
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Uittenbogaard and Ceccato 2012) and can be defined as a sub-area of a main area with a 
concentration of an event of interest higher than what would be expected if that event was 
distributed randomly in the main area. Hotspots of malaria transmission have been observed 
and reported to occur at various scales ranging from regional to homestead level (Bejon, 
Williams et al. 2014). 
The risk and spread of malaria are driven by various types of factors. Factors for which 
evidence exists include environmental factors such as temperature, altitude, distance to water 
bodies, wind direction and urbanization (Brooker, Clarke et al. 2004, De Silva and Marshall 
2012, Midega, Smith et al. 2012). They also include intrinsic human characteristics such as 
red blood cell polymorphisms, differential host attractiveness to anopheline mosquitoes, 
foetal haemoglobin and dietary factors in early infancy, and extrinsic actors such as farming 
practices, socio-economic factors, housing design, level of education and behaviour (Pasvol, 
Weatherall et al. , Kicska, Ting et al. 2003, Lacroix, Mukabana et al. 2005, Yadouléton, 
N'Guessan et al. 2010, Amoako, Asante et al. 2014, Sonko, Jaiteh et al. 2014, Fernández-
Grandon, Gezan et al. 2015, Malaria Genomic Epidemiology Network 2015, Tusting, 
Ippolito et al. 2015). 
The interest in detecting malaria transmission hotspots is that, as a hypothetical driving force 
of malaria infection spread, they represent an opportunity for targeted control interventions 
that are expected to be more efficient than untargeted interventions and ultimately benefit 
the whole community (Bousema, Griffin et al. 2012). 
Challenges in targeting hotspots of transmission include the choice of the transmission 
marker to measure, the choice of the method of detection, the choice of the scale at which to 
detect them, when to detect them and how stable they are (Bousema, Griffin et al. 2012, 
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Mosha, Sturrock et al. 2014). Asymptomatic parasite carriage, clinical malaria episodes, 
vector biting intensities or antibody responses to selected malaria antigens have been 
proposed as potential markers of malaria transmission in detecting hotspots in areas of low 
to moderate transmission intensity (Bousema, Drakeley et al. 2010).  
Primary objective:  
To detect malaria transmission hotspots using different biomarkers within the same study 
area and time period and examine the spatial associations between these hotspots. 
Secondary objectives: 
 To examine the spatial correlations of the different markers using a raster map of the 
study area. 
 To examine the spatial stability of the detected hotspots. 
 
4.3.1 Ethical approval 
The study was approved by the Kenya Medical Research Institute (KEMRI) National Ethical 
Review Committee. The study procedures were explained and a written informed consent 
was sought and obtained from the parents/guardians of each individual child participating in 
the study prior to any study procedures. The study was conducted according to the 
Declaration of Helsinki. 
4.2 Study objectives 
4.3 Methods 
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4.3.2 Study area, population and surveillance method 
The data used in the present study were collected from 2012 to 2013 taken from a study area 
in Ganze in Kilifi County on the Kenyan Coast (Figure 4.1). Two cohorts were monitored in 
this study: one for clinical episodes during two years of follow up and a second cohort 
monitored via cross-sectional surveys. 
A total of 831 children aged 5-17 months residing in 633 homesteads were recruited into a 
vaccine trial in which longitudinal monitoring of malaria episodes was done (RTS 2015).  
Febrile malaria episodes were detected by passive case detection as previously described 
(RTS 2015). Clinical malaria was defined as the presence of fever (axillary 
temperature≥37.5°C) or history of fever in the past 24 hours and parasitaemia ≥ 2500µl 
(Mwangi, Ross et al. 2005).  
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Figure 4.1. Study area. Spatial distribution of homesteads sampled for the different studies. 
 
The second cohort of children and adults was recruited by selecting homesteads at random 
based on enumeration areas.  Twenty enumeration areas were selected at random and then 
25 households were selected from each enumeration area.  This provided a sample of 800 
individuals living in the same study area as the children monitored for clinical malaria but 
in different homesteads. The surveys were used to measure asymptomatic parasitaemia, by 
microscopy of thick and thin blood smears and by PCR, and antibody responses to P. 
falciparum merozoite antigens (apical membrane antigen (AMA1) and merozoite surface 
protein 1 (MSP1-19) by indirect ELISA. 
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Data from an entomological study also conducted within the same study area were also 
available for 2012 and 2013. Mosquito captures using CDC light traps were conducted in 
150 sampled houses, chosen at random, at six rounds covering the dry season, the long and 
the short rains. Anopheles gambiae and Anopheles funestus were the major human malaria 
vectors captured in the study area. Longitude and latitude data for each homestead involved 
in the clinical and entomological studies was recorded during the surveys.  
4.3.3 Detection of hotspots 
Using the scan statistic method by Kulldorff (Kulldorff 1997), we examined the study area 
for clusters of individuals positive for the biomarker of interest, at rates higher than what we 
would have expected if the distribution of positive cases was random in the study area. The 
following markers were examined: clinical malaria, positive blood films, positive PCR tests, 
seropositivity to AMA1 and MSP1 and densities of anopheline mosquitoes. The cut offs for 
seropositivity to AMA1 and MSP1 in normalized optical density were respectively 0.132 
and -0.108 in 2012, and -0.091 and 0.13 in 2013, defined using previously described methods 
(Bousema, Youssef et al. 2010).  The application of the Scan statistic by SaTScan has been 
described previously (Kulldorff 1997). Briefly, a scanning window (set to “circular” in our 
analysis) moves across the study area, and the maximum number of events that are captured 
by the window is recorded. The maximum window size was arbitrarily set to 30% of the 
population at risk. Though some attempts have been proposed to optimize maximum window 
size setting in scan statistic (Ma, Yin et al. 2016), none of these approaches have been 
validated and no clear guidelines exist to date. We have selected a window size below the 
default (and maximum size, 50%) in Kulldorf Scan statistics (implemented in SaTScan 
software (Kulldorff 2014)) because it has been argued that  using a too large window size 
may result in a single large cluster covering multiple smaller cluster with lower rates (Ball, 
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LeFevre et al. 2008). Each of the different scanning windows is evaluated as a potential 
cluster by the calculation of a likelihood ratio test statistic based on the observed, expected 
and total number of cases. The corresponding p value is calculated using a Monte Carlo 
method (Dwass 1957).  
To detect hotspots of clinical malaria cases, we used a discrete Poisson model where the 
cases were the clinical malaria cases detected at each homestead; the population was the 
population monitored in the corresponding homesteads.  
A Bernoulli probability model was used to detect hotspots of positive blood films, hotspots 
of positive PCR tests and hotspots of individuals seropositive for AMA1 and MSP1. The 
cases were the individuals with a positive test (blood film, PCR or ELISA) in each 
homestead; the controls were defined as the individuals with negative tests in the 
corresponding homestead.  
To detect hotspots of Anopheles mosquitoes, we used a discrete Poisson model in which the 
cases were the Anopheles mosquitoes captured in each house; the population was defined as 
the number of homesteads. 
For each detected hotspot, a relative risk (RR) was computed. The RR is the magnitude of 
the risk of malaria for individuals residing within the hotspot compared with those residing 
outside the hotspot. It is calculated as the ratio of the estimated risk within the hotspot and 
the estimated risk in the surrounding area. The estimated risk is calculated as the number of 
observed cases divided by the number of expected cases if the null hypothesis was true i.e. 
if the distribution of cases was totally random. The threshold for statistical significance of 
the hotspots was set to 0.05.  
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Observations with missing coordinates data were 4.5%, 3% and < 1% for serological, 
entomological and clinical surveillance data respectively; they were dropped prior to any 
analysis. Observations with missing data for anopheline mosquito capture and AMA1/MSP1 
serology were < 1% in the respective datasets.  
4.3.4 Statistical analysis 
The markers of malaria transmission were summarized at the homestead level by calculating 
the sum of clinical malaria cases, sum of positive blood films, sum of positive PCR tests and 
geometric mean antibody titre.   
To aggregate the data, we have derived a raster map of the study area from a Kilifi County 
administrative map (the original shapefile was downloaded from 
http://www.wri.org/resources/data-sets/kenya-gis-data, accessed 04/08/2015). The 
resolution of the raster surface was set to 0.9 km x 0.9 km. At this resolution and for each 
marker, each homestead was assigned to a unique cell by computing the shortest distance 
between the index homestead and the surrounding grid points. The values of each of the 
markers summarized at the homestead level were then aggregated at the grid cell level. The 
statistics used to aggregate the markers were the mean for counts of positive blood films and 
positive PCR tests, the weighted mean for count of clinical malaria cases, the weighted 
geometric mean for antibody titres and the mean for vector numbers. This aggregation was 
repeated for each year. We then examined spatial correlations between these markers using 
Spearman Rank correlation coefficient on aggregated data. 
SaTScanTM v9.4.1 was used to detect the hotspots and Stata 13.1 for Windows, StataCorp 
LP was used to perform data analysis and produce the maps. 
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4.4.1 Malaria morbidity and transmission markers in the study area 
The distribution of all the markers of malaria transmission is highly right skewed as shown 
in Figure 4.2 and Figure 4.3. Most individuals or homesteads have zero quantity of the 
measured transmission markers indicating a very low transmission intensity. 
 
 
Figure 4.2. Distribution of clinical, parasitological and entomological markers of malaria transmission. 
The data are aggregated at homestead level. 
 
4.4 Results 
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Figure 4.3. Distribution of antibody titres to AMA1 and MSP1. The data are aggregated at homestead 
level. 
 
The clinical, parasitological, serological and entomological markers measured in these 
studies are summarized in Table 4.1. Malaria transmission intensity was low in 2012 with 
parasite rate by microscopy at 2% in the general population, and underwent a tenfold decline, 
at 0.2% in 2013. Similarly, there was a decline in densities of malaria vectors in the study 
area in 2013 with anopheline mosquitoes captured in only 6% of the surveyed houses 
compared with 24% in 2012. Table 4.2 shows the detailed frequency distribution of 
seropositivity to AMA1 and MSP1. 
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Table 4.1. Yearly summary of clinical, parasitological, serological and entomological markers in the 
study area. 
 Year 2012 2013 
Longitudinal 
study 
Homestead locations / Population 633 / 831 633 / 831 
Locations with febrile malaria 65 (10.3%) 22 (3.5%) 
Febrile malaria cases  112 (13.5%) 28 (3.4%) 
Cross-sectional 
studies 
Homestead locations / Population 211 / 779 183 / 797 
Locations with positive blood films 8 (3.8%) 2 (1.1%) 
Locations with positive PCR tests 31 (14.7%) 22 (12%) 
Prevalence of infection (Microscopy), (95% CI) 2% (1.2-3.2) 0.2% (0.03-0.9) 
Prevalence of infection (PCR), (95% CI) 6.2% (4.6-8) 3.3% (2.2-4.8) 
Seroprevalence of antibodies to AMA1, (95% CI) 36.1% (32.7-39.5) 20.4% (17.7-23.4) 
Seroprevalence of antibodies to MSP1, (95% CI) 19.9% (17.1-22.9) 10.5% (8.5-12.9) 
Entomological 
surveys 
House locations 145 142 
Locations with Anopheles 35 (24%) 8 (6%) 
Range of Anopheles captured/house 0 – 17 0 - 6 
Total Anopheles captured 101 15 
Total An. Gambiae captured 85 5 
Total An. Funestus captured 16 10 
 
Table 4.2. Contingency table of seropositivity to AMA1 and MSP1 in the cross-sectional studies in 
2012 and 2013. Sero+ stands for seropositivity. 
2012 2013 
Sero+ to 
MSP1 
Sero+ to AMA1  Sero+ to 
MSP1 
Sero+ to AMA1  
0 1 . Total 0 1 . Total 
0 459 154 9 622 0 603 103 3 709 
1 31 124 0 155 1 25 59 0 84 
. 2 0 0 2 . 4 0 0 4 
Total 492 278 9 779 Total 632 162 3 797 
 
4.4.2 Malaria hotspots in the study area 
For clinical malaria, asymptomatic parasitaemia determined by microscopy and anopheline 
mosquitoes captures, there were fewer positive cases in 2013 compared to 2012 and fewer 
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hotspots were identified (Figures 4.4, 4.5 and 4.11). The hotspots were also reduced in size 
(Figures 4.6 and 4.8) with some of them limited to single homesteads in 2013 (Figures 4.4 
and 4.11). There was one stable hotspot of clinical malaria (Figure 4.4, Vitengeni area) in 
terms of position and size, limited to a single homestead, but the other hotspots identified in 
2012 were not identified in 2013. There was some overlap between the hotspots of 
asymptomatic malaria detected by PCR in 2012 and 2013 (Figure 4.7) and no hotspots of 
asymptomatic malaria detected by microscopy in 2013 (Figure 4.5).  
 
 
 
 
 
Figure 4.4. Hotspots of clinical malaria cases. Each blue circle represents a statistically significant 
hotspot with its relative risk (RR) and p value (p) displayed beside the circles. 
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Figure 4.5. Hotspots of asymptomatic malaria infections detected by light microscopy. Each blue 
circle represents a statistically significant hotspot with its relative risk (RR) and p value (p) displayed 
beside the circles.  No hotspots were identified in 2013. 
Figure 4.6. Hotspots of asymptomatic malaria infections detected by polymerase chain reaction 
(PCR). Each blue circle represents a statistically significant hotspot with its relative risk (RR) 
displayed beside the circles. 
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The sampling of homesteads for malaria serology differed between 2012 and 2013 (Figure 
4.1). However, we observed, within the same year, a consistent overlapping of hotspots of 
seropositive children to AMA1 and MSP1. When we scanned for hotspots of children 
seropositive to both AMA1 and MSP1, we detected hotspots that substantially overlapped 
hotspots of children seropositive to AMA1 or MSP1. There was one location in 2012 where 
the three types of serology hotspots (i.e. seropositive to AMA1, seropositive to MSP1 and 
seropositive to both AMA1 and MSP1) exactly overlapped each other (Figure 4.10). 
Figure 4.7. Dynamics of hotspots of asymptomatic parasite carriers detected by PCR. Each 
green dot represents a homestead. 
 Page 127 of 349 
 
 
 
Figure 4.8. Hotspots of individuals seropositive to Plasmodium falciparum AMA1. Each green dot 
is a homestead. Each blue circle represents a hotspot with its relative risk (RR) displayed beside the 
circles. The homesteads sampled in 2013 were different from those sampled in 2012. 
Figure 4.9. Hotspots of individuals seropositive to Plasmodium falciparum MSP1. Each green dot 
is a homestead. Each blue circle represents a hotspot with its relative risk (RR) displayed beside the 
circles. The homesteads sampled in 2013 were different from those sampled in 2012. 
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Figure 4.10. Spatial overlapping of hotspots of serological markers of malaria transmission. Each 
green dot is a homestead. The homesteads sampled in 2013 were different from those sampled in 
2012. 
Figure 4.11. Hotspots of 
Anopheles mosquitoes. 
Anopheles gambiae and 
Anopheles funestus were 
the only human malaria 
vector species captured 
during the survey.  The 
orange and black circles 
represent the statistically 
significant hotspots of 
anopheline mosquitoes in 
2012 and 2013 
respectively. Each hotspot 
is displayed with its malaria 
relative risk (RR) and p 
value beside the circles. 
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Variable overlapping of hotspots of clinical and parasitological markers of transmission 
occurred in 2012 (Figure 4.12). Only the two single-homestead hotspots of clinical malaria 
did not overlap the hotspot determined by positive PCR tests. The hotspot of asymptomatic 
malaria detected by microscopy was totally contained within the hotspot determined by 
positive PCR tests.  
 
Although the data was collected from different sets of homesteads for each study, these 
homesteads were all contained within a single study area. We visualized the different 
hotspots to examine the extent of overlapping between them (Figure 4.13). Most hotspots 
concentrated in the southern part of the study area and moved towards the northern part in 
2013. There were considerable overlapping between hotspots of all the types of the 
transmission markers examined. The substantial overlapping of the hotspots of serological 
Figure 4.12. Spatial overlapping of hotspots of clinical and parasitological markers of malaria 
transmission. The homesteads sampled in 2012 were the same as those sampled in 2013 for the 
cross-sectional study. 
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markers with those of asymptomatic infections detected by PCR observed in 2012 was also 
observed in 2013 when the transmission declined further. 
 
Figure 4.13. Overlapping hotspots of malaria transmission markers. Each green spot is a 
homestead. All homesteads involved in the clinical surveillance, serology and entomology studies 
and the specific hotspots are overlaid on the same map for each year.  
   
4.4.3 Spatial correlations between markers of malaria transmission 
The study area has been subdivided into 0.9 x 0.9 km square-shaped cells as shown in Figure 
4.14. All markers are expressed as an average per cell.  
 
Figure 4.14. Tessellation of the study area and densities of homesteads. Each square measures 0.9 by 
0.9 km. In A the green dots indicate the homesteads. In B the shades of green colour are proportional 
to the densities of homesteads with darker shades representing higher densities. 
 
With the exception of Anopheles mosquito densities, weak to moderate statistically 
significant correlations were found between the other markers of transmission in 2012 when 
the markers were averaged at grid cell level (Table 4.3, Figure 4.15). Clinical malaria was 
moderately correlated with positive blood films, but not with any other marker. Serological 
markers were better correlated with asymptomatic parasitaemia detected by PCR than with 
asymptomatic parasitaemia detected by microscopy. Asymptomatic parasitaemia detected 
by microscopy was correlated with asymptomatic parasitaemia detected by PCR and 
serological markers well correlated with each other. However, in 2013, when the 
transmission intensity declined further, only asymptomatic parasitaemia detected by 
microscopy correlated with positive PCR tests (Table 4.4). When correlations were analysed 
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between 2012 and 2013 for each marker, only clinical malaria and PCR showed significant 
but weak correlation (rho < 0.21) (Figure 4.16). 
Table 4.3. Correlations between malaria transmission markers in 2012 at 0.9 x 0.9 km resolution. Each 
table cell reports from top to bottom the correlation coefficient (rho), the number of grid cells (n) and 
the p value for rs. 
 Clinical 
malaria 
cases 
Positive 
blood 
films 
Positive 
PCR 
tests 
Anti-
AMA1 
Abs 
titres 
Anti-
MSP1 
Abs 
titres 
Anopheles 
mosquitoes 
captured 
Clinical 
malaria 
cases 
 
1      
266      
       
Positive 
Blood 
films 
 
0.2672 1     
266 292     
<0.0001      
Positive 
PCR tests 
 
0.0328 0.5114 1    
266 292 292    
0.5944 <0.0001     
Anti-
AMA1 
Abs titres 
 
0.0215 0.2927 0.5413 1   
41 42 42 43   
0.8937 0.06 0.0002    
Anti-
MSP1 Abs 
titres 
 
-0.0444 0.3509 0.5745 0.6338 1  
41 42 42 43 43  
0.7828 0.0227 0.0001 <0.0001   
Anopheles 
mosquitoes 
captured 
 
0.0929 . 0.0648 -0.2398 -0.0218 1 
87 87 87 20 20 90 
0.3923 . 0.5513 0.3086 0.9272  
Table 4.4. Correlations between malaria transmission markers in 2013 at 0.9 x 0.9 km resolution. Each 
table cell reports from top to bottom the correlation coefficient (rs), the number of grid cells (n) and 
the p value for rs. 
 Clinical 
malaria 
cases 
Positive 
blood 
films 
Positive 
PCR 
tests 
Anti-
AMA1 
Abs 
titres 
Anti-
MSP1 
Abs 
titres 
Anopheles 
mosquitoes 
captured 
Clinical 
malaria 
cases 
1      
266      
       
Positive 
Blood 
films 
-0.0165 1     
266 292     
0.7884      
Positive 
PCR tests 
0.057 0.3295 1    
266 292 292    
0.3544 <0.0001     
Anti-
AMA1 
Abs titres 
-0.0339 0.0516 0.002 1   
22 22 22 22   
0.8808 0.8196 0.9931    
Anti-
MSP1 Abs 
titres 
-0.2376 0.0172 -0.0773 -0.0627 1  
22 22 22 22 22  
0.2869 0.9394 0.7323 0.7817   
Anopheles 
mosquitoes 
captured 
0.1693 -0.0343 0.116 0.1943 0.583 1 
87 87 87 12 12 90 
0.1169 0.7527 0.2846 0.5451 0.0467  
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Figure 4.15. Correlations between clinical, parasitological, serological and entomological malaria 
transmission markers. All markers are expressed as an average per cell of a 0.9 x 0.9 km resolution 
grid superimposed on the study area. 
 
 
Figure 4.16. Correlations between malaria transmission markers measured in 2012 and 2013. All 
markers are expressed as an average per cell of a 0.9 x 0.9 km resolution grid superimposed on the 
study area. 
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The present study describes the fine-scale spatial distribution of P. falciparum malaria and 
examines the relationships between different markers of malaria transmission in a low 
malaria transmission area on the coast of Kenya. The levels of the malaria transmission 
markers seen in this study were lower in 2013 compared with 2012. The low number of 
asymptomatic infections detected by microscopy prevented us having enough power to 
detect hotspots in 2013, but we could still detect hotspots with the larger number of positives 
seen by PCR.  Most of the hotspots were unstable (i.e. inconsistent in location between 2012 
and 2013), but one hotspot of clinical malaria was maintained in its position and size over 
the two years. When the transmission intensity declined, the spatial correlations observed 
between the markers were reduced to correlations between parasitological markers on the 
one hand, and between serological and entomological markers on the other hand.  
The decline of malaria transmission observed in the present study appears opposite to the 
observed trends in the study of Snow and colleagues who reported rising P. falciparum 
parasite rates along the Coast since 2010 following a steady decline from 1998 (Snow, 
Kibuchi et al. 2015). However, our study was conducted in a restricted area and time 
window, and previous studies have reported high rates of heterogeneity in malaria 
transmission in the region, and that differing trends can be observed in sub-locations within 
the same area (Bejon, Williams et al. 2014). 
From 2012 to 2013, most of the malaria transmission hotspots disappeared or shrank to 
single homestead hotspots except for PCR and serological markers. Hotspots of 
asymptomatic carriers detected by microscopy disappeared in 2013 despite ongoing 
transmission evidenced by clinical malaria cases. This suggests that cross-sectional surveys 
4.5 Discussion 
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using microscopy may not be ideal when transmission intensity declines to very low levels. 
The hotspots that persisted were asymptomatic parasite carriers detected by molecular and 
serological methods, suggesting these markers as good candidates for sensitive hotspot 
detection in settings with declining malaria transmission. 
In 2012, there was a total overlap of hotspots of asymptomatic parasite carriers detected by 
microscopy with hotspots of asymptomatic parasite carriers detected by PCR, as expected 
given that the sensitivity of PCR is higher than that of light microscopy (Bejon, Andrews et 
al. 2006).  This is consistent with the statistically significant spatial correlation observed 
between these markers when the data was analysed at the grid cell level. On the other hand 
epidemiological studies have shown that parasite density can be inversely proportional to 
the intensity of transmission at a micro-epidemiological scale (Mosha, Sturrock et al. 2013), 
and this might have led microscopy-defined hotspots to be differently located from PCR-
defined hotspots.  In our study the transmission intensity was much lower and we did not 
observe this phenomenon. The hotspots of asymptomatic parasite carriers detected by PCR 
overlapped the hotspots of AMA1 and MSP1-seropositive individuals in 2012 and 2013, 
supporting the idea of the use serological markers as an alternative to PCR in the detection 
of hotspots. It has been previously shown that children living in hotspots of asymptomatic 
parasitaemia have higher antibody titres compared with those living in clinical malaria 
hotspots (Bejon, Williams et al. 2010), and antibody titres have been described as a marker 
of exposure (Badu, Gyan et al. 2015).  
One clinical malaria hotspot was found to be stable across the two years, which is not 
consistent with previous reports in which hotspots of clinical malaria were found to be 
unstable compared with hotspots of asymptomatic parasitaemia (Bejon, Williams et al. 
2010). However, the short period of observation in the present study and the low age of 
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children assessed (i.e. 5 to 17 months olds) in a low transmission setting is a likely 
explanation of this observation since immunity to clinical malaria builds up over a much 
longer period at lower transmission intensities (Langhorne, Ndungu et al. 2008, Griffin, 
Hollingsworth et al. 2015).  
The relative simplicity and lower cost of serology compared with PCR may make the use of 
serological markers more attractive for large-scale surveillance. However the fact that 
serological surveys may not distinguish recent from medium-term exposure may be a 
disadvantage, since the location of hotspots may vary from year to year. This could be 
overcome by including only young children in surveys (Singer, Mirel et al. 2003) whose 
antibody responses have been attributed to short-lived plasma cells (Kinyanjui, Conway et 
al. 2007, Weiss, Traore et al. 2010) or by measuring responses to antigens for which evidence 
suggests that they have limited capacity to induce long-lived plasma cells (Proietti, Verra et 
al. 2013).  Helb and colleagues have recently identified Plasmodium falciparum antigens 
whose specific antibody responses reflect very recent exposure i.e. within the last 30 days 
(Helb, Tetteh et al. 2015). 
Regardless of the marker used to detect transmission hotspots, the analysis output in Satscan 
enables a very precise mapping of the detected hotspots. However, hotspot detection in 
Satscan is limited to regular shapes. The detected hotspots will always be an approximation 
of the true underlying hotspots and applying different detection methods may help increase 
confidence in the boundaries of the hotspots (Ward and Carpenter 2000, Hu, Xiong et al. 
2014, Xia, Cai et al. 2015). 
In chapter 2, we have been able to detect hotspots in a high transmission setting using clinical 
markers as has been done in previous studies (Gaudart, Poudiougou et al. 2006, Kreuels, 
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Kobbe et al. 2008, Cook, Kleinschmidt et al. 2011, Sissoko, van den Hoogen et al. 2015). 
Serological markers have been used too (Sissoko, van den Hoogen et al. 2015). Malaria 
transmission usually seasonal and it would be easier and advantageous, in high transmission 
settings, to detect and at least start control interventions during the low transmission season 
(generally the dry season) and before the next high transmission season.  
Where control programmes opt for targeted control interventions, this should not be taken 
to mean an absence of interventions outside hotspots. Rather, targeting should consist of 
intensification of activities within hotspots and the addition of less commonly used measures 
like indoor residual spraying and larviciding. This approach in high transmission settings 
may bring malaria prevalence to lower levels faster than the untargeted approach. (Bejon, 
Williams et al. 2010, Bousema, Griffin et al. 2012).  
In low transmission settings, unless antigens with antibody responses reflecting recent 
exposure are available, it would be useful to confirm ongoing transmission by appropriate 
parasitological tests (PCR). What makes targeted interventions attractive is that in theory, 
hotspots are believed to act a reservoir of parasite maintaining transmission during the dry 
season when conditions are not suitable for vector breeding and spreading infection in the 
surrounding community, and during this period it may be tractable to interrupt transmission  
(Bousema, Griffin et al. 2012). Additional research in various settings of differing 
transmission intensity is needed to better characterize the dynamics of malaria transmission 
around hotspots and verify this theory. 
Our study was opportunistic based on the datasets available and has some limitations. The 
sampled homesteads were not the same for the entomology, serology and clinical 
surveillance studies and this prevented us from examining homestead-level correlations in 
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more detail. Our sample size was not large and the limited period of observation does not 
allow a definitive assessment of temporal stability. 
The global decline of malaria transmission and plans for elimination have led to increased 
interest in the fine-scale epidemiology of malaria. One of the challenges in targeted 
interventions is the appropriate detection of residual transmission foci at the pre-elimination 
stage. The choice of a cost-effective marker that can be logistically feasible and readily 
implemented across sites by malaria control programs would be decisive in the elimination 
efforts as well as the post-elimination surveillance. Our findings may support the choice of 
serology or of PCR as markers in detecting the hotspots to which malaria control 
interventions should be targeted. 
4.6  Conclusion 
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Malaria transmission is markedly seasonal in Banfora, south-western Burkina Faso, with 
93% of febrile episodes in children occurring between June and November. The children 
with higher exposure indexes and the febrile malaria cases tend to cluster in the northern part 
of the study area. Indeed, this part of the study area is rural and marshy with a few rice fields 
compared to the southern part that overlaps Banfora town. 
In the present study conducted in Banfora, there was no evidence of protective effect in any 
of the antibodies to the six synthetic or recombinant merozoite antigens tested (GLURP R0, 
GLURP R2, AMA1, MSP1-19, MSP2, MSP3). In the published literature, only antibodies 
to MSP1-19 have been associated with protection against clinical malaria in young infants 
(Høgh, Marbiah et al. 1995, Branch, Udhayakumar et al. 1998). In contrast, there are a 
number of reports of a protective effect of antibodies to these merozoite antigens in older 
children (Fowkes, Richards et al. 2010, Rono, Osier et al. 2013, Tran, Ongoiba et al. 2014, 
Dent, Nakajima et al. 2015, Irani, Ramsland et al. 2015). 
When high and low malaria transmission settings were compared, we found that the antibody 
titres in the young children were well below the previously established protective levels 
during the first two years of life regardless of the transmission intensity. That was expected 
in the low transmission setting, but not in the high transmission one. In addition to the lack 
of protective effect, these findings suggest that the antibody responses to these six P. 
falciparum merozoite antigens are not responsible of the early and short-lived resistance of 
5. CHAPTER 5: General discussion  
 
5.1 The key findings 
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young infants to febrile malaria. It is noteworthy that the recruitment in this study started 
well before the rains and therefore the strongest malaria challenge occurred at a time when 
the maternally-derived antibody levels had already fallen. However, this limitation is 
unlikely to be the sole explanation of the lack of association we found in our analysis since 
the antibody titres were well below previously defined protective concentrations. The 
question remains unsolved but, at least, we have shown that the antibody titres are below the 
established protective threshold concentrations. 
There was a steady decline of the antibody titres in the first six months of life. The rates of 
decay were variable from antigen to antigens and were not necessarily higher in the high 
transmission area. The effect of malaria transmission intensity on antibody responses was 
more apparent when looking at the dynamics of seroprevalences and the individual 
trajectories of antibody concentrations. Spikes in antibody concentrations approximately 
coinciding with the rainy season were more noticeable in magnitude and frequency in the 
high transmission setting when no spike was observed for some antigens (MSP1-19) in the 
low transmission setting. However, overall, only antibodies to MSP2 showed a moderate 
and steady increase until the end of the monitoring period in the high transmission setting 
following the decline of the presumably maternally-derived antibodies at the end of the first 
six months of life. This suggests that the endogenous antibody production in young children 
might require a much longer period to reach protective levels. 
Foetal haemoglobin is believed to play a role in the protection of young infants against 
febrile malaria (Pasvol, Weatherall et al. 1976, Amaratunga, Lopera-Mesa et al. 2011) but 
there is limited evidence from field studies of this putative protective effect. In our study, 
although of small effect size, we found that foetal haemoglobin was significantly associated 
with protection against febrile malaria after adjusting for exposure in the multivariable 
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analysis. The Kaplan Meier estimates analysis showed that this protective effect was 
apparent after six months of age when we expect foetal haemoglobin to have reached its 
lowest levels. We make the hypothesis that this delayed protective effect could have resulted 
from an interaction between malaria exposure and foetal haemoglobin where initial low 
parasitaemia in the presence of high levels of foetal haemoglobin would have led to a more 
rapid acquisition of immunity (Pombo, Lawrence et al. 2002). 
Antibody responses have been proposed as a marker for the detection of fine scale spatial 
variation in malaria transmission (Bousema, Drakeley et al. 2010). However, few studies 
have compared the suitability of different possible markers for the detection of malaria 
hotspots in a context of declining malaria transmission. In the study conducted in Ganze, we 
found that hotspots of positive PCR tests partially or totally overlapped with at least one of 
the other types of hotspots. On the one hand, the critical role of asymptomatic parasites 
carriers in sustaining malaria transmission and the high sensitivity of the test advocate for 
the choice of PCR for the detection of hotspots of malaria transmission. On the other hand, 
the simplicity and low cost of serology compared with PCR advocate for the choice of 
serological markers for the detection of hotspots. 
 
At least 1.3% of the predicted 5268 proteins coded by the genes of P. falciparum are believed 
to be involved in RBCs invasion (Gardner, Hall et al. 2002) and we have only tested six.  
The findings that the endogenous antibody production in infants is low in the first two years 
of life in our cohort study needs to be validated in larger cohort studies in settings of variable 
5.2 The future directions 
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malaria transmission intensity and testing a much wider repertoire of antigens for which 
protective concentrations would need to be estimated. High throughput ELISA technologies 
would be ideal for large scale testing.  
The high concentrations of immunoglobulin preparations used in successful malaria 
immuno-therapeutic experiments suggest that the quantity of antibody matters (Cohen, 
McGregor et al. 1961). However, other studies suggest that the quality of antibody response 
is also critical. Indeed, it has been shown that passive transfer antibodies that are protective 
in vivo do not necessarily interfere with asexual parasites invasion and growth in vitro, and 
that sera from unprotected individuals fail to exert in vitro anti-parasitic effect in presence 
of monocytes (Bouharoun-Tayoun, Attanath et al. 1990). Though the antibody levels were 
low in infants in our studies, we speculate that they may be protected by antibodies not 
directly, but through cooperation with other immune cells such as monocytes or neutrophils 
and/or with other immune factors such as the complement. 
Young children do get infected by malaria parasites (Wagner, Koram et al. 1998) despite the 
circulating maternally-derived antibodies, but fever is generally absent. Moreover, there is 
evidence that the pyrogenic threshold parasitaemia is much higher in children compared with 
adults (Miller 1958) suggesting the existence of an immune tolerance (of the parasite 
presence) mechanism. An anti-toxic immunity more efficient than the anti-parasite 
immunity might then be preventing the clinical manifestations in young infants. The 
transplacental passage of soluble antigens has been linked to foetal T-cells priming and 
immunosuppression (immune tolerance) (Brustoski, Möller et al. 2006). Haemozoin, a 
byproduct of haemoglobin metabolism by malaria parasites and 
glycosylphosphatidylinositol (GPI), a membrane anchor for a number of malaria parasite 
surface antigens, have been shown to promote the production of pro-inflammatory cytokines 
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by monocytes and proposed as putative malaria toxins (Schofield and Hackett 1993, Sherry, 
Alava et al. 1995). On the one hand, anti-GPI antibodies have been associated to protection 
against the clinical manifestations of malaria (Naik, Branch et al. 2000) and other studies 
suggest that anti-haemozoin antibodies may have an inhibitory effect on pro-inflammatory 
cytokine production (Biswas, Karmarkar et al. 2001). On the other hand, an increased 
production of nitric oxide (a molecule that has anti-inflammatory effects) by peripheral 
mononuclear cells has been proposed as a mechanism of the anti-toxic immunity (Boutlis, 
Tjitra et al. 2003). However, subsequent studies yielded conflicting results and it is still 
unclear which mechanisms support the anti-toxic immunity (Boutlis, Gowda et al. 2002, de 
Souza, Todd et al. 2002, Boutlis, Weinberg et al. 2004). Anti-GPI antibodies are mainly IgG 
(Boutlis, Gowda et al. 2002) and there is evidence that IgG are the most efficiently 
transferred antibodies across the placenta (Gitlin, Kumate et al. 1964). The fact that this 
proposed anti-toxic immunity ends with the decline of maternal antibodies and foetal 
haemoglobin at around four months of age supports the hypothesis of the presence of anti-
toxin antibodies among in the pool of maternally-derived antibodies. The kinetics of foetal 
haemoglobin is almost parallel to that of maternally-derived antibodies and we cannot rule 
out a protective effect of an interaction between both factors. 
In the current context of high-level and global commitment to malaria 
elimination/eradication, some successes have been achieved over the last fifteen years with 
four countries certified as having completed elimination, twenty in pre-elimination or 
elimination phase and nine working to prevent re-introduction (WHO 2015). In areas where 
malaria transmission has already declined to moderate to low intensity or where malaria has 
been eliminated, the micro-epidemiological patterns of malaria take a critical importance 
since targeted interventions are likely to override the large-scale ones for cost and efficiency 
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reasons (Woolhouse, Dye et al. 1997). Methods for the identification of malaria transmission 
hotspots that are cost-effective and appropriate to the transmission intensity need to be 
validated for large scale use and for comparability purposes. Vaccines are predicted to 
contribute substantially to malaria control and elimination (Nunes, Cardenas et al. 2013). In 
the current race to the development of a malaria vaccine of high and long-lasting efficacy, a 
number of studies advocate for multicomponent vaccines (Hill, Biswas et al. 2014, Osier, 
Mackinnon et al. 2014). Sero-epidemiological studies and immunological correlates of 
protection if validated, would provide useful guidance to these antigen combinations as it 
has been done for other infectious diseases (O’Ryan, Stoddard et al. 2014). 
The present work aimed at contributing to fill the gap of knowledge in the role of antibodies 
in the immunity to malaria in infancy and early childhood by examining antibody responses 
to P. falciparum merozoite antigens, the blood stage form responsible of the clinical 
manifestations of the disease. Especially, we have analysed the dynamics of antibody 
responses in relation to previously established protective threshold antibody concentrations. 
In addition, we have examined the place of serological markers in the detection of hotspots 
of malaria transmission among other clinical, parasitological and entomological markers.  
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7.1.1 ELISA conducted in CNRFP laboratories 
REAGENTS  SOURCES  
Synthetic Merozoite surface protein 3 (MSP3-LSP) Statens Serum Institute, Copenhagen 
Synthetic Glutamate Rich Protein R0 (GLURP-R0) Statens Serum Institute, Copenhagen 
Synthetic Glutamate Rich Protein R2 (GLURP-R2) Statens Serum Institute, Copenhagen 
Positive control serum  Adults sera from Saponé donors 
Negative control sera  Adults sera from UK donnors 
Distilled water CNRFP laboratories 
Phosphate buffered saline tablets (salt) Sigma# P4417-100 Tab 
Tween 20 (detergent) Sigma Aldrich 
Skimmed milk FLUKA Analytical #70166 
Na2CO3 (Sodium carbonate) Sigma Aldrich#S2127 
NaHCO3 (Sodium hydrogen carbonate) VWR# 27778.236 
HRP-conjugated rabbit anti-human IgG Sigma Aldrich 
C6H8O7 (Citric acid) NA 
Na2HPO4 (Sodium hydrogen phosphate) FICHER Scientific# BP 329-500 
H2O2 (Hydrogen peroxide) NA 
C6H8N2 (O-phenylenediamine) Sigma Aldrich#N2764 
H2SO4 (Sulfuric acid) Sigma Aldrich#S45917-048 
 
EQUIPEMENTS SOURCES 
96-well Microtiter Microplates NUNC 439454 Maxisorb 
Microplates washer BIOTEK ELx405 
Microplate reader BIOTEK ELx808 
 
7.1.2 ELISA conducted in KEMRI-WTRP laboratories 
REAGENTS  SOURCES  
Recombinant Apical membrane antigen 1 (AMA1) KEMRI-WTRP Immunology Lab 
Recombinant Merozoite surface protein 1 (MSP1-19) KEMRI-WTRP Immunology Lab 
Recombinant Merozoite surface protein 2 (MSP2-Dd2) KEMRI-WTRP Immunology Lab 
Recombinant Merozoite surface protein 3 (MSP3-3D7) KEMRI-WTRP Immunology Lab 
Malaria Immune Globuline (MIG) Central Laboratory Blood Transfusion Service 
SRC, Switzerland Positive control serum Adult sera samples from Kilifi donors 
Negative control sera Adult sera samples from UK donors  
Distilled water KEMRI-WTRP Immunology Lab 
Phosphate buffered saline tablets (salt) Oxoid Limited 
7. Appendices 
7.1 ELISA reagents and laboratory equipment 
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REAGENTS  SOURCES  
Tween 20 (detergent) Sigma-Aldrich 
Skimmed milk Marvel® Premier Foods Group, UK 
Na2CO3 (Sodium carbonate) Sigma 
NaHCO3 (Sodium hydrogen carbonate) Sigma 
HRP-conjugated rabbit anti-human IgG Dako 
C6H8O7 (Citric acid) AnalaR® 
Na2HPO4 (Sodium hydrogen phosphate) Sigma 
H2O2 (Hydrogen peroxide) AnalaR® 
C6H8N2 (O-phenylenediamine) Sigma 
H2SO4 (Sulfuric acid) Sigma 
 
EQUIPEMENTS SOURCES (trademark, manufacturer) 
96-well Microtiter Microplates IMMULON 4HBX – Thermo Scientific 
Microplates washer BIOTEK 
Microplate reader BIOTEK 
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7.2.1 Cox regression Stata code / Chapter2 
clear all 
macro drop _all 
capture log close 
set more off 
log using chap2_coxreg,replace text 
* chap2_coxreg.do: survival analysis of bics data 
*david kangoye,PhD student,Open University/KEMRI-WTRP 
version 11.2 
set linesize 80 
*=============================================================== 
 
cd "C:\Users\dkangoye\Dropbox\projects\phdprogram_ou\work\data\data_bics\elisa_bics"  
 
use bicsV0,clear 
 
*combine morbidity data with exposure data 
*=============================== 
joinby code using dist1.5ei,unm(both) 
tab _merge,m 
list code if _merge==2 
drop if _merge==2 
drop _merge 
 
codebook mob 
recode mob (10=1) (11=2) (12=3) (1=4) 
codebook mob 
order mob,after(dob) 
 
lab def cald 1"October" 2"November" 3"December" 4"January" 
lab val mob cald 
tab mob 
tab mob,nolabel 
 
foreach i in logmsp3 logr0 logr2{ 
        gen b`i'=`i' if months=="M00" 
        sort code datevisit 
        replace b`i'=b`i'[_n-1] if code==code[_n-1] 
        lab var b`i' "baseline anti-`i' titer" 
        order b`i',after(`i') 
        replace b`i'=round(b`i',.01)  
        sum b`i',d 
} 
 
codebook hb_type 
recode hb_type (1=1) (2=.) (3=2) (4=3) 
lab def types 1"AA" 2"AC" 3"CC" 
lab val hb_type types 
codebook hb_type 
 
stset  datevisit, failure(malar10) id(code) origin(datscren) scale(28)  
 
*univariate cox regression 
*================== 
   
*create local macros for explanatory variables 
local envfac i.season i.mob i.zone ei    
local socufac i.educ 
local matfac agem i.primgrav i.sg_birth i.itn_use i.iptp_n  
local infac1 i.sex  muac height_scr weight_scr i.del_way i.rea i.epi_stat i.neo_inf    
local infac2 i.hb_type hbf logmsp3 logr0 logr2 
 
foreach i in `infac1' `infac2' `envfac' `socufac' `matfac' {    
        stcox `i' 
} 
 
*perform collinearity diagnostic 
7.2 Appendix 2: Stata code and output log 
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*====================== 
corr season ei hbf logmsp3 logr0 logr2 mob hb_type itn_use educ muac_scr 
collin season ei hbf logmsp3 logr0 logr2 mob hb_type itn_use educ muac_scr 
 
*multivariate cox regression 
*==================== 
 
*include in baseline multivariable model if p<0.2 or high importance variable 
 
xi:stcox i.season ei hbf logmsp3 logr0 logr2 i.mob i.hb_type i.itn_use i.educ muac_scr 
est store model0 
 
*drop variables with highest non significant p values one by one 
 
*drop educ 
xi:stcox i.season ei hbf logmsp3 logr0 logr2 i.mob i.hb_type i.itn_use muac_scr 
est store model1 
est table model0 model1,b(%5.3f) p(%4.3f) stats(N ll aic bic) 
lrtest model0 model1,stats 
 
*drop mob 
xi:stcox i.season ei hbf logmsp3 logr0 logr2 i.hb_type i.itn_use muac_scr 
est store model2 
est table model0 model1 model2,b(%5.3f) p(%4.3f) stats(N ll aic bic) 
lrtest model0 model2,stats 
 
*drop muac_scr 
xi:stcox i.season ei hbf logmsp3 logr0 logr2 i.hb_type i.itn_use  
est store model3 
est table model0 model1 model2 model3,b(%5.3f) p(%4.3f) stats(N ll aic bic) 
lrtest model0 model3,stats  
 
*test for interaction between foetal haemoglobin and exposure index 
xi:stcox i.season ei hbf logmsp3 logr0 logr2 i.hb_type i.itn_use c.ei#c.hbf 
 
*test of proportional hazards assumption 
*============================ 
estat phtest,d 
 
local grafreg "graphregion(fcolor(white) lcolor(white) ifcolor(white) ilcolor(white))" 
local plotreg "plotregion(fcolor(white) lcolor(white) ifcolor(white) ilcolor(white))" 
estat phtest,plot(logmsp3) yline(0) `grafreg' `plotreg' title(D) 
graph save 4,replace 
estat phtest,plot(logr0) yline(0) `grafreg' `plotreg' title(E) 
graph save 5,replace 
estat phtest,plot(logr2) yline(0) `grafreg' `plotreg' title(F) 
graph save 6,replace 
estat phtest,plot(ei) yline(0) `grafreg' `plotreg' title(G) 
graph save 7,replace 
estat phtest,plot(hbf) yline(0) `grafreg' `plotreg' title(H) 
graph save 8,replace 
 
graph combine 4.gph 5.gph 6.gph 7.gph 8.gph,`grafreg' `plotreg' 
graph save phtest,replace 
graph export phtest.tif,width(2049) replace 
 
log close 
exit 
 
7.2.2 Cox regression output log / Chaper 2 
----------------------------------------------------------------------- 
      name:  <unnamed> 
       log:  C:\Users\dkangoye\Documents\chap2_coxreg.log 
  log type:  text 
 opened on:  13 Sep 2016, 18:35:31 
 
. *chap2_coxreg.do: survival analysis of bics data 
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. *david kangoye,PhD student,Open University/KEMRI-WTRP 
. version 11.2 
 
. set linesize 80 
 
. *============================================================================= 
> ====== 
.  
. cd "C:\Users\dkangoye\Dropbox\projects\phdprogram_ou\work\data\data_bics\elisa 
> _bics"  
C:\Users\dkangoye\Dropbox\projects\phdprogram_ou\work\data\data_bics\elisa_bics 
 
.  
. use bicsV0,clear 
(combination of all data sets (morb+geo+sero)) 
 
.  
. *combine morbidity data with exposure data 
. *========================================= 
. joinby code using dist1.5ei,unm(both) 
 
. tab _merge,m 
 
                       _merge |      Freq.     Percent        Cum. 
------------------------------+----------------------------------- 
both in master and using data |     14,148      100.00      100.00 
------------------------------+----------------------------------- 
                        Total |     14,148      100.00 
 
. list code if _merge==2 
 
. drop if _merge==2 
(0 observations deleted) 
 
. drop _merge 
 
.  
. codebook mob 
 
-------------------------------------------------------------------------------- 
mob                                                               month of birth 
-------------------------------------------------------------------------------- 
 
                  type:  numeric (float) 
 
                 range:  [1,12]                       units:  1 
         unique values:  4                        missing .:  0/14148 
 
            tabulation:  Freq.  Value 
                          2906  1 
                          1273  10 
                          4435  11 
                          5534  12 
 
. recode mob (10=1) (11=2) (12=3) (1=4) 
(mob: 14148 changes made) 
 
. codebook mob 
 
-------------------------------------------------------------------------------- 
mob                                                               month of birth 
-------------------------------------------------------------------------------- 
 
                  type:  numeric (float) 
 
                 range:  [1,4]                        units:  1 
         unique values:  4                        missing .:  0/14148 
 
            tabulation:  Freq.  Value 
                          1273  1 
                          4435  2 
                          5534  3 
                          2906  4 
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. order mob,after(dob) 
 
.  
. lab def cald 1"October" 2"November" 3"December" 4"January" 
 
. lab val mob cald 
 
. tab mob 
 
   month of | 
      birth |      Freq.     Percent        Cum. 
------------+----------------------------------- 
    October |      1,273        9.00        9.00 
   November |      4,435       31.35       40.34 
   December |      5,534       39.12       79.46 
    January |      2,906       20.54      100.00 
------------+----------------------------------- 
      Total |     14,148      100.00 
 
. tab mob,nolabel 
 
   month of | 
      birth |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          1 |      1,273        9.00        9.00 
          2 |      4,435       31.35       40.34 
          3 |      5,534       39.12       79.46 
          4 |      2,906       20.54      100.00 
------------+----------------------------------- 
      Total |     14,148      100.00 
 
.  
. foreach i in logmsp3 logr0 logr2{ 
  2.         gen b`i'=`i' if months=="M00" 
  3.         sort code datevisit 
  4.         replace b`i'=b`i'[_n-1] if code==code[_n-1] 
  5.         lab var b`i' "baseline anti-`i' titer" 
  6.         order b`i',after(`i') 
  7.         replace b`i'=round(b`i',.01)  
  8.         sum b`i',d 
  9. } 
(14025 missing values generated) 
(13824 real changes made) 
(13947 real changes made) 
 
                 baseline anti-logmsp3 titer 
------------------------------------------------------------- 
      Percentiles      Smallest 
 1%          .29            .18 
 5%           .8            .18 
10%         2.05            .18       Obs               13947 
25%         2.84            .18       Sum of Wgt.       13947 
 
50%         4.33                      Mean            4.15911 
                        Largest       Std. Dev.      1.761113 
75%         5.37           8.21 
90%          6.5           8.21       Variance        3.10152 
95%         6.83           8.21       Skewness       -.132732 
99%         7.58           8.21       Kurtosis       2.487097 
(14025 missing values generated) 
(13824 real changes made) 
(13947 real changes made) 
 
                  baseline anti-logr0 titer 
------------------------------------------------------------- 
      Percentiles      Smallest 
 1%          .52            .39 
 5%         2.01            .39 
10%         2.13            .39       Obs               13947 
25%         2.96            .39       Sum of Wgt.       13947 
 
50%         3.86                      Mean           3.925452 
                        Largest       Std. Dev.      1.462806 
75%         4.91           7.82 
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90%         5.98           7.82       Variance       2.139802 
95%         6.51           7.82       Skewness       .1080209 
99%         7.46           7.82       Kurtosis       2.911145 
(14025 missing values generated) 
(13824 real changes made) 
(13947 real changes made) 
 
                  baseline anti-logr2 titer 
------------------------------------------------------------- 
      Percentiles      Smallest 
 1%          .97            .52 
 5%         2.71            .52 
10%         2.92            .52       Obs               13947 
25%         4.31            .52       Sum of Wgt.       13947 
 
50%         5.34                      Mean           5.337898 
                        Largest       Std. Dev.      1.653574 
75%         6.51              9 
90%         7.29              9       Variance       2.734306 
95%         7.78              9       Skewness      -.3830149 
99%         8.82              9       Kurtosis       3.218267 
 
.  
. codebook hb_type 
 
-------------------------------------------------------------------------------- 
hb_type                                                              (unlabeled) 
-------------------------------------------------------------------------------- 
 
                  type:  numeric (float) 
                 label:  catg 
 
                 range:  [1,4]                        units:  1 
         unique values:  4                        missing .:  100/14148 
 
            tabulation:  Freq.   Numeric  Label 
                         11595         1  AA 
                           112         2  AS 
                          1839         3  AC 
                           502         4  CC 
                           100         .   
 
. recode hb_type (1=1) (2=.) (3=2) (4=3) 
(hb_type: 2453 changes made) 
 
. lab def types 1"AA" 2"AC" 3"CC" 
 
. lab val hb_type types 
 
. codebook hb_type 
 
-------------------------------------------------------------------------------- 
hb_type                                                              (unlabeled) 
-------------------------------------------------------------------------------- 
 
                  type:  numeric (float) 
                 label:  types 
 
                 range:  [1,3]                        units:  1 
         unique values:  3                        missing .:  212/14148 
 
            tabulation:  Freq.   Numeric  Label 
                         11595         1  AA 
                          1839         2  AC 
                           502         3  CC 
                           212         .   
 
.  
. stset  datevisit, failure(malar10) id(code) origin(datscren) scale(28)  
 
                id:  code 
     failure event:  malar10 != 0 & malar10 < . 
obs. time interval:  (datevisit[_n-1], datevisit] 
 exit on or before:  failure 
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    t for analysis:  (time-origin)/28 
            origin:  time datscren 
 
------------------------------------------------------------------------------ 
    14148  total observations 
      124  observations end on or before enter() 
     4678  observations begin on or after (first) failure 
------------------------------------------------------------------------------ 
     9346  observations remaining, representing 
      125  subjects 
       90  failures in single-failure-per-subject data 
 2112.929  total analysis time at risk and under observation 
                                              at risk from t =         0 
                                   earliest observed entry t =         0 
                                        last observed exit t =  26.60714 
 
.  
. *univariate cox regression 
. *========================= 
.    
. *create local macros for explanatory variables 
. local envfac i.season i.mob i.zone ei    
 
. local socufac i.educ 
 
. local matfac agem i.primgrav i.sg_birth i.itn_use i.iptp_n  
 
. local infac1 i.sex  muac height_scr weight_scr i.del_way i.rea i.epi_stat i.ne 
> o_inf    
 
. local infac2 i.hb_type hbf logmsp3 logr0 logr2 
 
.  
. foreach i in `infac1' `infac2' `envfac' `socufac' `matfac' {    
  2.         stcox `i' 
  3. } 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood =  -386.0048 
Iteration 1:   log likelihood = -385.74996 
Iteration 2:   log likelihood = -385.74996 
Refining estimates: 
Iteration 0:   log likelihood = -385.74996 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      9346 
No. of failures =           90 
Time at risk    =  2112.928571 
                                                   LR chi2(1)      =      0.51 
Log likelihood  =   -385.74996                     Prob > chi2     =    0.4753 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
       2.sex |   .8599306   .1817821    -0.71   0.475     .5682332    1.301368 
------------------------------------------------------------------------------ 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood =  -386.0048 
Iteration 1:   log likelihood = -385.14403 
Iteration 2:   log likelihood = -385.14197 
Iteration 3:   log likelihood = -385.14197 
Refining estimates: 
Iteration 0:   log likelihood = -385.14197 
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Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      9346 
No. of failures =           90 
Time at risk    =  2112.928571 
                                                   LR chi2(1)      =      1.73 
Log likelihood  =   -385.14197                     Prob > chi2     =    0.1890 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    muac_scr |   1.127406   .1012997     1.33   0.182      .945362    1.344505 
------------------------------------------------------------------------------ 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -384.65069 
Iteration 1:   log likelihood = -384.35241 
Iteration 2:   log likelihood = -384.35234 
Refining estimates: 
Iteration 0:   log likelihood = -384.35234 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          124                     Number of obs   =      9232 
No. of failures =           90 
Time at risk    =  2086.892857 
                                                   LR chi2(1)      =      0.60 
Log likelihood  =   -384.35234                     Prob > chi2     =    0.4398 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  height_scr |   1.034446    .045581     0.77   0.442     .9488578    1.127754 
------------------------------------------------------------------------------ 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -381.24858 
Iteration 1:   log likelihood = -381.19957 
Iteration 2:   log likelihood = -381.19957 
Refining estimates: 
Iteration 0:   log likelihood = -381.19957 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          124                     Number of obs   =      9252 
No. of failures =           89 
Time at risk    =      2090.25 
                                                   LR chi2(1)      =      0.10 
Log likelihood  =   -381.19957                     Prob > chi2     =    0.7542 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  weight_scr |   1.057692   .1890977     0.31   0.754     .7450378     1.50155 
------------------------------------------------------------------------------ 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -376.47846 
Iteration 1:   log likelihood = -375.61234 
Iteration 2:   log likelihood = -375.54215 
Iteration 3:   log likelihood = -375.54132 
Iteration 4:   log likelihood = -375.54132 
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Refining estimates: 
Iteration 0:   log likelihood = -375.54132 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          123                     Number of obs   =      9161 
No. of failures =           88 
Time at risk    =  2070.071429 
                                                   LR chi2(1)      =      1.87 
Log likelihood  =   -375.54132                     Prob > chi2     =    0.1710 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     del_way | 
   cesarean  |   .4272051   .3058909    -1.19   0.235      .104991    1.738284 
------------------------------------------------------------------------------ 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood =  -386.0048 
Iteration 1:   log likelihood = -385.95161 
Iteration 2:   log likelihood = -385.95146 
Iteration 3:   log likelihood = -385.95146 
Refining estimates: 
Iteration 0:   log likelihood = -385.95146 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      9346 
No. of failures =           90 
Time at risk    =  2112.928571 
                                                   LR chi2(1)      =      0.11 
Log likelihood  =   -385.95146                     Prob > chi2     =    0.7439 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         rea | 
         no  |   .8838838   .3284886    -0.33   0.740     .4266313    1.831208 
------------------------------------------------------------------------------ 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood =  -386.0048 
Iteration 1:   log likelihood = -385.76567 
Iteration 2:   log likelihood = -385.76389 
Iteration 3:   log likelihood = -385.76389 
Refining estimates: 
Iteration 0:   log likelihood = -385.76389 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      9346 
No. of failures =           90 
Time at risk    =  2112.928571 
                                                   LR chi2(1)      =      0.48 
Log likelihood  =   -385.76389                     Prob > chi2     =    0.4876 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    epi_stat | 
         no  |   1.238263   .3716989     0.71   0.476     .6875455    2.230102 
------------------------------------------------------------------------------ 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
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             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood =  -386.0048 
Iteration 1:   log likelihood = -384.48472 
Iteration 2:   log likelihood =  -384.4845 
Refining estimates: 
Iteration 0:   log likelihood =  -384.4845 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      9346 
No. of failures =           90 
Time at risk    =  2112.928571 
                                                   LR chi2(1)      =      3.04 
Log likelihood  =    -384.4845                     Prob > chi2     =    0.0812 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     neo_inf | 
         no  |   .0840198   .0881232    -2.36   0.018      .010755    .6563778 
------------------------------------------------------------------------------ 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -383.27184 
Iteration 1:   log likelihood =  -382.3204 
Iteration 2:   log likelihood = -382.27486 
Iteration 3:   log likelihood = -382.27458 
Iteration 4:   log likelihood = -382.27458 
Refining estimates: 
Iteration 0:   log likelihood = -382.27458 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          123                     Number of obs   =      9135 
No. of failures =           90 
Time at risk    =  2061.071429 
                                                   LR chi2(2)      =      1.99 
Log likelihood  =   -382.27458                     Prob > chi2     =    0.3689 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     hb_type | 
         AC  |   1.299099   .4045907     0.84   0.401     .7055772    2.391883 
         CC  |   .4972872    .356377    -0.97   0.330     .1220676    2.025883 
------------------------------------------------------------------------------ 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -384.65069 
Iteration 1:   log likelihood =  -383.1016 
Iteration 2:   log likelihood = -383.09965 
Refining estimates: 
Iteration 0:   log likelihood = -383.09965 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          124                     Number of obs   =      9246 
No. of failures =           90 
Time at risk    =         2087 
                                                   LR chi2(1)      =      3.10 
Log likelihood  =   -383.09965                     Prob > chi2     =    0.0782 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
 200 
 
-------------+---------------------------------------------------------------- 
         hbf |   .9848312   .0084409    -1.78   0.075     .9684256    1.001515 
------------------------------------------------------------------------------ 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood =  -386.0048 
Iteration 1:   log likelihood =  -380.0881 
Iteration 2:   log likelihood = -380.07542 
Iteration 3:   log likelihood = -380.07542 
Refining estimates: 
Iteration 0:   log likelihood = -380.07542 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      9346 
No. of failures =           90 
Time at risk    =  2112.928571 
                                                   LR chi2(1)      =     11.86 
Log likelihood  =   -380.07542                     Prob > chi2     =    0.0006 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     logmsp3 |   1.406028   .1367318     3.50   0.000      1.16203     1.70126 
------------------------------------------------------------------------------ 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood =  -386.0048 
Iteration 1:   log likelihood = -385.52832 
Iteration 2:   log likelihood = -385.52819 
Refining estimates: 
Iteration 0:   log likelihood = -385.52819 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      9346 
No. of failures =           90 
Time at risk    =  2112.928571 
                                                   LR chi2(1)      =      0.95 
Log likelihood  =   -385.52819                     Prob > chi2     =    0.3289 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
       logr0 |   1.109708   .1176061     0.98   0.326     .9015686    1.365898 
------------------------------------------------------------------------------ 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood =  -386.0048 
Iteration 1:   log likelihood = -385.91068 
Iteration 2:   log likelihood = -385.91068 
Refining estimates: 
Iteration 0:   log likelihood = -385.91068 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      9346 
No. of failures =           90 
Time at risk    =  2112.928571 
                                                   LR chi2(1)      =      0.19 
Log likelihood  =   -385.91068                     Prob > chi2     =    0.6644 
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------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
       logr2 |    1.03344   .0783198     0.43   0.664     .8907923     1.19893 
------------------------------------------------------------------------------ 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood =  -386.0048 
Iteration 1:   log likelihood =  -377.7847 
Iteration 2:   log likelihood = -377.15557 
Iteration 3:   log likelihood = -377.14563 
Iteration 4:   log likelihood = -377.14563 
Refining estimates: 
Iteration 0:   log likelihood = -377.14563 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      9346 
No. of failures =           90 
Time at risk    =  2112.928571 
                                                   LR chi2(1)      =     17.72 
Log likelihood  =   -377.14563                     Prob > chi2     =    0.0000 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
      season | 
    high_ts  |   10.09555   6.548771     3.56   0.000     2.831221    35.99867 
------------------------------------------------------------------------------ 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood =  -386.0048 
Iteration 1:   log likelihood = -382.89532 
Iteration 2:   log likelihood = -382.69299 
Iteration 3:   log likelihood = -382.69276 
Refining estimates: 
Iteration 0:   log likelihood = -382.69276 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      9346 
No. of failures =           90 
Time at risk    =  2112.928571 
                                                   LR chi2(3)      =      6.62 
Log likelihood  =   -382.69276                     Prob > chi2     =    0.0849 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         mob | 
   November  |   1.408442   .5631323     0.86   0.392     .6432892    3.083698 
   December  |   1.325864   .5250798     0.71   0.476     .6100973     2.88137 
    January  |   2.489854    1.03978     2.18   0.029     1.098263    5.644708 
------------------------------------------------------------------------------ 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood =  -386.0048 
Iteration 1:   log likelihood =  -376.3595 
Iteration 2:   log likelihood =   -376.208 
Iteration 3:   log likelihood = -376.20795 
Refining estimates: 
Iteration 0:   log likelihood = -376.20795 
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Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      9346 
No. of failures =           90 
Time at risk    =  2112.928571 
                                                   LR chi2(2)      =     19.59 
Log likelihood  =   -376.20795                     Prob > chi2     =    0.0001 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        zone | 
      urban  |   .4270694   .1166378    -3.12   0.002     .2500491    .7294101 
      mixed  |   1.324263   .3245323     1.15   0.252     .8191688    2.140795 
------------------------------------------------------------------------------ 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood =  -386.0048 
Iteration 1:   log likelihood = -376.55189 
Iteration 2:   log likelihood = -376.52682 
Iteration 3:   log likelihood = -376.52682 
Refining estimates: 
Iteration 0:   log likelihood = -376.52682 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      9346 
No. of failures =           90 
Time at risk    =  2112.928571 
                                                   LR chi2(1)      =     18.96 
Log likelihood  =   -376.52682                     Prob > chi2     =    0.0000 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
          ei |   1.076501   .0188788     4.20   0.000     1.040127    1.114146 
------------------------------------------------------------------------------ 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood =  -386.0048 
Iteration 1:   log likelihood = -383.49799 
Iteration 2:   log likelihood = -383.45047 
Iteration 3:   log likelihood = -383.45046 
Refining estimates: 
Iteration 0:   log likelihood = -383.45046 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      9346 
No. of failures =           90 
Time at risk    =  2112.928571 
                                                   LR chi2(2)      =      5.11 
Log likelihood  =   -383.45046                     Prob > chi2     =    0.0777 
 
------------------------------------------------------------------------------- 
           _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
         educ | 
primary sc..  |   1.385446   .3182677     1.42   0.156     .8831812    2.173349 
secondary ..  |    .642815   .2233491    -1.27   0.203     .3253359    1.270106 
------------------------------------------------------------------------------- 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
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                 id:  code 
 
Iteration 0:   log likelihood =  -386.0048 
Iteration 1:   log likelihood = -385.57725 
Iteration 2:   log likelihood =  -385.5764 
Refining estimates: 
Iteration 0:   log likelihood =  -385.5764 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      9346 
No. of failures =           90 
Time at risk    =  2112.928571 
                                                   LR chi2(1)      =      0.86 
Log likelihood  =    -385.5764                     Prob > chi2     =    0.3546 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        agem |   1.016155   .0173533     0.94   0.348     .9827059    1.050742 
------------------------------------------------------------------------------ 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -381.17704 
Iteration 1:   log likelihood = -381.17556 
Iteration 2:   log likelihood = -381.17556 
Refining estimates: 
Iteration 0:   log likelihood = -381.17556 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          124                     Number of obs   =      9307 
No. of failures =           89 
Time at risk    =  2103.964286 
                                                   LR chi2(1)      =      0.00 
Log likelihood  =   -381.17556                     Prob > chi2     =    0.9567 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    primgrav | 
         no  |   .9860174   .2551392    -0.05   0.957     .5937861    1.637341 
------------------------------------------------------------------------------ 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood =  -386.0048 
Iteration 1:   log likelihood = -384.87796 
Iteration 2:   log likelihood = -384.77099 
Iteration 3:   log likelihood = -384.76917 
Iteration 4:   log likelihood = -384.76917 
Refining estimates: 
Iteration 0:   log likelihood = -384.76917 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      9346 
No. of failures =           90 
Time at risk    =  2112.928571 
                                                   LR chi2(1)      =      2.47 
Log likelihood  =   -384.76917                     Prob > chi2     =    0.1159 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    sg_birth | 
         no  |   .3834371   .2746089    -1.34   0.181      .094207    1.560649 
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------------------------------------------------------------------------------ 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood =    -381.19 
Iteration 1:   log likelihood = -381.11466 
Iteration 2:   log likelihood = -381.11448 
Iteration 3:   log likelihood = -381.11448 
Refining estimates: 
Iteration 0:   log likelihood = -381.11448 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          124                     Number of obs   =      9289 
No. of failures =           89 
Time at risk    =  2100.285714 
                                                   LR chi2(1)      =      0.15 
Log likelihood  =   -381.11448                     Prob > chi2     =    0.6975 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     itn_use | 
         no  |   .8742819   .3076698    -0.38   0.703     .4386357    1.742605 
------------------------------------------------------------------------------ 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood =  -386.0048 
Iteration 1:   log likelihood = -384.80566 
Iteration 2:   log likelihood = -384.77529 
Iteration 3:   log likelihood = -384.77516 
Iteration 4:   log likelihood = -384.77516 
Refining estimates: 
Iteration 0:   log likelihood = -384.77516 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      9346 
No. of failures =           90 
Time at risk    =  2112.928571 
                                                   LR chi2(3)      =      2.46 
Log likelihood  =   -384.77516                     Prob > chi2     =    0.4827 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
      iptp_n | 
          1  |   1.705241   .8494711     1.07   0.284     .6423284    4.527041 
          2  |   1.260928    .585985     0.50   0.618     .5071253    3.135199 
          3  |   .6471596   .7090459    -0.40   0.691     .0755808    5.541295 
------------------------------------------------------------------------------ 
 
.  
. *perform collinearity diagnostic 
. *=============================== 
. corr season ei hbf logmsp3 logr0 logr2 mob hb_type itn_use educ muac_scr 
(obs=13830) 
 
             |   season       ei      hbf  logmsp3    logr0    logr2      mob 
-------------+--------------------------------------------------------------- 
      season |   1.0000 
          ei |   0.0034   1.0000 
         hbf |  -0.0093   0.1472   1.0000 
     logmsp3 |  -0.1149   0.1549   0.0043   1.0000 
       logr0 |  -0.0866  -0.0121  -0.0138   0.3297   1.0000 
       logr2 |  -0.1472   0.0803   0.0536   0.3884   0.5101   1.0000 
         mob |   0.0069   0.2531  -0.1123   0.0322   0.0776   0.0088   1.0000 
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     hb_type |  -0.0068   0.0991   0.0807  -0.0155   0.0294   0.0348   0.0853 
     itn_use |  -0.0033  -0.0029   0.1125  -0.0195   0.0340   0.0439   0.1716 
        educ |  -0.0016  -0.1473   0.1013  -0.0472  -0.0980  -0.1199  -0.0432 
    muac_scr |   0.0043  -0.0508  -0.0915   0.0203   0.0127  -0.0131  -0.0764 
 
             |  hb_type  itn_use     educ muac_scr 
-------------+------------------------------------ 
     hb_type |   1.0000 
     itn_use |   0.0727   1.0000 
        educ |  -0.1433  -0.0961   1.0000 
    muac_scr |  -0.0224  -0.0691  -0.0132   1.0000 
 
 
. collin season ei hbf logmsp3 logr0 logr2 mob hb_type itn_use educ muac_scr 
(obs=13830) 
 
  Collinearity Diagnostics 
 
                        SQRT                   R- 
  Variable      VIF     VIF    Tolerance    Squared 
---------------------------------------------------- 
    season      1.03    1.01    0.9734      0.0266 
        ei      1.19    1.09    0.8410      0.1590 
       hbf      1.11    1.06    0.8980      0.1020 
   logmsp3      1.25    1.12    0.7996      0.2004 
     logr0      1.42    1.19    0.7033      0.2967 
     logr2      1.50    1.22    0.6664      0.3336 
       mob      1.17    1.08    0.8582      0.1418 
   hb_type      1.04    1.02    0.9575      0.0425 
   itn_use      1.08    1.04    0.9295      0.0705 
      educ      1.09    1.04    0.9170      0.0830 
  muac_scr      1.02    1.01    0.9803      0.0197 
---------------------------------------------------- 
  Mean VIF      1.17 
 
                           Cond 
        Eigenval          Index 
--------------------------------- 
    1    10.0226          1.0000 
    2     0.6286          3.9931 
    3     0.5056          4.4524 
    4     0.2278          6.6331 
    5     0.1733          7.6042 
    6     0.1155          9.3141 
    7     0.1118          9.4702 
    8     0.0773         11.3870 
    9     0.0612         12.7935 
    10     0.0522         13.8626 
    11     0.0210         21.8404 
    12     0.0031         56.8802 
--------------------------------- 
 Condition Number        56.8802  
 Eigenvalues & Cond Index computed from scaled raw sscp (w/ intercept) 
 Det(correlation matrix)    0.4198 
 
.  
. *multivariate cox regression 
. *=========================== 
.  
. *include in baseline multivariable model if p<0.2 or high importance variable 
.  
. xi:stcox i.season ei hbf logmsp3 logr0 logr2 i.mob i.hb_type i.itn_use i.educ  
> muac_scr 
i.season          _Iseason_0-1        (naturally coded; _Iseason_0 omitted) 
i.mob             _Imob_1-4           (naturally coded; _Imob_1 omitted) 
i.hb_type         _Ihb_type_1-3       (naturally coded; _Ihb_type_1 omitted) 
i.itn_use         _Iitn_use_1-2       (naturally coded; _Iitn_use_1 omitted) 
i.educ            _Ieduc_0-2          (naturally coded; _Ieduc_0 omitted) 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
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Iteration 0:   log likelihood = -378.47353 
Iteration 1:   log likelihood = -346.40614 
Iteration 2:   log likelihood = -344.88137 
Iteration 3:   log likelihood = -344.85786 
Iteration 4:   log likelihood = -344.85784 
Refining estimates: 
Iteration 0:   log likelihood = -344.85784 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          122                     Number of obs   =      9078 
No. of failures =           89 
Time at risk    =  2048.428571 
                                                   LR chi2(15)     =     67.23 
Log likelihood  =   -344.85784                     Prob > chi2     =    0.0000 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  _Iseason_1 |   9.956209   6.806982     3.36   0.001     2.606959    38.02365 
          ei |    1.07433   .0231541     3.33   0.001     1.029894    1.120683 
         hbf |   .9664748   .0102502    -3.22   0.001     .9465921    .9867752 
     logmsp3 |   1.382536   .1550887     2.89   0.004     1.109663     1.72251 
       logr0 |   1.127786   .1378904     0.98   0.325     .8874693    1.433178 
       logr2 |   1.033757   .0917989     0.37   0.709     .8686219    1.230287 
     _Imob_2 |    1.99559   .8674811     1.59   0.112     .8512454    4.678298 
     _Imob_3 |   1.717923   .7562386     1.23   0.219     .7249369    4.071056 
     _Imob_4 |   2.603881   1.253705     1.99   0.047     1.013418    6.690426 
 _Ihb_type_2 |   1.113114   .3792671     0.31   0.753     .5708383    2.170533 
 _Ihb_type_3 |   .5729062   .4298735    -0.74   0.458     .1316419     2.49329 
 _Iitn_use_2 |   .8415139   .3398041    -0.43   0.669     .3813689    1.856852 
    _Ieduc_1 |   1.837735   .4729232     2.36   0.018     1.109774    3.043205 
    _Ieduc_2 |   .9339809   .3790047    -0.17   0.866     .4216234    2.068956 
    muac_scr |   1.220963   .1393585     1.75   0.080     .9762205    1.527064 
------------------------------------------------------------------------------ 
 
. est store model0 
 
.  
. *drop  variables with highest non significant p values one by one 
.  
. *drop educ 
. xi:stcox i.season ei hbf logmsp3 logr0 logr2 i.mob i.hb_type i.itn_use muac_sc 
> r 
i.season          _Iseason_0-1        (naturally coded; _Iseason_0 omitted) 
i.mob             _Imob_1-4           (naturally coded; _Imob_1 omitted) 
i.hb_type         _Ihb_type_1-3       (naturally coded; _Ihb_type_1 omitted) 
i.itn_use         _Iitn_use_1-2       (naturally coded; _Iitn_use_1 omitted) 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -378.47353 
Iteration 1:   log likelihood =  -349.3221 
Iteration 2:   log likelihood = -347.81266 
Iteration 3:   log likelihood = -347.78781 
Iteration 4:   log likelihood = -347.78778 
Refining estimates: 
Iteration 0:   log likelihood = -347.78778 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          122                     Number of obs   =      9078 
No. of failures =           89 
Time at risk    =  2048.428571 
                                                   LR chi2(13)     =     61.37 
Log likelihood  =   -347.78778                     Prob > chi2     =    0.0000 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  _Iseason_1 |   9.876878   6.663235     3.39   0.001     2.632533    37.05659 
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          ei |   1.081073   .0216822     3.89   0.000     1.039402    1.124416 
         hbf |   .9726745   .0097668    -2.76   0.006     .9537191    .9920065 
     logmsp3 |   1.339551     .14696     2.66   0.008     1.080377    1.660899 
       logr0 |   1.148908   .1379159     1.16   0.248     .9080426    1.453664 
       logr2 |   .9997401   .0869305    -0.00   0.998     .8430872    1.185501 
     _Imob_2 |   1.610657   .6838817     1.12   0.262     .7007843    3.701873 
     _Imob_3 |   1.474164   .6328224     0.90   0.366     .6355447    3.419367 
     _Imob_4 |   2.042248   .9637324     1.51   0.130     .8098946     5.14978 
 _Ihb_type_2 |   1.160129   .3968754     0.43   0.664     .5933539    2.268291 
 _Ihb_type_3 |   .4860787   .3630158    -0.97   0.334     .1124626    2.100899 
 _Iitn_use_2 |    .825092   .3377882    -0.47   0.639     .3698495    1.840686 
    muac_scr |     1.1932   .1329509     1.59   0.113     .9591112    1.484422 
------------------------------------------------------------------------------ 
 
. est store model1 
 
. est table model0 model1,b(%5.3f) p(%4.3f) stats(N ll aic bic) 
 
---------------------------------- 
    Variable | model0    model1    
-------------+-------------------- 
  _Iseason_1 |   2.298     2.290   
             |   0.001     0.001   
          ei |   0.072     0.078   
             |   0.001     0.000   
         hbf |  -0.034    -0.028   
             |   0.001     0.006   
     logmsp3 |   0.324     0.292   
             |   0.004     0.008   
       logr0 |   0.120     0.139   
             |   0.325     0.248   
       logr2 |   0.033    -0.000   
             |   0.709     0.998   
     _Imob_2 |   0.691     0.477   
             |   0.112     0.262   
     _Imob_3 |   0.541     0.388   
             |   0.219     0.366   
     _Imob_4 |   0.957     0.714   
             |   0.047     0.130   
 _Ihb_type_2 |   0.107     0.149   
             |   0.753     0.664   
 _Ihb_type_3 |  -0.557    -0.721   
             |   0.458     0.334   
 _Iitn_use_2 |  -0.173    -0.192   
             |   0.669     0.639   
    _Ieduc_1 |   0.609             
             |   0.018             
    _Ieduc_2 |  -0.068             
             |   0.866             
    muac_scr |   0.200     0.177   
             |   0.080     0.113   
-------------+-------------------- 
           N |    9078      9078   
          ll | -344.858   -347.788   
         aic | 719.716   721.576   
         bic | 826.420   814.052   
---------------------------------- 
                       legend: b/p 
 
. lrtest model0 model1,stats 
 
Likelihood-ratio test                                 LR chi2(2)  =      5.86 
(Assumption: model1 nested in model0)                 Prob > chi2 =    0.0534 
 
Akaike's information criterion and Bayesian information criterion 
 
----------------------------------------------------------------------------- 
       Model |    Obs    ll(null)   ll(model)     df          AIC         BIC 
-------------+--------------------------------------------------------------- 
      model1 |   9078   -378.4735   -347.7878     13     721.5756    814.0525 
      model0 |   9078   -378.4735   -344.8578     15     719.7157    826.4198 
----------------------------------------------------------------------------- 
               Note:  N=Obs used in calculating BIC; see [R] BIC note 
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.  
. *drop mob 
. xi:stcox i.season ei hbf logmsp3 logr0 logr2 i.hb_type i.itn_use muac_scr 
i.season          _Iseason_0-1        (naturally coded; _Iseason_0 omitted) 
i.hb_type         _Ihb_type_1-3       (naturally coded; _Ihb_type_1 omitted) 
i.itn_use         _Iitn_use_1-2       (naturally coded; _Iitn_use_1 omitted) 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -378.47353 
Iteration 1:   log likelihood = -349.96533 
Iteration 2:   log likelihood = -349.09659 
Iteration 3:   log likelihood = -349.07859 
Iteration 4:   log likelihood = -349.07857 
Refining estimates: 
Iteration 0:   log likelihood = -349.07857 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          122                     Number of obs   =      9078 
No. of failures =           89 
Time at risk    =  2048.428571 
                                                   LR chi2(10)     =     58.79 
Log likelihood  =   -349.07857                     Prob > chi2     =    0.0000 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  _Iseason_1 |   10.41847   7.163339     3.41   0.001     2.707391    40.09196 
          ei |   1.083885   .0213378     4.09   0.000      1.04286    1.126523 
         hbf |   .9736989   .0091795    -2.83   0.005     .9558726    .9918578 
     logmsp3 |   1.363777   .1494158     2.83   0.005     1.100235    1.690445 
       logr0 |   1.163793   .1379263     1.28   0.201     .9225626    1.468099 
       logr2 |   .9884921   .0842469    -0.14   0.892     .8364254    1.168205 
 _Ihb_type_2 |   1.292225   .4262081     0.78   0.437     .6770028    2.466526 
 _Ihb_type_3 |   .4686875   .3454411    -1.03   0.304     .1105387    1.987249 
 _Iitn_use_2 |   .9727559   .3728144    -0.07   0.943     .4589612     2.06173 
    muac_scr |   1.172246   .1212585     1.54   0.124     .9571266    1.435714 
------------------------------------------------------------------------------ 
 
. est store model2 
 
. est table model0 model1 model2,b(%5.3f) p(%4.3f) stats(N ll aic bic) 
 
-------------------------------------------- 
    Variable | model0    model1    model2    
-------------+------------------------------ 
  _Iseason_1 |   2.298     2.290     2.344   
             |   0.001     0.001     0.001   
          ei |   0.072     0.078     0.081   
             |   0.001     0.000     0.000   
         hbf |  -0.034    -0.028    -0.027   
             |   0.001     0.006     0.005   
     logmsp3 |   0.324     0.292     0.310   
             |   0.004     0.008     0.005   
       logr0 |   0.120     0.139     0.152   
             |   0.325     0.248     0.201   
       logr2 |   0.033    -0.000    -0.012   
             |   0.709     0.998     0.892   
     _Imob_2 |   0.691     0.477             
             |   0.112     0.262             
     _Imob_3 |   0.541     0.388             
             |   0.219     0.366             
     _Imob_4 |   0.957     0.714             
             |   0.047     0.130             
 _Ihb_type_2 |   0.107     0.149     0.256   
             |   0.753     0.664     0.437   
 _Ihb_type_3 |  -0.557    -0.721    -0.758   
             |   0.458     0.334     0.304   
 _Iitn_use_2 |  -0.173    -0.192    -0.028   
             |   0.669     0.639     0.943   
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    _Ieduc_1 |   0.609                       
             |   0.018                       
    _Ieduc_2 |  -0.068                       
             |   0.866                       
    muac_scr |   0.200     0.177     0.159   
             |   0.080     0.113     0.124   
-------------+------------------------------ 
           N |    9078      9078      9078   
          ll | -344.858   -347.788   -349.079   
         aic | 719.716   721.576   718.157   
         bic | 826.420   814.052   789.293   
-------------------------------------------- 
                                 legend: b/p 
 
. lrtest model0 model2,stats 
 
Likelihood-ratio test                                 LR chi2(5)  =      8.44 
(Assumption: model2 nested in model0)                 Prob > chi2 =    0.1335 
 
Akaike's information criterion and Bayesian information criterion 
 
----------------------------------------------------------------------------- 
       Model |    Obs    ll(null)   ll(model)     df          AIC         BIC 
-------------+--------------------------------------------------------------- 
      model2 |   9078   -378.4735   -349.0786     10     718.1571    789.2932 
      model0 |   9078   -378.4735   -344.8578     15     719.7157    826.4198 
----------------------------------------------------------------------------- 
               Note:  N=Obs used in calculating BIC; see [R] BIC note 
 
.  
. *drop muac_scr 
. xi:stcox i.season ei hbf logmsp3 logr0 logr2 i.hb_type i.itn_use  
i.season          _Iseason_0-1        (naturally coded; _Iseason_0 omitted) 
i.hb_type         _Ihb_type_1-3       (naturally coded; _Ihb_type_1 omitted) 
i.itn_use         _Iitn_use_1-2       (naturally coded; _Iitn_use_1 omitted) 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -378.47353 
Iteration 1:   log likelihood = -351.08804 
Iteration 2:   log likelihood = -350.23558 
Iteration 3:   log likelihood = -350.21671 
Iteration 4:   log likelihood = -350.21669 
Refining estimates: 
Iteration 0:   log likelihood = -350.21669 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          122                     Number of obs   =      9078 
No. of failures =           89 
Time at risk    =  2048.428571 
                                                   LR chi2(9)      =     56.51 
Log likelihood  =   -350.21669                     Prob > chi2     =    0.0000 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  _Iseason_1 |   10.85486   7.513924     3.44   0.001     2.795168    42.15419 
          ei |   1.084239   .0215202     4.07   0.000      1.04287    1.127249 
         hbf |   .9727917   .0090551    -2.96   0.003      .955205    .9907022 
     logmsp3 |   1.340013   .1450433     2.70   0.007     1.083864    1.656698 
       logr0 |   1.149006   .1337748     1.19   0.233     .9145765    1.443527 
       logr2 |   .9849329   .0841889    -0.18   0.859     .8330071    1.164567 
 _Ihb_type_2 |   1.294033   .4264765     0.78   0.434     .6782867     2.46875 
 _Ihb_type_3 |    .517231   .3805478    -0.90   0.370     .1222985    2.187499 
 _Iitn_use_2 |   .8602875   .3216058    -0.40   0.687     .4134609    1.789999 
------------------------------------------------------------------------------ 
 
. est store model3 
 
. est table model0 model1 model2 model3,b(%5.3f) p(%4.3f) stats(N ll aic bic) 
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------------------------------------------------------ 
    Variable | model0    model1    model2    model3    
-------------+---------------------------------------- 
  _Iseason_1 |   2.298     2.290     2.344     2.385   
             |   0.001     0.001     0.001     0.001   
          ei |   0.072     0.078     0.081     0.081   
             |   0.001     0.000     0.000     0.000   
         hbf |  -0.034    -0.028    -0.027    -0.028   
             |   0.001     0.006     0.005     0.003   
     logmsp3 |   0.324     0.292     0.310     0.293   
             |   0.004     0.008     0.005     0.007   
       logr0 |   0.120     0.139     0.152     0.139   
             |   0.325     0.248     0.201     0.233   
       logr2 |   0.033    -0.000    -0.012    -0.015   
             |   0.709     0.998     0.892     0.859   
     _Imob_2 |   0.691     0.477                       
             |   0.112     0.262                       
     _Imob_3 |   0.541     0.388                       
             |   0.219     0.366                       
     _Imob_4 |   0.957     0.714                       
             |   0.047     0.130                       
 _Ihb_type_2 |   0.107     0.149     0.256     0.258   
             |   0.753     0.664     0.437     0.434   
 _Ihb_type_3 |  -0.557    -0.721    -0.758    -0.659   
             |   0.458     0.334     0.304     0.370   
 _Iitn_use_2 |  -0.173    -0.192    -0.028    -0.150   
             |   0.669     0.639     0.943     0.687   
    _Ieduc_1 |   0.609                                 
             |   0.018                                 
    _Ieduc_2 |  -0.068                                 
             |   0.866                                 
    muac_scr |   0.200     0.177     0.159             
             |   0.080     0.113     0.124             
-------------+---------------------------------------- 
           N |    9078      9078      9078      9078   
          ll | -344.858   -347.788   -349.079   -350.217   
         aic | 719.716   721.576   718.157   718.433   
         bic | 826.420   814.052   789.293   782.456   
------------------------------------------------------ 
                                           legend: b/p 
 
. lrtest model0 model3,stats  
 
Likelihood-ratio test                                 LR chi2(6)  =     10.72 
(Assumption: model3 nested in model0)                 Prob > chi2 =    0.0975 
 
Akaike's information criterion and Bayesian information criterion 
 
----------------------------------------------------------------------------- 
       Model |    Obs    ll(null)   ll(model)     df          AIC         BIC 
-------------+--------------------------------------------------------------- 
      model3 |   9078   -378.4735   -350.2167      9     718.4334    782.4559 
      model0 |   9078   -378.4735   -344.8578     15     719.7157    826.4198 
----------------------------------------------------------------------------- 
               Note:  N=Obs used in calculating BIC; see [R] BIC note 
 
.  
. *test for interaction between foetal haemoglobin and exposure index 
. xi:stcox i.season ei hbf logmsp3 logr0 logr2 i.hb_type i.itn_use c.ei#c.hbf 
i.season          _Iseason_0-1        (naturally coded; _Iseason_0 omitted) 
i.hb_type         _Ihb_type_1-3       (naturally coded; _Ihb_type_1 omitted) 
i.itn_use         _Iitn_use_1-2       (naturally coded; _Iitn_use_1 omitted) 
 
         failure _d:  malar10 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -378.47353 
Iteration 1:   log likelihood = -350.16068 
Iteration 2:   log likelihood = -348.43686 
Iteration 3:   log likelihood = -348.38462 
Iteration 4:   log likelihood = -348.38439 
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Iteration 5:   log likelihood = -348.38439 
Refining estimates: 
Iteration 0:   log likelihood = -348.38439 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          122                     Number of obs   =      9078 
No. of failures =           89 
Time at risk    =  2048.428571 
                                                   LR chi2(10)     =     60.18 
Log likelihood  =   -348.38439                     Prob > chi2     =    0.0000 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  _Iseason_1 |    10.5854   7.351466     3.40   0.001     2.713662    41.29135 
          ei |   1.294586      .1237     2.70   0.007     1.073487    1.561222 
         hbf |   .9287129   .0240401    -2.86   0.004     .8827705    .9770463 
     logmsp3 |   1.370113   .1496851     2.88   0.004     1.106019    1.697268 
       logr0 |   1.145049   .1318252     1.18   0.239     .9137519    1.434893 
       logr2 |   .9777683   .0841912    -0.26   0.794     .8259292    1.157522 
 _Ihb_type_2 |    1.29324    .425738     0.78   0.435     .6783617    2.465454 
 _Ihb_type_3 |   .5614829   .4096002    -0.79   0.429     .1343964    2.345771 
 _Iitn_use_2 |   .8942001   .3323705    -0.30   0.764     .4315654    1.852776 
             | 
  c.ei#c.hbf |   .9969782   .0015849    -1.90   0.057     .9938768    1.000089 
------------------------------------------------------------------------------ 
 
.  
. *test of proportional hazards assumption 
. *======================================= 
. estat phtest,d 
 
      Test of proportional-hazards assumption 
 
      Time:  Time 
      ---------------------------------------------------------------- 
                  |       rho            chi2       df       Prob>chi2 
      ------------+--------------------------------------------------- 
      _Iseason_1  |     -0.02008         0.03        1         0.8702 
      ei          |      0.07569         0.65        1         0.4204 
      hbf         |     -0.05874         0.36        1         0.5509 
      logmsp3     |      0.00773         0.01        1         0.9383 
      logr0       |      0.03187         0.11        1         0.7376 
      logr2       |      0.02203         0.05        1         0.8179 
      _Ihb_type_2 |     -0.17879         2.97        1         0.0850 
      _Ihb_type_3 |      0.07955         0.56        1         0.4549 
      _Iitn_use_2 |     -0.12949         1.79        1         0.1811 
      c.ei#c.hbf  |     -0.10322         1.14        1         0.2859 
      ------------+--------------------------------------------------- 
      global test |                      8.70       10         0.5610 
      ---------------------------------------------------------------- 
 
.  
. local grafreg "graphregion(fcolor(white) lcolor(white) ifcolor(white) ilcolor( 
> white))" 
 
. local plotreg "plotregion(fcolor(white) lcolor(white) ifcolor(white) ilcolor(w 
> hite))" 
 
. estat phtest,plot(logmsp3) yline(0) `grafreg' `plotreg' title(D) 
 
. graph save 4,replace 
(file 4.gph saved) 
 
. estat phtest,plot(logr0) yline(0) `grafreg' `plotreg' title(E) 
 
. graph save 5,replace 
(file 5.gph saved) 
 
. estat phtest,plot(logr2) yline(0) `grafreg' `plotreg' title(F) 
 
. graph save 6,replace 
(file 6.gph saved) 
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. estat phtest,plot(ei) yline(0) `grafreg' `plotreg' title(G) 
 
. graph save 7,replace 
(file 7.gph saved) 
 
. estat phtest,plot(hbf) yline(0) `grafreg' `plotreg' title(H) 
 
. graph save 8,replace 
(file 8.gph saved) 
 
.  
. graph combine 4.gph 5.gph 6.gph 7.gph 8.gph,`grafreg' `plotreg' 
 
. graph save phtest,replace 
(file phtest.gph saved) 
 
. graph export phtest.tif,width(2049) replace 
(file phtest.tif written in TIFF format) 
 
.  
. log close 
      name:  <unnamed> 
       log:  C:\Users\dkangoye\Documents\chap2_coxreg.log 
  log type:  text 
 closed on:  13 Sep 2016, 18:35:48 
-------------------------------------------------------------------------------- 
 
7.2.3 Negative binomial regression Stata code / Chapter 2 
clear all 
macro drop _all 
capture log close 
set more off 
log using chap2_nbreg,replace text 
*chap2_nbreg.do: construct predictive model for number of episodes 
*david kangoye,PhD student,Open University/KEMRI-WTRP 
version 11.2 
set linesize 80 
*=============================================================== 
 
cd "C:\Users\dkangoye\Dropbox\projects\phdprogram_ou\work\data\data_bics\elisa_bics"  
 
use bicsV0,clear 
 
*combine morbidity data with exposure data 
*=============================== 
joinby code using dist15ei,unm(both) 
tab _merge,m 
list code if _merge==2 
drop if _merge==2 
drop _merge 
 
*gen data set with an id that uniquely identify each couple of (code+period) 
*===================================================== 
sort code datevisit 
egen id=concat(code period) 
order id,before(code) 
 
*generate variable for number of episodes for each child for each period 
*=================================================== 
egen numep=total(malar10),by (id) 
order numep,after(malar4) 
 
*keep only one observ per child for each period 
*================================= 
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bysort id (datevisit):keep if _n==1 
sort code datevisit 
 
*gen variable for number of episodes occured in the previous period 
*================================================ 
gen numpep=numep[_n-1] if code==code[_n-1] & period != period[_n-1] 
replace numpep=0 if period=="0-3" 
order numep numpep,after(malar4) 
 
*gen variable for age 
*============== 
drop age  
gen age=(datevisit-dob)/28 
order age,after(numpep) 
order period,after(malar4) 
 
*define local macros for potential explanatory variables 
*======================================== 
local envfac season ei mob zone    
local socufac ethn  
local matfac agem primgrav del_n sg_birth itn_use iptp_n educ 
local infac1 age sex hb_type hbf muac height_scr weight_scr epi_stat neo_inf    
local infac2 logmsp3 logr0 logr2 
local infac3 msp3 r0 r2 
 
*keep/order variables of interest and sort observations 
*====================================== 
keep id code dob datevisit period numep numpep `envfac' `socufac' `matfac' /// 
  `infac1' `infac2' `infac3' monthn months 
order id code datevisit age period season ei numep numpep msp3 r0 r2 logmsp3 /// 
   logr0 logr2 
sort code datevisit 
 
save bicsVx,replace 
 
*select between poisson/nbreg for non negative count data regression: 
*compare mean and variance of outcome variable 
*================================== 
use bicsVx,clear 
hist numep,freq 
tabstat numep,s(mean v) 
 
codebook mob 
recode mob (10=1) (11=2) (12=3) (1=4) 
codebook mob 
order mob,after(dob) 
 
lab def cald 1"October" 2"November" 3"December" 4"January" 
lab val mob cald 
tab mob 
tab mob,nolabel 
 
foreach i in logmsp3 logr0 logr2{ 
 gen b`i'=`i' if months=="M00" 
 sort code datevisit 
 replace b`i'=b`i'[_n-1] if code==code[_n-1] 
 lab var b`i' "baseline anti-`i' titer" 
 order b`i',after(`i') 
 replace b`i'=round(b`i',.01)  
 sum b`i',d 
} 
 
*compute mfp of age for nbreg model 
*========================== 
mfp nbreg numep age  
corr age Iage__1 Iage__2 
 
*define local macros for predictor var to be used in regression analysis 
*================================================= 
local envfac i.season ei i.mob i.zone    
local socufac i.educ 
local matfac agem i.primgrav i.itn_use i.iptp_n  
local infac1 i.sex  muac_scr height_scr weight_scr i.epi_stat     
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local infac2 i.hb_type hbf logmsp3 logr0 logr2 blogmsp3 blogr0 blogr2 
local age Iage__1 Iage__2 
 
*run univariate nbreg adjusting for clusters 
*============================== 
foreach i in age `age' `infac2' `infac1' `matfac' `envfac' `socufac'{ 
   xi:nbreg numep `i',cluster(code) irr 
} 
 
*perform collinearity diagnostics 
*======================= 
corr numep age logmsp3 logr0 logr2 hbf hb_type muac_scr mob epi_stat /// 
     agem itn_use educ season ei 
xi:collin numep age logmsp3 logr0 logr2 hbf i.hb_type muac_scr i.mob i.epi_stat /// 
       agem i.itn_use i.educ i.season ei 
  
*multivariate regression analysis using changing antibody titres adjusting for clusters 
*============================================================ 
 
*model0: include if p<0.2 or high importance var  
xi:nbreg numep age logmsp3 logr0 logr2 hbf i.hb_type muac_scr i.mob i.epi_stat /// 
  agem i.itn_use i.educ i.season ei,cluster(code) irr     
 
xi:glm numep age logmsp3 logr0 logr2 hbf i.hb_type muac_scr i.mob i.epi_stat /// 
  agem i.itn_use i.educ i.season ei,family(nb) cluster(code)      
 
*run wald test to select covariates for the final model 
xi:testparm i.epi_stat 
test agem 
xi:testparm i.mob 
xi:testparm i.educ 
test muac_scr 
 
xi:nbreg numep age logmsp3 logr0 logr2 hbf i.hb_type muac_scr /// 
      i.itn_use i.educ i.season ei,cluster(code) irr     
 
   
log close 
exit 
 
7.2.4 Negative binomial regression output log / Chapter 2 
-------------------------------------------------------------------------------- 
      name:  <unnamed> 
       log:  C:\Users\dkangoye\Dropbox\projects\phdprogram_ou\work\data\data_bic 
> s\elisa_bics\chap2_nbreg.log 
  log type:  text 
 opened on:  13 Sep 2016, 18:56:55 
 
. *chap2_nbreg.do: construct predictive model for number of episodes 
. *david kangoye,PhD student,Open University/KEMRI-WTRP 
. version 11.2 
 
. set linesize 80 
 
.  
. *============================================================================= 
> ===== 
.  
. cd "C:\Users\dkangoye\Dropbox\projects\phdprogram_ou\work\data\data_bics\elisa 
> _bics"  
C:\Users\dkangoye\Dropbox\projects\phdprogram_ou\work\data\data_bics\elisa_bics 
 
.  
. use bicsV0,clear 
(combination of all data sets (morb+geo+sero)) 
 
.  
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. *combine morbidity data with exposure data 
. *========================================= 
. joinby code using dist15ei,unm(both) 
 
. tab _merge,m 
 
                       _merge |      Freq.     Percent        Cum. 
------------------------------+----------------------------------- 
both in master and using data |     14,148      100.00      100.00 
------------------------------+----------------------------------- 
                        Total |     14,148      100.00 
 
. list code if _merge==2 
 
. drop if _merge==2 
(0 observations deleted) 
 
. drop _merge 
 
.  
. *gen data set with an id that uniquely identify each couple of (code+period) 
. *=========================================================================== 
. sort code datevisit 
 
. egen id=concat(code period) 
 
. order id,before(code) 
 
.  
. *generate variable for number of episodes for each child for each period 
. *======================================================================= 
. egen numep=total(malar10),by (id) 
 
. order numep,after(malar4) 
 
.  
. *keep only one observ per child for each period 
. *============================================== 
. bysort id (datevisit):keep if _n==1 
(13300 observations deleted) 
 
. sort code datevisit 
 
.  
. *gen variable for number of episodes occured in the previous period 
. *================================================================== 
. gen numpep=numep[_n-1] if code==code[_n-1] & period != period[_n-1] 
(125 missing values generated) 
 
. replace numpep=0 if period=="0-3" 
(123 real changes made) 
 
. order numep numpep,after(malar4) 
 
.  
. *gen variable for age 
. *==================== 
. drop age  
 
. gen age=(datevisit-dob)/28 
 
. order age,after(numpep) 
 
. order period,after(malar4) 
 
.  
. *define local macros for potential explanatory variables 
. *======================================================= 
. local envfac season ei mob zone    
 
. local socufac ethn  
 
. local matfac agem primgrav del_n sg_birth itn_use iptp_n educ 
 
 216 
 
. local infac1 age sex hb_type hbf muac height_scr weight_scr epi_stat neo_inf   
>   
 
. local infac2 logmsp3 logr0 logr2 
 
. local infac3 msp3 r0 r2 
 
.  
. *keep/order variables of interest and sort observations 
. *====================================================== 
. keep id code dob datevisit period numep numpep `envfac' `socufac' `matfac' /// 
>          `infac1' `infac2' `infac3' monthn months 
 
. order id code datevisit age period season ei numep numpep msp3 r0 r2 logmsp3 / 
> // 
>           logr0 logr2 
 
. sort code datevisit 
 
.  
. save bicsVx,replace 
file bicsVx.dta saved 
 
.  
. *select between poisson/nbreg for non negative count data regression: 
. *compare mean and variance of outcome variable 
. *==================================================================== 
. use bicsVx,clear 
(combination of all data sets (morb+geo+sero)) 
 
. hist numep,freq 
(bin=29, start=0, width=.17241379) 
 
. tabstat numep,s(mean v) 
 
    variable |      mean  variance 
-------------+-------------------- 
       numep |  .3419811   .631435 
---------------------------------- 
 
.  
. codebook mob 
 
-------------------------------------------------------------------------------- 
mob                                                               month of birth 
-------------------------------------------------------------------------------- 
 
                  type:  numeric (float) 
 
                 range:  [1,12]                       units:  1 
         unique values:  4                        missing .:  0/848 
 
            tabulation:  Freq.  Value 
                           177  1 
                            74  10 
                           267  11 
                           330  12 
 
. recode mob (10=1) (11=2) (12=3) (1=4) 
(mob: 848 changes made) 
 
. codebook mob 
 
-------------------------------------------------------------------------------- 
mob                                                               month of birth 
-------------------------------------------------------------------------------- 
 
                  type:  numeric (float) 
 
                 range:  [1,4]                        units:  1 
         unique values:  4                        missing .:  0/848 
 
            tabulation:  Freq.  Value 
                            74  1 
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                           267  2 
                           330  3 
                           177  4 
 
. order mob,after(dob) 
 
.  
. lab def cald 1"October" 2"November" 3"December" 4"January" 
 
. lab val mob cald 
 
. tab mob 
 
   month of | 
      birth |      Freq.     Percent        Cum. 
------------+----------------------------------- 
    October |         74        8.73        8.73 
   November |        267       31.49       40.21 
   December |        330       38.92       79.13 
    January |        177       20.87      100.00 
------------+----------------------------------- 
      Total |        848      100.00 
 
. tab mob,nolabel 
 
   month of | 
      birth |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          1 |         74        8.73        8.73 
          2 |        267       31.49       40.21 
          3 |        330       38.92       79.13 
          4 |        177       20.87      100.00 
------------+----------------------------------- 
      Total |        848      100.00 
 
.  
. foreach i in logmsp3 logr0 logr2{ 
  2.         gen b`i'=`i' if months=="M00" 
  3.         sort code datevisit 
  4.         replace b`i'=b`i'[_n-1] if code==code[_n-1] 
  5.         lab var b`i' "baseline anti-`i' titer" 
  6.         order b`i',after(`i') 
  7.         replace b`i'=round(b`i',.01)  
  8.         sum b`i',d 
  9. } 
(725 missing values generated) 
(713 real changes made) 
(836 real changes made) 
 
                 baseline anti-logmsp3 titer 
------------------------------------------------------------- 
      Percentiles      Smallest 
 1%          .29            .18 
 5%           .8            .18 
10%         2.05            .18       Obs                 836 
25%         2.84            .18       Sum of Wgt.         836 
 
50%         4.33                      Mean           4.160275 
                        Largest       Std. Dev.      1.758796 
75%         5.37           8.21 
90%          6.5           8.21       Variance       3.093364 
95%         6.83           8.21       Skewness      -.1311114 
99%         7.58           8.21       Kurtosis       2.483507 
(725 missing values generated) 
(713 real changes made) 
(836 real changes made) 
 
                  baseline anti-logr0 titer 
------------------------------------------------------------- 
      Percentiles      Smallest 
 1%          .52            .39 
 5%          1.7            .39 
10%         2.13            .39       Obs                 836 
25%         2.96            .39       Sum of Wgt.         836 
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50%         3.85                      Mean           3.908612 
                        Largest       Std. Dev.        1.4613 
75%         4.91           7.82 
90%         5.84           7.82       Variance       2.135399 
95%         6.51           7.82       Skewness       .1160334 
99%         7.46           7.82       Kurtosis       2.914036 
(725 missing values generated) 
(713 real changes made) 
(836 real changes made) 
 
                  baseline anti-logr2 titer 
------------------------------------------------------------- 
      Percentiles      Smallest 
 1%          .97            .52 
 5%         2.71            .52 
10%         2.92            .52       Obs                 836 
25%        4.315            .52       Sum of Wgt.         836 
 
50%         5.34                      Mean            5.32549 
                        Largest       Std. Dev.      1.635094 
75%         6.45              9 
90%         7.22              9       Variance       2.673533 
95%          7.7              9       Skewness      -.3984221 
99%         8.82              9       Kurtosis       3.236337 
 
.  
. *compute mfp of age for nbreg model 
. *================================== 
. mfp nbreg numep age  
 
Deviance for model with all terms untransformed =  1164.137, 848 observations 
 
Variable     Model (vs.)   Deviance  Dev diff.   P      Powers   (vs.) 
---------------------------------------------------------------------- 
age          lin.   FP2    1164.137    88.502  0.000+   1         3 3 
             FP1           1126.569    50.934  0.000+   -.5        
             Final         1075.635                     3 3 
 
 
Transformations of covariates: 
 
-> gen double Iage__1 = X^3-1.440072283 if e(sample)  
-> gen double Iage__2 = X^3*ln(X)-.1750615751 if e(sample)  
   (where: X = age/10) 
 
Final multivariable fractional polynomial model for numep 
-------------------------------------------------------------------- 
    Variable |    -----Initial-----          -----Final----- 
             |   df     Select   Alpha    Status    df    Powers 
-------------+------------------------------------------------------ 
         age |    4     1.0000   0.0500     in      4     3 3 
-------------------------------------------------------------------- 
 
Negative binomial regression                      Number of obs   =        848 
                                                  LR chi2(2)      =     180.66 
Dispersion     = mean                             Prob > chi2     =     0.0000 
Log likelihood = -537.81752                       Pseudo R2       =     0.1438 
 
------------------------------------------------------------------------------ 
       numep |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     Iage__1 |   1.231002   .0910916    13.51   0.000     1.052466    1.409538 
     Iage__2 |  -1.218107   .0944402   -12.90   0.000    -1.403206   -1.033007 
       _cons |  -1.324822   .0967993   -13.69   0.000    -1.514545   -1.135098 
-------------+---------------------------------------------------------------- 
    /lnalpha |  -.4898762   .3375371                     -1.151437    .1716843 
-------------+---------------------------------------------------------------- 
       alpha |   .6127022   .2068097                      .3161822    1.187303 
------------------------------------------------------------------------------ 
Likelihood-ratio test of alpha=0:  chibar2(01) =   17.48 Prob>=chibar2 = 0.000 
Deviance: 1075.635. 
 
. corr age Iage__1 Iage__2 
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(obs=848) 
 
             |      age  Iage__1  Iage__2 
-------------+--------------------------- 
         age |   1.0000 
     Iage__1 |   0.9132   1.0000 
     Iage__2 |   0.8519   0.9900   1.0000 
 
 
.  
. *define local macros for predictor var to be used in regression analysis 
. *======================================================================= 
. local envfac i.season ei i.mob i.zone    
 
. local socufac i.educ 
 
. local matfac agem i.primgrav i.itn_use i.iptp_n  
 
. local infac1 i.sex  muac_scr height_scr weight_scr i.epi_stat     
 
. local infac2 i.hb_type hbf logmsp3 logr0 logr2 blogmsp3 blogr0 blogr2 
 
. local age Iage__1 Iage__2 
 
.  
. *run univariate nbreg adjusting for clusters 
. *=========================================== 
. foreach i in age `age' `infac2' `infac1' `matfac' `envfac' `socufac'{ 
  2.    xi:nbreg numep `i',cluster(code) irr 
  3. } 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -633.52912   
Iteration 1:   log pseudolikelihood = -633.52897   
Iteration 2:   log pseudolikelihood = -633.52897   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -645.90918   
Iteration 1:   log pseudolikelihood = -628.39289   
Iteration 2:   log pseudolikelihood = -628.14696   
Iteration 3:   log pseudolikelihood = -628.14648   
Iteration 4:   log pseudolikelihood = -628.14648   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -591.75095   
Iteration 1:   log pseudolikelihood = -582.30352   
Iteration 2:   log pseudolikelihood = -582.06864   
Iteration 3:   log pseudolikelihood = -582.06863   
 
Negative binomial regression                      Number of obs   =        848 
                                                  Wald chi2(1)    =     245.35 
Dispersion           = mean                       Prob > chi2     =     0.0000 
Log pseudolikelihood = -582.06863                 Pseudo R2       =     0.0734 
 
                                 (Std. Err. adjusted for 125 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         age |   1.115524   .0077858    15.66   0.000     1.100368    1.130888 
       _cons |   .0732308   .0114692   -16.69   0.000     .0538742     .099542 
-------------+---------------------------------------------------------------- 
    /lnalpha |   .6900406   .1458838                      .4041136    .9759676 
-------------+---------------------------------------------------------------- 
       alpha |   1.993797   .2908626                      1.497974    2.653734 
------------------------------------------------------------------------------ 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -676.65514   
Iteration 1:   log pseudolikelihood = -676.64564   
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Iteration 2:   log pseudolikelihood = -676.64564   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -645.90918   
Iteration 1:   log pseudolikelihood = -628.39289   
Iteration 2:   log pseudolikelihood = -628.14696   
Iteration 3:   log pseudolikelihood = -628.14648   
Iteration 4:   log pseudolikelihood = -628.14648   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -613.16418   
Iteration 1:   log pseudolikelihood = -610.26627   
Iteration 2:   log pseudolikelihood = -610.19808   
Iteration 3:   log pseudolikelihood = -610.19806   
 
Negative binomial regression                      Number of obs   =        848 
                                                  Wald chi2(1)    =     117.29 
Dispersion           = mean                       Prob > chi2     =     0.0000 
Log pseudolikelihood = -610.19806                 Pseudo R2       =     0.0286 
 
                                 (Std. Err. adjusted for 125 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     Iage__1 |   1.106173   .0103066    10.83   0.000     1.086156    1.126559 
       _cons |   .2429008   .0244185   -14.08   0.000     .1994615    .2958006 
-------------+---------------------------------------------------------------- 
    /lnalpha |   .9787589   .1357827                      .7126296    1.244888 
-------------+---------------------------------------------------------------- 
       alpha |   2.661151   .3613384                      2.039347    3.472546 
------------------------------------------------------------------------------ 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -689.59582   
Iteration 1:   log pseudolikelihood = -689.59375   
Iteration 2:   log pseudolikelihood = -689.59375   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -645.90918   
Iteration 1:   log pseudolikelihood = -628.39289   
Iteration 2:   log pseudolikelihood = -628.14696   
Iteration 3:   log pseudolikelihood = -628.14648   
Iteration 4:   log pseudolikelihood = -628.14648   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood =  -620.6087   
Iteration 1:   log pseudolikelihood = -619.45368   
Iteration 2:   log pseudolikelihood = -619.44364   
Iteration 3:   log pseudolikelihood = -619.44364   
 
Negative binomial regression                      Number of obs   =        848 
                                                  Wald chi2(1)    =      61.71 
Dispersion           = mean                       Prob > chi2     =     0.0000 
Log pseudolikelihood = -619.44364                 Pseudo R2       =     0.0139 
 
                                 (Std. Err. adjusted for 125 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     Iage__2 |   1.079488   .0105103     7.86   0.000     1.059084    1.100285 
       _cons |   .2663619   .0264981   -13.30   0.000     .2191762    .3237061 
-------------+---------------------------------------------------------------- 
    /lnalpha |   1.053741   .1340746                      .7909595    1.316522 
-------------+---------------------------------------------------------------- 
       alpha |   2.868361   .3845744                      2.205512    3.730426 
------------------------------------------------------------------------------ 
i.hb_type         _Ihb_type_1-4       (naturally coded; _Ihb_type_1 omitted) 
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Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -697.05025   
Iteration 1:   log pseudolikelihood = -696.72745   
Iteration 2:   log pseudolikelihood =  -696.7261   
Iteration 3:   log pseudolikelihood = -696.72609   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -644.13887   
Iteration 1:   log pseudolikelihood = -642.54052   
Iteration 2:   log pseudolikelihood =  -626.7411   
Iteration 3:   log pseudolikelihood = -626.73975   
Iteration 4:   log pseudolikelihood = -626.73975   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -625.50456   
Iteration 1:   log pseudolikelihood = -624.51526   
Iteration 2:   log pseudolikelihood = -624.51071   
Iteration 3:   log pseudolikelihood = -624.51071   
 
Negative binomial regression                      Number of obs   =        842 
                                                  Wald chi2(3)    =     312.50 
Dispersion           = mean                       Prob > chi2     =     0.0000 
Log pseudolikelihood = -624.51071                 Pseudo R2       =     0.0036 
 
                                 (Std. Err. adjusted for 124 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
 _Ihb_type_2 |   1.93e-08   1.94e-08   -17.62   0.000     2.67e-09    1.39e-07 
 _Ihb_type_3 |   1.149385   .2426495     0.66   0.510     .7599168     1.73846 
 _Ihb_type_4 |    .654743   .4725322    -0.59   0.557     .1591304    2.693944 
       _cons |   .3448782   .0313111   -11.73   0.000     .2886596    .4120458 
-------------+---------------------------------------------------------------- 
    /lnalpha |   1.096003   .1308127                      .8396149    1.352391 
-------------+---------------------------------------------------------------- 
       alpha |   2.992182   .3914153                      2.315475     3.86666 
------------------------------------------------------------------------------ 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -698.36129   
Iteration 1:   log pseudolikelihood = -698.36129   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -644.13887   
Iteration 1:   log pseudolikelihood = -642.54052   
Iteration 2:   log pseudolikelihood =  -626.7411   
Iteration 3:   log pseudolikelihood = -626.73975   
Iteration 4:   log pseudolikelihood = -626.73975   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -625.75335   
Iteration 1:   log pseudolikelihood = -625.74249   
Iteration 2:   log pseudolikelihood = -625.74249   
 
Negative binomial regression                      Number of obs   =        842 
                                                  Wald chi2(1)    =       2.26 
Dispersion           = mean                       Prob > chi2     =     0.1326 
Log pseudolikelihood = -625.74249                 Pseudo R2       =     0.0016 
 
                                 (Std. Err. adjusted for 124 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         hbf |   .9895375   .0069201    -1.50   0.133     .9760668    1.003194 
       _cons |   .6341641   .2599422    -1.11   0.267     .2839856    1.416142 
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-------------+---------------------------------------------------------------- 
    /lnalpha |   1.103286   .1313702                      .8458051    1.360767 
-------------+---------------------------------------------------------------- 
       alpha |   3.014054   .3959567                      2.329853    3.899182 
------------------------------------------------------------------------------ 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood =  -699.2549   
Iteration 1:   log pseudolikelihood =  -699.2549   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -645.90918   
Iteration 1:   log pseudolikelihood = -628.39289   
Iteration 2:   log pseudolikelihood = -628.14696   
Iteration 3:   log pseudolikelihood = -628.14648   
Iteration 4:   log pseudolikelihood = -628.14648   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -626.43682   
Iteration 1:   log pseudolikelihood =  -626.3765   
Iteration 2:   log pseudolikelihood = -626.37649   
 
Negative binomial regression                      Number of obs   =        848 
                                                  Wald chi2(1)    =       4.37 
Dispersion           = mean                       Prob > chi2     =     0.0365 
Log pseudolikelihood = -626.37649                 Pseudo R2       =     0.0028 
 
                                 (Std. Err. adjusted for 125 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     logmsp3 |   1.115937   .0585453     2.09   0.037     1.006893    1.236791 
       _cons |   .2475726   .0453485    -7.62   0.000     .1728964    .3545024 
-------------+---------------------------------------------------------------- 
    /lnalpha |   1.106734   .1307607                      .8504481    1.363021 
-------------+---------------------------------------------------------------- 
       alpha |   3.024465   .3954812                      2.340695     3.90798 
------------------------------------------------------------------------------ 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -699.72369   
Iteration 1:   log pseudolikelihood = -699.72369   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -645.90918   
Iteration 1:   log pseudolikelihood = -628.39289   
Iteration 2:   log pseudolikelihood = -628.14696   
Iteration 3:   log pseudolikelihood = -628.14648   
Iteration 4:   log pseudolikelihood = -628.14648   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -626.74277   
Iteration 1:   log pseudolikelihood = -626.70723   
Iteration 2:   log pseudolikelihood = -626.70722   
 
Negative binomial regression                      Number of obs   =        848 
                                                  Wald chi2(1)    =       5.34 
Dispersion           = mean                       Prob > chi2     =     0.0209 
Log pseudolikelihood = -626.70722                 Pseudo R2       =     0.0023 
 
                                 (Std. Err. adjusted for 125 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
       logr0 |   1.123359   .0565638     2.31   0.021     1.017791    1.239877 
       _cons |    .235293   .0451131    -7.55   0.000     .1615871     .342619 
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-------------+---------------------------------------------------------------- 
    /lnalpha |   1.109341    .130001                      .8545433    1.364138 
-------------+---------------------------------------------------------------- 
       alpha |   3.032358   .3942097                      2.350301    3.912349 
------------------------------------------------------------------------------ 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -702.32192   
Iteration 1:   log pseudolikelihood = -702.32192   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -645.90918   
Iteration 1:   log pseudolikelihood = -628.39289   
Iteration 2:   log pseudolikelihood = -628.14696   
Iteration 3:   log pseudolikelihood = -628.14648   
Iteration 4:   log pseudolikelihood = -628.14648   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -628.14133   
Iteration 1:   log pseudolikelihood = -628.14131   
 
Negative binomial regression                      Number of obs   =        848 
                                                  Wald chi2(1)    =       0.01 
Dispersion           = mean                       Prob > chi2     =     0.9145 
Log pseudolikelihood = -628.14131                 Pseudo R2       =     0.0000 
 
                                 (Std. Err. adjusted for 125 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
       logr2 |   1.005065   .0473049     0.11   0.915     .9164973    1.102192 
       _cons |   .3349677   .0700962    -5.23   0.000     .2222687    .5048095 
-------------+---------------------------------------------------------------- 
    /lnalpha |   1.125944   .1299277                        .87129    1.380597 
-------------+---------------------------------------------------------------- 
       alpha |   3.083125   .4005834                      2.389992    3.977277 
------------------------------------------------------------------------------ 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -692.14524   
Iteration 1:   log pseudolikelihood = -692.14524   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -636.91081   
Iteration 1:   log pseudolikelihood = -635.75433   
Iteration 2:   log pseudolikelihood = -619.75637   
Iteration 3:   log pseudolikelihood = -619.75511   
Iteration 4:   log pseudolikelihood = -619.75511   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -619.75496   
Iteration 1:   log pseudolikelihood = -619.75496   
 
Negative binomial regression                      Number of obs   =        836 
                                                  Wald chi2(1)    =       0.00 
Dispersion           = mean                       Prob > chi2     =     0.9856 
Log pseudolikelihood = -619.75496                 Pseudo R2       =     0.0000 
 
                                 (Std. Err. adjusted for 123 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    blogmsp3 |   .9991332   .0481583    -0.02   0.986     .9090659    1.098124 
       _cons |   .3433414   .0770791    -4.76   0.000      .221123    .5331118 
-------------+---------------------------------------------------------------- 
    /lnalpha |   1.116411   .1315353                      .8586065    1.374215 
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-------------+---------------------------------------------------------------- 
       alpha |   3.053874    .401692                       2.35987    3.951974 
------------------------------------------------------------------------------ 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -691.31192   
Iteration 1:   log pseudolikelihood = -691.31192   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -636.91081   
Iteration 1:   log pseudolikelihood = -635.75433   
Iteration 2:   log pseudolikelihood = -619.75637   
Iteration 3:   log pseudolikelihood = -619.75511   
Iteration 4:   log pseudolikelihood = -619.75511   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -619.35038   
Iteration 1:   log pseudolikelihood = -619.34922   
Iteration 2:   log pseudolikelihood = -619.34922   
 
Negative binomial regression                      Number of obs   =        836 
                                                  Wald chi2(1)    =       0.94 
Dispersion           = mean                       Prob > chi2     =     0.3310 
Log pseudolikelihood = -619.34922                 Pseudo R2       =     0.0007 
 
                                 (Std. Err. adjusted for 123 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
      blogr0 |   1.053311   .0562765     0.97   0.331     .9485893    1.169593 
       _cons |    .278444   .0643055    -5.54   0.000     .1770746    .4378441 
-------------+---------------------------------------------------------------- 
    /lnalpha |   1.110943   .1316374                      .8529389    1.368948 
-------------+---------------------------------------------------------------- 
       alpha |   3.037223   .3998121                      2.346533    3.931213 
------------------------------------------------------------------------------ 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood =  -689.9109   
Iteration 1:   log pseudolikelihood =  -689.9109   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -636.91081   
Iteration 1:   log pseudolikelihood = -635.75433   
Iteration 2:   log pseudolikelihood = -619.75637   
Iteration 3:   log pseudolikelihood = -619.75511   
Iteration 4:   log pseudolikelihood = -619.75511   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -618.66005   
Iteration 1:   log pseudolikelihood = -618.65157   
Iteration 2:   log pseudolikelihood = -618.65157   
 
Negative binomial regression                      Number of obs   =        836 
                                                  Wald chi2(1)    =       2.87 
Dispersion           = mean                       Prob > chi2     =     0.0903 
Log pseudolikelihood = -618.65157                 Pseudo R2       =     0.0018 
 
                                 (Std. Err. adjusted for 123 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
      blogr2 |    1.08085   .0496169     1.69   0.090     .9878486    1.182606 
       _cons |   .2243337   .0613088    -5.47   0.000     .1313007    .3832851 
-------------+---------------------------------------------------------------- 
    /lnalpha |   1.101714    .133179                      .8406883     1.36274 
 225 
 
-------------+---------------------------------------------------------------- 
       alpha |   3.009321   .4007784                      2.317962    3.906885 
------------------------------------------------------------------------------ 
i.sex             _Isex_1-2           (naturally coded; _Isex_1 omitted) 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -701.67573   
Iteration 1:   log pseudolikelihood = -701.67573   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -645.90918   
Iteration 1:   log pseudolikelihood = -628.39289   
Iteration 2:   log pseudolikelihood = -628.14696   
Iteration 3:   log pseudolikelihood = -628.14648   
Iteration 4:   log pseudolikelihood = -628.14648   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -627.82688   
Iteration 1:   log pseudolikelihood = -627.82617   
Iteration 2:   log pseudolikelihood = -627.82617   
 
Negative binomial regression                      Number of obs   =        848 
                                                  Wald chi2(1)    =       0.66 
Dispersion           = mean                       Prob > chi2     =     0.4183 
Log pseudolikelihood = -627.82617                 Pseudo R2       =     0.0005 
 
                                 (Std. Err. adjusted for 125 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     _Isex_2 |   .8739743   .1454422    -0.81   0.418     .6307338     1.21102 
       _cons |   .3656174   .0402862    -9.13   0.000     .2946021    .4537514 
-------------+---------------------------------------------------------------- 
    /lnalpha |   1.121781    .129468                      .8680288    1.375534 
-------------+---------------------------------------------------------------- 
       alpha |   3.070319   .3975081                       2.38221     3.95719 
------------------------------------------------------------------------------ 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -695.95391   
Iteration 1:   log pseudolikelihood = -695.95391   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -645.90918   
Iteration 1:   log pseudolikelihood = -628.39289   
Iteration 2:   log pseudolikelihood = -628.14696   
Iteration 3:   log pseudolikelihood = -628.14648   
Iteration 4:   log pseudolikelihood = -628.14648   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -625.03772   
Iteration 1:   log pseudolikelihood = -624.96878   
Iteration 2:   log pseudolikelihood = -624.96876   
 
Negative binomial regression                      Number of obs   =        848 
                                                  Wald chi2(1)    =       6.35 
Dispersion           = mean                       Prob > chi2     =     0.0118 
Log pseudolikelihood = -624.96876                 Pseudo R2       =     0.0051 
 
                                 (Std. Err. adjusted for 125 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    muac_scr |   1.219128    .095878     2.52   0.012     1.044977    1.422302 
       _cons |   .0311978   .0298971    -3.62   0.000     .0047688    .2040979 
-------------+---------------------------------------------------------------- 
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    /lnalpha |   1.084546   .1310607                      .8276722    1.341421 
-------------+---------------------------------------------------------------- 
       alpha |   2.958098   .3876902                      2.287987    3.824472 
------------------------------------------------------------------------------ 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -698.63185   
Iteration 1:   log pseudolikelihood = -698.63185   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -643.84275   
Iteration 1:   log pseudolikelihood = -641.93474   
Iteration 2:   log pseudolikelihood = -626.50538   
Iteration 3:   log pseudolikelihood = -626.50419   
Iteration 4:   log pseudolikelihood = -626.50419   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -625.92657   
Iteration 1:   log pseudolikelihood = -625.91939   
Iteration 2:   log pseudolikelihood = -625.91939   
 
Negative binomial regression                      Number of obs   =        841 
                                                  Wald chi2(1)    =       1.27 
Dispersion           = mean                       Prob > chi2     =     0.2595 
Log pseudolikelihood = -625.91939                 Pseudo R2       =     0.0009 
 
                                 (Std. Err. adjusted for 124 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  height_scr |   1.034575   .0311853     1.13   0.259     .9752235    1.097539 
       _cons |   .0541612   .0892531    -1.77   0.077     .0021428    1.368976 
-------------+---------------------------------------------------------------- 
    /lnalpha |   1.105535   .1300929                      .8505576    1.360513 
-------------+---------------------------------------------------------------- 
       alpha |    3.02084     .39299                      2.340952    3.898191 
------------------------------------------------------------------------------ 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -698.42233   
Iteration 1:   log pseudolikelihood = -698.42233   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -642.48049   
Iteration 1:   log pseudolikelihood = -624.96432   
Iteration 2:   log pseudolikelihood = -624.71768   
Iteration 3:   log pseudolikelihood = -624.71721   
Iteration 4:   log pseudolikelihood = -624.71721   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -624.51178   
Iteration 1:   log pseudolikelihood = -624.51122   
Iteration 2:   log pseudolikelihood = -624.51122   
 
Negative binomial regression                      Number of obs   =        841 
                                                  Wald chi2(1)    =       0.44 
Dispersion           = mean                       Prob > chi2     =     0.5095 
Log pseudolikelihood = -624.51122                 Pseudo R2       =     0.0003 
 
                                 (Std. Err. adjusted for 124 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  weight_scr |   1.095997   .1522895     0.66   0.509     .8347072    1.439078 
       _cons |   .2347934   .1366372    -2.49   0.013     .0750468    .7345812 
-------------+---------------------------------------------------------------- 
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    /lnalpha |   1.124291   .1304111                        .86869    1.379892 
-------------+---------------------------------------------------------------- 
       alpha |   3.078034   .4014097                      2.383786    3.974472 
------------------------------------------------------------------------------ 
i.epi_stat        _Iepi_stat_1-2      (naturally coded; _Iepi_stat_1 omitted) 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -700.47843   
Iteration 1:   log pseudolikelihood = -700.47843   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -645.90918   
Iteration 1:   log pseudolikelihood = -628.39289   
Iteration 2:   log pseudolikelihood = -628.14696   
Iteration 3:   log pseudolikelihood = -628.14648   
Iteration 4:   log pseudolikelihood = -628.14648   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -627.28304   
Iteration 1:   log pseudolikelihood = -627.27783   
Iteration 2:   log pseudolikelihood = -627.27783   
 
Negative binomial regression                      Number of obs   =        848 
                                                  Wald chi2(1)    =       2.90 
Dispersion           = mean                       Prob > chi2     =     0.0886 
Log pseudolikelihood = -627.27783                 Pseudo R2       =     0.0014 
 
                                 (Std. Err. adjusted for 125 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
_Iepi_stat_2 |   1.378817   .2601219     1.70   0.089     .9526262     1.99568 
       _cons |   .3270777   .0304211   -12.02   0.000     .2725723    .3924825 
-------------+---------------------------------------------------------------- 
    /lnalpha |   1.114089   .1284982                      .8622367     1.36594 
-------------+---------------------------------------------------------------- 
       alpha |    3.04679   .3915071                      2.368452    3.919407 
------------------------------------------------------------------------------ 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -699.12461   
Iteration 1:   log pseudolikelihood = -699.12461   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -645.90918   
Iteration 1:   log pseudolikelihood = -628.39289   
Iteration 2:   log pseudolikelihood = -628.14696   
Iteration 3:   log pseudolikelihood = -628.14648   
Iteration 4:   log pseudolikelihood = -628.14648   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -626.65079   
Iteration 1:   log pseudolikelihood = -626.63393   
Iteration 2:   log pseudolikelihood = -626.63393   
 
Negative binomial regression                      Number of obs   =        848 
                                                  Wald chi2(1)    =       3.67 
Dispersion           = mean                       Prob > chi2     =     0.0554 
Log pseudolikelihood = -626.63393                 Pseudo R2       =     0.0024 
 
                                 (Std. Err. adjusted for 125 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        agem |   1.022515   .0118834     1.92   0.055     .9994871    1.046073 
       _cons |   .1884063   .0626125    -5.02   0.000     .0982241    .3613872 
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-------------+---------------------------------------------------------------- 
    /lnalpha |   1.105245   .1341747                      .8422678    1.368223 
-------------+---------------------------------------------------------------- 
       alpha |   3.019965   .4052028                      2.321626    3.928363 
------------------------------------------------------------------------------ 
i.primgrav        _Iprimgrav_1-2      (naturally coded; _Iprimgrav_1 omitted) 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -695.53486   
Iteration 1:   log pseudolikelihood = -695.53486   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -639.74823   
Iteration 1:   log pseudolikelihood = -622.03197   
Iteration 2:   log pseudolikelihood = -621.84529   
Iteration 3:   log pseudolikelihood = -621.84503   
Iteration 4:   log pseudolikelihood = -621.84503   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -621.60308   
Iteration 1:   log pseudolikelihood = -621.60267   
Iteration 2:   log pseudolikelihood = -621.60267   
 
Negative binomial regression                      Number of obs   =        841 
                                                  Wald chi2(1)    =       0.52 
Dispersion           = mean                       Prob > chi2     =     0.4697 
Log pseudolikelihood = -621.60267                 Pseudo R2       =     0.0004 
 
                                 (Std. Err. adjusted for 124 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
_Iprimgrav_2 |   1.160122   .2383361     0.72   0.470     .7755907    1.735302 
       _cons |   .3028571   .0553221    -6.54   0.000     .2117148    .4332359 
-------------+---------------------------------------------------------------- 
    /lnalpha |   1.131013   .1324086                      .8714971    1.390529 
-------------+---------------------------------------------------------------- 
       alpha |   3.098794    .410307                      2.390487    4.016975 
------------------------------------------------------------------------------ 
i.itn_use         _Iitn_use_1-2       (naturally coded; _Iitn_use_1 omitted) 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -699.02896   
Iteration 1:   log pseudolikelihood = -699.02896   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -642.77572   
Iteration 1:   log pseudolikelihood =  -625.1816   
Iteration 2:   log pseudolikelihood =  -624.9517   
Iteration 3:   log pseudolikelihood =  -624.9513   
Iteration 4:   log pseudolikelihood =  -624.9513   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -624.86646   
Iteration 1:   log pseudolikelihood = -624.86641   
 
Negative binomial regression                      Number of obs   =        842 
                                                  Wald chi2(1)    =       0.14 
Dispersion           = mean                       Prob > chi2     =     0.7047 
Log pseudolikelihood = -624.86641                 Pseudo R2       =     0.0001 
 
                                 (Std. Err. adjusted for 124 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
 _Iitn_use_2 |   1.110725   .3077197     0.38   0.705     .6453369    1.911732 
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       _cons |   .3387313   .0295137   -12.42   0.000     .2855551      .40181 
-------------+---------------------------------------------------------------- 
    /lnalpha |   1.127725   .1304907                      .8719677    1.383482 
-------------+---------------------------------------------------------------- 
       alpha |   3.088621   .4030363                      2.391612    3.988766 
------------------------------------------------------------------------------ 
i.iptp_n          _Iiptp_n_0-3        (naturally coded; _Iiptp_n_0 omitted) 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -697.36495   
Iteration 1:   log pseudolikelihood = -697.36428   
Iteration 2:   log pseudolikelihood = -697.36428   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -645.90918   
Iteration 1:   log pseudolikelihood = -628.39289   
Iteration 2:   log pseudolikelihood = -628.14696   
Iteration 3:   log pseudolikelihood = -628.14648   
Iteration 4:   log pseudolikelihood = -628.14648   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -625.70365   
Iteration 1:   log pseudolikelihood = -625.66106   
Iteration 2:   log pseudolikelihood = -625.66105   
 
Negative binomial regression                      Number of obs   =        848 
                                                  Wald chi2(3)    =       5.41 
Dispersion           = mean                       Prob > chi2     =     0.1440 
Log pseudolikelihood = -625.66105                 Pseudo R2       =     0.0040 
 
                                 (Std. Err. adjusted for 125 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  _Iiptp_n_1 |   2.042857   .8610699     1.69   0.090     .8942402    4.666828 
  _Iiptp_n_2 |        1.5   .6046066     1.01   0.314     .6807639    3.305111 
  _Iiptp_n_3 |   .7051282   .6054798    -0.41   0.684     .1310261    3.794707 
       _cons |   .2181818   .0852793    -3.90   0.000      .101418    .4693772 
-------------+---------------------------------------------------------------- 
    /lnalpha |   1.093923   .1299848                      .8391572    1.348688 
-------------+---------------------------------------------------------------- 
       alpha |   2.985964   .3881301                      2.314415    3.852369 
------------------------------------------------------------------------------ 
i.season          _Iseason_0-1        (naturally coded; _Iseason_0 omitted) 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood =  -685.2339   
Iteration 1:   log pseudolikelihood =  -685.2339   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -645.90918   
Iteration 1:   log pseudolikelihood = -628.39289   
Iteration 2:   log pseudolikelihood = -628.14696   
Iteration 3:   log pseudolikelihood = -628.14648   
Iteration 4:   log pseudolikelihood = -628.14648   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood =  -619.9728   
Iteration 1:   log pseudolikelihood = -619.47995   
Iteration 2:   log pseudolikelihood = -619.47886   
Iteration 3:   log pseudolikelihood = -619.47886   
 
Negative binomial regression                      Number of obs   =        848 
                                                  Wald chi2(1)    =      19.75 
Dispersion           = mean                       Prob > chi2     =     0.0000 
Log pseudolikelihood = -619.47886                 Pseudo R2       =     0.0138 
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                                 (Std. Err. adjusted for 125 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  _Iseason_1 |   2.022495    .320576     4.44   0.000     1.482408    2.759354 
       _cons |   .2281106   .0284638   -11.84   0.000     .1786208    .2913123 
-------------+---------------------------------------------------------------- 
    /lnalpha |   1.012293   .1443095                      .7294516    1.295134 
-------------+---------------------------------------------------------------- 
       alpha |   2.751904   .3971258                      2.073943    3.651486 
------------------------------------------------------------------------------ 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -679.68018   
Iteration 1:   log pseudolikelihood = -679.67988   
Iteration 2:   log pseudolikelihood = -679.67988   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -645.90918   
Iteration 1:   log pseudolikelihood = -628.39289   
Iteration 2:   log pseudolikelihood = -628.14696   
Iteration 3:   log pseudolikelihood = -628.14648   
Iteration 4:   log pseudolikelihood = -628.14648   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -617.89562   
Iteration 1:   log pseudolikelihood = -616.92559   
Iteration 2:   log pseudolikelihood = -616.91966   
Iteration 3:   log pseudolikelihood = -616.91966   
 
Negative binomial regression                      Number of obs   =        848 
                                                  Wald chi2(1)    =      12.12 
Dispersion           = mean                       Prob > chi2     =     0.0005 
Log pseudolikelihood = -616.91966                 Pseudo R2       =     0.0179 
 
                                 (Std. Err. adjusted for 125 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
          ei |   1.063371   .0187659     3.48   0.000     1.027219    1.100795 
       _cons |   .8058415   .1861696    -0.93   0.350     .5123901    1.267356 
-------------+---------------------------------------------------------------- 
    /lnalpha |   .9712251   .1435151                      .6899407     1.25251 
-------------+---------------------------------------------------------------- 
       alpha |   2.641178   .3790489                      1.993597    3.499113 
------------------------------------------------------------------------------ 
i.mob             _Imob_1-4           (naturally coded; _Imob_1 omitted) 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -694.38589   
Iteration 1:   log pseudolikelihood = -694.38581   
Iteration 2:   log pseudolikelihood = -694.38581   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -645.90918   
Iteration 1:   log pseudolikelihood = -628.39289   
Iteration 2:   log pseudolikelihood = -628.14696   
Iteration 3:   log pseudolikelihood = -628.14648   
Iteration 4:   log pseudolikelihood = -628.14648   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood =  -624.4042   
Iteration 1:   log pseudolikelihood = -624.30405   
Iteration 2:   log pseudolikelihood = -624.30401   
 
Negative binomial regression                      Number of obs   =        848 
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                                                  Wald chi2(3)    =       8.80 
Dispersion           = mean                       Prob > chi2     =     0.0321 
Log pseudolikelihood = -624.30401                 Pseudo R2       =     0.0061 
 
                                 (Std. Err. adjusted for 125 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     _Imob_2 |   1.385768   .4832643     0.94   0.350     .6995964    2.744943 
     _Imob_3 |   1.499621   .5175153     1.17   0.240     .7624901    2.949368 
     _Imob_4 |   2.273305   .8000737     2.33   0.020     1.140469    4.531397 
       _cons |   .2162162   .0686894    -4.82   0.000     .1160035    .4030003 
-------------+---------------------------------------------------------------- 
    /lnalpha |   1.074252    .136689                      .8063463    1.342157 
-------------+---------------------------------------------------------------- 
       alpha |   2.927802   .4001982                       2.23971    3.827291 
------------------------------------------------------------------------------ 
i.zone            _Izone_1-3          (naturally coded; _Izone_1 omitted) 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -675.28941   
Iteration 1:   log pseudolikelihood = -675.28552   
Iteration 2:   log pseudolikelihood = -675.28552   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -645.90918   
Iteration 1:   log pseudolikelihood = -628.39289   
Iteration 2:   log pseudolikelihood = -628.14696   
Iteration 3:   log pseudolikelihood = -628.14648   
Iteration 4:   log pseudolikelihood = -628.14648   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -614.86058   
Iteration 1:   log pseudolikelihood = -613.47266   
Iteration 2:   log pseudolikelihood =  -613.4616   
Iteration 3:   log pseudolikelihood =  -613.4616   
 
Negative binomial regression                      Number of obs   =        848 
                                                  Wald chi2(2)    =      27.12 
Dispersion           = mean                       Prob > chi2     =     0.0000 
Log pseudolikelihood =  -613.4616                 Pseudo R2       =     0.0234 
 
                                 (Std. Err. adjusted for 125 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    _Izone_2 |   .3795115   .0851906    -4.32   0.000     .2444286    .5892478 
    _Izone_3 |   1.152234   .1872394     0.87   0.383     .8379528     1.58439 
       _cons |   .4128114   .0506615    -7.21   0.000      .324556    .5250657 
-------------+---------------------------------------------------------------- 
    /lnalpha |    .945621   .1339842                      .6830169    1.208225 
-------------+---------------------------------------------------------------- 
       alpha |   2.574412   .3449304                      1.979842    3.347538 
------------------------------------------------------------------------------ 
i.educ            _Ieduc_0-2          (naturally coded; _Ieduc_0 omitted) 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -688.70062   
Iteration 1:   log pseudolikelihood = -688.67148   
Iteration 2:   log pseudolikelihood = -688.67145   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -645.90918   
Iteration 1:   log pseudolikelihood = -628.39289   
Iteration 2:   log pseudolikelihood = -628.14696   
Iteration 3:   log pseudolikelihood = -628.14648   
Iteration 4:   log pseudolikelihood = -628.14648   
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Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -620.91549   
Iteration 1:   log pseudolikelihood = -620.49811   
Iteration 2:   log pseudolikelihood = -620.49732   
Iteration 3:   log pseudolikelihood = -620.49732   
 
Negative binomial regression                      Number of obs   =        848 
                                                  Wald chi2(2)    =      24.63 
Dispersion           = mean                       Prob > chi2     =     0.0000 
Log pseudolikelihood = -620.49732                 Pseudo R2       =     0.0122 
 
                                 (Std. Err. adjusted for 125 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    _Ieduc_1 |    1.20926   .2013976     1.14   0.254     .8724795    1.676039 
    _Ieduc_2 |   .3309418   .0843897    -4.34   0.000     .2007688    .5455152 
       _cons |   .3507307   .0377223    -9.74   0.000     .2840692    .4330353 
-------------+---------------------------------------------------------------- 
    /lnalpha |   1.038688   .1338688                      .7763099    1.301066 
-------------+---------------------------------------------------------------- 
       alpha |   2.825507   .3782474                      2.173437    3.673211 
------------------------------------------------------------------------------ 
 
.  
. *perform collinearity diagnostics 
. *================================ 
. corr numep age logmsp3 logr0 logr2 hbf hb_type muac_scr mob epi_stat /// 
>      agem itn_use educ season ei 
(obs=836) 
 
             |    numep      age  logmsp3    logr0    logr2      hbf  hb_type 
-------------+--------------------------------------------------------------- 
       numep |   1.0000 
         age |   0.3071   1.0000 
     logmsp3 |   0.0625  -0.2057   1.0000 
       logr0 |   0.0593   0.0504   0.3533   1.0000 
       logr2 |   0.0074  -0.0534   0.3993   0.5321   1.0000 
         hbf |  -0.0513  -0.0055   0.0414   0.0028   0.0654   1.0000 
     hb_type |  -0.0003  -0.0119  -0.0257   0.0172   0.0307   0.0684   1.0000 
    muac_scr |   0.0915  -0.0027   0.0401   0.0090  -0.0187  -0.1038  -0.0337 
         mob |   0.0899  -0.0119  -0.0444   0.0551   0.0017  -0.1098   0.0897 
    epi_stat |   0.0492   0.0164   0.0442   0.0733  -0.0013   0.0178  -0.1644 
        agem |   0.0688   0.0031   0.0706   0.0646   0.0545  -0.0998   0.1827 
     itn_use |   0.0142  -0.0145  -0.0203   0.0383   0.0438   0.1277   0.0548 
        educ |  -0.0573  -0.0182  -0.0281  -0.0674  -0.1034   0.1029  -0.1461 
      season |   0.1497   0.3578  -0.0339   0.0427  -0.0292  -0.0006  -0.0008 
          ei |   0.1599  -0.0090   0.1134  -0.0038   0.1005   0.1560   0.0835 
 
             | muac_scr      mob epi_stat     agem  itn_use     educ   season 
-------------+--------------------------------------------------------------- 
    muac_scr |   1.0000 
         mob |  -0.0765   1.0000 
    epi_stat |   0.0628  -0.0431   1.0000 
        agem |   0.0822   0.1203   0.0039   1.0000 
     itn_use |  -0.0840   0.1713   0.0973   0.0736   1.0000 
        educ |  -0.0216  -0.0474  -0.0748  -0.2637  -0.0930   1.0000 
      season |   0.0056  -0.0343   0.0089  -0.0205  -0.0462   0.0170   1.0000 
          ei |  -0.0498   0.2507   0.0986   0.1938   0.0140  -0.1364  -0.0047 
 
             |       ei 
-------------+--------- 
          ei |   1.0000 
 
 
. xi:collin numep age logmsp3 logr0 logr2 hbf i.hb_type muac_scr i.mob i.epi_sta 
> t /// 
>               agem i.itn_use i.educ i.season ei 
i.hb_type         _Ihb_type_1-4       (naturally coded; _Ihb_type_1 omitted) 
i.mob             _Imob_1-4           (naturally coded; _Imob_1 omitted) 
i.epi_stat        _Iepi_stat_1-2      (naturally coded; _Iepi_stat_1 omitted) 
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i.itn_use         _Iitn_use_1-2       (naturally coded; _Iitn_use_1 omitted) 
i.educ            _Ieduc_0-2          (naturally coded; _Ieduc_0 omitted) 
i.season          _Iseason_0-1        (naturally coded; _Iseason_0 omitted) 
(obs=836) 
 
  Collinearity Diagnostics 
 
                        SQRT                   R- 
  Variable      VIF     VIF    Tolerance    Squared 
---------------------------------------------------- 
     numep      1.19    1.09    0.8384      0.1616 
       age      1.34    1.16    0.7468      0.2532 
   logmsp3      1.38    1.17    0.7270      0.2730 
     logr0      1.52    1.23    0.6579      0.3421 
     logr2      1.58    1.26    0.6327      0.3673 
       hbf      1.26    1.12    0.7912      0.2088 
_Ihb_type_2      1.05    1.03    0.9493      0.0507 
_Ihb_type_3      1.09    1.04    0.9169      0.0831 
_Ihb_type_4      1.19    1.09    0.8376      0.1624 
  muac_scr      1.07    1.03    0.9354      0.0646 
   _Imob_2      3.81    1.95    0.2625      0.7375 
   _Imob_3      3.89    1.97    0.2569      0.7431 
   _Imob_4      3.22    1.79    0.3105      0.6895 
_Iepi_stat_2      1.09    1.04    0.9198      0.0802 
      agem      1.20    1.10    0.8326      0.1674 
_Iitn_use_2      1.18    1.09    0.8492      0.1508 
  _Ieduc_1      1.28    1.13    0.7835      0.2165 
  _Ieduc_2      1.30    1.14    0.7700      0.2300 
_Iseason_1      1.16    1.08    0.8612      0.1388 
        ei      1.49    1.22    0.6703      0.3297 
---------------------------------------------------- 
  Mean VIF      1.61 
 
                           Cond 
        Eigenval          Index 
--------------------------------- 
    1    10.5383          1.0000 
    2     1.4329          2.7119 
    3     1.1651          3.0074 
    4     1.0801          3.1236 
    5     1.0078          3.2337 
    6     0.9397          3.3488 
    7     0.8480          3.5252 
    8     0.7708          3.6977 
    9     0.6841          3.9248 
    10     0.6707          3.9640 
    11     0.5006          4.5883 
    12     0.4932          4.6225 
    13     0.2783          6.1535 
    14     0.1749          7.7614 
    15     0.1223          9.2820 
    16     0.1096          9.8053 
    17     0.0670         12.5392 
    18     0.0583         13.4464 
    19     0.0387         16.5006 
    20     0.0165         25.2868 
    21     0.0029         60.0076 
--------------------------------- 
 Condition Number        60.0076  
 Eigenvalues & Cond Index computed from scaled raw sscp (w/ intercept) 
 Det(correlation matrix)    0.0287 
 
.   
. *multivariate regression analysis using changing antibody titres adjusting for 
>  clusters 
. *============================================================================= 
> ========= 
.  
. *model0: include if p<0.2 or high importance var  
. xi:nbreg numep age logmsp3 logr0 logr2 hbf i.hb_type muac_scr i.mob i.epi_stat 
>  /// 
>          agem i.itn_use i.educ i.season ei,cluster(code) irr       
i.hb_type         _Ihb_type_1-4       (naturally coded; _Ihb_type_1 omitted) 
i.mob             _Imob_1-4           (naturally coded; _Imob_1 omitted) 
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i.epi_stat        _Iepi_stat_1-2      (naturally coded; _Iepi_stat_1 omitted) 
i.itn_use         _Iitn_use_1-2       (naturally coded; _Iitn_use_1 omitted) 
i.educ            _Ieduc_0-2          (naturally coded; _Ieduc_0 omitted) 
i.season          _Iseason_0-1        (naturally coded; _Iseason_0 omitted) 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -571.09016   
Iteration 1:   log pseudolikelihood = -570.82309   
Iteration 2:   log pseudolikelihood = -570.77072   
Iteration 3:   log pseudolikelihood = -570.75883   
Iteration 4:   log pseudolikelihood = -570.75621   
Iteration 5:   log pseudolikelihood = -570.75556   
Iteration 6:   log pseudolikelihood = -570.75543   
Iteration 7:   log pseudolikelihood = -570.75541   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -640.99977   
Iteration 1:   log pseudolikelihood = -639.67455   
Iteration 2:   log pseudolikelihood = -623.54382   
Iteration 3:   log pseudolikelihood = -623.54202   
Iteration 4:   log pseudolikelihood = -623.54202   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -574.98152   
Iteration 1:   log pseudolikelihood = -543.99099   
Iteration 2:   log pseudolikelihood = -542.31197   
Iteration 3:   log pseudolikelihood = -542.30631   
Iteration 4:   log pseudolikelihood = -542.30631   
 
Negative binomial regression                      Number of obs   =        836 
                                                  Wald chi2(19)   =     674.95 
Dispersion           = mean                       Prob > chi2     =     0.0000 
Log pseudolikelihood = -542.30631                 Pseudo R2       =     0.1303 
 
                                 (Std. Err. adjusted for 123 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         age |   1.114544   .0092731    13.03   0.000     1.096516    1.132868 
     logmsp3 |   1.163622   .0657381     2.68   0.007     1.041655     1.29987 
       logr0 |    .981701   .0639584    -0.28   0.777     .8640184    1.115412 
       logr2 |    .922641   .0545965    -1.36   0.174      .821606      1.0361 
         hbf |    .986981   .0066038    -1.96   0.050     .9741224    1.000009 
 _Ihb_type_2 |   1.06e-07   1.09e-07   -15.52   0.000     1.39e-08    8.04e-07 
 _Ihb_type_3 |   1.082621   .2497315     0.34   0.731     .6888539    1.701475 
 _Ihb_type_4 |   .3923899   .1462107    -2.51   0.012     .1890369    .8144963 
    muac_scr |   1.273454   .0973677     3.16   0.002     1.096228    1.479333 
     _Imob_2 |   1.501543   .5402344     1.13   0.259     .7418005    3.039403 
     _Imob_3 |   1.423391   .4789914     1.05   0.294     .7360086    2.752743 
     _Imob_4 |    1.87437   .6199199     1.90   0.057     .9802418    3.584079 
_Iepi_stat_2 |   1.073276   .2087134     0.36   0.716     .7331345    1.571229 
        agem |   1.010588   .0123516     0.86   0.389     .9866675    1.035089 
 _Iitn_use_2 |   1.065135    .250555     0.27   0.789     .6716976    1.689022 
    _Ieduc_1 |   1.233071      .2177     1.19   0.235     .8723838    1.742885 
    _Ieduc_2 |   .4939981   .1554438    -2.24   0.025     .2666135    .9153104 
  _Iseason_1 |   1.382405   .2231467     2.01   0.045     1.007477    1.896862 
          ei |   1.049381   .0148523     3.41   0.001     1.020671    1.078899 
       _cons |   .0064554    .007756    -4.20   0.000     .0006127    .0680172 
-------------+---------------------------------------------------------------- 
    /lnalpha |   .2450085   .1908958                     -.1291404    .6191573 
-------------+---------------------------------------------------------------- 
       alpha |   1.277632   .2438946                      .8788506    1.857362 
------------------------------------------------------------------------------ 
 
.  
. xi:glm numep age logmsp3 logr0 logr2 hbf i.hb_type muac_scr i.mob i.epi_stat / 
> // 
>          agem i.itn_use i.educ i.season ei,family(nb) cluster(code)        
i.hb_type         _Ihb_type_1-4       (naturally coded; _Ihb_type_1 omitted) 
i.mob             _Imob_1-4           (naturally coded; _Imob_1 omitted) 
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i.epi_stat        _Iepi_stat_1-2      (naturally coded; _Iepi_stat_1 omitted) 
i.itn_use         _Iitn_use_1-2       (naturally coded; _Iitn_use_1 omitted) 
i.educ            _Ieduc_0-2          (naturally coded; _Ieduc_0 omitted) 
i.season          _Iseason_0-1        (naturally coded; _Iseason_0 omitted) 
 
Iteration 0:   log pseudolikelihood = -545.48237   
Iteration 1:   log pseudolikelihood = -543.08806   
Iteration 2:   log pseudolikelihood = -542.92962   
Iteration 3:   log pseudolikelihood = -542.91109   
Iteration 4:   log pseudolikelihood = -542.90861   
Iteration 5:   log pseudolikelihood = -542.90815   
Iteration 6:   log pseudolikelihood = -542.90805   
Iteration 7:   log pseudolikelihood = -542.90803   
 
Generalized linear models                          No. of obs      =       836 
Optimization     : ML                              Residual df     =       816 
                                                   Scale parameter =         1 
Deviance         =  501.3042028                    (1/df) Deviance =  .6143434 
Pearson          =  707.0400259                    (1/df) Pearson  =  .8664706 
 
Variance function: V(u) = u+(1)u^2                 [Neg. Binomial] 
Link function    : g(u) = ln(u)                    [Log] 
 
                                                   AIC             =   1.34667 
Log pseudolikelihood =  -542.908029                BIC             = -4989.257 
 
                                 (Std. Err. adjusted for 123 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         age |   .1053882   .0077728    13.56   0.000     .0901537    .1206227 
     logmsp3 |   .1532178   .0548552     2.79   0.005     .0457036     .260732 
       logr0 |   -.016589   .0649053    -0.26   0.798     -.143801     .110623 
       logr2 |  -.0804812    .059533    -1.35   0.176    -.1971637    .0362013 
         hbf |  -.0127331   .0066385    -1.92   0.055    -.0257444    .0002781 
 _Ihb_type_2 |  -13.26747   1.034017   -12.83   0.000     -15.2941   -11.24083 
 _Ihb_type_3 |   .0775009   .2254079     0.34   0.731    -.3642905    .5192923 
 _Ihb_type_4 |  -.8973213   .3696066    -2.43   0.015    -1.621737   -.1729057 
    muac_scr |   .2429429    .075917     3.20   0.001     .0941483    .3917375 
     _Imob_2 |   .3995843   .3588732     1.11   0.266    -.3037942    1.102963 
     _Imob_3 |   .3519822   .3370354     1.04   0.296    -.3085951     1.01256 
     _Imob_4 |   .6264551   .3313514     1.89   0.059    -.0229817    1.275892 
_Iepi_stat_2 |   .0779836   .1890837     0.41   0.680    -.2926137     .448581 
        agem |   .0106353   .0119971     0.89   0.375    -.0128787    .0341492 
 _Iitn_use_2 |    .074523   .2308985     0.32   0.747    -.3780297    .5270757 
    _Ieduc_1 |   .2100605    .173029     1.21   0.225    -.1290701    .5491911 
    _Ieduc_2 |   -.698954   .3148028    -2.22   0.026    -1.315956   -.0819519 
  _Iseason_1 |   .3130504   .1663306     1.88   0.060    -.0129516    .6390524 
          ei |   .0476603   .0139306     3.42   0.001     .0203568    .0749638 
       _cons |  -5.050858   1.199093    -4.21   0.000    -7.401038   -2.700679 
------------------------------------------------------------------------------ 
 
.  
. *run wald test to select covariates for the final model 
. xi:testparm i.epi_stat 
i.epi_stat        _Iepi_stat_1-2      (naturally coded; _Iepi_stat_1 omitted) 
 
 ( 1)  [numep]_Iepi_stat_2 = 0 
 
           chi2(  1) =    0.17 
         Prob > chi2 =    0.6800 
 
. test agem 
 
 ( 1)  [numep]agem = 0 
 
           chi2(  1) =    0.79 
         Prob > chi2 =    0.3754 
 
. xi:testparm i.mob 
i.mob             _Imob_1-4           (naturally coded; _Imob_1 omitted) 
 
 ( 1)  [numep]_Imob_2 = 0 
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 ( 2)  [numep]_Imob_3 = 0 
 ( 3)  [numep]_Imob_4 = 0 
 
           chi2(  3) =    4.65 
         Prob > chi2 =    0.1991 
 
. xi:testparm i.educ 
i.educ            _Ieduc_0-2          (naturally coded; _Ieduc_0 omitted) 
 
 ( 1)  [numep]_Ieduc_1 = 0 
 ( 2)  [numep]_Ieduc_2 = 0 
 
           chi2(  2) =    8.00 
         Prob > chi2 =    0.0183 
 
. test muac_scr 
 
 ( 1)  [numep]muac_scr = 0 
 
           chi2(  1) =   10.24 
         Prob > chi2 =    0.0014 
 
.  
. xi:nbreg numep age logmsp3 logr0 logr2 hbf i.hb_type muac_scr /// 
>              i.itn_use i.educ i.season ei,cluster(code) irr        
i.hb_type         _Ihb_type_1-4       (naturally coded; _Ihb_type_1 omitted) 
i.itn_use         _Iitn_use_1-2       (naturally coded; _Iitn_use_1 omitted) 
i.educ            _Ieduc_0-2          (naturally coded; _Ieduc_0 omitted) 
i.season          _Iseason_0-1        (naturally coded; _Iseason_0 omitted) 
 
Fitting Poisson model: 
 
Iteration 0:   log pseudolikelihood = -575.47803   
Iteration 1:   log pseudolikelihood = -575.20508   
Iteration 2:   log pseudolikelihood = -575.14994   
Iteration 3:   log pseudolikelihood =  -575.1369   
Iteration 4:   log pseudolikelihood = -575.13477   
Iteration 5:   log pseudolikelihood = -575.13425   
Iteration 6:   log pseudolikelihood = -575.13414   
Iteration 7:   log pseudolikelihood = -575.13412   
 
Fitting constant-only model: 
 
Iteration 0:   log pseudolikelihood = -640.99977   
Iteration 1:   log pseudolikelihood = -639.67455   
Iteration 2:   log pseudolikelihood = -623.54382   
Iteration 3:   log pseudolikelihood = -623.54202   
Iteration 4:   log pseudolikelihood = -623.54202   
 
Fitting full model: 
 
Iteration 0:   log pseudolikelihood = -575.61397   
Iteration 1:   log pseudolikelihood = -570.17976   
Iteration 2:   log pseudolikelihood = -544.97805   
Iteration 3:   log pseudolikelihood = -544.39906   
Iteration 4:   log pseudolikelihood = -544.39838   
Iteration 5:   log pseudolikelihood = -544.39838   
 
Negative binomial regression                      Number of obs   =        836 
                                                  Wald chi2(14)   =     747.53 
Dispersion           = mean                       Prob > chi2     =     0.0000 
Log pseudolikelihood = -544.39838                 Pseudo R2       =     0.1269 
 
                                 (Std. Err. adjusted for 123 clusters in code) 
------------------------------------------------------------------------------ 
             |               Robust 
       numep |        IRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         age |   1.113275   .0094163    12.69   0.000     1.094972    1.131885 
     logmsp3 |   1.165051   .0660603     2.69   0.007      1.04251    1.301995 
       logr0 |   1.002688   .0661288     0.04   0.968     .8811053    1.141048 
       logr2 |    .920025   .0531677    -1.44   0.149     .8215032    1.030362 
         hbf |   .9849169   .0060504    -2.47   0.013     .9731294    .9968472 
 _Ihb_type_2 |   4.11e-09   4.22e-09   -18.79   0.000     5.48e-10    3.08e-08 
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 _Ihb_type_3 |   1.137996   .2403105     0.61   0.540     .7523026    1.721428 
 _Ihb_type_4 |   .4350848   .1815632    -1.99   0.046     .1920273    .9857912 
    muac_scr |   1.260214   .0923251     3.16   0.002     1.091652    1.454805 
 _Iitn_use_2 |   1.227399   .2681961     0.94   0.348     .7998186    1.883561 
    _Ieduc_1 |   1.159241   .1852088     0.92   0.355     .8475777    1.585506 
    _Ieduc_2 |   .4746557   .1471361    -2.40   0.016     .2585348    .8714418 
  _Iseason_1 |   1.400435   .2257414     2.09   0.037     1.021067    1.920752 
          ei |    1.05879   .0148527     4.07   0.000     1.030075    1.088304 
       _cons |   .0180154   .0188777    -3.83   0.000     .0023105    .1404715 
-------------+---------------------------------------------------------------- 
    /lnalpha |   .2785767   .1806264                     -.0754446     .632598 
-------------+---------------------------------------------------------------- 
       alpha |   1.321248   .2386523                      .9273311    1.882495 
------------------------------------------------------------------------------ 
 
.  
.           
. log close 
      name:  <unnamed> 
       log:  C:\Users\dkangoye\Dropbox\projects\phdprogram_ou\work\data\data_bic 
> s\elisa_bics\chap2_nbreg.log 
  log type:  text 
 closed on:  13 Sep 2016, 18:57:05 
-------------------------------------------------------------------------------- 
 
7.2.5 Cox regression Stata code / Chapter 3 
clear all 
macro drop _all 
capture log close 
set more off 
log using chap3_coxreg,replace text 
*chap3_coxreg.do: construct predictive model for number of episodes 
*david kangoye,PhD student,Open University/KEMRI-WTRP 
version 11.2 
set linesize 80 
*================================================================ 
 
cd "C:\Users\dkangoye\Dropbox\projects\phdprogram_ou\work\data\data_bics\elisa_bics_labwork\davidk_bics2014" 
 
use bics_kwtrpV0,clear 
 
*combine morbidity data with exposure data 
*=============================== 
joinby code using "C:\Users\dkangoye\Dropbox\projects\phdprogram_ou\work\data\data_bics\elisa_bics\dist15ei",unm(both) 
tab _merge,m 
list code if _merge==2 
drop if _merge==2 
drop _merge 
 
*define febrile malaria episodes 
*=============================== 
 
*generate var for fever 
gen fever=1 if (temp>=37.5 & temp !=.) | hof==1 
lab var fever "presence of subjetive and/or objective fever" 
tab fever,m 
 
*generate new variables for malaria 
gen byte malar1=1 if fever==1 & tf>0 & tf !=. 
lab var malar1 "febrile malaria episode_tf>0" 
replace malar1=0 if malar1==. 
 
gen byte malar2=1 if fever==1 & tf>10000 & tf !=. 
lab var malar2 "febrile malaria episode_tf>10000" 
replace malar2=0 if malar2==. 
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*order malaria variables 
order malar1 malar2,after(tf) 
 
*censor episodes occuring within 21 days following previous malaria episode 
*====================================================== 
 
*check number of episodes by definition before censoring 
local defs "malar1 malar2" 
foreach def in `defs'{ 
tab `def',m 
} 
*censor epdisodes 
sort malar1 code datevisit 
replace malar1=0 if malar1[_n-1]==1 & code==code[_n-1] & datevisit-datevisit[_n-1]<=21  
 
*check number of episodes by definition after censoring 
foreach def in malar1 malar2{ 
tab `def',m 
} 
 
*_3_generate additional variables and explore distribution 
*========================================================= 
 
*generate variable age 
gen age= (datevisit - dob)/30 
lab var age "age of infant at current visit" 
sum age 
 
*gen variable season 
 
gen moy=month(datevisit) 
lab var moy "calendar month" 
tab moy,m 
 
gen season=1 if moy >=6 & moy <=11 
replace season=0 if moy==12 | moy>=1 & moy<=5 
lab var season "malaria transmission season" 
tab season,m 
 
*generate season of birth 
gen sob=1 if month(dob)>=6 & month(dob)<=11 
replace sob=0 if month(dob)==12 | month(dob)>=1 & month(dob)<=5 
lab var sob "season of birth" 
tab sob,m 
 
*generate month of birth 
gen mob=month(dob) 
lab var mob "month of birth" 
tab mob,m 
 
*gen variables for seropositivity 
gen ama1_sp=(AMA1_AU>-1.1401198) 
gen msp1_sp=(MSP1_AU>1.2326468) 
gen msp2_sp=(MSP2_AU>0.09898795) 
gen msp3_sp=(MSP3_AU>0.81264652) 
 
save bics_kwtrpV1,replace 
 
************************************************************************** 
use bics_kwtrpV1,clear 
keep if monthn<22 
 
*univariate cox regression 
*========================= 
use bics_kwtrpV1,clear 
keep if monthn<21 
stset  datevisit, failure(malar2) id(code) origin(datscren) scale(28)  
stdes 
stsum 
 
recode iptp_n 3=2 
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*create local macros for explanatory variables 
local envfac i.season i.mob i.zone ei    
local socufac i.educ 
local matfac agem i.primgrav i.sg_birth i.itn_use i.iptp_n  
local infac1 i.sex  muac height_scr weight_scr i.del_way i.rea i.epi_stat i.neo_inf    
local infac2 i.hb_type hbf AMA1_AU MSP1_AU MSP2_AU MSP3_AU 
local infac3 i.ama1_sp i.msp1_sp i.msp2_sp i.msp3_sp /*i.ama1_pl i.msp1_pl i.msp2_pl i.msp3_pl*/ 
 
foreach i in `infac1' `infac2' `infac3' `envfac' `socufac' `matfac' {    
        stcox `i' 
} 
 
stcox i.zone 
testparm i.zone 
 
stcox i.educ 
testparm i.educ 
 
stcox i.iptp_n 
testparm i.iptp_n 
 
stcox i.mob 
testparm i.mob 
 
stcox i.hb_type 
testparm i.hb_type 
 
*perform collinearity diagnostic 
*=============================== 
pwcorr AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf muac_scr ei,star(.05) 
 
graph matrix AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf muac_scr ei 
 
collin AMA1_AU MSP1_AU MSP2_AU MSP3_AU 
collin AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf muac_scr ei 
 
*multivariate cox regression 
*=========================== 
*include in baseline multivariable model if p<0.2 or theoritically high importance variable 
 
stcox hbf i.hb_type AMA1_AU MSP1_AU MSP2_AU MSP3_AU i.ama1_sp i.msp1_sp i.msp2_sp ///  
   i.mob i.itn_use i.educ i.season ei 
est store model0 
 
*model simplification: backward elimination 
*========================================== 
* important variables that should not be removed: 
* antibody titres, itn use, season, exposure index, foetal haemoglobin (literature) 
 
*drop msp1_sp 
stcox hbf i.hb_type AMA1_AU MSP1_AU MSP2_AU MSP3_AU i.ama1_sp i.msp2_sp /// 
   i.mob i.itn_use i.educ i.season ei 
est store model1 
est table model0 model1,b(%5.3f) p(%4.3f) stats(N ll aic bic) 
testparm i.mob 
testparm i.educ 
 
*drop ama1_sp 
stcox hbf i.hb_type AMA1_AU MSP1_AU MSP2_AU MSP3_AU i.msp2_sp /// 
   i.mob i.itn_use i.educ i.season ei 
est store model2 
est table model0 model1 model2,b(%5.3f) p(%4.3f) stats(N ll aic bic) 
testparm i.mob 
testparm i.educ 
 
*drop msp2_sp 
stcox AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf i.hb_type  /// 
   i.itn_use i.mob i.educ i.season ei 
est store model3 
est table model0 model1 model2 model3,b(%5.3f) p(%4.3f) stats(N ll aic bic) 
testparm i.mob 
testparm i.educ 
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*drop educ 
stcox AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf i.hb_type  /// 
   i.itn_use i.mob i.season ei 
est store model4 
est table model0 model1 model2 model3 model4,b(%5.3f) p(%4.3f) stats(N ll aic bic) 
testparm i.mob 
testparm i.hb_type 
 
stcox AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf i.hb_type  /// 
   i.itn_use i.mob i.season##c.ei 
    
*test of proportional hazards assumption 
*======================================= 
 
estat phtest, detail      
 
estat phtest,plot(ei) yline(0) title(Exposure index)  
graph save 1,replace 
 
estat phtest,plot(hbf) yline(0) title(Foetal Haemoglobin rate)  
graph save 2,replace 
 
estat phtest,plot(AMA1_AU) yline(0) title(Antibodies to AMA1)  
graph save 3,replace 
 
estat phtest,plot(MSP1_AU) yline(0) title(Antibodies to MSP1-19)  
graph save 4,replace 
 
estat phtest,plot(MSP2_AU) yline(0) title(Antibodies to MSP2)  
graph save 5,replace 
 
estat phtest,plot(MSP3_AU) yline(0) title(Antibodies to MSP3)  
graph save 6,replace 
 
grc1leg 1.gph 2.gph 3.gph 4.gph 5.gph 6.gph, /// 
      xcom l1(Scaled Schoenfeld) b1(Time (months))  
graph save schoenfeld,replace 
graph export schoenfeld.tif,width(2049) replace 
 
log close 
exit 
 
7.2.6 Cox regression output log / Chapter 3 
-------------------------------------------------------------------------------- 
      name:  <unnamed> 
       log:  C:\Users\dkangoye\Dropbox\projects\phdprogram_ou\work\data\data_bic 
> s\elisa_bics\chap3_coxreg.log 
  log type:  text 
 opened on:  13 Sep 2016, 18:59:38 
 
. *chap3_coxreg.do: construct predictive model for number of episodes 
. *david kangoye,PhD student,Open University/KEMRI-WTRP 
. version 11.2 
 
. set linesize 80 
 
. *============================================================================= 
> ============================== 
.  
. cd "C:\Users\dkangoye\Dropbox\projects\phdprogram_ou\work\data\data_bics\elisa 
> _bics_labwork\davidk_bics2014" 
C:\Users\dkangoye\Dropbox\projects\phdprogram_ou\work\data\data_bics\elisa_bics_ 
> labwork\davidk_bics2014 
 
.  
. use bics_kwtrpV0,clear 
(combination of all data sets (morb+geo+sero)) 
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.  
. *combine morbidity data with exposure data 
. *========================================= 
. joinby code using "C:\Users\dkangoye\Dropbox\projects\phdprogram_ou\work\data\ 
> data_bics\elisa_bics\dist15ei",unm(both) 
 
. tab _merge,m 
 
                       _merge |      Freq.     Percent        Cum. 
------------------------------+----------------------------------- 
both in master and using data |     14,089      100.00      100.00 
------------------------------+----------------------------------- 
                        Total |     14,089      100.00 
 
. list code if _merge==2 
 
. drop if _merge==2 
(0 observations deleted) 
 
. drop _merge 
 
.  
. *define febrile malaria episodes 
. *=============================== 
.  
. *generate var for fever 
. gen fever=1 if (temp>=37.5 & temp !=.) | hof==1 
(12982 missing values generated) 
 
. lab var fever "presence of subjetive and/or objective fever" 
 
. tab fever,m 
 
presence of | 
  subjetive | 
     and/or | 
  objective | 
      fever |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          1 |      1,107        7.86        7.86 
          . |     12,982       92.14      100.00 
------------+----------------------------------- 
      Total |     14,089      100.00 
 
.  
. *generate new variables for malaria 
. gen byte malar1=1 if fever==1 & tf>0 & tf !=. 
(13696 missing values generated) 
 
. lab var malar1 "febrile malaria episode_tf>0" 
 
. replace malar1=0 if malar1==. 
(13696 real changes made) 
 
.  
. gen byte malar2=1 if fever==1 & tf>10000 & tf !=. 
(13799 missing values generated) 
 
. lab var malar2 "febrile malaria episode_tf>10000" 
 
. replace malar2=0 if malar2==. 
(13799 real changes made) 
 
.  
. *order malaria variables 
. order malar1 malar2,after(tf) 
 
.  
. *censor episodes occuring within 21 days following previous malaria episode 
. *========================================================================== 
.  
. *check number of episodes by definition before censoring 
. local defs "malar1 malar2" 
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. foreach def in `defs'{ 
  2. tab `def',m 
  3. } 
 
    febrile | 
    malaria | 
episode_tf> | 
          0 |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          0 |     13,696       97.21       97.21 
          1 |        393        2.79      100.00 
------------+----------------------------------- 
      Total |     14,089      100.00 
 
    febrile | 
    malaria | 
episode_tf> | 
      10000 |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          0 |     13,799       97.94       97.94 
          1 |        290        2.06      100.00 
------------+----------------------------------- 
      Total |     14,089      100.00 
 
. *censor epdisodes 
. sort malar1 code datevisit 
 
. replace malar1=0 if malar1[_n-1]==1 & code==code[_n-1] & datevisit-datevisit[_ 
> n-1]<=21  
(50 real changes made) 
 
.  
. *check number of episodes by definition after censoring 
. foreach def in malar1 malar2{ 
  2. tab `def',m 
  3. } 
 
    febrile | 
    malaria | 
episode_tf> | 
          0 |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          0 |     13,746       97.57       97.57 
          1 |        343        2.43      100.00 
------------+----------------------------------- 
      Total |     14,089      100.00 
 
    febrile | 
    malaria | 
episode_tf> | 
      10000 |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          0 |     13,799       97.94       97.94 
          1 |        290        2.06      100.00 
------------+----------------------------------- 
      Total |     14,089      100.00 
 
.  
. *_3_generate additional variables and explore distribution 
. *========================================================= 
.  
. *generate variable age 
. gen age= (datevisit - dob)/30 
 
. lab var age "age of infant at current visit" 
 
. sum age 
 
    Variable |       Obs        Mean    Std. Dev.       Min        Max 
-------------+-------------------------------------------------------- 
         age |     14089    13.11088    7.012261         .9   25.93333 
 
.  
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. *gen variable season 
.  
. gen moy=month(datevisit) 
 
. lab var moy "calendar month" 
 
. tab moy,m 
 
   calendar | 
      month |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          1 |      1,161        8.24        8.24 
          2 |      1,088        7.72       15.96 
          3 |      1,205        8.55       24.52 
          4 |      1,148        8.15       32.66 
          5 |      1,185        8.41       41.07 
          6 |      1,187        8.43       49.50 
          7 |      1,151        8.17       57.67 
          8 |      1,231        8.74       66.41 
          9 |      1,196        8.49       74.90 
         10 |      1,205        8.55       83.45 
         11 |      1,190        8.45       91.89 
         12 |      1,142        8.11      100.00 
------------+----------------------------------- 
      Total |     14,089      100.00 
 
.  
. gen season=1 if moy >=6 & moy <=11 
(6929 missing values generated) 
 
. replace season=0 if moy==12 | moy>=1 & moy<=5 
(6929 real changes made) 
 
. lab var season "malaria transmission season" 
 
. tab season,m 
 
    malaria | 
transmissio | 
   n season |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          0 |      6,929       49.18       49.18 
          1 |      7,160       50.82      100.00 
------------+----------------------------------- 
      Total |     14,089      100.00 
 
.  
. *generate season of birth 
. gen sob=1 if month(dob)>=6 & month(dob)<=11 
(8425 missing values generated) 
 
. replace sob=0 if month(dob)==12 | month(dob)>=1 & month(dob)<=5 
(8425 real changes made) 
 
. lab var sob "season of birth" 
 
. tab sob,m 
 
  season of | 
      birth |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          0 |      8,425       59.80       59.80 
          1 |      5,664       40.20      100.00 
------------+----------------------------------- 
      Total |     14,089      100.00 
 
.  
. *generate month of birth 
. gen mob=month(dob) 
 
. lab var mob "month of birth" 
 
. tab mob,m 
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   month of | 
      birth |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          1 |      2,905       20.62       20.62 
         10 |      1,243        8.82       29.44 
         11 |      4,421       31.38       60.82 
         12 |      5,520       39.18      100.00 
------------+----------------------------------- 
      Total |     14,089      100.00 
 
.  
. save bics_kwtrpV1,replace 
file bics_kwtrpV1.dta saved 
 
.  
. ****************************************************************************** 
> ********* 
. use bics_kwtrpV1,clear 
(combination of all data sets (morb+geo+sero)) 
 
. keep if monthn<22 
(1539 observations deleted) 
 
.  
. *univariate cox regression 
. *========================= 
. use bics_kwtrpV1,clear 
(combination of all data sets (morb+geo+sero)) 
 
. keep if monthn<21 
(2717 observations deleted) 
 
. stset  datevisit, failure(malar2) id(code) origin(datscren) scale(28)  
 
                id:  code 
     failure event:  malar2 != 0 & malar2 < . 
obs. time interval:  (datevisit[_n-1], datevisit] 
 exit on or before:  failure 
    t for analysis:  (time-origin)/28 
            origin:  time datscren 
 
------------------------------------------------------------------------------ 
    11372  total observations 
      118  observations end on or before enter() 
     2856  observations begin on or after (first) failure 
------------------------------------------------------------------------------ 
     8398  observations remaining, representing 
      125  subjects 
       69  failures in single-failure-per-subject data 
 1907.821  total analysis time at risk and under observation 
                                              at risk from t =         0 
                                   earliest observed entry t =         0 
                                        last observed exit t =  22.39286 
 
. stdes 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
                                   |-------------- per subject --------------| 
Category                   total        mean         min     median        max 
------------------------------------------------------------------------------ 
no. of subjects              125    
no. of records              8398      67.184           5         81        100 
 
(first) entry time                         0           0          0          0 
(final) exit time                   15.26257    1.142857   19.07143   22.39286 
 
subjects with gap              0    
time on gap if gap             0           .           .          .          . 
time at risk           1907.8214    15.26257    1.142857   19.07143   22.39286 
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failures                      69        .552           0          1          1 
------------------------------------------------------------------------------ 
 
. stsum 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
         |               incidence       no. of    |------ Survival time -----| 
         | time at risk     rate        subjects        25%       50%       75% 
---------+--------------------------------------------------------------------- 
   total |  1907.821429   .0361669           125   9.142857  19.71429  22.39286 
 
.  
. recode iptp_n 3=2 
(iptp_n: 185 changes made) 
 
.  
. *create local macros for explanatory variables 
. local envfac i.season i.mob i.zone ei    
 
. local socufac i.educ 
 
. local matfac agem i.primgrav i.sg_birth i.itn_use i.iptp_n  
 
. local infac1 i.sex  muac height_scr weight_scr i.del_way i.rea i.epi_stat i.ne 
> o_inf    
 
. local infac2 i.hb_type hbf AMA1_AU MSP1_AU MSP2_AU MSP3_AU 
 
. local infac3 i.ama1_sp i.msp1_sp i.msp2_sp i.msp3_sp /*i.ama1_pl i.msp1_pl i.m 
> sp2_pl i.msp3_pl*/ 
 
.  
. foreach i in `infac1' `infac2' `infac3' `envfac' `socufac' `matfac' {    
  2.         stcox `i' 
  3. } 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -303.78456 
Refining estimates: 
Iteration 0:   log likelihood = -303.78456 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =      0.52 
Log likelihood  =   -303.78456                     Prob > chi2     =    0.4720 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
       2.sex |    .839564   .2043459    -0.72   0.472     .5210452    1.352796 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -303.70078 
Iteration 2:   log likelihood = -303.70034 
Refining estimates: 
Iteration 0:   log likelihood = -303.70034 
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Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =      0.69 
Log likelihood  =   -303.70034                     Prob > chi2     =    0.4076 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    muac_scr |   1.092771   .1156848     0.84   0.402     .8880101    1.344747 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -303.23335 
Iteration 1:   log likelihood = -303.16663 
Iteration 2:   log likelihood = -303.16663 
Refining estimates: 
Iteration 0:   log likelihood = -303.16663 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          124                     Number of obs   =      8307 
No. of failures =           69 
Time at risk    =  1887.035714 
                                                   LR chi2(1)      =      0.13 
Log likelihood  =   -303.16663                     Prob > chi2     =    0.7149 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  height_scr |   1.018011   .0498422     0.36   0.715     .9248628    1.120541 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -303.23335 
Iteration 1:   log likelihood =  -303.2065 
Iteration 2:   log likelihood =  -303.2065 
Refining estimates: 
Iteration 0:   log likelihood =  -303.2065 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          124                     Number of obs   =      8312 
No. of failures =           69 
Time at risk    =  1887.071429 
                                                   LR chi2(1)      =      0.05 
Log likelihood  =    -303.2065                     Prob > chi2     =    0.8168 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  weight_scr |   .9538994   .1947292    -0.23   0.817     .6393493    1.423203 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -302.41294 
Iteration 1:   log likelihood = -302.21728 
Iteration 2:   log likelihood = -302.21195 
Iteration 3:   log likelihood = -302.21195 
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Refining estimates: 
Iteration 0:   log likelihood = -302.21195 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          123                     Number of obs   =      8220 
No. of failures =           69 
Time at risk    =  1866.321429 
                                                   LR chi2(1)      =      0.40 
Log likelihood  =   -302.21195                     Prob > chi2     =    0.5261 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     del_way | 
   cesarean  |   .6537055   .4692959    -0.59   0.554     .1600676    2.669689 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -304.04319 
Iteration 2:   log likelihood = -304.04319 
Refining estimates: 
Iteration 0:   log likelihood = -304.04319 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =      0.00 
Log likelihood  =   -304.04319                     Prob > chi2     =    0.9939 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         rea | 
         no  |   .9967242   .4268286    -0.01   0.994     .4305898    2.307205 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -304.02786 
Iteration 2:   log likelihood = -304.02785 
Refining estimates: 
Iteration 0:   log likelihood = -304.02785 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =      0.03 
Log likelihood  =   -304.02785                     Prob > chi2     =    0.8609 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    epi_stat | 
         no  |   .9366541   .3526131    -0.17   0.862     .4478532    1.958948 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
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Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -302.52313 
Iteration 2:   log likelihood = -302.52291 
Refining estimates: 
Iteration 0:   log likelihood = -302.52291 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =      3.04 
Log likelihood  =   -302.52291                     Prob > chi2     =    0.0812 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     neo_inf | 
         no  |   .0840198   .0881232    -2.36   0.018      .010755    .6563778 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -303.25634 
Iteration 1:   log likelihood = -300.58057 
Iteration 2:   log likelihood = -300.16018 
Iteration 3:   log likelihood = -300.09198 
Iteration 4:   log likelihood =  -300.0676 
Iteration 5:   log likelihood = -300.05863 
Iteration 6:   log likelihood = -300.05533 
Iteration 7:   log likelihood = -300.05412 
Iteration 8:   log likelihood = -300.05367 
Iteration 9:   log likelihood = -300.05351 
Iteration 10:  log likelihood = -300.05345 
Iteration 11:  log likelihood = -300.05343 
Iteration 12:  log likelihood = -300.05342 
Iteration 13:  log likelihood = -300.05342 
Iteration 14:  log likelihood = -300.05341 
Iteration 15:  log likelihood = -300.05341 
Iteration 16:  log likelihood = -300.05341 
Iteration 17:  log likelihood = -300.05341 
Iteration 18:  log likelihood = -300.05341 
Iteration 19:  log likelihood = -300.05341 
Iteration 20:  log likelihood = -300.05341 
Iteration 21:  log likelihood = -300.05341 
Iteration 22:  log likelihood = -300.05341 
Iteration 23:  log likelihood = -300.05341 
Iteration 24:  log likelihood = -300.05341 
Iteration 25:  log likelihood = -300.05341 
Iteration 26:  log likelihood = -300.05341 
Iteration 27:  log likelihood = -300.05341 
Iteration 28:  log likelihood = -300.05341 
Iteration 29:  log likelihood = -300.05341 
Iteration 30:  log likelihood = -300.05341 
Iteration 31:  log likelihood = -300.05341 
Iteration 32:  log likelihood = -300.05341 
Iteration 33:  log likelihood = -300.05341 
Iteration 34:  log likelihood = -300.05341 
Iteration 35:  log likelihood = -300.05341 
Iteration 36:  log likelihood = -300.05341 
Refining estimates: 
Iteration 0:   log likelihood = -300.05341 
Iteration 1:   log likelihood = -300.05341 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          124                     Number of obs   =      8321 
No. of failures =           69 
Time at risk    =  1887.142857 
                                                   LR chi2(3)      =      6.41 
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Log likelihood  =   -300.05341                     Prob > chi2     =    0.0935 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     hb_type | 
         AS  |   8.42e-17   1.04e-08    -0.00   1.000            0           . 
         AC  |    1.80663   .5776198     1.85   0.064     .9654311    3.380783 
         CC  |   .3613151   .3646519    -1.01   0.313     .0499831    2.611853 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -303.25634 
Iteration 1:   log likelihood = -301.69767 
Iteration 2:   log likelihood = -301.69451 
Refining estimates: 
Iteration 0:   log likelihood = -301.69451 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          124                     Number of obs   =      8321 
No. of failures =           69 
Time at risk    =  1887.142857 
                                                   LR chi2(1)      =      3.12 
Log likelihood  =   -301.69451                     Prob > chi2     =    0.0772 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         hbf |   .9823996   .0097131    -1.80   0.072     .9635456    1.001622 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -299.22394 
Iteration 2:   log likelihood = -299.22366 
Refining estimates: 
Iteration 0:   log likelihood = -299.22366 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =      9.64 
Log likelihood  =   -299.22366                     Prob > chi2     =    0.0019 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     AMA1_AU |   1.343157   .1279268     3.10   0.002     1.114437    1.618818 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -299.33605 
Iteration 2:   log likelihood = -298.27137 
Iteration 3:   log likelihood =  -298.2656 
Iteration 4:   log likelihood =  -298.2656 
Refining estimates: 
Iteration 0:   log likelihood =  -298.2656 
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Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =     11.56 
Log likelihood  =    -298.2656                     Prob > chi2     =    0.0007 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     MSP1_AU |   1.439863   .1411553     3.72   0.000     1.188159    1.744888 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -303.17352 
Iteration 2:   log likelihood = -302.95982 
Iteration 3:   log likelihood = -302.95718 
Iteration 4:   log likelihood = -302.95718 
Refining estimates: 
Iteration 0:   log likelihood = -302.95718 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =      2.17 
Log likelihood  =   -302.95718                     Prob > chi2     =    0.1405 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     MSP2_AU |   1.272589   .1879093     1.63   0.103     .9527977    1.699714 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -303.73807 
Iteration 2:   log likelihood = -303.73744 
Refining estimates: 
Iteration 0:   log likelihood = -303.73744 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =      0.61 
Log likelihood  =   -303.73744                     Prob > chi2     =    0.4342 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     MSP3_AU |   1.277101   .3939102     0.79   0.428     .6977178    2.337602 
------------------------------------------------------------------------------ 
variable ama1_sp not found 
r(111); 
 
end of do-file 
 
r(111); 
 
. do "C:\Users\dkangoye\AppData\Local\Temp\STD0f000000.tmp" 
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. clear all 
 
. macro drop _all 
 
. capture log close 
 
7.2.7 Negative binomial regression Stata code / Chapter 3 
clear all 
macro drop _all 
capture log close 
set more off 
log using chap3_nbreg,replace text 
*chap3_nbreg.do: construct predictive model for number of episodes 
*david kangoye,PhD student,Open University/KEMRI-WTRP 
version 11.2 
set linesize 80 
*================================================================= 
 
cd "C:\Users\dkangoye\Dropbox\projects\phdprogram_ou\work\data\data_bics\elisa_bics_labwork\davidk_bics2014" 
 
use bics_kwtrpV0,clear 
 
*combine morbidity data with exposure data 
*=============================== 
joinby code using "C:\Users\dkangoye\Dropbox\projects\phdprogram_ou\work\data\data_bics\elisa_bics\dist15ei",unm(both) 
tab _merge,m 
list code if _merge==2 
drop if _merge==2 
drop _merge 
br 
 
gen period=""  
lab var period "period of observation" 
replace period="0-3" if monthn==0 | monthn==1 | monthn==2  
replace period="3-6" if monthn==3 | monthn==4 | monthn==5  
replace period="6-9" if monthn==6 
replace period="9-12" if monthn==9 | monthn==10 | monthn==11  
replace period="12-15" if monthn==12 | monthn==13 | monthn==14  
replace period="18-21" if monthn==18 | monthn==19 | monthn==20  
order period,after(datevisit) 
drop if period=="" 
codebook period 
sort code datevisit 
 
*_2_define clinical malaria episodes 
*========================= 
 
*generate var for fever 
gen fever=1 if (temp>=37.5 & temp !=.) | hof==1 
lab var fever "presence of subjetive and/or objective fever" 
tab fever,m 
 
*generate new variables for malaria 
gen byte malar1=1 if fever==1 & tf>0 & tf !=. 
lab var malar1 "febrile malaria episode_tf>0" 
replace malar1=0 if malar1==. 
 
gen byte malar2=1 if fever==1 & tf>10000 & tf !=. 
lab var malar2 "febrile malaria episode_tf>10000" 
replace malar2=0 if malar2==. 
 
*order malaria variables 
order malar1 malar2,after(tf) 
 
*_3_censor episodes occuring within 21 days following previous malaria episode 
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*========================================================= 
 
*check number of episodes by definition before censoring 
local defs "malar1 malar2" 
foreach def in `defs'{ 
tab `def',m 
} 
*censor epdisodes 
sort malar1 code datevisit 
replace malar1=0 if malar1[_n-1]==1 & code==code[_n-1] & datevisit-datevisit[_n-1]<=21  
 
*check number of episodes by definition after censoring 
foreach def in malar1 malar2{ 
tab `def',m 
} 
 
*_4_generate additional variables and explore distribution 
*========================================= 
 
*generate variable age 
gen age= (datevisit - dob)/30 
lab var age "age of infant at current visit" 
sum age 
 
*gen variable season 
gen moy=month(datevisit) 
lab var moy "calendar month" 
tab moy,m 
 
gen season=1 if moy >=6 & moy <=11 
replace season=0 if moy==12 | moy>=1 & moy<=5 
lab var season "malaria transmission season" 
tab season,m 
 
*generate season of birth 
gen sob=1 if month(dob)>=6 & month(dob)<=11 
replace sob=0 if month(dob)==12 | month(dob)>=1 & month(dob)<=5 
lab var sob "season of birth" 
tab sob,m 
 
*generate month of birth 
gen mob=month(dob) 
lab var mob "month of birth" 
tab mob,m 
 
*gen variables for seropositivity 
gen ama1_sp=(AMA1_AU>-1.1401198) 
gen msp1_sp=(MSP1_AU>1.2326468) 
gen msp2_sp=(MSP2_AU>0.09898795) 
gen msp3_sp=(MSP3_AU>0.81264652) 
 
*_5_gen data set with an id that uniquely identify each couple of (code+period) 
*======================================================== 
 
sort code datevisit 
egen id=concat(code period) 
order id,before(code) 
br 
 
*_6_generate variable for number of episodes for each child for each period 
*===================================================== 
 
egen numep=total(malar2),by (id) 
order numep,after(malar2) 
 
*_7_keep only one observ per child for each period 
*==================================== 
 
bysort id (datevisit):keep if _n==1 
sort code datevisit 
 
*_8_define local macros for potential explanatory variables 
*========================================= 
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*create local macros for explanatory variables 
local envfac season mob zone ei    
local socufac educ 
local matfac agem primgrav sg_birth itn_use iptp_n  
local infac1 age sex  muac height_scr weight_scr del_way rea epi_stat neo_inf    
local infac2 hb_type hbf AMA1_AU MSP1_AU MSP2_AU MSP3_AU 
local infac3 ama1_sp msp1_sp msp2_sp msp3_sp /*ama1_pl msp1_pl msp2_pl msp3_pl*/ 
 
*_9_keep/order variables of interest and sort observations 
*======================================== 
 
keep id code dob datevisit period numep `envfac' `socufac' `matfac' /// 
  `infac1' `infac2' `infac3' monthn month 
sort code datevisit 
 
drop if code=="B010" | code=="B016" | code=="B022" | code=="B034" | code=="F003" | ///  
        code=="F019" | code=="F022" | code=="F031" | code=="F036" | code=="K008" | ///  
  code=="N004" | code=="N010" 
 
br 
save bics_kwtrpV2,replace 
 
*_10_select between pos/nbreg for non negative count data regression: 
*compare mean and variance of outcome variable 
*================================================== 
 
use bics_kwtrpV2,clear 
hist numep,freq 
tabstat numep,s(mean v) 
 
*_11_compute mfp of age for nbreg model 
*============================== 
mfp nbreg numep age  
corr age Iage__1 Iage__2 
pwcorr age Iage__1 Iage__2 
pcorr age Iage__1 Iage__2 
 
*_12_define local macros for predictor var to be used in regression analysis 
*===================================================== 
*_13_run univariate nbreg adjusting for clusters 
*================================= 
local envfac i.season ei i.mob i.zone    
local socufac i.educ 
local matfac agem i.primgrav i.sg_birth i.itn_use i.iptp_n  
local infac1 age Iage__1 Iage__2 i.sex  muac height_scr weight_scr i.del_way i.rea i.epi_stat i.neo_inf    
local infac2 i.hb_type hbf AMA1_AU MSP1_AU MSP2_AU MSP3_AU 
local infac3 i.ama1_sp i.msp1_sp i.msp2_sp i.msp3_sp  
 
foreach i in `infac3' `infac2' `infac1' `matfac' `envfac' `socufac'{ 
       nbreg numep `i',cluster(code) irr 
} 
 
nbreg numep i.zone,cluster(code) irr 
testparm i.zone 
 
nbreg numep i.educ,cluster(code) irr 
testparm i.educ 
 
recode iptp_n 3=2 
nbreg numep i.iptp_n,cluster(code) irr 
testparm i.iptp_n 
 
nbreg numep i.mob,cluster(code) irr 
testparm i.mob 
 
nbreg numep i.hb_type,cluster(code) irr 
testparm i.hb_type 
 
 
*_14_perform collinearity diagnostics 
*========================== 
pwcorr age AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf muac_scr ei,star(.05) 
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graph matrix age AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf muac_scr ei 
 
collin AMA1_AU MSP1_AU MSP2_AU MSP3_AU 
collin age AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf muac_scr ei 
  
*_15_multivariate regression analysis using changing antibody titres adjusting for clusters 
*=============================================================== 
 
*include in baseline multivariable model if p<0.2 or high importance variable 
*====================================================== 
nbreg numep age AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf i.hb_type i.itn_use i.mob i.season ei /// 
         i.ama1_sp i.msp1_sp i.msp3_sp agem i.iptp_n i.educ,cluster(code) irr     
est store model0 
 
*model simplification: backward elimination 
*=============================== 
*important variables that should not be removed: 
*antibody titres, itn use, season, exposure index, foetal haemoglobin (literature) 
 
*drop msp3_sp 
nbreg numep age AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf i.hb_type i.itn_use i.mob i.season ei ///  
         i.ama1_sp i.msp1_sp agem i.iptp_n i.educ,cluster(code) irr       
est store model1 
est table model0 model1,b(%5.3f) p(%4.3f) stats(N ll aic bic) 
   
*drop msp1_sp 
nbreg numep age AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf i.hb_type i.itn_use i.mob i.season ei ///  
         i.ama1_sp agem i.iptp_n i.educ,cluster(code) irr       
est store model2 
est table model0 model1 model2,b(%5.3f) p(%4.3f) stats(N ll aic bic) 
testparm i.iptp_n 
 
*drop iptp_n 
nbreg numep age AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf i.hb_type i.itn_use i.mob i.season ei /// 
         i.ama1_sp agem i.educ,cluster(code) irr       
est store model3 
est table model0 model1 model2 model3,b(%5.3f) p(%4.3f) stats(N ll aic bic) 
testparm i.mob 
testparm i.educ 
 
*drop ama1_sp 
nbreg numep age AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf i.hb_type i.itn_use i.mob i.season ei /// 
         agem i.educ,cluster(code) irr       
est store model4 
est table model0 model1 model2 model3 model4,b(%5.3f) p(%4.3f) stats(N ll aic bic) 
testparm i.mob 
testparm i.hb_type 
testparm i.educ 
 
*drop agem 
nbreg numep age AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf i.hb_type i.itn_use i.mob i.season ei ///  
         i.educ,cluster(code) irr     
est store model5 
est table model3 model4 model5,b(%5.3f) p(%4.3f) stats(N ll aic bic) 
testparm i.mob 
testparm i.hb_type 
testparm i.educ 
 
*drop educ 
nbreg numep age AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf i.hb_type i.itn_use i.mob i.season ei, ///  
         cluster(code) irr     
est store model6 
est table model5 model6,b(%5.3f) p(%4.3f) stats(N ll aic bic) 
testparm i.mob 
testparm i.hb_type 
 
nbreg numep age AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf i.hb_type i.itn_use i.mob i.season##c.ei, ///  
         cluster(code) irr    
    
log close 
exit 
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7.2.8 Negative binomial regression output log / Chapter 3 
-------------------------------------------------------------------------------- 
      name:  <unnamed> 
       log:  C:\Users\dkangoye\Dropbox\projects\phdprogram_ou\work\data\data_bic 
> s\elisa_bics_labwork\davidk_bics2014\chap3_coxreg.log 
  log type:  text 
 opened on:  13 Sep 2016, 19:31:02 
 
. *chap3_coxreg.do: construct predictive model for number of episodes 
. *david kangoye,PhD student,Open University/KEMRI-WTRP 
. version 11.2 
 
. set linesize 80 
 
. *============================================================================= 
> ============================== 
.  
. cd "C:\Users\dkangoye\Dropbox\projects\phdprogram_ou\work\data\data_bics\elisa 
> _bics_labwork\davidk_bics2014" 
C:\Users\dkangoye\Dropbox\projects\phdprogram_ou\work\data\data_bics\elisa_bics_ 
> labwork\davidk_bics2014 
 
.  
. use bics_kwtrpV0,clear 
(combination of all data sets (morb+geo+sero)) 
 
.  
. *combine morbidity data with exposure data 
. *========================================= 
. joinby code using "C:\Users\dkangoye\Dropbox\projects\phdprogram_ou\work\data\ 
> data_bics\elisa_bics\dist15ei",unm(both) 
 
. tab _merge,m 
 
                       _merge |      Freq.     Percent        Cum. 
------------------------------+----------------------------------- 
both in master and using data |     14,089      100.00      100.00 
------------------------------+----------------------------------- 
                        Total |     14,089      100.00 
 
. list code if _merge==2 
 
. drop if _merge==2 
(0 observations deleted) 
 
. drop _merge 
 
.  
. *define febrile malaria episodes 
. *=============================== 
.  
. *generate var for fever 
. gen fever=1 if (temp>=37.5 & temp !=.) | hof==1 
(12982 missing values generated) 
 
. lab var fever "presence of subjetive and/or objective fever" 
 
. tab fever,m 
 
presence of | 
  subjetive | 
     and/or | 
  objective | 
      fever |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          1 |      1,107        7.86        7.86 
          . |     12,982       92.14      100.00 
------------+----------------------------------- 
      Total |     14,089      100.00 
 
.  
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. *generate new variables for malaria 
. gen byte malar1=1 if fever==1 & tf>0 & tf !=. 
(13696 missing values generated) 
 
. lab var malar1 "febrile malaria episode_tf>0" 
 
. replace malar1=0 if malar1==. 
(13696 real changes made) 
 
.  
. gen byte malar2=1 if fever==1 & tf>10000 & tf !=. 
(13799 missing values generated) 
 
. lab var malar2 "febrile malaria episode_tf>10000" 
 
. replace malar2=0 if malar2==. 
(13799 real changes made) 
 
.  
. *order malaria variables 
. order malar1 malar2,after(tf) 
 
.  
. *censor episodes occuring within 21 days following previous malaria episode 
. *========================================================================== 
.  
. *check number of episodes by definition before censoring 
. local defs "malar1 malar2" 
 
. foreach def in `defs'{ 
  2. tab `def',m 
  3. } 
 
    febrile | 
    malaria | 
episode_tf> | 
          0 |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          0 |     13,696       97.21       97.21 
          1 |        393        2.79      100.00 
------------+----------------------------------- 
      Total |     14,089      100.00 
 
    febrile | 
    malaria | 
episode_tf> | 
      10000 |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          0 |     13,799       97.94       97.94 
          1 |        290        2.06      100.00 
------------+----------------------------------- 
      Total |     14,089      100.00 
 
. *censor epdisodes 
. sort malar1 code datevisit 
 
. replace malar1=0 if malar1[_n-1]==1 & code==code[_n-1] & datevisit-datevisit[_ 
> n-1]<=21  
(50 real changes made) 
 
.  
. *check number of episodes by definition after censoring 
. foreach def in malar1 malar2{ 
  2. tab `def',m 
  3. } 
 
    febrile | 
    malaria | 
episode_tf> | 
          0 |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          0 |     13,746       97.57       97.57 
          1 |        343        2.43      100.00 
------------+----------------------------------- 
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      Total |     14,089      100.00 
 
    febrile | 
    malaria | 
episode_tf> | 
      10000 |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          0 |     13,799       97.94       97.94 
          1 |        290        2.06      100.00 
------------+----------------------------------- 
      Total |     14,089      100.00 
 
.  
. *_3_generate additional variables and explore distribution 
. *========================================================= 
.  
. *generate variable age 
. gen age= (datevisit - dob)/30 
 
. lab var age "age of infant at current visit" 
 
. sum age 
 
    Variable |       Obs        Mean    Std. Dev.       Min        Max 
-------------+-------------------------------------------------------- 
         age |     14089    13.11088    7.012261         .9   25.93333 
 
.  
. *gen variable season 
.  
. gen moy=month(datevisit) 
 
. lab var moy "calendar month" 
 
. tab moy,m 
 
   calendar | 
      month |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          1 |      1,161        8.24        8.24 
          2 |      1,088        7.72       15.96 
          3 |      1,205        8.55       24.52 
          4 |      1,148        8.15       32.66 
          5 |      1,185        8.41       41.07 
          6 |      1,187        8.43       49.50 
          7 |      1,151        8.17       57.67 
          8 |      1,231        8.74       66.41 
          9 |      1,196        8.49       74.90 
         10 |      1,205        8.55       83.45 
         11 |      1,190        8.45       91.89 
         12 |      1,142        8.11      100.00 
------------+----------------------------------- 
      Total |     14,089      100.00 
 
.  
. gen season=1 if moy >=6 & moy <=11 
(6929 missing values generated) 
 
. replace season=0 if moy==12 | moy>=1 & moy<=5 
(6929 real changes made) 
 
. lab var season "malaria transmission season" 
 
. tab season,m 
 
    malaria | 
transmissio | 
   n season |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          0 |      6,929       49.18       49.18 
          1 |      7,160       50.82      100.00 
------------+----------------------------------- 
      Total |     14,089      100.00 
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.  
. *generate season of birth 
. gen sob=1 if month(dob)>=6 & month(dob)<=11 
(8425 missing values generated) 
 
. replace sob=0 if month(dob)==12 | month(dob)>=1 & month(dob)<=5 
(8425 real changes made) 
 
. lab var sob "season of birth" 
 
. tab sob,m 
 
  season of | 
      birth |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          0 |      8,425       59.80       59.80 
          1 |      5,664       40.20      100.00 
------------+----------------------------------- 
      Total |     14,089      100.00 
 
.  
. *generate month of birth 
. gen mob=month(dob) 
 
. lab var mob "month of birth" 
 
. tab mob,m 
 
   month of | 
      birth |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          1 |      2,905       20.62       20.62 
         10 |      1,243        8.82       29.44 
         11 |      4,421       31.38       60.82 
         12 |      5,520       39.18      100.00 
------------+----------------------------------- 
      Total |     14,089      100.00 
 
.  
. *gen variables for seropositivity 
. gen ama1_sp=(AMA1_AU>-1.1401198) 
 
. gen msp1_sp=(MSP1_AU>1.2326468) 
 
. gen msp2_sp=(MSP2_AU>0.09898795) 
 
. gen msp3_sp=(MSP3_AU>0.81264652) 
 
.  
. save bics_kwtrpV1,replace 
file bics_kwtrpV1.dta saved 
 
.  
. ****************************************************************************** 
> ********* 
. use bics_kwtrpV1,clear 
(combination of all data sets (morb+geo+sero)) 
 
. keep if monthn<22 
(1539 observations deleted) 
 
.  
. *univariate cox regression 
. *========================= 
. use bics_kwtrpV1,clear 
(combination of all data sets (morb+geo+sero)) 
 
. keep if monthn<21 
(2717 observations deleted) 
 
. stset  datevisit, failure(malar2) id(code) origin(datscren) scale(28)  
 
                id:  code 
     failure event:  malar2 != 0 & malar2 < . 
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obs. time interval:  (datevisit[_n-1], datevisit] 
 exit on or before:  failure 
    t for analysis:  (time-origin)/28 
            origin:  time datscren 
 
------------------------------------------------------------------------------ 
    11372  total observations 
      118  observations end on or before enter() 
     2856  observations begin on or after (first) failure 
------------------------------------------------------------------------------ 
     8398  observations remaining, representing 
      125  subjects 
       69  failures in single-failure-per-subject data 
 1907.821  total analysis time at risk and under observation 
                                              at risk from t =         0 
                                   earliest observed entry t =         0 
                                        last observed exit t =  22.39286 
 
. stdes 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
                                   |-------------- per subject --------------| 
Category                   total        mean         min     median        max 
------------------------------------------------------------------------------ 
no. of subjects              125    
no. of records              8398      67.184           5         81        100 
 
(first) entry time                         0           0          0          0 
(final) exit time                   15.26257    1.142857   19.07143   22.39286 
 
subjects with gap              0    
time on gap if gap             0           .           .          .          . 
time at risk           1907.8214    15.26257    1.142857   19.07143   22.39286 
 
failures                      69        .552           0          1          1 
------------------------------------------------------------------------------ 
 
. stsum 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
         |               incidence       no. of    |------ Survival time -----| 
         | time at risk     rate        subjects        25%       50%       75% 
---------+--------------------------------------------------------------------- 
   total |  1907.821429   .0361669           125   9.142857  19.71429  22.39286 
 
.  
. recode iptp_n 3=2 
(iptp_n: 185 changes made) 
 
.  
. *create local macros for explanatory variables 
. local envfac i.season i.mob i.zone ei    
 
. local socufac i.educ 
 
. local matfac agem i.primgrav i.sg_birth i.itn_use i.iptp_n  
 
. local infac1 i.sex  muac height_scr weight_scr i.del_way i.rea i.epi_stat i.ne 
> o_inf    
 
. local infac2 i.hb_type hbf AMA1_AU MSP1_AU MSP2_AU MSP3_AU 
 
. local infac3 i.ama1_sp i.msp1_sp i.msp2_sp i.msp3_sp /*i.ama1_pl i.msp1_pl i.m 
> sp2_pl i.msp3_pl*/ 
 
.  
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. foreach i in `infac1' `infac2' `infac3' `envfac' `socufac' `matfac' {    
  2.         stcox `i' 
  3. } 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -303.78456 
Refining estimates: 
Iteration 0:   log likelihood = -303.78456 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =      0.52 
Log likelihood  =   -303.78456                     Prob > chi2     =    0.4720 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
       2.sex |    .839564   .2043459    -0.72   0.472     .5210452    1.352796 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -303.70078 
Iteration 2:   log likelihood = -303.70034 
Refining estimates: 
Iteration 0:   log likelihood = -303.70034 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =      0.69 
Log likelihood  =   -303.70034                     Prob > chi2     =    0.4076 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    muac_scr |   1.092771   .1156848     0.84   0.402     .8880101    1.344747 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -303.23335 
Iteration 1:   log likelihood = -303.16663 
Iteration 2:   log likelihood = -303.16663 
Refining estimates: 
Iteration 0:   log likelihood = -303.16663 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          124                     Number of obs   =      8307 
No. of failures =           69 
Time at risk    =  1887.035714 
                                                   LR chi2(1)      =      0.13 
Log likelihood  =   -303.16663                     Prob > chi2     =    0.7149 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
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-------------+---------------------------------------------------------------- 
  height_scr |   1.018011   .0498422     0.36   0.715     .9248628    1.120541 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -303.23335 
Iteration 1:   log likelihood =  -303.2065 
Iteration 2:   log likelihood =  -303.2065 
Refining estimates: 
Iteration 0:   log likelihood =  -303.2065 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          124                     Number of obs   =      8312 
No. of failures =           69 
Time at risk    =  1887.071429 
                                                   LR chi2(1)      =      0.05 
Log likelihood  =    -303.2065                     Prob > chi2     =    0.8168 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
  weight_scr |   .9538994   .1947292    -0.23   0.817     .6393493    1.423203 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -302.41294 
Iteration 1:   log likelihood = -302.21728 
Iteration 2:   log likelihood = -302.21195 
Iteration 3:   log likelihood = -302.21195 
Refining estimates: 
Iteration 0:   log likelihood = -302.21195 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          123                     Number of obs   =      8220 
No. of failures =           69 
Time at risk    =  1866.321429 
                                                   LR chi2(1)      =      0.40 
Log likelihood  =   -302.21195                     Prob > chi2     =    0.5261 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     del_way | 
   cesarean  |   .6537055   .4692959    -0.59   0.554     .1600676    2.669689 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -304.04319 
Iteration 2:   log likelihood = -304.04319 
Refining estimates: 
Iteration 0:   log likelihood = -304.04319 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =      0.00 
Log likelihood  =   -304.04319                     Prob > chi2     =    0.9939 
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------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         rea | 
         no  |   .9967242   .4268286    -0.01   0.994     .4305898    2.307205 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -304.02786 
Iteration 2:   log likelihood = -304.02785 
Refining estimates: 
Iteration 0:   log likelihood = -304.02785 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =      0.03 
Log likelihood  =   -304.02785                     Prob > chi2     =    0.8609 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    epi_stat | 
         no  |   .9366541   .3526131    -0.17   0.862     .4478532    1.958948 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -302.52313 
Iteration 2:   log likelihood = -302.52291 
Refining estimates: 
Iteration 0:   log likelihood = -302.52291 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =      3.04 
Log likelihood  =   -302.52291                     Prob > chi2     =    0.0812 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     neo_inf | 
         no  |   .0840198   .0881232    -2.36   0.018      .010755    .6563778 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -303.25634 
Iteration 1:   log likelihood = -300.58057 
Iteration 2:   log likelihood = -300.16018 
Iteration 3:   log likelihood = -300.09198 
Iteration 4:   log likelihood =  -300.0676 
Iteration 5:   log likelihood = -300.05863 
Iteration 6:   log likelihood = -300.05533 
Iteration 7:   log likelihood = -300.05412 
Iteration 8:   log likelihood = -300.05367 
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Iteration 9:   log likelihood = -300.05351 
Iteration 10:  log likelihood = -300.05345 
Iteration 11:  log likelihood = -300.05343 
Iteration 12:  log likelihood = -300.05342 
Iteration 13:  log likelihood = -300.05342 
Iteration 14:  log likelihood = -300.05341 
Iteration 15:  log likelihood = -300.05341 
Iteration 16:  log likelihood = -300.05341 
Iteration 17:  log likelihood = -300.05341 
Iteration 18:  log likelihood = -300.05341 
Iteration 19:  log likelihood = -300.05341 
Iteration 20:  log likelihood = -300.05341 
Iteration 21:  log likelihood = -300.05341 
Iteration 22:  log likelihood = -300.05341 
Iteration 23:  log likelihood = -300.05341 
Iteration 24:  log likelihood = -300.05341 
Iteration 25:  log likelihood = -300.05341 
Iteration 26:  log likelihood = -300.05341 
Iteration 27:  log likelihood = -300.05341 
Iteration 28:  log likelihood = -300.05341 
Iteration 29:  log likelihood = -300.05341 
Iteration 30:  log likelihood = -300.05341 
Iteration 31:  log likelihood = -300.05341 
Iteration 32:  log likelihood = -300.05341 
Iteration 33:  log likelihood = -300.05341 
Iteration 34:  log likelihood = -300.05341 
Iteration 35:  log likelihood = -300.05341 
Iteration 36:  log likelihood = -300.05341 
Refining estimates: 
Iteration 0:   log likelihood = -300.05341 
Iteration 1:   log likelihood = -300.05341 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          124                     Number of obs   =      8321 
No. of failures =           69 
Time at risk    =  1887.142857 
                                                   LR chi2(3)      =      6.41 
Log likelihood  =   -300.05341                     Prob > chi2     =    0.0935 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     hb_type | 
         AS  |   8.42e-17   1.04e-08    -0.00   1.000            0           . 
         AC  |    1.80663   .5776198     1.85   0.064     .9654311    3.380783 
         CC  |   .3613151   .3646519    -1.01   0.313     .0499831    2.611853 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -303.25634 
Iteration 1:   log likelihood = -301.69767 
Iteration 2:   log likelihood = -301.69451 
Refining estimates: 
Iteration 0:   log likelihood = -301.69451 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          124                     Number of obs   =      8321 
No. of failures =           69 
Time at risk    =  1887.142857 
                                                   LR chi2(1)      =      3.12 
Log likelihood  =   -301.69451                     Prob > chi2     =    0.0772 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         hbf |   .9823996   .0097131    -1.80   0.072     .9635456    1.001622 
------------------------------------------------------------------------------ 
 
 264 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -299.22394 
Iteration 2:   log likelihood = -299.22366 
Refining estimates: 
Iteration 0:   log likelihood = -299.22366 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =      9.64 
Log likelihood  =   -299.22366                     Prob > chi2     =    0.0019 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     AMA1_AU |   1.343157   .1279268     3.10   0.002     1.114437    1.618818 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -299.33605 
Iteration 2:   log likelihood = -298.27137 
Iteration 3:   log likelihood =  -298.2656 
Iteration 4:   log likelihood =  -298.2656 
Refining estimates: 
Iteration 0:   log likelihood =  -298.2656 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =     11.56 
Log likelihood  =    -298.2656                     Prob > chi2     =    0.0007 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     MSP1_AU |   1.439863   .1411553     3.72   0.000     1.188159    1.744888 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -303.17352 
Iteration 2:   log likelihood = -302.95982 
Iteration 3:   log likelihood = -302.95718 
Iteration 4:   log likelihood = -302.95718 
Refining estimates: 
Iteration 0:   log likelihood = -302.95718 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =      2.17 
Log likelihood  =   -302.95718                     Prob > chi2     =    0.1405 
 
------------------------------------------------------------------------------ 
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          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     MSP2_AU |   1.272589   .1879093     1.63   0.103     .9527977    1.699714 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -303.73807 
Iteration 2:   log likelihood = -303.73744 
Refining estimates: 
Iteration 0:   log likelihood = -303.73744 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =      0.61 
Log likelihood  =   -303.73744                     Prob > chi2     =    0.4342 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     MSP3_AU |   1.277101   .3939102     0.79   0.428     .6977178    2.337602 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -302.71067 
Iteration 2:   log likelihood =  -302.7041 
Iteration 3:   log likelihood =  -302.7041 
Refining estimates: 
Iteration 0:   log likelihood =  -302.7041 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =      2.68 
Log likelihood  =    -302.7041                     Prob > chi2     =    0.1017 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
   1.ama1_sp |    1.62308   .4724889     1.66   0.096     .9173807    2.871641 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -301.14735 
Iteration 2:   log likelihood = -299.70465 
Iteration 3:   log likelihood = -299.69025 
Iteration 4:   log likelihood = -299.69025 
Refining estimates: 
Iteration 0:   log likelihood = -299.69025 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
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                                                   LR chi2(1)      =      8.71 
Log likelihood  =   -299.69025                     Prob > chi2     =    0.0032 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
   1.msp1_sp |   2.988049   1.001652     3.27   0.001     1.548989    5.764041 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -302.05448 
Iteration 2:   log likelihood =  -301.8613 
Iteration 3:   log likelihood = -301.86087 
Refining estimates: 
Iteration 0:   log likelihood = -301.86087 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =      4.36 
Log likelihood  =   -301.86087                     Prob > chi2     =    0.0367 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
   1.msp2_sp |   2.003354   .6227979     2.24   0.025     1.089277    3.684488 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -303.51434 
Iteration 2:   log likelihood = -303.51033 
Iteration 3:   log likelihood = -303.51033 
Refining estimates: 
Iteration 0:   log likelihood = -303.51033 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =      1.07 
Log likelihood  =   -303.51033                     Prob > chi2     =    0.3019 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
   1.msp3_sp |   1.389899   .4327121     1.06   0.290     .7550607    2.558496 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -298.21816 
Iteration 2:   log likelihood = -297.86159 
Iteration 3:   log likelihood = -297.85889 
Iteration 4:   log likelihood = -297.85889 
Refining estimates: 
Iteration 0:   log likelihood = -297.85889 
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Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =     12.37 
Log likelihood  =   -297.85889                     Prob > chi2     =    0.0004 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    1.season |   8.275027   5.635893     3.10   0.002     2.177908    31.44122 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -298.83732 
Iteration 2:   log likelihood = -298.28853 
Iteration 3:   log likelihood = -298.28696 
Iteration 4:   log likelihood = -298.28696 
Refining estimates: 
Iteration 0:   log likelihood = -298.28696 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(3)      =     11.51 
Log likelihood  =   -298.28696                     Prob > chi2     =    0.0093 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         mob | 
         10  |   .1891056   .1177809    -2.67   0.007     .0557891    .6410018 
         11  |   .4389449   .1428056    -2.53   0.011     .2319965     .830498 
         12  |    .531245   .1594509    -2.11   0.035     .2949921    .9567077 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -293.26189 
Iteration 2:   log likelihood = -292.92575 
Iteration 3:   log likelihood = -292.92499 
Refining estimates: 
Iteration 0:   log likelihood = -292.92499 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(2)      =     22.24 
Log likelihood  =   -292.92499                     Prob > chi2     =    0.0000 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        zone | 
      urban  |   .3093051   .1075754    -3.37   0.001     .1564378    .6115508 
      mixed  |   1.317749   .3532878     1.03   0.303     .7791591    2.228638 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
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             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -293.57271 
Iteration 2:   log likelihood = -293.49031 
Iteration 3:   log likelihood = -293.49028 
Refining estimates: 
Iteration 0:   log likelihood = -293.49028 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =     21.11 
Log likelihood  =   -293.49028                     Prob > chi2     =    0.0000 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
          ei |   1.096877   .0234741     4.32   0.000      1.05182    1.143864 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -300.22379 
Iteration 2:   log likelihood = -300.04145 
Iteration 3:   log likelihood = -300.04046 
Iteration 4:   log likelihood = -300.04046 
Refining estimates: 
Iteration 0:   log likelihood = -300.04046 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(2)      =      8.01 
Log likelihood  =   -300.04046                     Prob > chi2     =    0.0183 
 
------------------------------------------------------------------------------- 
           _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
         educ | 
primary sc..  |    1.51729   .3885309     1.63   0.103     .9185491    2.506311 
secondary ..  |   .4512767   .2152045    -1.67   0.095      .177224    1.149115 
------------------------------------------------------------------------------- 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -302.09653 
Iteration 2:   log likelihood = -302.07665 
Iteration 3:   log likelihood = -302.07665 
Refining estimates: 
Iteration 0:   log likelihood = -302.07665 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =      3.93 
Log likelihood  =   -302.07665                     Prob > chi2     =    0.0473 
 
------------------------------------------------------------------------------ 
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          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        agem |   1.038145   .0190669     2.04   0.042     1.001439    1.076196 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -299.21545 
Iteration 1:   log likelihood = -299.14403 
Iteration 2:   log likelihood = -299.14395 
Refining estimates: 
Iteration 0:   log likelihood = -299.14395 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          124                     Number of obs   =      8359 
No. of failures =           68 
Time at risk    =  1898.857143 
                                                   LR chi2(1)      =      0.14 
Log likelihood  =   -299.14395                     Prob > chi2     =    0.7053 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    primgrav | 
         no  |   1.122431   .3468379     0.37   0.709     .6125381    2.056771 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -301.91106 
Iteration 2:   log likelihood = -301.16487 
Iteration 3:   log likelihood = -300.89514 
Iteration 4:   log likelihood = -300.79655 
Iteration 5:   log likelihood = -300.76036 
Iteration 6:   log likelihood = -300.74706 
Iteration 7:   log likelihood = -300.74217 
Iteration 8:   log likelihood = -300.74037 
Iteration 9:   log likelihood =  -300.7397 
Iteration 10:  log likelihood = -300.73946 
Iteration 11:  log likelihood = -300.73937 
Iteration 12:  log likelihood = -300.73934 
Iteration 13:  log likelihood = -300.73933 
Iteration 14:  log likelihood = -300.73932 
Iteration 15:  log likelihood = -300.73932 
Iteration 16:  log likelihood = -300.73932 
Iteration 17:  log likelihood = -300.73932 
Iteration 18:  log likelihood = -300.73932 
Iteration 19:  log likelihood = -300.73932 
Iteration 20:  log likelihood = -300.73932 
Iteration 21:  log likelihood = -300.73932 
Iteration 22:  log likelihood = -300.73932 
Iteration 23:  log likelihood = -300.73932 
Iteration 24:  log likelihood = -300.73932 
Iteration 25:  log likelihood = -300.73932 
Iteration 26:  log likelihood = -300.73932 
Iteration 27:  log likelihood = -300.73932 
Iteration 28:  log likelihood = -300.73932 
Iteration 29:  log likelihood = -300.73932 
Iteration 30:  log likelihood = -300.73932 
Iteration 31:  log likelihood = -300.73932 
Iteration 32:  log likelihood = -300.73932 
Iteration 33:  log likelihood = -300.73932 
Iteration 34:  log likelihood = -300.73932 
Iteration 35:  log likelihood = -300.73932 
Refining estimates: 
Iteration 0:   log likelihood = -300.73932 
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Iteration 1:   log likelihood = -300.73932 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(1)      =      6.61 
Log likelihood  =   -300.73932                     Prob > chi2     =    0.0102 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    sg_birth | 
         no  |   2.13e-16   7.93e-09    -0.00   1.000            0           . 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -299.22841 
Iteration 1:   log likelihood = -299.05981 
Iteration 2:   log likelihood = -299.05847 
Iteration 3:   log likelihood = -299.05847 
Refining estimates: 
Iteration 0:   log likelihood = -299.05847 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          124                     Number of obs   =      8341 
No. of failures =           68 
Time at risk    =  1895.178571 
                                                   LR chi2(1)      =      0.34 
Log likelihood  =   -299.05847                     Prob > chi2     =    0.5599 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     itn_use | 
         no  |   1.239298   .4442999     0.60   0.550     .6137794    2.502301 
------------------------------------------------------------------------------ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -303.61417 
Iteration 2:   log likelihood = -303.61123 
Iteration 3:   log likelihood = -303.61123 
Refining estimates: 
Iteration 0:   log likelihood = -303.61123 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(2)      =      0.86 
Log likelihood  =   -303.61123                     Prob > chi2     =    0.6492 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
      iptp_n | 
          1  |   1.474334    .824449     0.69   0.488     .4927236    4.411524 
          2  |   1.149532   .5983478     0.27   0.789     .4144369    3.188479 
------------------------------------------------------------------------------ 
 
.  
. stcox i.zone 
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         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -293.26189 
Iteration 2:   log likelihood = -292.92575 
Iteration 3:   log likelihood = -292.92499 
Refining estimates: 
Iteration 0:   log likelihood = -292.92499 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(2)      =     22.24 
Log likelihood  =   -292.92499                     Prob > chi2     =    0.0000 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        zone | 
      urban  |   .3093051   .1075754    -3.37   0.001     .1564378    .6115508 
      mixed  |   1.317749   .3532878     1.03   0.303     .7791591    2.228638 
------------------------------------------------------------------------------ 
 
. testparm i.zone 
 
 ( 1)  2.zone = 0 
 ( 2)  3.zone = 0 
 
           chi2(  2) =   17.97 
         Prob > chi2 =    0.0001 
 
.  
. stcox i.educ 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -300.22379 
Iteration 2:   log likelihood = -300.04145 
Iteration 3:   log likelihood = -300.04046 
Iteration 4:   log likelihood = -300.04046 
Refining estimates: 
Iteration 0:   log likelihood = -300.04046 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(2)      =      8.01 
Log likelihood  =   -300.04046                     Prob > chi2     =    0.0183 
 
------------------------------------------------------------------------------- 
           _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
         educ | 
primary sc..  |    1.51729   .3885309     1.63   0.103     .9185491    2.506311 
secondary ..  |   .4512767   .2152045    -1.67   0.095      .177224    1.149115 
------------------------------------------------------------------------------- 
 
. testparm i.educ 
 
 ( 1)  1.educ = 0 
 ( 2)  2.educ = 0 
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           chi2(  2) =    6.97 
         Prob > chi2 =    0.0306 
 
.  
. stcox i.iptp_n 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -303.61417 
Iteration 2:   log likelihood = -303.61123 
Iteration 3:   log likelihood = -303.61123 
Refining estimates: 
Iteration 0:   log likelihood = -303.61123 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(2)      =      0.86 
Log likelihood  =   -303.61123                     Prob > chi2     =    0.6492 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
      iptp_n | 
          1  |   1.474334    .824449     0.69   0.488     .4927236    4.411524 
          2  |   1.149532   .5983478     0.27   0.789     .4144369    3.188479 
------------------------------------------------------------------------------ 
 
. testparm i.iptp_n 
 
 ( 1)  1.iptp_n = 0 
 ( 2)  2.iptp_n = 0 
 
           chi2(  2) =    0.89 
         Prob > chi2 =    0.6393 
 
.  
. stcox i.mob 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -304.04321 
Iteration 1:   log likelihood = -298.83732 
Iteration 2:   log likelihood = -298.28853 
Iteration 3:   log likelihood = -298.28696 
Iteration 4:   log likelihood = -298.28696 
Refining estimates: 
Iteration 0:   log likelihood = -298.28696 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          125                     Number of obs   =      8398 
No. of failures =           69 
Time at risk    =  1907.821429 
                                                   LR chi2(3)      =     11.51 
Log likelihood  =   -298.28696                     Prob > chi2     =    0.0093 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         mob | 
         10  |   .1891056   .1177809    -2.67   0.007     .0557891    .6410018 
         11  |   .4389449   .1428056    -2.53   0.011     .2319965     .830498 
         12  |    .531245   .1594509    -2.11   0.035     .2949921    .9567077 
------------------------------------------------------------------------------ 
 273 
 
 
. testparm i.mob 
 
 ( 1)  10.mob = 0 
 ( 2)  11.mob = 0 
 ( 3)  12.mob = 0 
 
           chi2(  3) =   10.99 
         Prob > chi2 =    0.0118 
 
.  
. stcox i.hb_type 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -303.25634 
Iteration 1:   log likelihood = -300.58057 
Iteration 2:   log likelihood = -300.16018 
Iteration 3:   log likelihood = -300.09198 
Iteration 4:   log likelihood =  -300.0676 
Iteration 5:   log likelihood = -300.05863 
Iteration 6:   log likelihood = -300.05533 
Iteration 7:   log likelihood = -300.05412 
Iteration 8:   log likelihood = -300.05367 
Iteration 9:   log likelihood = -300.05351 
Iteration 10:  log likelihood = -300.05345 
Iteration 11:  log likelihood = -300.05343 
Iteration 12:  log likelihood = -300.05342 
Iteration 13:  log likelihood = -300.05342 
Iteration 14:  log likelihood = -300.05341 
Iteration 15:  log likelihood = -300.05341 
Iteration 16:  log likelihood = -300.05341 
Iteration 17:  log likelihood = -300.05341 
Iteration 18:  log likelihood = -300.05341 
Iteration 19:  log likelihood = -300.05341 
Iteration 20:  log likelihood = -300.05341 
Iteration 21:  log likelihood = -300.05341 
Iteration 22:  log likelihood = -300.05341 
Iteration 23:  log likelihood = -300.05341 
Iteration 24:  log likelihood = -300.05341 
Iteration 25:  log likelihood = -300.05341 
Iteration 26:  log likelihood = -300.05341 
Iteration 27:  log likelihood = -300.05341 
Iteration 28:  log likelihood = -300.05341 
Iteration 29:  log likelihood = -300.05341 
Iteration 30:  log likelihood = -300.05341 
Iteration 31:  log likelihood = -300.05341 
Iteration 32:  log likelihood = -300.05341 
Iteration 33:  log likelihood = -300.05341 
Iteration 34:  log likelihood = -300.05341 
Iteration 35:  log likelihood = -300.05341 
Iteration 36:  log likelihood = -300.05341 
Refining estimates: 
Iteration 0:   log likelihood = -300.05341 
Iteration 1:   log likelihood = -300.05341 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          124                     Number of obs   =      8321 
No. of failures =           69 
Time at risk    =  1887.142857 
                                                   LR chi2(3)      =      6.41 
Log likelihood  =   -300.05341                     Prob > chi2     =    0.0935 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     hb_type | 
         AS  |   8.42e-17   1.04e-08    -0.00   1.000            0           . 
         AC  |    1.80663   .5776198     1.85   0.064     .9654311    3.380783 
         CC  |   .3613151   .3646519    -1.01   0.313     .0499831    2.611853 
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------------------------------------------------------------------------------ 
 
. testparm i.hb_type 
 
 ( 1)  2.hb_type = 0 
 ( 2)  3.hb_type = 0 
 ( 3)  4.hb_type = 0 
 
           chi2(  3) =    4.67 
         Prob > chi2 =    0.1979 
 
.  
. *perform collinearity diagnostic 
. *=============================== 
. pwcorr AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf muac_scr ei,star(.05) 
 
             |  AMA1_AU  MSP1_AU  MSP2_AU  MSP3_AU      hbf muac_scr       ei 
-------------+--------------------------------------------------------------- 
     AMA1_AU |   1.0000  
     MSP1_AU |   0.3177*  1.0000  
     MSP2_AU |   0.4796*  0.4885*  1.0000  
     MSP3_AU |   0.3856*  0.2244*  0.4260*  1.0000  
         hbf |   0.0109  -0.0226* -0.0185*  0.0428*  1.0000  
    muac_scr |  -0.0519*  0.0138  -0.0120  -0.0195* -0.0901*  1.0000  
          ei |   0.1304*  0.1585*  0.0707*  0.1066*  0.1596* -0.0557*  1.0000  
 
.  
. graph matrix AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf muac_scr ei 
 
.  
. collin AMA1_AU MSP1_AU MSP2_AU MSP3_AU 
(obs=11372) 
 
  Collinearity Diagnostics 
 
                        SQRT                   R- 
  Variable      VIF     VIF    Tolerance    Squared 
---------------------------------------------------- 
   AMA1_AU      1.39    1.18    0.7215      0.2785 
   MSP1_AU      1.33    1.15    0.7523      0.2477 
   MSP2_AU      1.68    1.30    0.5953      0.4047 
   MSP3_AU      1.29    1.14    0.7759      0.2241 
---------------------------------------------------- 
  Mean VIF      1.42 
 
                           Cond 
        Eigenval          Index 
--------------------------------- 
    1     1.8894          1.0000 
    2     1.7846          1.0289 
    3     0.6842          1.6618 
    4     0.4115          2.1427 
    5     0.2303          2.8642 
--------------------------------- 
 Condition Number         2.8642  
 Eigenvalues & Cond Index computed from scaled raw sscp (w/ intercept) 
 Det(correlation matrix)    0.4495 
 
. collin AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf muac_scr ei 
(obs=11295) 
 
  Collinearity Diagnostics 
 
                        SQRT                   R- 
  Variable      VIF     VIF    Tolerance    Squared 
---------------------------------------------------- 
   AMA1_AU      1.40    1.18    0.7157      0.2843 
   MSP1_AU      1.36    1.17    0.7352      0.2648 
   MSP2_AU      1.70    1.30    0.5894      0.4106 
   MSP3_AU      1.30    1.14    0.7704      0.2296 
       hbf      1.04    1.02    0.9641      0.0359 
  muac_scr      1.01    1.01    0.9859      0.0141 
        ei      1.07    1.03    0.9339      0.0661 
---------------------------------------------------- 
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  Mean VIF      1.27 
 
                           Cond 
        Eigenval          Index 
--------------------------------- 
    1     4.4933          1.0000 
    2     1.8936          1.5404 
    3     0.6883          2.5550 
    4     0.4231          3.2590 
    5     0.3453          3.6075 
    6     0.1282          5.9213 
    7     0.0249         13.4377 
    8     0.0035         36.0141 
--------------------------------- 
 Condition Number        36.0141  
 Eigenvalues & Cond Index computed from scaled raw sscp (w/ intercept) 
 Det(correlation matrix)    0.4120 
 
.  
. *multivariate cox regression 
. *=========================== 
. *include in baseline multivariable model if p<0.2 or theoritically high import 
> ance variable 
.  
. stcox hbf i.hb_type AMA1_AU MSP1_AU MSP2_AU MSP3_AU i.ama1_sp i.msp1_sp i.msp2 
> _sp /// 
>                  i.mob i.itn_use i.educ i.season ei 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -298.44974 
Iteration 1:   log likelihood =   -266.375 
Iteration 2:   log likelihood = -261.61083 
Iteration 3:   log likelihood = -261.49205 
Iteration 4:   log likelihood = -261.47772 
Iteration 5:   log likelihood = -261.47248 
Iteration 6:   log likelihood = -261.47055 
Iteration 7:   log likelihood = -261.46984 
Iteration 8:   log likelihood = -261.46958 
Iteration 9:   log likelihood = -261.46948 
Iteration 10:  log likelihood = -261.46945 
Iteration 11:  log likelihood = -261.46944 
Iteration 12:  log likelihood = -261.46943 
Iteration 13:  log likelihood = -261.46943 
Iteration 14:  log likelihood = -261.46943 
Iteration 15:  log likelihood = -261.46943 
Iteration 16:  log likelihood = -261.46943 
Iteration 17:  log likelihood = -261.46943 
Iteration 18:  log likelihood = -261.46943 
Iteration 19:  log likelihood = -261.46943 
Iteration 20:  log likelihood = -261.46943 
Iteration 21:  log likelihood = -261.46943 
Iteration 22:  log likelihood = -261.46943 
Iteration 23:  log likelihood = -261.46943 
Iteration 24:  log likelihood = -261.46943 
Iteration 25:  log likelihood = -261.46943 
Iteration 26:  log likelihood = -261.46943 
Iteration 27:  log likelihood = -261.46943 
Iteration 28:  log likelihood = -261.46943 
Iteration 29:  log likelihood = -261.46943 
Iteration 30:  log likelihood = -261.46943 
Iteration 31:  log likelihood = -261.46943 
Iteration 32:  log likelihood = -261.46943 
Iteration 33:  log likelihood = -261.46943 
Iteration 34:  log likelihood = -261.46943 
Iteration 35:  log likelihood = -261.46943 
Iteration 36:  log likelihood = -261.46943 
Iteration 37:  log likelihood = -261.46943 
Iteration 38:  log likelihood = -261.46943 
Iteration 39:  log likelihood = -261.46943 
Iteration 40:  log likelihood = -261.46943 
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Iteration 41:  log likelihood = -261.46943 
Iteration 42:  log likelihood = -261.46943 
Iteration 43:  log likelihood = -261.46943 
Refining estimates: 
Iteration 0:   log likelihood = -261.46943 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          123                     Number of obs   =      8264 
No. of failures =           68 
Time at risk    =       1874.5 
                                                   LR chi2(18)     =     73.96 
Log likelihood  =   -261.46943                     Prob > chi2     =    0.0000 
 
------------------------------------------------------------------------------- 
           _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
          hbf |   .9602224   .0123249    -3.16   0.002     .9363674    .9846852 
              | 
      hb_type | 
          AS  |   2.42e-19          .        .       .            .           . 
          AC  |   1.623269   .5801645     1.36   0.175     .8056875      3.2705 
          CC  |   .2685015   .2834482    -1.25   0.213     .0339126    2.125847 
              | 
      AMA1_AU |   1.262122   .1863322     1.58   0.115     .9450069    1.685651 
      MSP1_AU |   1.316635    .240752     1.50   0.132     .9200674     1.88413 
      MSP2_AU |   .6530574   .2248826    -1.24   0.216     .3325348    1.282524 
      MSP3_AU |   1.282759   .4460321     0.72   0.474     .6488904    2.535824 
    1.ama1_sp |   .6040203   .2567994    -1.19   0.236     .2625204    1.389761 
    1.msp1_sp |   1.186647   .7086464     0.29   0.774     .3681268    3.825123 
    1.msp2_sp |   2.575378   1.651516     1.48   0.140     .7328073    9.050908 
              | 
          mob | 
          10  |   .2017084   .1391441    -2.32   0.020     .0521845    .7796625 
          11  |   .6807494   .2558631    -1.02   0.306     .3258809    1.422053 
          12  |   .6460694   .2214892    -1.27   0.203     .3299631    1.265007 
              | 
      itn_use | 
          no  |   1.072824   .4373913     0.17   0.863     .4824947    2.385416 
              | 
         educ | 
primary sc..  |   1.870156   .5355262     2.19   0.029     1.066923    3.278103 
secondary ..  |    1.07591   .6307863     0.12   0.901     .3409828    3.394843 
              | 
     1.season |   9.233465   6.726386     3.05   0.002     2.214533    38.49881 
           ei |   1.094685   .0283509     3.49   0.000     1.040505    1.151686 
------------------------------------------------------------------------------- 
 
. est store model0 
 
.  
. *model simplification: backward elimination 
. *========================================== 
. * important variables that should not be removed: 
. * antibody titres, itn use, season, exposure index, foetal haemoglobin (literat 
> ure) 
.  
. *drop msp1_sp 
. stcox hbf i.hb_type AMA1_AU MSP1_AU MSP2_AU MSP3_AU i.ama1_sp i.msp2_sp /// 
>                  i.mob i.itn_use i.educ i.season ei 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -298.44974 
Iteration 1:   log likelihood = -264.81816 
Iteration 2:   log likelihood = -261.62226 
Iteration 3:   log likelihood = -261.53433 
Iteration 4:   log likelihood = -261.51928 
Iteration 5:   log likelihood = -261.51377 
Iteration 6:   log likelihood = -261.51174 
Iteration 7:   log likelihood =   -261.511 
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Iteration 8:   log likelihood = -261.51072 
Iteration 9:   log likelihood = -261.51062 
Iteration 10:  log likelihood = -261.51059 
Iteration 11:  log likelihood = -261.51057 
Iteration 12:  log likelihood = -261.51057 
Iteration 13:  log likelihood = -261.51057 
Iteration 14:  log likelihood = -261.51056 
Iteration 15:  log likelihood = -261.51056 
Iteration 16:  log likelihood = -261.51056 
Iteration 17:  log likelihood = -261.51056 
Iteration 18:  log likelihood = -261.51056 
Iteration 19:  log likelihood = -261.51056 
Iteration 20:  log likelihood = -261.51056 
Iteration 21:  log likelihood = -261.51056 
Iteration 22:  log likelihood = -261.51056 
Iteration 23:  log likelihood = -261.51056 
Iteration 24:  log likelihood = -261.51056 
Iteration 25:  log likelihood = -261.51056 
Iteration 26:  log likelihood = -261.51056 
Refining estimates: 
Iteration 0:   log likelihood = -261.51056 
Iteration 1:   log likelihood = -261.51056 
Iteration 2:   log likelihood = -261.51056 
Iteration 3:   log likelihood = -261.51056 
Iteration 4:   log likelihood = -261.51056 
Iteration 5:   log likelihood = -261.51056 
Iteration 6:   log likelihood = -261.51056 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          123                     Number of obs   =      8264 
No. of failures =           68 
Time at risk    =       1874.5 
                                                   LR chi2(18)     =     73.88 
Log likelihood  =   -261.51056                     Prob > chi2     =    0.0000 
 
------------------------------------------------------------------------------- 
           _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
          hbf |   .9601089   .0123754    -3.16   0.002     .9361573    .9846732 
              | 
      hb_type | 
          AS  |   1.52e-14   1.96e-07    -0.00   1.000            0           . 
          AC  |   1.633136   .5824928     1.38   0.169     .8117515    3.285652 
          CC  |   .2717637   .2865681    -1.24   0.217     .0344049    2.146655 
              | 
      AMA1_AU |   1.267528   .1861146     1.61   0.106     .9505467    1.690215 
      MSP1_AU |   1.365064    .178841     2.38   0.018     1.055929    1.764702 
      MSP2_AU |   .6453629   .2207394    -1.28   0.200     .3301108    1.261677 
      MSP3_AU |   1.287881   .4463949     0.73   0.465     .6528889     2.54046 
    1.ama1_sp |   .6009246   .2547343    -1.20   0.230     .2618136    1.379265 
    1.msp2_sp |   2.691987   1.672628     1.59   0.111     .7965093    9.098189 
              | 
          mob | 
          10  |   .2004842   .1383139    -2.33   0.020     .0518605    .7750385 
          11  |   .6790914   .2550871    -1.03   0.303     .3252306    1.417964 
          12  |   .6473024   .2215481    -1.27   0.204     .3309572    1.266026 
              | 
      itn_use | 
          no  |   1.063971   .4327034     0.15   0.879     .4794654    2.361036 
              | 
         educ | 
primary sc..  |   1.859814   .5307199     2.17   0.030     1.063088    3.253643 
secondary ..  |   1.070595   .6270348     0.12   0.907     .3396931    3.374146 
              | 
     1.season |   9.175112    6.64336     3.06   0.002     2.219666    37.92582 
           ei |   1.094991   .0282963     3.51   0.000     1.040912    1.151879 
------------------------------------------------------------------------------- 
 
. est store model1 
 
. est table model0 model1,b(%5.3f) p(%4.3f) stats(N ll aic bic) 
 
---------------------------------- 
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    Variable | model0    model1    
-------------+-------------------- 
         hbf |  -0.041    -0.041   
             |   0.002     0.002   
             | 
     hb_type | 
         AS  | -42.867   -31.817   
             |       .     1.000   
         AC  |   0.484     0.491   
             |   0.175     0.169   
         CC  |  -1.315    -1.303   
             |   0.213     0.217   
             | 
     AMA1_AU |   0.233     0.237   
             |   0.115     0.106   
     MSP1_AU |   0.275     0.311   
             |   0.132     0.018   
     MSP2_AU |  -0.426    -0.438   
             |   0.216     0.200   
     MSP3_AU |   0.249     0.253   
             |   0.474     0.465   
             | 
     ama1_sp | 
          1  |  -0.504    -0.509   
             |   0.236     0.230   
             | 
     msp1_sp | 
          1  |   0.171             
             |   0.774             
             | 
     msp2_sp | 
          1  |   0.946     0.990   
             |   0.140     0.111   
             | 
         mob | 
         10  |  -1.601    -1.607   
             |   0.020     0.020   
         11  |  -0.385    -0.387   
             |   0.306     0.303   
         12  |  -0.437    -0.435   
             |   0.203     0.204   
             | 
     itn_use | 
         no  |   0.070     0.062   
             |   0.863     0.879   
             | 
        educ | 
primary s..  |   0.626     0.620   
             |   0.029     0.030   
secondary..  |   0.073     0.068   
             |   0.901     0.907   
             | 
      season | 
          1  |   2.223     2.216   
             |   0.002     0.002   
             | 
          ei |   0.090     0.091   
             |   0.000     0.000   
-------------+-------------------- 
           N |    8264      8264   
          ll | -261.469   -261.511   
         aic | 558.939   559.021   
         bic | 685.293   685.375   
---------------------------------- 
                       legend: b/p 
 
. testparm i.mob 
 
 ( 1)  10.mob = 0 
 ( 2)  11.mob = 0 
 ( 3)  12.mob = 0 
 
           chi2(  3) =    5.72 
         Prob > chi2 =    0.1262 
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. testparm i.educ 
 
 ( 1)  1.educ = 0 
 ( 2)  2.educ = 0 
 
           chi2(  2) =    4.85 
         Prob > chi2 =    0.0886 
 
.  
. *drop ama1_sp 
. stcox hbf i.hb_type AMA1_AU MSP1_AU MSP2_AU MSP3_AU i.msp2_sp /// 
>                  i.mob i.itn_use i.educ i.season ei 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -298.44974 
Iteration 1:   log likelihood = -265.98151 
Iteration 2:   log likelihood = -262.35205 
Iteration 3:   log likelihood = -262.25917 
Iteration 4:   log likelihood = -262.24408 
Iteration 5:   log likelihood = -262.23855 
Iteration 6:   log likelihood = -262.23652 
Iteration 7:   log likelihood = -262.23577 
Iteration 8:   log likelihood =  -262.2355 
Iteration 9:   log likelihood =  -262.2354 
Iteration 10:  log likelihood = -262.23536 
Iteration 11:  log likelihood = -262.23535 
Iteration 12:  log likelihood = -262.23534 
Iteration 13:  log likelihood = -262.23534 
Iteration 14:  log likelihood = -262.23534 
Iteration 15:  log likelihood = -262.23534 
Iteration 16:  log likelihood = -262.23534 
Iteration 17:  log likelihood = -262.23534 
Iteration 18:  log likelihood = -262.23534 
Iteration 19:  log likelihood = -262.23534 
Iteration 20:  log likelihood = -262.23534 
Iteration 21:  log likelihood = -262.23534 
Iteration 22:  log likelihood = -262.23534 
Iteration 23:  log likelihood = -262.23534 
Iteration 24:  log likelihood = -262.23534 
Iteration 25:  log likelihood = -262.23534 
Iteration 26:  log likelihood = -262.23534 
Iteration 27:  log likelihood = -262.23534 
Iteration 28:  log likelihood = -262.23534 
Iteration 29:  log likelihood = -262.23534 
Iteration 30:  log likelihood = -262.23534 
Iteration 31:  log likelihood = -262.23534 
Iteration 32:  log likelihood = -262.23534 
Iteration 33:  log likelihood = -262.23534 
Iteration 34:  log likelihood = -262.23534 
Iteration 35:  log likelihood = -262.23534 
Iteration 36:  log likelihood = -262.23534 
Iteration 37:  log likelihood = -262.23534 
Iteration 38:  log likelihood = -262.23534 
Iteration 39:  log likelihood = -262.23534 
Iteration 40:  log likelihood = -262.23534 
Iteration 41:  log likelihood = -262.23534 
Iteration 42:  log likelihood = -262.23534 
Iteration 43:  log likelihood = -262.23534 
Iteration 44:  log likelihood = -262.23534 
Refining estimates: 
Iteration 0:   log likelihood = -262.23534 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          123                     Number of obs   =      8264 
No. of failures =           68 
Time at risk    =       1874.5 
                                                   LR chi2(16)     =     72.43 
Log likelihood  =   -262.23534                     Prob > chi2     =    0.0000 
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------------------------------------------------------------------------------- 
           _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
          hbf |   .9602003   .0124723    -3.13   0.002     .9360636    .9849593 
              | 
      hb_type | 
          AS  |   1.03e-19          .        .       .            .           . 
          AC  |   1.667372   .5950362     1.43   0.152     .8284451    3.355841 
          CC  |   .2949369   .3094506    -1.16   0.245      .037726     2.30578 
              | 
      AMA1_AU |   1.127067     .12368     1.09   0.276      .908955    1.397518 
      MSP1_AU |   1.364107   .1789437     2.37   0.018     1.054843    1.764043 
      MSP2_AU |   .6389871   .2125111    -1.35   0.178     .3329689    1.226254 
      MSP3_AU |   1.387617   .4736641     0.96   0.337     .7107408    2.709118 
    1.msp2_sp |   2.555521   1.558997     1.54   0.124     .7730426    8.448028 
              | 
          mob | 
          10  |   .2080973   .1430321    -2.28   0.022     .0541013    .8004338 
          11  |   .6814446    .256321    -1.02   0.308     .3260293     1.42431 
          12  |   .6475021   .2231985    -1.26   0.207     .3294777    1.272496 
              | 
      itn_use | 
          no  |   1.058391    .433304     0.14   0.890     .4744221    2.361169 
              | 
         educ | 
primary sc..  |   1.827461   .5159321     2.14   0.033     1.050837    3.178051 
secondary ..  |   1.043523   .6076163     0.07   0.942     .3333259    3.266891 
              | 
     1.season |   9.250968   6.645039     3.10   0.002     2.263408    37.81042 
           ei |   1.097981   .0284054     3.61   0.000     1.043695     1.15509 
------------------------------------------------------------------------------- 
 
. est store model2 
 
. est table model0 model1 model2,b(%5.3f) p(%4.3f) stats(N ll aic bic) 
 
-------------------------------------------- 
    Variable | model0    model1    model2    
-------------+------------------------------ 
         hbf |  -0.041    -0.041    -0.041   
             |   0.002     0.002     0.002   
             | 
     hb_type | 
         AS  | -42.867   -31.817   -43.719   
             |       .     1.000         .   
         AC  |   0.484     0.491     0.511   
             |   0.175     0.169     0.152   
         CC  |  -1.315    -1.303    -1.221   
             |   0.213     0.217     0.245   
             | 
     AMA1_AU |   0.233     0.237     0.120   
             |   0.115     0.106     0.276   
     MSP1_AU |   0.275     0.311     0.310   
             |   0.132     0.018     0.018   
     MSP2_AU |  -0.426    -0.438    -0.448   
             |   0.216     0.200     0.178   
     MSP3_AU |   0.249     0.253     0.328   
             |   0.474     0.465     0.337   
             | 
     ama1_sp | 
          1  |  -0.504    -0.509             
             |   0.236     0.230             
             | 
     msp1_sp | 
          1  |   0.171                       
             |   0.774                       
             | 
     msp2_sp | 
          1  |   0.946     0.990     0.938   
             |   0.140     0.111     0.124   
             | 
         mob | 
         10  |  -1.601    -1.607    -1.570   
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             |   0.020     0.020     0.022   
         11  |  -0.385    -0.387    -0.384   
             |   0.306     0.303     0.308   
         12  |  -0.437    -0.435    -0.435   
             |   0.203     0.204     0.207   
             | 
     itn_use | 
         no  |   0.070     0.062     0.057   
             |   0.863     0.879     0.890   
             | 
        educ | 
primary s..  |   0.626     0.620     0.603   
             |   0.029     0.030     0.033   
secondary..  |   0.073     0.068     0.043   
             |   0.901     0.907     0.942   
             | 
      season | 
          1  |   2.223     2.216     2.225   
             |   0.002     0.002     0.002   
             | 
          ei |   0.090     0.091     0.093   
             |   0.000     0.000     0.000   
-------------+------------------------------ 
           N |    8264      8264      8264   
          ll | -261.469   -261.511   -262.235   
         aic | 558.939   559.021   556.471   
         bic | 685.293   685.375   668.785   
-------------------------------------------- 
                                 legend: b/p 
 
. testparm i.mob 
 
 ( 1)  10.mob = 0 
 ( 2)  11.mob = 0 
 ( 3)  12.mob = 0 
 
           chi2(  3) =    5.50 
         Prob > chi2 =    0.1385 
 
. testparm i.educ 
 
 ( 1)  1.educ = 0 
 ( 2)  2.educ = 0 
 
           chi2(  2) =    4.71 
         Prob > chi2 =    0.0948 
 
.  
. *drop msp2_sp 
. stcox AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf i.hb_type  /// 
>                  i.itn_use i.mob i.educ i.season ei 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -298.44974 
Iteration 1:   log likelihood = -266.55962 
Iteration 2:   log likelihood = -263.52072 
Iteration 3:   log likelihood = -263.42878 
Iteration 4:   log likelihood = -263.41319 
Iteration 5:   log likelihood = -263.40749 
Iteration 6:   log likelihood = -263.40539 
Iteration 7:   log likelihood = -263.40462 
Iteration 8:   log likelihood = -263.40434 
Iteration 9:   log likelihood = -263.40423 
Iteration 10:  log likelihood = -263.40419 
Iteration 11:  log likelihood = -263.40418 
Iteration 12:  log likelihood = -263.40417 
Iteration 13:  log likelihood = -263.40417 
Iteration 14:  log likelihood = -263.40417 
Iteration 15:  log likelihood = -263.40417 
Iteration 16:  log likelihood = -263.40417 
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Iteration 17:  log likelihood = -263.40417 
Iteration 18:  log likelihood = -263.40417 
Iteration 19:  log likelihood = -263.40417 
Iteration 20:  log likelihood = -263.40417 
Iteration 21:  log likelihood = -263.40417 
Iteration 22:  log likelihood = -263.40417 
Iteration 23:  log likelihood = -263.40417 
Iteration 24:  log likelihood = -263.40417 
Iteration 25:  log likelihood = -263.40417 
Iteration 26:  log likelihood = -263.40417 
Iteration 27:  log likelihood = -263.40417 
Iteration 28:  log likelihood = -263.40417 
Iteration 29:  log likelihood = -263.40417 
Iteration 30:  log likelihood = -263.40417 
Iteration 31:  log likelihood = -263.40417 
Iteration 32:  log likelihood = -263.40417 
Iteration 33:  log likelihood = -263.40417 
Iteration 34:  log likelihood = -263.40417 
Iteration 35:  log likelihood = -263.40417 
Iteration 36:  log likelihood = -263.40417 
Iteration 37:  log likelihood = -263.40417 
Iteration 38:  log likelihood = -263.40417 
Iteration 39:  log likelihood = -263.40417 
Iteration 40:  log likelihood = -263.40417 
Iteration 41:  log likelihood = -263.40417 
Iteration 42:  log likelihood = -263.40417 
Iteration 43:  log likelihood = -263.40417 
Iteration 44:  log likelihood = -263.40417 
Refining estimates: 
Iteration 0:   log likelihood = -263.40417 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          123                     Number of obs   =      8264 
No. of failures =           68 
Time at risk    =       1874.5 
                                                   LR chi2(15)     =     70.09 
Log likelihood  =   -263.40417                     Prob > chi2     =    0.0000 
 
------------------------------------------------------------------------------- 
           _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
      AMA1_AU |   1.137384      .1234     1.19   0.235     .9195097    1.406883 
      MSP1_AU |   1.393096   .1789241     2.58   0.010     1.083068    1.791869 
      MSP2_AU |   .9140762   .1664022    -0.49   0.622     .6397733    1.305986 
      MSP3_AU |   1.201256   .3939675     0.56   0.576      .631645    2.284537 
          hbf |   .9602566   .0123626    -3.15   0.002     .9363295    .9847951 
              | 
      hb_type | 
          AS  |   1.05e-19          .        .       .            .           . 
          AC  |   1.598977   .5736798     1.31   0.191     .7914962    3.230247 
          CC  |   .3081119   .3222807    -1.13   0.260      .039661     2.39361 
              | 
      itn_use | 
          no  |    1.10239   .4515609     0.24   0.812     .4939312    2.460393 
              | 
          mob | 
          10  |   .2072943   .1420115    -2.30   0.022     .0541319    .7938191 
          11  |   .7084804   .2649145    -0.92   0.357     .3404451    1.474377 
          12  |   .6451689   .2224681    -1.27   0.204     .3282168    1.268195 
              | 
         educ | 
primary sc..  |   1.778631   .4979711     2.06   0.040     1.027475    3.078934 
secondary ..  |   1.033114   .6015039     0.06   0.955     .3300339    3.233987 
              | 
     1.season |   9.215965   6.708862     3.05   0.002     2.212582    38.38683 
           ei |   1.098306   .0284761     3.62   0.000     1.043888     1.15556 
------------------------------------------------------------------------------- 
 
. est store model3 
 
. est table model0 model1 model2 model3,b(%5.3f) p(%4.3f) stats(N ll aic bic) 
 
------------------------------------------------------ 
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    Variable | model0    model1    model2    model3    
-------------+---------------------------------------- 
         hbf |  -0.041    -0.041    -0.041    -0.041   
             |   0.002     0.002     0.002     0.002   
             | 
     hb_type | 
         AS  | -42.867   -31.817   -43.719   -43.698   
             |       .     1.000         .         .   
         AC  |   0.484     0.491     0.511     0.469   
             |   0.175     0.169     0.152     0.191   
         CC  |  -1.315    -1.303    -1.221    -1.177   
             |   0.213     0.217     0.245     0.260   
             | 
     AMA1_AU |   0.233     0.237     0.120     0.129   
             |   0.115     0.106     0.276     0.235   
     MSP1_AU |   0.275     0.311     0.310     0.332   
             |   0.132     0.018     0.018     0.010   
     MSP2_AU |  -0.426    -0.438    -0.448    -0.090   
             |   0.216     0.200     0.178     0.622   
     MSP3_AU |   0.249     0.253     0.328     0.183   
             |   0.474     0.465     0.337     0.576   
             | 
     ama1_sp | 
          1  |  -0.504    -0.509                       
             |   0.236     0.230                       
             | 
     msp1_sp | 
          1  |   0.171                                 
             |   0.774                                 
             | 
     msp2_sp | 
          1  |   0.946     0.990     0.938             
             |   0.140     0.111     0.124             
             | 
         mob | 
         10  |  -1.601    -1.607    -1.570    -1.574   
             |   0.020     0.020     0.022     0.022   
         11  |  -0.385    -0.387    -0.384    -0.345   
             |   0.306     0.303     0.308     0.357   
         12  |  -0.437    -0.435    -0.435    -0.438   
             |   0.203     0.204     0.207     0.204   
             | 
     itn_use | 
         no  |   0.070     0.062     0.057     0.097   
             |   0.863     0.879     0.890     0.812   
             | 
        educ | 
primary s..  |   0.626     0.620     0.603     0.576   
             |   0.029     0.030     0.033     0.040   
secondary..  |   0.073     0.068     0.043     0.033   
             |   0.901     0.907     0.942     0.955   
             | 
      season | 
          1  |   2.223     2.216     2.225     2.221   
             |   0.002     0.002     0.002     0.002   
             | 
          ei |   0.090     0.091     0.093     0.094   
             |   0.000     0.000     0.000     0.000   
-------------+---------------------------------------- 
           N |    8264      8264      8264      8264   
          ll | -261.469   -261.511   -262.235   -263.404   
         aic | 558.939   559.021   556.471   556.808   
         bic | 685.293   685.375   668.785   662.103   
------------------------------------------------------ 
                                           legend: b/p 
 
. testparm i.mob 
 
 ( 1)  10.mob = 0 
 ( 2)  11.mob = 0 
 ( 3)  12.mob = 0 
 
           chi2(  3) =    5.55 
         Prob > chi2 =    0.1354 
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. testparm i.educ 
 
 ( 1)  1.educ = 0 
 ( 2)  2.educ = 0 
 
           chi2(  2) =    4.38 
         Prob > chi2 =    0.1117 
 
.  
. *drop educ 
. stcox AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf i.hb_type  /// 
>                  i.itn_use i.mob i.season ei 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -298.44974 
Iteration 1:   log likelihood = -268.64842 
Iteration 2:   log likelihood = -265.62348 
Iteration 3:   log likelihood = -265.53694 
Iteration 4:   log likelihood = -265.52139 
Iteration 5:   log likelihood = -265.51569 
Iteration 6:   log likelihood = -265.51359 
Iteration 7:   log likelihood = -265.51282 
Iteration 8:   log likelihood = -265.51253 
Iteration 9:   log likelihood = -265.51243 
Iteration 10:  log likelihood = -265.51239 
Iteration 11:  log likelihood = -265.51238 
Iteration 12:  log likelihood = -265.51237 
Iteration 13:  log likelihood = -265.51237 
Iteration 14:  log likelihood = -265.51237 
Iteration 15:  log likelihood = -265.51237 
Iteration 16:  log likelihood = -265.51237 
Iteration 17:  log likelihood = -265.51237 
Iteration 18:  log likelihood = -265.51237 
Iteration 19:  log likelihood = -265.51237 
Iteration 20:  log likelihood = -265.51237 
Iteration 21:  log likelihood = -265.51237 
Iteration 22:  log likelihood = -265.51237 
Iteration 23:  log likelihood = -265.51237 
Iteration 24:  log likelihood = -265.51237 
Iteration 25:  log likelihood = -265.51237 
Iteration 26:  log likelihood = -265.51237 
Iteration 27:  log likelihood = -265.51237 
Iteration 28:  log likelihood = -265.51237 
Iteration 29:  log likelihood = -265.51237 
Iteration 30:  log likelihood = -265.51237 
Iteration 31:  log likelihood = -265.51237 
Iteration 32:  log likelihood = -265.51237 
Iteration 33:  log likelihood = -265.51237 
Iteration 34:  log likelihood = -265.51237 
Iteration 35:  log likelihood = -265.51237 
Iteration 36:  log likelihood = -265.51237 
Iteration 37:  log likelihood = -265.51237 
Iteration 38:  log likelihood = -265.51237 
Iteration 39:  log likelihood = -265.51237 
Iteration 40:  log likelihood = -265.51237 
Iteration 41:  log likelihood = -265.51237 
Iteration 42:  log likelihood = -265.51237 
Iteration 43:  log likelihood = -265.51237 
Iteration 44:  log likelihood = -265.51237 
Refining estimates: 
Iteration 0:   log likelihood = -265.51237 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          123                     Number of obs   =      8264 
No. of failures =           68 
Time at risk    =       1874.5 
                                                   LR chi2(13)     =     65.87 
Log likelihood  =   -265.51237                     Prob > chi2     =    0.0000 
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------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     AMA1_AU |   1.144443   .1248271     1.24   0.216     .9241689    1.417218 
     MSP1_AU |   1.401727     .17976     2.63   0.008     1.090194    1.802283 
     MSP2_AU |   .8926263   .1607007    -0.63   0.528     .6272299    1.270318 
     MSP3_AU |   1.198263   .3901044     0.56   0.578     .6330475    2.268129 
         hbf |   .9661007   .0116542    -2.86   0.004     .9435268    .9892147 
             | 
     hb_type | 
         AS  |   9.12e-20          .        .       .            .           . 
         AC  |   1.753293   .6204923     1.59   0.113     .8762201    3.508291 
         CC  |   .2844071   .2962591    -1.21   0.227     .0369205    2.190855 
             | 
     itn_use | 
         no  |   1.046871   .4330595     0.11   0.912     .4653465    2.355104 
             | 
         mob | 
         10  |   .2713248   .1814794    -1.95   0.051     .0731394    1.006532 
         11  |   .7134122   .2696853    -0.89   0.372     .3400697    1.496626 
         12  |   .7031505   .2447015    -1.01   0.312     .3554872    1.390825 
             | 
    1.season |   9.391718   6.695874     3.14   0.002     2.322077    37.98513 
          ei |   1.101219   .0265336     4.00   0.000     1.050423    1.154472 
------------------------------------------------------------------------------ 
 
. est store model4 
 
. est table model0 model1 model2 model3 model4,b(%5.3f) p(%4.3f) stats(N ll aic  
> bic) 
 
---------------------------------------------------------------- 
    Variable | model0    model1    model2    model3    model4    
-------------+-------------------------------------------------- 
         hbf |  -0.041    -0.041    -0.041    -0.041    -0.034   
             |   0.002     0.002     0.002     0.002     0.004   
             | 
     hb_type | 
         AS  | -42.867   -31.817   -43.719   -43.698   -43.841   
             |       .     1.000         .         .         .   
         AC  |   0.484     0.491     0.511     0.469     0.561   
             |   0.175     0.169     0.152     0.191     0.113   
         CC  |  -1.315    -1.303    -1.221    -1.177    -1.257   
             |   0.213     0.217     0.245     0.260     0.227   
             | 
     AMA1_AU |   0.233     0.237     0.120     0.129     0.135   
             |   0.115     0.106     0.276     0.235     0.216   
     MSP1_AU |   0.275     0.311     0.310     0.332     0.338   
             |   0.132     0.018     0.018     0.010     0.008   
     MSP2_AU |  -0.426    -0.438    -0.448    -0.090    -0.114   
             |   0.216     0.200     0.178     0.622     0.528   
     MSP3_AU |   0.249     0.253     0.328     0.183     0.181   
             |   0.474     0.465     0.337     0.576     0.578   
             | 
     ama1_sp | 
          1  |  -0.504    -0.509                                 
             |   0.236     0.230                                 
             | 
     msp1_sp | 
          1  |   0.171                                           
             |   0.774                                           
             | 
     msp2_sp | 
          1  |   0.946     0.990     0.938                       
             |   0.140     0.111     0.124                       
             | 
         mob | 
         10  |  -1.601    -1.607    -1.570    -1.574    -1.304   
             |   0.020     0.020     0.022     0.022     0.051   
         11  |  -0.385    -0.387    -0.384    -0.345    -0.338   
             |   0.306     0.303     0.308     0.357     0.372   
         12  |  -0.437    -0.435    -0.435    -0.438    -0.352   
             |   0.203     0.204     0.207     0.204     0.312   
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             | 
     itn_use | 
         no  |   0.070     0.062     0.057     0.097     0.046   
             |   0.863     0.879     0.890     0.812     0.912   
             | 
        educ | 
          1  |   0.626     0.620     0.603     0.576             
             |   0.029     0.030     0.033     0.040             
          2  |   0.073     0.068     0.043     0.033             
             |   0.901     0.907     0.942     0.955             
             | 
      season | 
          1  |   2.223     2.216     2.225     2.221     2.240   
             |   0.002     0.002     0.002     0.002     0.002   
             | 
          ei |   0.090     0.091     0.093     0.094     0.096   
             |   0.000     0.000     0.000     0.000     0.000   
-------------+-------------------------------------------------- 
           N |    8264      8264      8264      8264      8264   
          ll | -261.469   -261.511   -262.235   -263.404   -265.512   
         aic | 558.939   559.021   556.471   556.808   557.025   
         bic | 685.293   685.375   668.785   662.103   648.280   
---------------------------------------------------------------- 
                                                     legend: b/p 
 
. testparm i.mob 
 
 ( 1)  10.mob = 0 
 ( 2)  11.mob = 0 
 ( 3)  12.mob = 0 
 
           chi2(  3) =    3.93 
         Prob > chi2 =    0.2693 
 
. testparm i.hb_type 
 
 ( 1)  2.hb_type = 0 
 ( 2)  3.hb_type = 0 
 ( 3)  4.hb_type = 0 
       Constraint 1 dropped 
 
           chi2(  2) =    4.23 
         Prob > chi2 =    0.1205 
 
.  
. stcox AMA1_AU MSP1_AU MSP2_AU MSP3_AU hbf i.hb_type  /// 
>                  i.itn_use i.mob i.season##c.ei 
 
         failure _d:  malar2 
   analysis time _t:  (datevisit-origin)/28 
             origin:  time datscren 
                 id:  code 
 
Iteration 0:   log likelihood = -298.44974 
Iteration 1:   log likelihood = -268.44624 
Iteration 2:   log likelihood = -265.50167 
Iteration 3:   log likelihood = -265.41305 
Iteration 4:   log likelihood = -265.39794 
Iteration 5:   log likelihood = -265.39242 
Iteration 6:   log likelihood = -265.39039 
Iteration 7:   log likelihood = -265.38964 
Iteration 8:   log likelihood = -265.38936 
Iteration 9:   log likelihood = -265.38926 
Iteration 10:  log likelihood = -265.38922 
Iteration 11:  log likelihood = -265.38921 
Iteration 12:  log likelihood = -265.38921 
Iteration 13:  log likelihood =  -265.3892 
Iteration 14:  log likelihood =  -265.3892 
Iteration 15:  log likelihood =  -265.3892 
Iteration 16:  log likelihood =  -265.3892 
Iteration 17:  log likelihood =  -265.3892 
Iteration 18:  log likelihood =  -265.3892 
Iteration 19:  log likelihood =  -265.3892 
Iteration 20:  log likelihood =  -265.3892 
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Iteration 21:  log likelihood =  -265.3892 
Iteration 22:  log likelihood =  -265.3892 
Iteration 23:  log likelihood =  -265.3892 
Iteration 24:  log likelihood =  -265.3892 
Iteration 25:  log likelihood =  -265.3892 
Iteration 26:  log likelihood =  -265.3892 
Iteration 27:  log likelihood =  -265.3892 
Iteration 28:  log likelihood =  -265.3892 
Iteration 29:  log likelihood =  -265.3892 
Iteration 30:  log likelihood =  -265.3892 
Iteration 31:  log likelihood =  -265.3892 
Iteration 32:  log likelihood =  -265.3892 
Iteration 33:  log likelihood =  -265.3892 
Iteration 34:  log likelihood =  -265.3892 
Iteration 35:  log likelihood =  -265.3892 
Iteration 36:  log likelihood =  -265.3892 
Iteration 37:  log likelihood =  -265.3892 
Iteration 38:  log likelihood =  -265.3892 
Iteration 39:  log likelihood =  -265.3892 
Iteration 40:  log likelihood =  -265.3892 
Iteration 41:  log likelihood =  -265.3892 
Iteration 42:  log likelihood =  -265.3892 
Iteration 43:  log likelihood =  -265.3892 
Iteration 44:  log likelihood =  -265.3892 
Refining estimates: 
Iteration 0:   log likelihood =  -265.3892 
 
Cox regression -- Breslow method for ties 
 
No. of subjects =          123                     Number of obs   =      8264 
No. of failures =           68 
Time at risk    =       1874.5 
                                                   LR chi2(14)     =     66.12 
Log likelihood  =    -265.3892                     Prob > chi2     =    0.0000 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     AMA1_AU |   1.143541    .124997     1.23   0.220     .9230167    1.416753 
     MSP1_AU |   1.404919    .180271     2.65   0.008     1.092522    1.806644 
     MSP2_AU |   .8905581   .1604702    -0.64   0.520     .6255813    1.267771 
     MSP3_AU |   1.197047   .3896018     0.55   0.581     .6325162    2.265432 
         hbf |   .9660395   .0116639    -2.86   0.004      .943447    .9891729 
             | 
     hb_type | 
         AS  |   8.90e-20          .        .       .            .           . 
         AC  |   1.749607   .6193837     1.58   0.114     .8741867    3.501684 
         CC  |   .2825852    .294437    -1.21   0.225     .0366647    2.177964 
             | 
     itn_use | 
         no  |   1.049644   .4341386     0.12   0.907     .4666383    2.361042 
             | 
         mob | 
         10  |   .2688123   .1798908    -1.96   0.050     .0724136    .9978803 
         11  |    .711714   .2690564    -0.90   0.368      .339248    1.493117 
         12  |   .7019353   .2443532    -1.02   0.309     .3547989    1.388711 
             | 
    1.season |   16.26224   21.73668     2.09   0.037     1.184225    223.3193 
          ei |   1.060589   .0822129     0.76   0.448     .9110983    1.234608 
             | 
 season#c.ei | 
          1  |   1.041738   .0840586     0.51   0.612     .8893534    1.220233 
------------------------------------------------------------------------------ 
 
.                   
. *test of proportional hazards assumption 
. *======================================= 
.  
. estat phtest, detail      
 
      Test of proportional-hazards assumption 
 
      Time:  Time 
      ---------------------------------------------------------------- 
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                  |       rho            chi2       df       Prob>chi2 
      ------------+--------------------------------------------------- 
      AMA1_AU     |      0.05976         0.16        1         0.6903 
      MSP1_AU     |      0.07218         0.38        1         0.5360 
      MSP2_AU     |     -0.05662         0.16        1         0.6912 
      MSP3_AU     |      0.04988         0.19        1         0.6611 
      hbf         |      0.15833         1.76        1         0.1848 
      1b.hb_type  |            .            .        1             . 
      2.hb_type   |            .            .        1             . 
      3.hb_type   |      0.03645         0.10        1         0.7484 
      4.hb_type   |     -0.10178         0.78        1         0.3777 
      1b.itn_use  |            .            .        1             . 
      2.itn_use   |      0.12141         1.24        1         0.2657 
      1b.mob      |            .            .        1             . 
      10.mob      |      0.28979         5.76        1         0.0164 
      11.mob      |      0.07483         0.43        1         0.5110 
      12.mob      |      0.14021         1.47        1         0.2248 
      0b.season   |            .            .        1             . 
      1.season    |     -0.00316         0.00        1         0.9791 
      ei          |     -0.06432         0.25        1         0.6178 
      0b.season#~i|            .            .        1             . 
      1.season#c~i|      0.04279         0.11        1         0.7352 
      ------------+--------------------------------------------------- 
      global test |                     11.05       14         0.6818 
      ---------------------------------------------------------------- 
 
.  
. estat phtest,plot(ei) yline(0) title(Exposure index)  
 
. graph save 1,replace 
(file 1.gph saved) 
 
.  
. estat phtest,plot(hbf) yline(0) title(Foetal Haemoglobin rate)  
 
. graph save 2,replace 
(file 2.gph saved) 
 
.  
. estat phtest,plot(AMA1_AU) yline(0) title(Antibodies to AMA1)  
 
. graph save 3,replace 
(file 3.gph saved) 
 
.  
. estat phtest,plot(MSP1_AU) yline(0) title(Antibodies to MSP1-19)  
 
. graph save 4,replace 
(file 4.gph saved) 
 
.  
. estat phtest,plot(MSP2_AU) yline(0) title(Antibodies to MSP2)  
 
. graph save 5,replace 
(file 5.gph saved) 
 
.  
. estat phtest,plot(MSP3_AU) yline(0) title(Antibodies to MSP3)  
 
. graph save 6,replace 
(file 6.gph saved) 
 
.  
. grc1leg 1.gph 2.gph 3.gph 4.gph 5.gph 6.gph, /// 
>       xcom l1(Scaled Schoenfeld) b1(Time (months))  
 
. graph save schoenfeld,replace 
(file schoenfeld.gph saved) 
 
. graph export schoenfeld.tif,width(2049) replace 
(note: file schoenfeld.tif not found) 
(file schoenfeld.tif written in TIFF format) 
 
.  
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. log close 
      name:  <unnamed> 
       log:  C:\Users\dkangoye\Dropbox\projects\phdprogram_ou\work\data\data_bic 
> s\elisa_bics_labwork\davidk_bics2014\chap3_coxreg.log 
  log type:  text 
 closed on:  13 Sep 2016, 19:31:23 
-------------------------------------------------------------------------------- 
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LISTE OF ABBREVIATIONS AND DEFINITIONS 
Abbreviation Definition 
AB Antibodies 
Ad35 Adenovirus type 35 
Ad5 Adenovirus type 5 
AdCh63 Adenovirus type Ch63 
CI Confidence Interval 
CNRFP Centre National de Recherche et de Formation sur le Paludisme 
CNS Central Nervous System 
CRF Case Report Form 
CSPS Centre de Santé et de Promotion Sociale 
CVS Cardio-Vascular System 
DSS Demographic Surveillance System 
EDTA Ethylenediaminetertraacetic acid 
ELISA Enzyme-Linked Immunosorbant Assay 
ENT Eye-Nose-Throat 
EPI Expanded Program of Immunization 
GCP Good Clinical Practices 
GIS Geographic Information System 
GLP Good Laboratory Practices 
Hb Haemoglobin 
HbF Fœtal Haemoglobin 
HIV Human Immuno-deficiency Virus 
ID Identity 
IgG immunoglobulin G 
IgM immunoglobulin M 
IPT/SP Intermittent Preventive Treatment / Sulfadoxine-Pyrimethamine 
KEMRI Kenya Medical Research Institute 
MSS Musculo-Squeletal System 
MVVC Malaria Vectored Vaccine Consortium 
P. falciparum Plasmodium falciparum 
P. malariae Plasmodium malariae 
P. ovlae Plasmodium ovale 
PC Project Coordinator 
PNS Peripheral Nervous System 
PSC Project Scientific Coordinator 
RDT Rapid Diagnostic Test (for Malaria) 
T Temperature 
UCAD Université Cheikh Anta Diop 
WBC Wite Blood Cells 
β-HCG Beta-Human Chorionic Gonadotrophin 
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SYNOPSIS 
Study Title Assessing malaria morbidity during the first two years of life and age-
specific sero-prevalence of adenovirus type Ad5, Ad35 and AdCh63, 
potential malaria vectored vaccine candidates in two settings of seasonal 
malaria transmission. 
Objectives Primary objective 
To assess the incidence of clinical malaria in children from birth to two 
years of age 
To determine the age-specific seroprevalence of adenovirus types Ad5, 
Ad35 and AdCh63 
Secondary objectives 
To measure the antibody responses (IgG, IgM and IgG1 to 4) to malaria 
specific antigens in infants from birth to two years over a period of two 
years 
To measure the time to the first malaria infection from birth to two years 
of age 
To measure the time to the first  clinical malaria episode from birth to 
two years of age 
To establish a relationship between antibody level and time to the first 
malaria infection 
To establish a relationship between antibody level and time to first 
clinical malaria episode 
To assess the impact of maternal antibodies (and haemoglobin F) on 
morbidity in the first two years of life. 
To detect levels of antibodies which protect against Plasmodium 
falciparum infection 
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Tertiary objectives 
To assess the prevalence of plasmodial infection in study volunteers 
from 6 months to 45 years 
To assess P. falciparum parasites load (asexual and sexual forms) in 
study volunteers from 6 months to 45 years.  
Countries involved Burkina Faso, Senegal 
Study Sites  1 site in Burkina, 1 site in Senegal 
Study Design Assessment of malaria clinical incidence in infants: cohort study with 
and active longitudinal survey made of scheduled home visits, 
systematic monthly blood smear collection until a positive smear is 
obtained, scheduled blood sampling for immunological assessments 
once a month for the first six months and every 3 months for the 
remaining of the study duration, and a passive follow-up. 
Assessment of age-specific sero-prevalence of adenovirus type Ad5, 
Ad35, AdCh63: two cross-sectional survey, the one during the low 
transmission season and the other during the high transmission season. 
Volunteers included in the first survey may be included in the second 
survey. The volunteers will be divided in 3 age-groups [6months-3years 
[, [3years-10years [and above 10years. 
Study Population Assessment of malaria clinical incidence in infants: infants in good 
health, whose parents are residents of the study area, and aged 4 to 6 
weeks. 
 Assessment of age-specific sero-prevalence of adenovirus type Ad5, 
Ad35, AdCh63: volunteers in good health (male or female), aged 6 
months to 45 years and residents of the selected villages of the study 
area. 
Sample size Assessment of malaria clinical incidence in infants: 140 infants. 
Assessment of age-specific sero-prevalence of adenovirus type Ad5, 
Ad35, AdCh63: 200 volunteers per age-group. 
Inclusion Criteria 1. Assessment of malaria clinical incidence in infants:  
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Age between 4 to 6 weeks 
Written informed consent obtained from the parents/guardian prior to 
any study enrolment 
Available and willing to participate in the longitudinal follow up 
2. Assessment of age-specific sero-prevalence of adenovirus type Ad5, 
Ad35, AdCh63:  
Males or females aged six months to 45 years. 
Resident of the study areas in Burkina and Senegal at the start of the 
study, and intend to remain a resident for the duration of the study. 
Willingness to participate in the study as evidenced by the completed 
informed consent document. 
Exclusion criteria 1. Assessment of malaria clinical incidence in infants:  
Documented history clinical malaria  
Malaria infection or documented history of malaria infection  
Prematurity 
Anaemia (Hb  8 g/dL) 
Any confirmed or suspected condition of immunosuppressive diseases 
including HIV (no screening test will be done for this purpose) by the 
physician 
Any congenital abnormality (cardio-vascular, hepatic and renal) 
suspected by the physician to cause any supplementary risk to the 
infants 
Any other circumstances and condition suspected by the physician to be 
a risk for the infant health 
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2. Assessment of age-specific sero-prevalence of adenovirus type Ad5, 
Ad35, AdCh63 :  
Clinical evidence or suspected acute or chronic disease (respiratory, 
cardiovascular, gastrointestinal, hepatic, genitourinary or lymphatic 
system), or any other findings that in the opinion of the examining 
physician may impact the safety of individual at the assessment of the 
laboratory parameters that are under study. 
Acute allergy episode. 
History of splenectomy. 
All individuals on prescription drugs will be excluded. 
History of the administration of any blood products within the three 
months preceding the study. 
Pregnancy (either assessed clinically or by means of a positive urine β-
hCG test) or breast-feeding. 
Women with history of gynaecological disease (fibromyoma). 
Recent (within 4 weeks) hospitalisation. 
Recent (within 2 weeks) of blood donation. 
Participation duration Assessment of malaria clinical incidence in infants:  2 ans. 
Assessment of age-specific sero-prevalence of adenovirus type Ad5, 
Ad35, AdCh63: the day of the survey. 
Primary Endpoint Incidence of clinical malaria due to P.falciparum 
Seroprevalence of adenovirus type Ad5, Ad35 and AdCh63. 
Secondary Endpoints First malaria infection in infants 
First malaria episode in infants 
Clearance of maternal antibodies in infants 
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Assessment of neutralizing antibodies (Adenovirus) 
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1. BACKGROUND 
Malaria remains one of the major health problems in sub-Saharan Africa and Plasmodium falciparum 
causes much more severe and progressive illness than any of the other species of malaria parasites.  
Children living in endemic areas bear the major burden of the disease as well as the resultant 
mortality.  A relative insusceptibility to malaria of young infants has been observed (Garnham, 
P.C.C.; 1949), and the most important factor in modifying the clinical symptoms has been ascribed 
to the passive transfer of maternal anti-malarial IgG antibodies (Bruce-Chwatt, L. J.; 1952; Sehgal, 
V.M., 1989).  Previous studies have provided evidence for associations, at a population level, 
between decreasing levels of maternally derived malaria-specific IgG and increasing risk of clinical 
malaria (Hogh, Marbiah et al. 1995, Branch, Udhayakumar et al. 1998). These maternal antibodies 
against pathogen-specific antigens disappear during the first months of life while the neonate’s own 
immune system develops.  The interval between the loss of protection once maternal antibodies have 
disappeared and possible protection by vaccination should be as narrow as possible for all vaccine-
preventable diseases, because of the risk of early infection.  Vaccination at too young age could waste 
too much vaccine on children with maternally derived protection that could potentially lower vaccine 
efficacy.  Studies using mice have shown that the progeny of immune mothers respond poorly to 
active immunization, and it was concluded that maternal antibodies interfered with both priming and 
helper T-cell function (Harte PG et al., 1982), and neonatal T-cell tolerance was induced by peptides 
causing clonal inactivation in mice (Gammon G et al., 1986).  In other studies, active immunization 
with radiation-attenuated of human and monkey malaria parasite have been shown to induce sterile 
immunity against live sporozoite challenge (Nussenzweig et al Ad. Imm. 1989).However contrasting 
observations have been made in rats i.e. enhanced responsiveness to vaccination in offspring of P. 
berghei-infected female rats was demonstrated (Desowitz RS et al, 1971).  The immune 
responsiveness to malaria vaccination in infants in areas where malaria is endemic therefore needs 
careful consideration. 
We propose a cohort study involving a longitudinal follow up of infants from birth to two years of 
age to characterize the dynamics of maternal antibodies, asymptomatic infection and clinical 
episodes in infants from 0 to 2 years in hyperendemic areas of Burkina Faso and Senegal during a 
longitudinal follow up of two years.  Data from the study will help us understand the naturally 
acquired immunity to malaria, estimate sample size for the efficacy trial, in an evidence-based choice 
of the appropriate immunization schedule for the malaria vaccine candidate and capacity 
strengthening of these two institution in conducting cohort studies. 
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Adenovirus serotypes vector based vaccines have been proven to be immunogenic and are been used 
in clinical trials.  This approach has some limitations because in malaria endemic countries the 
majority of people have some pre-existing immunity to the serotypes that have been used as vectors 
(Thorner, Vogels et al. 2006).  However levels of antibodies to chimpanzee viruses are very low in 
humans in Africa and elsewhere and we have confirmed this recently for the AdCh63 strain in 
Kenyan children from Kilifi. As future clinical trials may need to use these vectors, we plan also to 
adequately assess Ad5, Ad35 (the vector for a Crucell candidate malaria vaccine) and AdCh63 
serotypes age specific prevalence in our investigational sites. 
2. OBJECTIVES 
2.1. Primary objective 
- To assess the incidence of clinical malaria in children from birth to two years of age 
- To determine the age-specific seroprevalence of adenovirus types Ad5, Ad35 and AdCh63 
2.2. Secondary objectives 
- To measure the antibody responses (IgG, IgM and IgG1 to 4) to malaria specific antigens in 
infants from birth to two years over a period of two years 
- To measure the time to the first malaria infection from birth to two years of age 
- To measure the time to the first clinical malaria episode from birth to two years of age 
- To establish a relationship between antibody level and time to the first malaria infection 
- To establish a relationship between antibody level and time to first clinical malaria episode 
- To assess the impact of maternal antibodies (and haemoglobin F) on morbidity in the first 
two years of life. 
- To detect levels of antibodies which protect against Plasmodium falciparum infection 
2.3. Tertiary objectives 
- To assess the prevalence of plasmodial infection in study volunteers from 6 months to 45 
years 
- To assess P. falciparum parasites load (asexual and sexual forms) in study volunteers from 
6 months to 45 years  
3. METHODOLOGY 
3.1. Study area 
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3.1.1. Burkina Faso 
In Burkina Faso the study will be conducted in the southern part of the country in the Province of 
Comoé located 441 km from Ouagadougou, the capital of Burkina Faso.  The surface area of the 
province is 15871 km2 and the total population is 277 384 inhabitants and 17% represent children 
between 0 and 4 years.  The entire province is covered by the health district of Banfora and has 24 
community clinics named Centre de Santé et de Promotion Sociale (CSPS) and the Banfora district 
hospital is the first level of referral for the community clinics.  These health centers provide basic 
health care services such as immunization of children, antenatal surveillance, delivery services and 
family planning. 
The study area belongs to the Sudan-Guinea zone with more than 900mm of rain a year and cooler 
average temperatures.  The malaria transmission is markedly seasonal; most transmission occurs 
during the rainy season from May to November and low during the dry season from December to 
April.  P. falciparum is the predominant species accounting for more than 95% of infections in 
children under five years of age. 
3.1.2. Senegal 
In Senegal, the survey will be carried out in the health post of Lamarame, located in the health district 
of Ndoffane.  Ndoffane is located 17 km to the south of Kaolack.  The relief is generally flat with 
depressions in this zone.  The climate is Sudano-Sahelian type and daytime temperatures between 
24°C and 40°C;.Average rainfall is about 600 mm per year. There are approximately 200 villages in 
the district of Ndoffane with a total population of nearly 75,000 inhabitants of which about 7% are 
between 0- to 24 months .Malaria is the most important public health problem, accounting for 45% 
of general morbidity. The most recent entomological surveys showed an entomological inoculation 
rate of between 9 and 12 infective bites per night during the period of high transmission. 
3.2. Study population 
This study will involve infants for the assessment of clinical malaria incidence and participants above 
six months for the assessment of age-specific seroprevalence of adenovirus type Ad5, Ad35 and 
AdCh63. 
3.2.1. For the assessment of clinical malaria incidence   
The study will enrol infants from parents living in the study areas in Burkina and Senegal.  Study 
staff will daily visit the maternity ward to identify potential participants.  Appointment will be made 
 304 
 
with parents interested to participate and they will be visited at home for the informed consent 
discussion. Infants from parents who have consented will be included in the study cohort. 
Due to the routine registration in the study areas, numerous background factors will be covered for 
the children living in the study areas, including maternal factors (age, parity, spacing, survival of 
previous children, maternal education); health related factors (breastfeeding, mid-arm circumference, 
vaccination status, reported infections, previous hospitalizations) and cultural and socio economic 
conditions (ethnic group, family structure, family size, housing) (See in appendix A). 
Existing breeding sites will be also reported and their distance to the households. 
Eligibility and exclusion criteria 
Inclusion criteria will be the following: 
- Age between 4 to 6 weeks 
- Written informed consent obtained from the parents/guardian prior to any study enrolment 
- Available and willing to participate in the longitudinal follow up 
The following exclusion criteria will be checked at the time of study entry; if any apply, the subject 
must not be included in the study. 
- Documented history clinical malaria  
- Malaria infection or documented history of malaria infection  
- Prematurity 
- Anemia (Hb  8 g/dL) 
- Any confirmed or suspected condition of immunosuppressive diseases including HIV (no 
screening test will be done for this purpose) by the physician 
- Any congenital abnormality (cardio-vascular, hepatic and renal) suspected by the physician 
to cause any supplementary risk to the infants 
- Any other circumstances and condition suspected by the physician to be a risk for the infant 
health 
3.2.2. For the assessment of the age-specific seroprevalence of adenovirus type Ad5, Ad35 and 
AdCh63  
The study population will be drawn from the population above six months who are permanent 
residents of Banfora health district in Burkina Faso, the health district of Ndoffane in Senegal. People 
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are mostly subsistence farmers growing millet as well as domestic animals (poultry, cattle etc.).  
Houses are typically made of mud walls and grass or corrugated iron roofs. 
Eligibility and exclusion criteria 
Inclusion criteria will be the followings: 
- Males or females aged six months to 45 years. 
- Resident of the study areas in Burkina and Senegal at the start of the study, and intend to 
remain a resident for the duration of the study. 
- Willingness to participate in the study as evidenced by the completed informed consent 
document. 
The following exclusion criteria will be checked at the time of study entry; if any apply, the subject 
must not be included in the study. 
- Clinical evidence or suspected acute or chronic disease (respiratory, cardiovascular, 
gastrointestinal, hepatic, genitourinary or lymphatic system), or any other findings that in the 
opinion of the examining physician may impact the safety of individual at the assessment of 
the laboratory parameters that are under study. 
- Acute allergy episode. 
- History of splenectomy. 
- All individuals on prescription drugs will be excluded. 
- History of the administration of any blood products within the three months preceding the 
study. 
- Pregnancy (either assessed clinically or by means of a positive urine β-hCG test) or breast-
feeding. 
- Women with history of gynecological disease (fibromyoma). 
- Recent (within 4 weeks) hospitalisation. 
- Recent (within 2 weeks) of blood donation. 
3.3. Study design 
3.3.1. Malaria clinical incidence in infants 
For the assessment of the clinical malaria incidence, we will carry out a longitudinal survey (See 
CRF in appendix B). Infants whose mothers consent to participate in the study will be actively 
followed-up throughout their first two years of life. This will involve bi weekly home visits to be 
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executed by a study nurse. During each home visit, the health status of the child will be checked. If 
history of fever within the last 24 hours or documented fever is observed (T37.5°C) blood sample 
will be obtained through finger prick to prepare a blood smear. A malaria rapid diagnostic test will 
be done for febrile infants. The study nurses will be provided with the essential drugs for the 
management of mild disease. Any other serious illness will be referred to the nearest local health 
staff or to the District Hospital to receive adequate treatment and follow-up as clinically appropriate. 
The treatment and transportation costs will be met by the study. Between the two scheduled field-
worker visits, parents of children will be encouraged to report to the nearest community clinic or 
hospital at any time should their child feels sick (See CRF in appendix C)... 
To assess the time to the first malaria infection, a blood smear will be systematically obtained every 
month from all the infants starting from the inclusion day (See appendix D).  This systematic monthly 
blood smear collection will end for a child when a positive smear is obtained during any visit. 
For immunological assessments 500µl of blood sample will be taken during the scheduled home 
visits. The sample collection schedule will be the following: once a month, during the first six (6) 
months of life and every three (3) months for the remaining study duration. 
Any infant who develops malaria during the follow up period will receive appropriate treatment 
according to local standard.  Treatment cost will be supported by the study. 
3.3.2. Age specific seroprevalence of Ad5, Ad35 and AdCh63. 
The volunteers will come from randomly selected villages of the study areas and the assessment of 
age specific seroprevalence will be done twice during the malaria high transmission season and 
during the malaria low transmission season.  Participants from the first survey may be included in 
the second survey.  All individuals in the sampled villages will be grouped into pre-specified age 
groupings and sex.  All persons in a village will qualify to participate if they satisfy the inclusion 
criteria.  As such, all healthy persons in a selected village will be invited to participate in the study. 
During each survey, each study participant will undergo clinical examination if he fulfils the study 
inclusion criteria, 5ml blood will be taken for thick/thin blood film preparation for malaria diagnosis 
purpose and the remaining blood will be centrifuged and the plasma collected will be used for the 
adenovirus serotyping. Malaria symptomatic participant will be treated following national guidelines 
and those presenting others symptoms will be referred to the nearest local health staff or to the 
District Hospital to receive adequate treatment and follow-up as clinically appropriate. CRP is 
appended in appendix E.  
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4. SAMPLE SIZE CONSIDERATION 
4.1. Malaria clinical incidence in infants 
Assuming an incidence of one or more episodes of febrile malaria of 20% during one year of follow 
up, with a sample size of 140 infants including 10% lost of follow up this incidence will be known 
within a 95% confidence interval of 13-27%. 
4.2. Age specific seroprevalence of Ad5, Ad35 and AdCh63. 
Compared to Ad5, Ad35 is reported to be less prevalent in sub-Saharan Africans (Thorner, Vogels 
et al. 2006).  Our sample size will be then calculated using the lowest age specific seroprevalence.  
Assuming age specific Ad35 seroprevalence rates of 1 % in the [six (6) months- three (3) years[, 3% 
in children aged [3years-10 years[ and 10% in individuals above 10 years, then with a sample size 
of 200 volunteers in each age group, the 95% confidence intervals will be 0.1-3.6%, 1.1-6.4% and 
6.2-15.0% respectively. 
5. LABORATORY PROCEDURES 
Capillary blood will be obtained by finger prick and collected in microtubes and on slides.  Thick 
and thin films will be stained with Giemsa stain.  Parasite density will be scored as the number of 
parasites per 200 white blood cells (WBC) and converted to parasites per microliter based on an 
average WBC count of 8000/µl of normal whole blood.  Slides will be classified negative only after 
one hundred fields (Approximately 2000 WBC) have been counted. 
At the central laboratory, the plasma will be separated and stored in EDTA tubes at -20ºC until 
analysis.  The antibody measurement will be done by ELISA.  The level of IgG, IgM and IgG 
subclasses will be determined using a standard curve. 
Ad5, Ad35 and AdCh63 serological assays will be run at Oxford University.  
6. STATISTICAL ANALYSES 
The clinical malaria incidence will be calculated as the number of episodes divided by the number 
of children per time at risk.  The times to the first infection and to the first clinical malaria episode 
will also be determined, and survival plots presented.  The effect of maternal antibody will be 
determined by proportional hazard models.  Time-dependent covariates will be used to account for 
age in months, and the effect of waning antibody titres.  We will also consider multiple events, using 
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variations on the Cox-proportional hazard model to enter individuals more than once (adjusting p 
values and confidence intervals by the Robust Sandwich Estimator), and by Poisson regression where 
events are clustered by individual only. The former method has the advantage of allowing for time-
dependent covariates, which is essential when the effects of waning maternal antibody are being 
considered. 
Age specific seroprevalence rates for Ad5, AdCh63 and Ad35 will be determined as proportions. 
95%CI will be computed using test based methods. 
7. EVALUATION AND QUALITY CONTROL 
Parasitaemia and anaemia at different time points:  Haemoglobin measurements using a Hemocue 
machine, and finger prick sampling for thick smears for parasite density determination, will be done 
at pre-defined time points (once a month, during the first six (6) months of life and every three (3) 
months for the remaining study duration) and at the end of the longitudinal survey (at 24 months of 
age). A slide will be declared parasite negative only after 200 high power fields have been examined.  
A second independent laboratory technician will reread all collected slides.  If parasite densities 
recorded by the two readers differ by more than 30%, a third senior laboratory technician will be 
asked to adjudicate.  Anemia will be defined by haemoglobin level of less than 8 g/dL. 
Clinical episodes: Impact on clinical malaria will be determined through active and passive 
surveillance, used to estimate the proportion of fever cases that have malaria, and by determining the 
prevalence of clinical malaria in cross-sectional surveys at different time points. 
8. DATA MANAGEMENT 
Data collection will done using CRF in hard copy. Collected data will be double entered, checked 
and validated.  In stream data cleaning process will be implemented.  A statistical analysis plan will 
be written before the data base is released to the statistician for analysis.   
9. INFORMED CONSENT 
The protocol, the informed consent form and any subsequent modifications will be reviewed and 
approved by the Institutional committee for bioethics of CNRFP and UCAD local Independent 
Ethical Committee responsible for oversight of the study.  The consent form will describe the purpose 
of the study, the procedures to be followed, and the risks and benefits of participation.  A copy of the 
consent form will be given to the subject representative, and acceptance or refusal of the copy 
provided will be documented in the subject’s record. 
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Informed consent will be obtained via oral presentation in local language, accompanied by a short-
form written consent document (stating the necessary elements and a written summary of what is 
presented orally) in French.  An impartial witness (A relative, friend, or social worker not affiliated 
with the study) to the oral presentation will be required.  The witness must be fluent in French and 
in the local language spoken by the subject.  The subject will be offered copies of the short-form 
document and the summary.  Acceptance or refusal of the copies provided will be documented.  All 
subjects will be asked to answer a standardized set of questions to show that they fully understand 
the purpose and procedures of the study. If the subjects cannot answer the questions correctly the 
pertinent information will be reviewed again and if they fail to answer questions correctly the second 
time, they will not be enrolled. Information sheets for volunteers and informed consent forms are in 
Appendix F and G. 
10. THE STUDY IMPORTANT MILESTONES 
The following milestones will be tracked during the course of the study to inform all the partners 
involved about the study status and the progress made: 
- The first infant enrolled 
- The last infant enrolled 
- The first infant first malaria infection 
- The first infant first malaria episode 
- The first infant last home visit 
- The last infant last home visit 
- The database release 
- The study draft report release 
- The study final report publication 
11. INITIAL CENSUS AT BASELINE AND DEMOGRAPHIC SURVEILLANCE SYSTEM 
Planning and delivering health interventions to specific population group is necessarily based on 
thorough knowledge of the target group.  Human populations are not stable as there are births, deaths, 
out and in migrations.  Therefore in our settings where there is no reliable system for the registration 
of vitals events, the Demographic Surveillance Systems (DSSs) are important to monitor all these 
events in order to provide the whole picture of the population under study at any point in time.  A 
demographic surveillance system will be established in the different field sites where there is no DSS 
(in Burkina Faso and Senegal). 
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11.1. Burkinabe investigational site, Banfora 
The setting up the Banfora DSS in South-Western Burkina Faso which covers the Banfora health 
district is ongoing.  
During the first quarter of the year 2009, the entire Banfora Health District has been mapped by a 
specialist in GIS (See map below).  The key points in each village (compounds community clinics, 
schools, village chief compound etc.) were geographically referenced. 
Due to the resource constraints in May 2009, the general census was carried out in six (6) villages of 
four (4) community clinics catchments areas surrounding the Regional Hospital of Banfora where 
vaccines will be administrated and the laboratory analysis performed.  During this general survey the 
following data on study population have been collected: 
- The compounds were numbered. 
- Demographic status (age, sex and matrimonial status). 
- Composition of the household (household head, links between the head and the others 
members, etc.). 
A total of 1046 children aged 0 to 59 months representing an average 19.5% of the total population, 
have been enumerated in these six (6) villages.  Every quarter, the DSS team will update the database 
by visiting each village and compound in order to record the demographic and vital events (birth, 
death, marriage, in and out migrations etc.).  To prepare for the phase IIb clinical trial of viral 
vectored candidate malaria vaccines we are planning to add 10 more villages as soon as resources 
are made available.  To date this embryonic Banfora DSS is managed by a team composed by five 
(5) field workers in charge of the data collection and two (2) supervisors.  The CNRFP GIS specialist, 
two (2) data manager and 10 Data clerks are also dedicating some time for the DSS data entry and 
management. 
A database prepared on the Access software is planned to be updated quarterly.  If an error is noticed 
at the community level or from the data base, the field workers will check and send the right 
information back to the computer centre (data base).  
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11.2. Senegalese investigational site, Keur Socé 
Keur Socé is in central Senegal, with a Soudano-Sahelian climate, characterized by a yearly average 
of 600 mm rainfall (mainly between July and September).  The rural community of Keur Socé is 
populated by 20,415 inhabitants divided into 71 villages.  The population is very young and under 
15 yrs old group is estimated at 10,738 (52.6%).  As it is at the national level, approximately 20 % 
of this population are children under 5 years. 
The vision of the Department of Parasitology Mycology is to upgrade the monitoring of the 
population through a DSS.  It is also our intention to build suitable centers for carrying out clinical 
trials in the best conditions respecting GCP and GLP guidelines. 
The Malaria Vectored Vaccine Consortium (MVVC) will give the site an opportunity to start this 
population surveillance. 
The first step is the mapping of the site using experienced field technicians.  This shouldn’t exceed 
24 working days.  We will follow this up with the baseline census enumeration using well trained 
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enumerators.  The census is designed for completion within six (6) weeks.  Finally a quarterly 
demographic surveillance will be performed (four (4) rounds per year). 
12. COMPLIANCE WITH NATIONAL AND INTERNATIONAL STANDARDS OR RESEARCH 
No potential ethical issue is anticipated and this study is considered as minimal risk to the 
participants.  All the blood sampling will be performed after appropriate disinfection using sterile 
materials.  For the FACS studies, consent for the sampling will be taken under the umbrella of 
ongoing immunologic studies in Kilifi.  Ethical approval is provided as appendix 8a. 
13. POTENTIAL IMPACT 
Beyond the scientific achievements expected, the project will provide the opportunity for trial staff 
to prepare for future clinical trials. 
In the three sites, the research staff is made up of young scientists, trained as MDs and PharmD’s 
with some staff receiving MSc training.  Some of the staff has participated in previous baseline 
epidemiological studies.  The investigational sites currently lack support staff (field workers, nurses).  
The clinical laboratory at the field station also needs to be set up. 
The project will contribute to strengthening the capacity of the staff in cohort studies.  These 
competencies will be needed when efficacy trials commence as this will require the longitudinal 
follow up of the vaccinated volunteers.  The study will also allow recruiting and training of support 
staff (field workers, nurses) who will be familiarized with the SOPs on home visits.  Basic laboratory 
equipment such as microscopes, Coulter counter, spectrophotometer will be acquired for the field 
laboratories.  Beyond their use in the current proposal, these equipments will be used for the setup 
of laboratory normal values for future clinical trials in the target population. 
Training the staff and equipping the field stations will significantly improve skills and quality of the 
work; direct consequence will be the ability of the teams to obtain more grants from other funding 
agencies; this will help in maintaining the sites when this epidemiological study ends. 
Networking with other research institutions will also increase the ability of the team in resource 
mobilization. 
14. PROJECT MANAGEMENT 
CNRFP 
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Dr Sodiomon Sirima of CNRFP will function as the work package leader for the capacity building 
work package.  As WP leader he will be responsible for formulating the detailed work plan of activity 
and proposing allocation of tasks and resources, identifying and discussing potential difficulties and 
barriers associated with achieving the objectives, highlighting and presenting any difficult issues that 
need the attention of the PC and PSC as well as technical and administrative reporting of the progress 
of the work plan to the PC.  He will also be responsible for coordinating the development of a multi-
site protocol for the conduct of the baseline study. 
Université Cheikh Anta Diop 
Dr Badara Cisse of the University of Dakar will participate in the development of the multi-site 
protocol for this baseline study.  Prior to the conduct of the baseline study, the greatest challenge of 
the Senegalese site will be to build up a reliable DSS.  In this regard, there will be close collaboration 
with an experienced demographer (Dr Momodou Jasseh) based at the site in The Gambia and the 
French Institut de Recherche pour le Développement (IRD).  Discussions on the modalities for this 
collaboration are on-going with Dr Kalifa Bojang and Dr Cheikh Sokhna. 
15. THE INVOLVEMENT OF THE PRIVATE SECTOR 
Many of the collaborators in this proposal have considerable experience in capacity building.  The 
Oxford and Kilifi partners are funded by the Wellcome Trust which has made major investments in 
African capacity building in several countries including Kenya, South Africa and Malawi.  The 
KEMRI-Wellcome programme at Kilifi is well recognized for supporting the development of young 
African scientists and will continue to do so in the key area of malaria vaccine development though 
this proposal.  Kilifi has the most recent experience of phase I and II trials of vectored vaccines for 
malaria in Africa and will play an active role in supporting optimized trial design and 
immunomonitoring.  All northern partners in the proposal have strong records and competencies in 
capacity building and will collaborate in this goal with the southern partners. 
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ANNEXE A 
 
 
 
 
 
 
 
 
1. DEMOGRAPHIE     
 
Numéro de Screening    |__|__|__|__|   
N°DSS du participant (si applicable): |__|__|__|__|__|__|__|__|__|__|                    
Nom de l’enfant ______________________________________________________ 
    Nom     Prénom(s) 
Date de naissance      |__|__|/|__|__|__|/|__|__|__|__| 
                          Jour             Mois               Année      
Sexe |__|     1=Masculin   2=Féminin 
Nom de la mère ______________________________________________________ 
    Nom     Prénom(s) 
Age de la mère |__|__|__| 
Nombre de grossesse |__|__| 
Parité |__|__| 
Nombre d’enfants vivants |__|__| 
Niveau d’éducation de la mère |__|__| 
Village: |__|__|    
N°DSS de la concession: |__|__|__|__|            
Nom du chef de ménage ________________________________________________ 
     Nom     Prénom(s) 
Groupe ethnique |__| 1= Gouin, 2= Turka, 3=Karaboro, 9=Autres (Spécifier ___________) 
 
2. ANTECEDANTS                                       
 
Accouchement à terme : |__| 1=Oui 2=Non, Si non Préciser : ………………….  
Accouchement unique |__| 1=Oui 2=Non, Si non Préciser : …………………. 
Voie d’accouchement : |__| 1=Basse 2=Césarienne 
Réanimation à la naissance : |__| 1=Oui 2=Non 
Infection néonatale : |__| 1=Oui 2=Non 
Statut vaccinal (est à jour selon son âge): |__| 1=Oui 2=Non 
Mode d’allaitement : |__|    1=lait maternel      2= lait artificiel 
L’enfant dort-il sous une moustiquaire depuis sa naissance?        |__|    1=Oui 2=Non     
Le nombre de TPI/SP reçu par la maman durant la grossesse : |__| 
Autres (préciser):……………………………………………………………………………… 
 
3. SIGNES VITAUX 
 
7.4 Appendix 4: study case report forms 
Etude épidémiologique de base MVVC : Morbidité palustre au cours des deux 
premières années de vie et cinétique des anticorps maternels, dans deux zones à 
transmission saisonnière. 
 
FORMULAIRE DE SELECTION 
Date de visite     |__|__| / |__|__|__| / |__|__|__|__| 
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Température axillaire |__|__|.|__|°C   
L’enfant est-il fébrile (Température axillaire > 37.5°C)? |__| 1=Oui 2=Non. 
Poids |__|__|.|__| kg 
Taille |__|__|.|__| cm 
FC : |__|__|__|/mn  
FR : |__|__|/mn 
Périmètre brachial : |__|__|.|__| cm 
 
4. HISTOIRE MEDICALE ET EXAMEN PHYSIQUE 
HISTOIRE MEDICALE  
 (1=Oui 2=Non) 
Traitement antipaludique depuis la naissance |__|  si oui, prière spécifier : 
|________________________________________| 
Histoire de fièvre (corps chaud) dans les 24 heures précédentes |__|   
Vomissement |__| ; si oui, fréquence |__|__|/24h 
Diarrhée |__| ; si oui, fréquence |__|__|/24h  
Constipation |__|  
Toux |__|  
Autres |__| si oui, préciser : …………  
EXAMEN PHYSIQUE 
 
Examen des appareils et systèmes  |__|     1=Normal / 2=Anormal           
 (Si 2, noter les anomalies)  
 
Etat général   |__|       ____________________________ 
Extrémité céphalique                  |__|       ____________________________ 
Appareil respiratoire        |__|       ____________________________ 
Appareil cardio-vasculaire |__|       ____________________________ 
Système nerveux  |__|       ____________________________ 
Appareil digestif  |__|       ____________________________ 
Peau et phanères  |__|       ____________________________ 
Appareil locomoteur              |__|       ____________________________ 
Autres anomalies:               |__|       ____________________________ 
 
Section complétée par: Initiales du clinicien |__|__|__|  Date : |__|__| / |__|__|__| / |__|__|__|__| 
 
5. EXAMENS BIOLOGIQUES DE BASE   
Le taux d’Hb a-t-il été mesuré? |__| 1=Oui 2=Non    
Si Oui, noter le résultat:       Hb: |__|__|.|__| g/dl 
*Un TDR a-t-il été réalisé: |__| 1=Oui,  2=Non,   3=Non disponible 
Si Oui, noter le résultat: |__| 1=Positif,  2=Négatif,  3=Invalide,  4=Non disponible 
*Le TDR sera fait uniquement si le l’enfant est fébrile (Température axillaire > 37.5°C) ou présente 
une histoire de fièvre dans les 24 heures précédentes. Le TDR est toujours associé à une goutte 
épaisse. 
Une goutte épaisse a-t-elle été réalisée |__| 1=Oui 2=Non    
Si oui noter le résultat : 
 P.falciparum P.malariae P.ovale 
Trophozoïtes    
Schizontes    
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Gamètocytes    
 
Un échantillon de sang a-t-il été prélevé pour le dosage des AC maternels?  
|__| 1=Oui 2=Non    
Un échantillon de sang a-t-il été prélevé pour le dosage de l’hémoglobine fœtale ?  
|__| 1=Oui 2=Non ;  
Si oui, résultat :      HbF: |__|__|  % 
Section complétée par: Initiales du technicien de laboratoire |__|__|__|   
Date : |__|__| / |__|__|__| / |__|__|__|__|    
 
6. ELIGIBILITE DU PARTICIPANT 
 
Critères d’inclusion 
Cocher tous les critères d’inclusion remplis par le participant 
 âge entre 4 et 6 semaines 
 consentement éclairé par écrit obtenu des parents/tuteurs avant tout enrôlement     
    dans l’étude 
 disponibilité et désir de participer au suivi longitudinal 
 
Critères d’exclusion 
Cocher tous les critères d’exclusion s’appliquant au participant 
Histoire d’épisode clinique de paludisme documentée  
 Infection paludique ou histoire d’infection paludique documentée  
Prématurité  
Anémie (Hb≤ 8g/dL) 
Toutes formes de maladies immunosuppressives dont le VIH (il n’y aura pas de      
     test de dépistage à cet effet) confirmées ou suspectées par le médecin 
Toute anomalité congénitale (cardio-vasculaire, hépatique et rénale) qui, selon le  
     médecin, pourrait créer un risque supplémentaire pour les enfants 
Toutes autres circonstances et conditions qui, selon le médecin, pourraient  
    constituer un risque pour la santé de l’enfant en bas âge 
Le participant remplit-il tous les critères d’inclusion et aucun critère d’exclusion?  
|__| 1=Oui 2=Non 
Si Non, donner la(les) raison(s): 
1.______________________________ 2.______________________________ 
3.______________________________ 4.______________________________ 
Si Oui attribuer un numéro d’étude : |__|__|__|__| 
L’enfant a-t-il été référé |__| 1=Oui 2=Non    
 
DECLARATION DE L’INVESTIGATEUR SUR LA VERIFICATION DES DONNEES DE 
L’ENQUETE 
 
J’ai vérifié l’exactitude, la cohérence et la complétude des données de toutes les pages de ce 
formulaire d’enquête de base. Pour autant que je sache, ces données sont complètes et correctes. 
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Toutes les informations collectées dans ce formulaire l’ont été soit par moi ou par une personne 
sous ma supervision. 
 
Date:     |__|__|/|__|__|__|/|__|__|__|__| ___________________________________ 
     Jour         Mois             Année      Initiales et Signature de l’investigateur  
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ANNEXE B 
      
 
 
 
 
 
 
 
 
 
1. L’enfant a-t-il été vu ?         
 
|__|    1=Oui 2=Non 
 
2. HISTOIRE MEDICALE 
 
L’enfant s’est-il rendu au CSPS depuis la dernière visite ? |__| 1=Oui 2=Non  
L’enfant a t-il reçu un traitement depuis la dernière visite ? |__| 1=Oui 2=Non 
Si Oui indiquer les traitements reçus :  
 Traitement antipaludique : …………………………………………….     Autres 
traitements : …………………………………………………… 
Histoire de fièvre dans les dernières 24 heures ? |__| 1=Oui 2=Non 
 
3. SIGNES/SYMPTOMES  
 
Température axillaire |__|__|.|__|°C   
L’enfant est-il fébrile (Température axillaire > 37.5°C)? |__| 1=Oui 2=Non. 
Vomissement |__|  si oui, fréquence |__|__|  /24h 
Diarrhée |__| si oui, fréquence |__|__|  /24h  
Constipation |__| 
Toux |__|  
Autres |__| si oui, préciser :…………………………………………………………. …………  
 
4. EXAMENS BIOLOGIQUES  
*Un TDR a-t-il été réalisé? |__| 1=Oui 2=Non 3=Non disponible.    
Si Oui, noter le résultat du TDR |___|   1=positif  2= négatif,   3=invalide, 4=Non disponible 
*Le TDR sera fait uniquement si le l’enfant est fébrile (Température axillaire > 37.5°C) ou présente 
une histoire de fièvre dans les 24 heures précédentes. Le TDR est toujours associé à une goutte 
épaisse. 
Une goutte épaisse a-t-elle été réalisée |__| 1=Oui 2=Non  3=Non disponible  
Si oui noter le résultat : 
 P.falciparum P.malariae P.ovale 
Trophozoïtes    
Schizontes    
Gamètocytes    
 
Date de visite |__|__| / |__|__|__| / |__|__|__|__| 
Etude épidémiologique de base MVVC : Morbidité palustre au cours des deux premières 
années de vie et cinétique des anticorps maternels, dans deux zones à transmission saisonnière. 
 
FORMULAIRE DE SUIVI ACTIF 
Code du participant : |__|__|__|__| 
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5. TRAITEMENT   
 
L’enfant a-t-il été traité par l’enquêteur ? |__| 1=Oui 2=Non    
Si oui, compléter le tableau ci-dessous : 
MEDICAMENT  1=Oui 
2=Non    
Si oui, indiquer le traitement Posologie 
Antipaludique |__|   
Antipyrétique |__|   
 
L’enfant a-t-il été référé au CSPS ? |__| 1=Oui 2=Non    
Si oui préciser Le motif : ……………………………………………………………………… 
………………………………………………………………………………………………….. 
Formulaire complété par: Initiales de l’enquêteur : |__|__|__| 
Date:|__|__|/|__|__|__|/|__|__|__|__| 
 
 
 
DECLARATION DE L’INVESTIGATEUR SUR LA VERIFICATION DES DONNEES DE 
L’ENQUETE 
 
J’ai vérifié l’exactitude, la cohérence et la complétude des données de toutes les pages de ce 
formulaire d’enquête de base. Pour autant que sache, ces données sont complètes et correctes. 
Toutes les informations collectées dans ce formulaire l’ont été soit par moi ou par une personne 
sous ma supervision. 
 
Date:     |__|__|/|__|__|__|/|__|__|__|__| ___________________________________ 
    Jour         Mois             Année       Initiales et Signature de l’investigateur 
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ANNEXE C 
            
 
 
 
 
 
 
 
1. MOTIFS DE CONSULTATION 
L’enfant a-t-il été référé au CSPS par  l’enquêteur? |__| 1=Oui 2=Non    
Symptôme Présent |__| 1=Oui 
2=Non    
Durée / Fréquence 
Histoire de fièvre de 24H 
hheures 
|__|     
Diarrhée |__| Fréquence  dans les dernières 
24h|__|__| Vomissement |__| Fréquence  dans les dernières 
24h|__|__| Toux |__| Durée en jours |__|__| 
Ecoulement nasal |__| Durée en jours |__|__| 
Difficultés respiratoires |__| Durée en jours |__|__| 
Convulsions |__| Fréquence  dans les dernières 
24h|__|__| Perte de connaissance |__| Durée en jours |__|__| 
Insomnie inhabituelle |__| Durée en jours |__|__| 
Perte d’appétit |__| Durée en jours |__|__| 
Autres (préciser)   
 |__| Durée en jours |__|__| 
 |__| Durée en jours |__|__| 
 |__| Durée en jours |__|__| 
 
2. SIGNES VITAUX 
 
Histoire de fièvre de 24 heures |__|   1=Oui 2=Non. 
Température axillaire |__|__|.|__|°C   
L’enfant est-il fébrile (Température axillaire > 37.5°C)?   |__| 1=Oui 2=Non. 
Fréquence cardiaque : |__|__|__| btm/ min 
Fréquence respiratoire : |__|__|__| cycles/min 
Poids : |__|__|.|__| kg 
Taille : |__|__|.|__| cm 
 
3. EXAMEN PHYSIQUE 
 
Examen des appareils et systèmes  |__|     1=Normal / 2=Anormal           
 (Si 2, noter les anomalies)  
Etat général   |__|       ____________________________ 
Extrémité céphalique                  |__|       ____________________________ 
Appareil respiratoire        |__|       ____________________________ 
Etude épidémiologique de base MVVC : Morbidité palustre au cours des deux 
premières années de vie et cinétique des anticorps maternels, dans deux zones à 
transmission saisonnière. 
 
FORMULAIRE DE SUIVI PASSIF 
Date de visite     |__|__| / |__|__|__| / |__|__|__|__| 
Code du participant : |__|__|__|__| 
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Appareil cardio-vasculaire |__|       ____________________________ 
Système nerveux  |__|       ____________________________ 
Appareil digestif  |__|       ____________________________ 
Peau et phanères  |__|       ____________________________ 
Appareil locomoteur        |__|       ____________________________ 
Autres anomalies:            |__|       ____________________________ 
 
4. EXAMENS BIOLOGIQUES    
*Un TDR a-t-il été réalisé? |__| 1=Oui 2=Non 3=Non disponible.  
Si Oui, noter le résultat du TDR |___|   1=positif  2= négatif,   3=invalide,  4= Non disponible    
*Le TDR sera fait uniquement si le l’enfant est fébrile (Température axillaire > 37.5°C) ou présente 
une histoire de fièvre dans les 24 heures précédentes. Le TDR est toujours associé à une goutte 
épaisse. 
Une goutte épaisse a-t-elle été réalisée |__| 1=Oui 2=Non    
Si oui noter le résultat : 
 P.falciparum P.malariae P.ovale 
Trophozoïtes    
Schizontes    
Gamètocytes    
 
Le taux d’Hb a-t-il été mesuré? |__| 1=Oui 2=Non    
Si Oui, noter le résultat ;       Hb: |__|__|.|__| g/dl 
Un prélèvement de sang capillaire a-t-il été prélevé pour la glycémie |__| 1=Oui 2=Non 
Si Oui, noter le résultat ;   Glycémie: |__|__|.|__| g/L 
        Autres examens (préciser) :                              Résultats : 
1.______________________________ :______________________________ 
3.______________________________ :______________________________ 
 
5. DIAGNOSTIC   
 
Diagnostic 1=Oui 2=Non 
Paludisme simple  |__| 
Paludisme grave |__| 
Infection respiratoire aigue haute |__| 
Infection respiratoire aigue basse |__| 
Otite moyenne |__| 
Gastroentérite |__| 
Infection de la peau/tissus mous |__| 
Méningite |__| 
Septicémie |__| 
Malnutrition  |__| 
Autre (préciser) |__| 
Autre (préciser) |__| 
 
Cet enfant devrait-il être hospitalisé |__| 1=Oui 2=Non 
6. TRAITEMENT 
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MEDICAMENT  1=Oui 
2=Non    
Si oui, indiquer traitement Posologie 
Antipaludique |__|   
Antibiotique |__|   
Antipyrétique |__|   
Antiparasitaire |__|   
Pansement |__|   
Autres (préciser) |__|   
 
Formulaire complété par : initiales de l’infirmier et date: |__|__|__| Date   |__|__| / |__|__|__| / 
|__|__| 
 
 
DECLARATION DE L’INVESTIGATEUR SUR LA VERIFICATION DES DONNEES DE 
L’ENQUETE 
 
J’ai vérifié l’exactitude, la cohérence et la complétude des données de toutes les pages de ce 
formulaire d’enquête de base. Pour autant que sache, ces données sont complètes et correctes. 
Toutes les informations collectées dans ce formulaire l’ont été soit par moi ou par une personne 
sous ma supervision. 
Date:     |__|__|/|__|__|__|/|__|__|__|__| 
__________________________________________________ 
                Jour         Mois             Année       Initiales et Signature de l’investigateur 
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ANNEXE D 
         
 
 
 
 
 
 
 
 
 
1. L’enfant a-t-il été vu ?  
 
|__| 1=Oui 2=Non. 
 
2. SIGNES VITAUX 
 
Température axillaire |__|__|.|__|°C   
L’enfant est-il fébrile (Température axillaire > 37.5°C)? |__| 1=Oui 2=Non. 
 
3. HISTOIRE MEDICALE ET EXAMEN PHYSIQUE 
HISTOIRE MEDICALE  
 (1=Oui 2=Non) 
Histoire de fièvre de 24 heures |__|   
Vomissement |__|  si oui, fréquence |__|__|/24h 
Diarrhée |__| si oui, fréquence |__|__|/24h  
Ecoulement nasal |__|  
Toux |__|  
Autres |__| si oui, préciser :…………………………………………………….. …………  
EXAMEN PHYSIQUE 
Examen des appareils et systèmes  |__|     1=Normal / 2=Anormal           
 (Si 2, noter les anomalies)  
Etat général   |__|       ____________________________ 
Extrémité céphalique                  |__|       ____________________________ 
Appareil respiratoire              |__|       ____________________________ 
Appareil cardio-vasculaire |__|       ____________________________ 
Système nerveux  |__|       ____________________________ 
Appareil digestif  |__|       ____________________________ 
Peau et phanères  |__|       ____________________________ 
Appareil locomoteur        |__|       ____________________________ 
Autres anomalies:            |__|       ____________________________ 
 
6. EXAMENS BIOLOGIQUES   
 
Un échantillon de sang a-t-il été prélevé pour le dosage des AC maternels? |__| 1=Oui 2=Non   
 
Une goutte épaisse a-t-elle été réalisée |__| 1=Oui 2=Non    
Si oui noter le résultat : 
 P.falciparum P.malariae P.ovale 
Etude épidémiologique de base MVVC : Morbidité palustre au cours des deux 
premières années de vie et cinétique des anticorps maternels, dans deux zones à 
transmission saisonnière. 
 
FORMULAIRE DE SUIVI DES ACs MATERNELS 
Date de visite     |__|__| / |__|__|__| / |__|__| 
Code du participant : |__|__|__|__| 
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Trophozoïtes    
Schizontes    
Gamètocytes    
 
 
7. TRAITEMENT   
 
L’enfant a-t-il été traité par l’enquêteur ? |__| 1=Oui 2=Non    
Si oui, préciser le traitement reçu : ………………………………………………………… 
………………………………………………………………………………………………….. 
L’enfant a-t-il été référé au CSPS ? |__| 1=Oui 2=Non    
Si oui préciser la raison : ………………………………………………………..………….. 
 
 
DECLARATION DE L’INVESTIGATEUR SUR LA VERIFICATION DES DONNEES DE 
L’ENQUETE 
 
J’ai vérifié l’exactitude, la cohérence et la complétude des données de toutes les pages de ce 
formulaire d’enquête de base. Pour autant que sache, ces données sont complètes et correctes. 
Toutes les informations collectées dans ce formulaire l’ont été soit par moi ou par une personne 
sous ma supervision. 
 
Date:     |__|__|/|__|__|__|/|__|__|__|__| ___________________________________ 
       Jour         Mois             Année       Initiales et Signature de l’investigateur 
 
 
 
